Patent Publication Number: US-2004053248-A1

Title: Novel nucleic acids and polypeptides

Description:
1. TECHNICAL FIELD  
       [0001] The present invention provides novel polynucleotides and proteins encoded by such polynucleotides, along with uses for these polynucleotides and proteins, for example in therapeutic, diagnostic and research methods. 2. BACKGROUND  
       [0002] Technology aimed at the discovery of protein factors (including e.g., cytokines, such as lymphokines, interferons, CSFs, chemokines, and interleukins) has matured rapidly over the past decade. The now routine hybridization cloning and expression cloning techniques clone novel polynucleotides “directly” in the sense that they rely on information directly related to the discovered protein (i.e., partial DNA/amino acid sequence of the protein in the case of hybridization cloning; activity of the protein in the case of expression cloning). More recent “indirect” cloning techniques such as signal sequence cloning, which isolates DNA sequences based on the presence of a now well-recognized secretory leader sequence motif, as well as various PCR-based or low stringency hybridization-based cloning techniques, have advanced the state of the art by making available large numbers of DNA/amino acid sequences for proteins that are known to have biological activity, for example, by virtue of their secreted nature in the case of leader sequence cloning, by virtue of their cell or tissue source in the case of PCR-based techniques, or by virtue of structural similarity to other genes of known biological activity.  
       [0003] Identified polynucleotide and polypeptide sequences have numerous applications in, for example, diagnostics, forensics, gene mapping; identification of mutations responsible for genetic disorders or other traits, to assess biodiversity, and to produce many other types of data and products dependent on DNA and amino acid sequences.  
       3. SUMMARY OF THE INVENTION  
       [0004] The compositions of the present invention include novel isolated polypeptides, novel isolated polynucleotides encoding such polypeptides, including recombinant DNA molecules, cloned genes or degenerate variants thereof, especially naturally occurring variants such as allelic variants, antisense polynucleotide molecules, and antibodies that specifically recognize one or more epitopes present on such polypeptides, as well as hybridomas producing such antibodies.  
       [0005] The compositions of the present invention additionally include vectors, including expression vectors, containing the polynucleotides of the invention, cells genetically engineered to contain such polynucleotides and cells genetically engineered to express such polynucleotides.  
       [0006] The present invention relates to a collection or library of at least one novel nucleic acid sequence assembled from expressed sequence tags (ESTs) isolated mainly by sequencing by hybridization (SBH), and in some cases, sequences obtained from one or more public databases. The invention relates also to the proteins encoded by such polynucleotides, along with therapeutic, diagnostic and research utilities for these polynucleotides and proteins. These nucleic acid sequences are designated as SEQ ID NO: 1-739. The polypeptides sequences are designated SEQ ID NO: 740-1478. The nucleic acids and polypeptides are provided in the Sequence Listing. In the nucleic acids provided in the Sequence Listing, A is adenosine; C is cytosine; G is guanine; T is thymine; and N is any of the four bases. In the amino acids provided in the Sequence Listing, * corresponds to the stop codon.  
       [0007] The nucleic acid sequences of the present invention also include, nucleic acid sequences that hybridize to the complement of SEQ ID NO: 1-739 under stringent hybridization conditions; nucleic acid sequences which are allelic variants or species homologues of any of the nucleic acid sequences recited above, or nucleic acid sequences that encode a peptide comprising a specific domain or truncation of the peptides encoded by SEQ ID NO: 1-739. A polynucleotide comprising a nucleotide sequence having at least 90% identity to an identifying sequence of SEQ ID NO: 1-739 or a degenerate variant or fragment thereof. The identifying sequence can be 100 base pairs in length.  
       [0008] The nucleic acid sequences of the present invention also include the sequence information from the nucleic acid sequences of SEQ ID NO: 1-739. The sequence information can be a segment of any one of SEQ ID NO: 1-739 that uniquely identifies or represents the sequence information of SEQ ID NO: 1-739.  
       [0009] A collection as used in this application can be a collection of only one polynucleotide. The collection of sequence information or identifying information of each sequence can be provided on a nucleic acid array. In one embodiment, segments of sequence information is provided on a nucleic acid array to detect the polynucleotide that contains the segment. The array can be designed to detect full-match or mismatch to the polynucleotide that contains the segment. The collection can also be provided in a computer-readable format.  
       [0010] This invention also includes the reverse or direct complement of any of the nucleic acid sequences recited above; cloning or expression vectors containing the nucleic acid sequences; and host cells or organisms transformed with these expression vectors. Nucleic acid sequences (or their reverse or direct complements) according to the invention have numerous applications in a variety of techniques known to those skilled in the art of molecular biology, such as use as hybridization probes, use as primers for PCR, use in an array, use in computer-readable media, use in sequencing full-length genes, use for chromosome and gene mapping, use in the recombinant production of protein, and use in the generation of anti-sense DNA or RNA, their chemical analogs and the like.  
       [0011] In a preferred embodiment, the nucleic acid sequences of SEQ ID NO: 1-739 or novel segments or parts of the nucleic acids of the invention are used as primers in expression assays that are well known in the art. In a particularly preferred embodiment, the nucleic acid sequences of SEQ ID NO:1-739 or novel segments or parts of the nucleic acids provided herein are used in diagnostics for identifying expressed genes or, as well known in the art and exemplified by Vollrath et al., Science 258:52-59 (1992), as expressed sequence tags for physical mapping of the human genome.  
       [0012] The isolated polynucleotides of the invention include, but are not limited to, a polynucleotide comprising any one of the nucleotide sequences set forth in SEQ ID NO: 1-739; a polynucleotide comprising any of the full length protein coding sequences of SEQ ID NO: 1-739; and a polynucleotide comprising any of the nucleotide sequences of the mature protein coding sequences of SEQ ID NO: 1-739. The polynucleotides of the present invention also include, but are not limited to, a polynucleotide that hybridizes under stringent hybridization conditions to (a) the complement of any one of the nucleotide sequences set forth in SEQ ID NO:1-739; (b) a nucleotide sequence encoding any one of the amino acid sequences set forth in the Sequence Listing; (c) a polynucleotide which is an allelic variant of any polynucleotides recited above; (d) a polynucleotide which encodes a species homolog (e.g. orthologs) of any of the proteins recited above; or (e) a polynucleotide that encodes a polypeptide comprising a specific domain or truncation of any of the polypeptides comprising an amino acid sequence set forth in the Sequence Listing.  
       [0013] The isolated polypeptides of the invention include, but are not limited to, a polypeptide comprising any of the amino acid sequences set forth in the Sequence Listing; or the corresponding full length or mature protein. Polypeptides of the invention also include polypeptides with biological activity that are encoded by (a) any of the polynucleotides having a nucleotide sequence set forth in SEQ ID NO: 1-739; or (b) polynucleotides that hybridize to the complement of the polynucleotides of (a) under stringent hybridization conditions. Biologically or immunologically active variants of any of the polypeptide sequences in the Sequence Listing, and “substantial equivalents” thereof (e.g., with at least about 65%, 70%, 75%, 80%, 85%, 90%, 95%, 98% or 99% amino acid sequence identity) that preferably retain biological activity are also contemplated. The polypeptides of the invention may be wholly or partially chemically synthesized but are preferably produced by recombinant means using the genetically engineered cells (e.g. host cells) of the invention.  
       [0014] The invention also provides compositions comprising a polypeptide of the invention. Polypeptide compositions of the invention may further comprise an acceptable carrier, such as a hydrophilic, e.g., pharmaceutically acceptable, carrier.  
       [0015] The invention also provides host cells transformed or transfected with a polynucleotide of the invention.  
       [0016] The invention also relates to methods for producing a polypeptide of the invention comprising growing a culture of the host cells of the invention in a suitable culture medium under conditions permitting expression of the desired polypeptide, and purifying the polypeptide from the culture or from the host cells. Preferred embodiments include those in which the protein produced by such process is a mature form of the protein.  
       [0017] Polynucleotides according to the invention have numerous applications in a variety of techniques known to those skilled in the art of molecular biology. These techniques include use as hybridization probes, use as oligomers, or primers, for PCR, use for chromosome and gene mapping, use in the recombinant production of protein, and use in generation of anti-sense DNA or RNA, their chemical analogs and the like. For example, when the expression of an mRNA is largely restricted to a particular cell or tissue type, polynucleotides of the invention can be used as hybridization probes to detect the presence of the particular cell or tissue mRNA in a sample using, e.g., in situ hybridization.  
       [0018] In other exemplary embodiments, the polynucleotides are used in diagnostics as expressed sequence tags for identifying expressed genes or, as well known in the art and exemplified by Vollrath et al., Science 258:52-59 (1992), as expressed sequence tags for physical mapping of the human genome.  
       [0019] The polypeptides according to the invention can be used in a variety of conventional procedures and methods that are currently applied to other proteins. For example, a polypeptide of the invention can be used to generate an antibody that specifically binds the polypeptide. Such antibodies, particularly monoclonal antibodies, are useful for detecting or quantitating the polypeptide in tissue. The polypeptides of the invention can also be used as molecular weight markers, and as a food supplement.  
       [0020] Methods are also provided for preventing, treating, or ameliorating a medical condition which comprises the step of administering to a mammalian subject a therapeutically effective amount of a composition comprising a polypeptide of the present invention and a pharmaceutically acceptable carrier.  
       [0021] In particular, the polypeptides and polynucleotides of the invention can be utilized, for example, in methods for the prevention and/or treatment of disorders involving aberrant protein expression or biological activity.  
       [0022] The present invention further relates to methods for detecting the presence of the polynucleotides or polypeptides of the invention in a sample. Such methods can, for example, be utilized as part of prognostic and diagnostic evaluation of disorders as recited herein and for the identification of subjects exhibiting a predisposition to such conditions. The invention provides a method for detecting the polynucleotides of the invention in a sample, comprising contacting the sample with a compound that binds to and forms a complex with the polynucleotide of interest for a period sufficient to form the complex and under conditions sufficient to form a complex and detecting the complex such that if a complex is detected, the polynucleotide of interest is detected. The invention also provides a method for detecting the polypeptides of the invention in a sample comprising contacting the sample with a compound that binds to and forms a complex with the polypeptide under conditions and for a period sufficient to form the complex and detecting the formation of the complex such that if a complex is formed, the polypeptide is detected.  
       [0023] The invention also provides kits comprising polynucleotide probes and/or monoclonal antibodies, and optionally quantitative standards, for carrying out methods of the invention. Furthermore, the invention provides methods for evaluating the efficacy of drugs, and monitoring the progress of patients, involved in clinical trials for the treatment of disorders as recited above.  
       [0024] The invention also provides methods for the identification of compounds that modulate (i.e., increase or decrease) the expression or activity of the polynucleotides and/or polypeptides of the invention. Such methods can be utilized, for example, for the identification of compounds that can ameliorate symptoms of disorders as recited herein. Such methods can include, but are not limited to, assays for identifying compounds and other substances that interact with (e.g., bind to) the polypeptides of the invention. The invention provides a method for identifying a compound that binds to the polypeptides of the invention comprising contacting the compound with a polypeptide of the invention in a cell for a time sufficient to form a polypeptide/compound complex, wherein the complex drives expression of a reporter gene sequence in the cell; and detecting the complex by detecting the reporter gene sequence expression such that if expression of the reporter gene is detected the compound the binds to a polypeptide of the invention is identified.  
       [0025] The methods of the invention also provides methods for treatment which involve the administration of the polynucleotides or polypeptides of the invention to individuals exhibiting symptoms or tendencies. In addition, the invention encompasses methods for treating diseases or disorders as recited herein comprising administering compounds and other substances that modulate the overall activity of the target gene products. Compounds and other substances can effect such modulation either on the level of target gene/protein expression or target protein activity.  
       [0026] The polypeptides of the present invention and the polynucleotides encoding them are also useful for the same functions known to one of skill in the art as the polypeptides and polynucleotides to which they have homology (set forth in Table 2). If no homology is set forth for a sequence, then the polypeptides and polynucleotides of the present invention are useful for a variety of applications, as described herein, including use in arrays for detection.  
       4. DETAILED DESCRIPTION OF THE INVENTION  
       4.1 DEFINITIONS  
       [0027] It must be noted that as used herein and in the appended claims, the singular forms “a”, “an” and “the” include plural references unless the context clearly dictates otherwise.  
       [0028] The term “active” refers to those forms of the polypeptide which retain the biologic and/or immunologic activities of any naturally occurring polypeptide. According to the invention, the terms “biologically active” or “biological activity” refer to a protein or peptide having structural, regulatory or biochemical functions of a naturally occurring molecule. Likewise “immunologically active” or “immunological activity” refers to the capability of the natural, recombinant or synthetic polypeptide to induce a specific immune response in appropriate animals or cells and to bind with specific antibodies.  
       [0029] The term “activated cells” as used in this application are those cells which are engaged in extracellular or intracellular membrane trafficking, including the export of secretory or enzymatic molecules as part of a normal or disease process.  
       [0030] The terms “complementary” or “complementarity” refer to the natural binding of polynucleotides by base pairing. For example, the sequence 5′-AGT-3′ binds to the complementary sequence 3′-TCA-5′. Complementarity between two single-stranded molecules may be “partial” such that only some of the nucleic acids bind or it may be “complete” such that total complementarity exists between the single stranded molecules. The degree of complementarity between the nucleic acid strands has significant effects on the efficiency and strength of the hybridization between the nucleic acid strands.  
       [0031] The term “embryonic stem cells (ES)” refers to a cell that can give rise to many ifferentiated cell types in an embryo or an adult, including the germ cells. The term “germ line stem cells (GSCs)” refers to stem cells derived from primordial stem cells that provide a steady and continuous source of germ cells for the production of gametes. The term “primordial germ cells (PGCs)” refers to a small population of cells set aside from other cell lineages particularly from the yolk sac, mesenteries, or gonadal ridges during embryogenesis that have the potential to differentiate into germ cells and other cells. PGCs are the source from which GSCs and ES cells are derived The PGCs, the GSCs and the ES cells are capable of self-renewal. Thus these cells not only populate the germ line and give rise to a plurality of terminally differentiated cells that comprise the adult specialized organs, but are able to regenerate themselves.  
       [0032] The term “expression modulating fragment,” EMF, means a series of nucleotides which modulates the expression of an operably linked ORF or another EMF.  
       [0033] As used herein, a sequence is said to “modulate the expression of an operably linked sequence” when the expression of the sequence is altered by the presence of the EMF. EMFs include, but are not limited to, promoters, and promoter modulating sequences (inducible elements). One class of EMFs are nucleic acid fragments which induce the expression of an operably linked ORF in response to a specific regulatory factor or physiological event.  
       [0034] The terms “nucleotide sequence” or “nucleic acid” or “polynucleotide” or “oligonculeotide” are used interchangeably and refer to a heteropolymer of nucleotides or the sequence of these nucleotides. These phrases also refer to DNA or RNA of genomic or synthetic origin which may be single-stranded or double-stranded and may represent the sense or the antisense strand, to peptide nucleic acid (PNA) or to any DNA-like or RNA-like material. In the sequences herein A is adenine, C is cytosine, T is thymine, G is guanine and N is A, C, G or T (U). It is contemplated that where the polynucleotide is RNA, the T (thymine) in the sequences provided herein is substituted with U (uracil). Generally, nucleic acid segments provided by this invention may be assembled from fragments of the genome and short oligonucleotide linkers, or from a series of oligonucleotides, or from individual nucleotides, to provide a synthetic nucleic acid which is capable of being expressed in a recombinant transcriptional unit comprising regulatory elements derived from a microbial or viral operon, or a eukaryotic gene.  
       [0035] The terms “oligonucleotide fragment” or a “polynucleotide fragment”, “portion,” or “segment” or “probe” or “primer” are used interchangeably and refer to a sequence of nucleotide residues which are at least about 5 nucleotides, more preferably at least about 7 nucleotides, more preferably at least about 9 nucleotides, more preferably at least about 11 nucleotides and most preferably at least about 17 nucleotides. The fragment is preferably less than about 500 nucleotides, preferably less than about 200 nucleotides, more preferably less than about 100 nucleotides, more preferably less than about 50 nucleotides and most preferably less than 30 nucleotides. Preferably the probe is from about 6 nucleotides to about 200 nucleotides, preferably from about 15 to about 50 nucleotides, more preferably from about 17 to 30 nucleotides and most preferably from about 20 to 25 nucleotides. Preferably the fragments can be used in polymerase chain reaction (PCR), various hybridization procedures or microarray procedures to identify or amplify identical or related parts of mRNA or DNA molecules. A fragment or segment may uniquely identify each polynucleotide sequence of the present invention. Preferably the fragment comprises a sequence substantially similar to any one of SEQ ID NOs: 1-20.  
       [0036] Probes may, for example, be used to determine whether specific mRNA molecules are present in a cell or tissue or to isolate similar nucleic acid sequences from chromosomal DNA as described by Walsh et al. (Walsh, P. S. et al., 1992, PCR Methods Appl 1:241-250). They may be labeled by nick translation, Klenow fill-in reaction, PCR, or other methods well known in the art. Probes of the present invention, their preparation and/or labeling are elaborated in Sambrook, J. et al., 1989, Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory, N.Y.; or Ausubel, F. M. et al., 1989, Current Protocols in Molecular Biology, John Wiley &amp; Sons, New York N.Y., both of which are incorporated herein by reference in their entirety.  
       [0037] The nucleic acid sequences of the present invention also include the sequence information from the nucleic acid sequences of SEQ ID NO: 1-739. The sequence information can be a segment of any one of SEQ ID NO: 1-739 that uniquely identifies or represents the sequence information of that sequence of SEQ ID NO: 1-739. One such segment can be a twenty-mer nucleic acid sequence because the probability that a twenty-mer is fully matched in the human genome is 1 in 300. In the human genome, there are three billion base pairs in one set of chromosomes. Because 4 20  possible twenty-mers exist, there are 300 times more twenty-mers than there are base pairs in a set of human chromosomes. Using the same analysis, the probability for a seventeen-mer to be fully matched in the human genome is approximately 1 in 5. When these segments are used in arrays for expression studies, fifteen-mer segments can be used. The probability that the fifteen-mer is fully matched in the expressed sequences is also approximately one in five because expressed sequences comprise less than approximately 5% of the entire genome sequence.  
       [0038] Similarly, when using sequence information for detecting a single mismatch, a segment can be a twenty-five mer. The probability that the twenty-five mer would appear in a human genome with a single mismatch is calculated by multiplying the probability for a full match (1÷4 25 ) times the increased probability for mismatch at each nucleotide position (3×25). The probability that an eighteen mer with a single mismatch can be detected in an array for expression studies is approximately one in five. The probability that a twenty-mer with a single mismatch can be detected in a human genome is approximately one in five.  
       [0039] The term “open reading flame,” ORF, means a series of nucleotide triplets coding for amino acids without any termination codons and is a sequence translatable into protein.  
       [0040] The terms “operably linked” or “operably associated” refer to functionally related nucleic acid sequences. For example, a promoter is operably associated or operably linked with a coding sequence if the promoter controls the transcription of the coding sequence. While operably linked nucleic acid sequences can be contiguous and in the same reading frame, certain genetic elements e.g. repressor genes are not contiguously linked to the coding sequence but still control transcription/translation of the coding sequence.  
       [0041] The term “pluripotent” refers to the capability of a cell to differentiate into a number of differentiated cell types that are present in an adult organism. A pluripotent cell is restricted in its differentiation capability in comparison to a totipotent cell.  
       [0042] The terms “polypeptide” or “peptide” or “amino acid sequence” refer to an oligopeptide, peptide, polypeptide or protein sequence or fragment thereof and to naturally occurring or synthetic molecules. A polypeptide “fragment,” “portion,” or “segment” is a stretch of amino acid residues of at least about 5 amino acids, preferably at least about 7 amino acids, more preferably at least about 9 amino acids and most preferably at least about 17 or more amino acids. The peptide preferably is not greater than about 200 amino acids, more preferably less than 150 amino acids and most preferably less than 100 amino acids. Preferably the peptide is from about 5 to about 200 amino acids. To be active, any polypeptide must have sufficient length to display biological and/or immunological activity.  
       [0043] The term “naturally occurring polypeptide” refers to polypeptides produced by cells that have not been genetically engineered and specifically contemplates various polypeptides arising from post-translational modifications of the polypeptide including, but not limited to, acetylation, carboxylation, glycosylation, phosphorylation, lipidation and acylation.  
       [0044] The term “translated protein coding portion” means a sequence which encodes for the full length protein which may include any leader sequence or any processing sequence.  
       [0045] The term “mature protein coding sequence” means a sequence which encodes a peptide or protein without a signal or leader sequence. The “mature protein portion” means that portion of the protein which does not include a signal or leader sequence. The peptide may have been produced by processing in the cell which removes any leader/signal sequence. The mature protein portion may or may not include the initial methionine residue. The methionine residue may be removed from the protein during processing in the cell. The peptide may be produced synthetically or the protein may have been produced using a polynucleotide only encoding for the mature protein coding sequence.  
       [0046] The term “derivative” refers to polypeptides chemically modified by such techniques as ubiquitination, labeling (e.g., with radionuclides or various enzymes), covalent polymer attachment such as pegylation (derivatization with polyethylene glycol) and insertion or substitution by chemical synthesis of amino acids such as ornithine, which do not normally occur in human proteins.  
       [0047] The term “variant” (or “analog”) refers to any polypeptide differing from naturally occurring polypeptides by amino acid insertions, deletions, and substitutions, created using, e g., recombinant DNA techniques. Guidance in determining which amino acid residues may be replaced, added or deleted without abolishing activities of interest, may be found by comparing the sequence of the particular polypeptide with that of homologous peptides and minimizing the number of amino acid sequence changes made in regions of high homology (conserved regions) or by replacing amino acids with consensus sequence.  
       [0048] Alternatively, recombinant variants encoding these same or similar polypeptides may be synthesized or selected by making use of the “redundancy” in the genetic code. Various codon substitutions, such as the silent changes which produce various restriction sites, may be introduced to optimize cloning into a plasmid or viral vector or expression in a particular prokaryotic or eukaryotic system. Mutations in the polynucleotide sequence may be reflected in the polypeptide or domains of other peptides added to the polypeptide to modify the properties of any part of the polypeptide, to change characteristics such as ligand-binding affinities, interchain affinities, or degradation/turnover rate.  
       [0049] Preferably, amino acid “substitutions” are the result of replacing one amino acid with another amino acid having similar structural and/or chemical properties, i.e., conservative amino acid replacements. “Conservative” amino acid substitutions may be made on the basis of similarity in polarity, charge, solubility, hydrophobicity, hydrophilicity, and/or the amphipathic nature of the residues involved. For example, nonpolar (hydrophobic) amino acids include alanine, leucine, isoleucine, valine, proline, phenylalanine, tryptophan, and methionine; polar neutral amino acids include glycine, serine, threonine, cysteine, tyrosine, asparagine, and glutamine; positively charged (basic) amino acids include arginine, lysine, and histidine; and negatively charged (acidic) amino acids include aspartic acid and glutamic acid. “Insertions” or “deletions” are preferably in the range of about 1 to 20 amino acids, more preferably 1 to 10 amino acids. The variation allowed may be experimentally determined by systematically making insertions, deletions, or substitutions of amino acids in a polypeptide molecule using recombinant DNA techniques and assaying the resulting recombinant variants for activity.  
       [0050] Alternatively, where alteration of function is desired, insertions, deletions or non-conservative alterations can be engineered to produce altered polypeptides. Such *alterations can, for example, alter one or more of the biological functions or biochemical characteristics of the polypeptides of the invention. For example, such alterations may change polypeptide characteristics such as ligand-binding affinities, interchain affinities, or degradation/turnover rate. Further, such alterations can be selected so as to generate polypeptides that are better suited for expression, scale up and the like in the host cells chosen for expression. For example, cysteine residues can be deleted or substituted with another amino acid residue in order to eliminate disulfide bridges.  
       [0051] The terms “purified” or “substantially purified” as used herein denotes that the indicated nucleic acid or polypeptide is present in the substantial absence of other biological macromolecules, e.g., polynucleotides, proteins, and the like. In one embodiment, the polynucleotide or polypeptide is purified such that it constitutes at least 95% by weight, more preferably at least 99% by weight, of the indicated biological macromolecules present (but water, buffers, and other small molecules, especially molecules having a molecular weight of less than 1000 daltons, can be present).  
       [0052] The term “isolated” as used herein refers to a nucleic acid or polypeptide separated from at least one other component (e.g., nucleic acid or polypeptide) present with the nucleic acid or polypeptide in its natural source. In one embodiment, the nucleic acid or polypeptide is found in the presence of (if anything) only a solvent, buffer, ion, or other component normally present in a solution of the same. The terms “isolated” and “purified” do not encompass nucleic acids or polypeptides present in their natural source.  
       [0053] The term “recombinant,” when used herein to refer to a polypeptide or protein, means that a polypeptide or protein is derived from recombinant (e.g., microbial, insect, or mammalian) expression systems. “Microbial” refers to recombinant polypeptides or proteins made in bacterial or fungal (e.g., yeast) expression systems. As a product, “recombinant microbial” defines a polypeptide or protein essentially free of native endogenous substances and unaccompanied by associated native glycosylation. Polypeptides or proteins expressed in most bacterial cultures, e.g.,  E. coli , will be free of glycosylation modifications; polypeptides or proteins expressed in yeast will have a glycosylation pattern in general different from those expressed in mammalian cells.  
       [0054] The term “recombinant expression vehicle or vector” refers to a plasmid or phage or virus or vector, for expressing a polypeptide from a DNA (RNA) sequence. An expression vehicle can comprise a transcriptional unit comprising an assembly of (1) a genetic element or elements having a regulatory role in gene expression, for example, promoters or enhancers, (2) a structural or coding sequence which is transcribed into mRNA and translated into protein, and (3) appropriate transcription initiation and termination sequences. Structural units intended for use in yeast or eukaryotic expression systems preferably include a leader sequence enabling extracellular secretion of translated protein by a host cell. Alternatively, where recombinant protein is expressed without a leader or transport sequence, it may include an amino terminal methionine residue. This residue may or may not be subsequently cleaved from the expressed recombinant protein to provide a final product.  
       [0055] The term “recombinant expression system” means host cells which have stably integrated a recombinant transcriptional unit into chromosomal DNA or carry the recombinant transcriptional unit extrachromosomally. Recombinant expression systems as defined herein will express heterologous polypeptides or proteins upon induction of the regulatory elements linked to the DNA segment or synthetic gene to be expressed. This term also means host cells which have stably integrated a recombinant genetic element or elements having a regulatory role in gene expression, for example, promoters or enhancers. Recombinant expression systems as defined herein will express polypeptides or proteins endogenous to the cell upon induction of the regulatory elements linked to the endogenous DNA segment or gene to be expressed. The cells can be prokaryotic or eukaryotic.  
       [0056] The term “secreted” includes a protein that is transported across or through a membrane, including transport as a result of signal sequences in its amino acid sequence when it is expressed in a suitable host cell. “Secreted” proteins include without limitation proteins secreted wholly (e.g., soluble proteins) or partially (e.g., receptors) from the cell in which they are expressed. “Secreted” proteins also include without limitation proteins that are transported across the membrane of the endoplasmic reticulum. “Secreted” proteins are also intended to include proteins containing non-typical signal sequences (e.g. Interleukin-1 Beta, see Krasney, P. A. and Young, P. R (1992) Cytokine 4(2):134-143) and factors released from damaged cells (e.g. Interleukin-1 Receptor Antagonist, see Arend, W. P. et. al. (1998) Annu. Rev. Immunol. 16:27-55).  
       [0057] Where desired, an expression vector may be designed to contain a “signal or leader sequence” which will direct the polypeptide through the membrane of a cell. Such sequence may be naturally present on the polypeptides of the present invention or provided from heterologous protein sources by recombinant DNA techniques.  
       [0058] The term “stringent” is used to refer to conditions that are commonly understood in the art as stringent. Stringent conditions can include highly stringent conditions (i.e., hybridization to filter-bound DNA in 0.5 M NaHPO 4 , 7% sodium dodecyl sulfate (SDS), 1 mM EDTA at 65° C., and washing in 0.1×SSC/0.1% SDS at 68° C.), and moderately stringent conditions (i.e., washing in 0.2×SSC/0.1% SDS at 42° C.). Other exemplary hybridization conditions are described herein in the examples.  
       [0059] In instances of hybridization of deoxyoligonucleotides, additional exemplary stringent hybridization conditions include washing in 6×SSC/0.05% sodium pyrophosphate at 37° C. (for 14-base oligonucleotides), 48° C. (for 17-base oligos), 55° C. (for 20-base oligonucleotides), and 60° C. (for 23-base oligonucleotides).  
       [0060] As used herein, “substantially equivalent” can refer both to nucleotide and amino acid sequences, for example a mutant sequence, that varies from a reference sequence by one or more substitutions, deletions, or additions, the net effect of which does not result in an adverse functional dissimilarity between the reference and subject sequences. Typically, such a substantially equivalent sequence varies from one of those listed herein by no more than about 35% (i.e., the number of individual residue substitutions, additions, and/or deletions in a substantially equivalent sequence, as compared to the corresponding reference sequence, divided by the total number of residues in the substantially equivalent sequence is about 0.35 or less). Such a sequence is said to have 65% sequence identity to the listed sequence. In one embodiment, a substantially equivalent, e.g., mutant, sequence of the invention varies from a listed sequence by no more than 30% (70% sequence identity); in a variation of this embodiment, by no more than 25% (75% sequence identity); and in a further variation of this embodiment, by no more than 20% (80% sequence identity) and in a firther variation of this embodiment, by no more than 10% (90% sequence identity) and in a further variation of this embodiment, by no more that 5% (95% sequence identity). Substantially equivalent, e.g., mutant, amino acid sequences according to the invention preferably have at least 80% sequence identity with a listed amino acid sequence, more preferably at least 90% sequence identity. Substantially equivalent nucleotide sequences of the invention can have lower percent sequence identities, taking into account, for example, the redundancy or degeneracy of the genetic code. Preferably, nucleotide sequence has at least about 65% identity, more preferably at least about 75% identity, and most preferably at least about 95% identity. For the purposes of the present invention, sequences having substantially equivalent biological activity and substantially equivalent expression characteristics are considered substantially equivalent. For the purposes of determining equivalence, truncation of the mature sequence (e.g., via a mutation which creates a spurious stop codon) should be disregarded. Sequence identity may be determined, e.g., using the Jotun Hein method (Hein, J. (1990) Methods Enzymol. 183:626-645). Identity between sequences can also be determined by other methods known in the art, e.g. by varying hybridization conditions.  
       [0061] The term “totipotent” refers to the capability of a cell to differentiate into all of the cell types of an adult organism.  
       [0062] The term “transformation” means introducing DNA into a suitable host cell so that the DNA is replicable, either as an extrachromosomal element, or by chromosomal integration. The term “transfection” refers to the taking up of an expression vector by a suitable host cell, whether or not any coding sequences are in fact expressed. The term “infection” refers to the introduction of nucleic acids into a suitable host cell by use of a virus or viral vector.  
       [0063] As used herein, an “uptake modulating fragment,” UMF, means a series of nucleotides which mediate the uptake of a linked DNA fragment into a cell. UMFs can be readily identified using known UMFs as a target sequence or target motif with the computer-based systems described below. The presence and activity of a UMF can be confirmed by attaching the suspected UMF to a marker sequence. The resulting nucleic acid molecule is then incubated with an appropriate host under appropriate conditions and the uptake of the marker sequence is determined. As described above, a UMF will increase the frequency of uptake of a linked marker sequence.  
       [0064] Each of the above terms is meant to encompass all that is described for each, unless the context dictates otherwise.  
       4.2 NUCLEIC ACIDS OF THE INVENTION  
       [0065] Nucleotide sequences of the invention are set forth in the Sequence Listing.  
       [0066] The isolated polynucleotides of the invention include a polynucleotide comprising the nucleotide sequences of SEQ ID NO: 1-739 ; a polynucleotide encoding any one of the peptide sequences of SEQ ID NO: 740-1478; and a polynucleotide comprising the nucleotide sequence encoding the mature protein coding sequence of the polypeptides of any one of SEQ ID NO: 740-1478. The polynucleotides of the present invention also include, but are not limited to, a polynucleotide that hybridizes under stringent conditions to (a) the complement of any of the nucleotides sequences of SEQ ID NO: 1-739 ; (b) nucleotide sequences encoding any one of the amino acid sequences set forth in the Sequence Listing; (c) a polynucleotide-which is an allelic variant of any polynucleotide recited above; (d) a polynucleotide which encodes a species homolog of any of the proteins recited above; or (e) a polynucleotide that encodes a polypeptide comprising a specific domain or truncation of the polypeptides of SEQ ID NO: 740-1478. Domains of interest may depend on the nature of the encoded polypeptide; e.g., domains in receptor-like polypeptides include ligand-binding, extracellular, transmembrane, or cytoplasmic domains, or combinations thereof; domains in immunoglobulin-like proteins include the variable immunoglobulin-like domains; domains in enzyme-like polypeptides include catalytic and substrate binding domains; and domains in ligand polypeptides include receptor-binding domains.  
       [0067] The polynucleotides of the invention include naturally occurring or wholly or partially synthetic DNA, e.g., cDNA and genomic DNA, and RNA, e.g., mRNA. The polynucleotides may include all of the coding region of the cDNA or may represent a portion of the coding region of the cDNA.  
       [0068] The present invention also provides genes corresponding to the cDNA sequences disclosed herein. The corresponding genes can be isolated in accordance with known methods using the sequence information disclosed herein. Such methods include the preparation of probes or primers from the disclosed sequence information for identification and/or amplification of genes in appropriate genomic libraries or other sources of genomic materials. Further 5′ and 3′ sequence can be obtained using methods known in the art For example, full length cDNA or genomic DNA that corresponds to any of the polynucleotides of SEQ ID NO: 1-739 can be obtained by screening appropriate cDNA or genomic DNA libraries under suitable hybridization conditions using any of the polynucleotides of SEQ ID NO: 1-739or a portion thereof as a probe. Altematively,the polynucleotides of SEQ ID NO: 1-739 may be used as the basis for suitable primer(s) that allow identification and/or amplification of genes in appropriate genomic DNA or cDNA libraries.  
       [0069] The nucleic acid sequences of the invention can be assembled from ESTs and sequences (including cDNA and genomic sequences) obtained from one or more public databases, such as dbEST, gbpri, and UniGene. The EST sequences can provide identifying sequence information, representative fragment or segment information, or novel segment information for the full-length gene.  
       [0070] The polynucleotides of the invention also provide polynucleotides including nucleotide sequences that are substantially equivalent to the polynucleotides recited above. Polynucleotides according to the invention can have, e.g., at least about 65%, at least about 70%, at least about 75%, at least about 80%, more typically at least about 90%, and even more typically at least about 95%, sequence identity to a polynucleotide recited above.  
       [0071] Included within the scope of the nucleic acid sequences of the invention are nucleic acid sequence fragments that hybridize under stringent conditions to any of the nucleotide sequences of SEQ ID NO: 1-739, or complements thereof, which fragment is greater than about 5 nucleotides, preferably 7 nucleotides, more preferably greater than 9 nucleotides and most preferably greater than 17 nucleotides. Fragments of, e.g. 15, 17, or 20 nucleotides or more that are selective for (i.e. specifically hybridize to any one of the polynucleotides of the invention) are contemplated. Probes capable of specifically hybridizing to a polynucleotide can differentiate polynucleotide sequences of the invention from other polynucleotide sequences in the same family of genes or can differentiate human genes from genes of other species, and are preferably based on unique nucleotide sequences.  
       [0072] The sequences falling within the scope of the present invention are not limited to these specific sequences, but also include allelic and species variations thereof. Allelic and species variations can be routinely determined by comparing the sequence provided SEQ ID NO: 1-739, a representative fragment thereof, or a nucleotide sequence at least 90% identical, preferably 95% identical, to SEQ ID NO: 1-739 with a sequence from another isolate of the same species. Furthermore, to accommodate codon variability, the invention includes nucleic acid molecules coding for the same amino acid sequences as do the specific ORFs disclosed herein. In other words, in the coding region of an ORF, substitution of one codon for another codon that encodes the same amino acid is expressly contemplated.  
       [0073] The nearest neighbor or homology result for the nucleic acids of the present invention, including SEQ ID NO: 1-739, can be obtained by searching a database using an algorithm or a program. Preferably, a BLAST which stands for Basic Local Alignment Search Tool is used to search for local sequence alignments (Altshul, S. F. J Mol. Evol. 36 290-300 (1993) and Altschul S. F. et al. J. Mol. Biol. 21:403-410 (1990)). Alternatively a FASTA version 3 search against Genpept, using Fastxy algorithm.  
       [0074] Species homologs (or orthologs) of the disclosed polynucleotides and proteins are also provided by the present invention. Species homologs may be isolated and identified by making suitable probes or primers from the sequences provided herein and screening a suitable nucleic acid source from the desired species.  
       [0075] The invention also encompasses allelic variants of the disclosed polynucleotides or proteins; that is, naturally-occurring alternative forms of the isolated polynucleotide which also encode proteins which are identical, homologous or related to that encoded by the polynucleotides.  
       [0076] The nucleic acid sequences of the invention are further directed to sequences which encode variants of the described nucleic acids. These amino acid sequence variants may be prepared by methods known in the art by introducing appropriate nucleotide changes into a native or variant polynucleotide. There are two variables in the construction of amino acid sequence variants: the location of the mutation and the nature of the mutation. Nucleic acids encoding the amino acid sequence variants are preferably constructed by mutating the polynucleotide to encode an amino acid sequence that does not occur in nature. These nucleic acid alterations can be made at sites that differ in the nucleic acids from different species (variable positions) or in highly conserved regions (constant regions). Sites at such locations will typically be modified in series, e.g., by substituting first with conservative choices (e.g., hydrophobic amino acid to a different hydrophobic amino acid) and then with more distant choices (e.g., hydrophobic amino acid to a charged amino acid), and then deletions or insertions may be made at the target site. Amino acid sequence deletions generally range from about 1 to 30 residues, preferably about 1 to 10 residues, and are typically contiguous. Amino acid insertions include amino- and/or carboxyl-terminal fusions ranging in length from one to one hundred or more residues, as well as intrasequence insertions of single or multiple amino acid residues. Intrasequence insertions may range generally from about 1 to 10 amino residues, preferably from 1 to 5 residues. Examples of terminal insertions include the heterologous signal sequences necessary for secretion or for intracellular targeting in different host cells and sequences such as FLAG or poly-histidine sequences useful for purifying the expressed protein.  
       [0077] In a preferred method, polynucleotides encoding the novel amino acid sequences are changed via site-directed mutagenesis. This method uses oligonucleotide sequences to alter a polynucleotide to encode the desired amino acid variant, as well as sufficient adjacent nucleotides on both sides of the changed amino acid to form a stable duplex on either side of the site of being changed. In general, the techniques of site-directed, mutagenesis are well known to those of skill in the art and this technique is exemplified by publications such as, Edelman et al.,  DNA  2:183 (1983). A versatile and efficient method for producing site-specific changes in a polynucleotide sequence was published by Zoller and Smith,  Nucleic Acids Res.  10:6487-6500 (1982). PCR may also be used to create amino acid sequence variants of the novel nucleic acids. When small amounts of template DNA are used as starting material, primer(s) that differs slightly in sequence from the corresponding region in the template DNA can generate the desired amino acid variant. PCR amplification results in a population of product DNA fragments that differ from the polynucleotide template encoding the polypeptide at the position specified by the primer. The product DNA fragments replace the corresponding region in the plasmid and this gives a polynucleotide encoding the desired amino acid variant.  
       [0078] A further technique for generating amino acid variants is the cassette mutagenesis technique described in Wells et al.,  Gene  34:315 (1985); and other mutagenesis techniques well known in the art, such as, for example, the techniques in Sambrook et al., supra, and  Current Protocols in Molecular Biology , Ausubel et al. Due to the inherent degeneracy of the genetic code, other DNA sequences which encode substantially the same or a functionally equivalent amino acid sequence may be used in the practice of the invention for the cloning and expression of these novel nucleic acids. Such DNA sequences include those which are capable of hybridizing to the appropriate novel nucleic acid sequence under stringent conditions.  
       [0079] Polynucleotides encoding preferred polypeptide truncations of the invention can be used to generate polynucleotides encoding chimeric or fusion proteins comprising one or more domains of the invention and heterologous protein sequences.  
       [0080] The polynucleotides of the invention additionally include the complement of any of the polynucleotides recited above. The polynucleotide can be DNA (genomic, cDNA, amplified, or synthetic) or RNA. Methods and algorithms for obtaining such polynucleotides are well known to those of skill in the art and can include, for example, methods for determining hybridization conditions that can routinely isolate polynucleotides of the desired sequence identities.  
       [0081] In accordance with the invention, polynucleotide sequences comprising the mature protein coding sequences corresponding to any one of SEQ ID NO: 1-739, or functional equivalents thereof, may be used to generate recombinant DNA molecules that direct the expression of that nucleic acid, or a functional equivalent thereof, in appropriate host cells. Also included are the cDNA inserts of any of the clones identified herein.  
       [0082] A polynucleotide according to the invention can be joined to any of a variety of other nucleotide sequences by well-established recombinant DNA techniques (see Sambrook J et al. (1989) Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory, NY). Useful nucleotide sequences for joining to polynucleotides include an assortment of vectors, e.g., plasmids, cosmids, lambda phage derivatives, phagemids, and the like, that are well known in the art. Accordingly, the invention also provides a vector including a polynucleotide of the invention and a host cell containing the polynucleotide. In general, the vector contains an origin of replication functional in at least one organism, convenient restriction endonuclease sites, and a selectable marker for the host cell. Vectors according to the invention include expression vectors, replication vectors, probe generation vectors, and sequencing vectors. A host cell according to the invention can be a prokaryotic or eukaryotic cell and can be a unicellular organism or part of a multicellular organism.  
       [0083] The present invention further provides recombinant constructs comprising a nucleic acid having any of the nucleotide sequences of SEQ ID NO: 1-739 or a fragment thereof or any other polynucleotides of the invention. In one embodiment, the recombinant constructs of the present invention comprise a vector, such as a plasmid or viral vector, into which a nucleic acid having any of the nucleotide sequences of SEQ ID NO: 1-739 or a fragment thereof is inserted, in a forward or reverse orientation. In the case of a vector comprising one of the ORFs of the present invention, the vector may further comprise regulatory sequences, including for example, a promoter, operably linked to the ORF. Large numbers of suitable vectors and promoters are known to those of skill in the art and are commercially available for generating the recombinant constructs of the present invention. The following vectors are provided by way of example. Bacterial: pBs, phagescript, PsiX174, pBluescript SK, pBs KS, pNH8a, pNH16a, pNH18a, pNH46a (Stratagene); pTrc99A, pKK223-3, pKK233-3, pDR540, pRIT5 (Pharmacia). Eukaryotic: pWLneo, pSV2cat, pOG44, PXTI, pSG (Stratagene) pSVK3, pBPV, pMSG, pSVL (Pharmacia).  
       [0084] The isolated polynucleotide of the invention may be operably linked to an expression control sequence such as the pMT2 or pED expression vectors disclosed in Kaufman et al.,  Nucleic Acids Res.  19, 4485-4490 (1991), in order to produce the protein recombinantly. Many suitable expression control sequences are known in the art. General methods of expressing recombinant proteins are also known and are exemplified in R. Kaufman,  Methods in Enzymology  185, 537-566 (1990). As defined herein “operably linked” means that the isolated polynucleotide of the invention and an expression control sequence are situated within a vector or cell in such a way that the protein is expressed by a host cell which has been transformed (transfected) with the ligated polynucleotide/expression control sequence.  
       [0085] Promoter regions can be selected from any desired gene using CAT (chloramphenicol transferase) vectors or other vectors with selectable markers. Two appropriate vectors are pKK232-8 and pCM7. Particular named bacterial promoters include lacI, lacZ, T3, T7, gpt, lambda PR, and trc. Eukaryotic promoters include CMV immediate early, HSV thymidine kinase, early and late SV40, LTRs from retrovirus, and mouse metallothionein-I. Selection of the appropriate vector and promoter is well within the level of ordinary skill in the art. Generally, recombinant expression vectors will include origins of replication and selectable markers permitting transformation of the host cell, e.g., the ampicillin resistance gene of  E. coli  and  S. cerevisiae  TRP1 gene, and a promoter derived from a highly-expressed gene to direct transcription of a downstream structural sequence. Such promoters can be derived from operons encoding glycolytic enzymes such as 3-phosphoglycerate kinase (PGK), a-factor, acid phosphatase, or heat shock proteins, among others. The heterologous structural sequence is assembled in appropriate phase with translation initiation and termination sequences, and preferably, a leader sequence capable of directing secretion of translated protein into the periplasmic space or extracellular medium. Optionally, the heterologous sequence can encode a fusion protein including an amino terminal identification peptide imparting desired characteristics, e.g., stabilization or simplified purification of expressed recombinant product. Useful expression vectors for bacterial use are constructed by inserting a structural DNA sequence encoding a desired protein together with suitable translation initiation and termination signals in operable reading phase with a functional promoter. The vector will comprise one or more phenotypic selectable markers and an origin of replication to ensure maintenance of the vector and to, if desirable, provide amplification within the host. Suitable prokaryotic hosts for transformation include  E. coli, Bacillus subtilis, Salmonella typhimurium  and various species within the genera Pseudomonas, Streptomyces, and Staphylococcus, although others may also be employed as a matter of choice.  
       [0086] As a representative but non-limiting example, useful expression vectors for bacterial use can comprise a selectable marker and bacterial origin of replication derived from commercially available plasmids comprising genetic elements of the well known cloning vector pBR322 (ATCC 37017). Such commercial vectors include, for example, pKK223-3 (Pharmacia Fine Chemicals, Uppsala, Sweden) and GEM 1 (Promega Biotech, Madison, Wis., USA). These pBR322 “backbone” sections are combined with an appropriate promoter and the structural sequence to be expressed. Following transformation of a suitable host strain and growth of the host strain to an appropriate cell density, the selected promoter is induced or derepressed by appropriate means (e.g., temperature shift or chemical induction) and cells are cultured for an additional period. Cells are typically harvested by centrifugation, disrupted by physical or chemical means, and the resulting crude extract retained for further purification.  
       [0087] Polynucleotides of the invention can also be used to induce immune responses. For example, as described in Fan et al.,  Nat. Biotech.  17:870-872 (1999), incorporated herein by reference, nucleic acid sequences encoding a polypeptide may be used to generate antibodies against the encoded polypeptide following topical administration of naked plasmid DNA or following injection, and preferably intramuscular injection of the DNA. The nucleic acid sequences are preferably inserted in a recombinant expression vector and may be in the form of naked DNA.  
       4.3 ANTISENSE  
       [0088] Another aspect of the invention pertains to isolated antisense nucleic acid molecules that are hybridizable to or complementary to the nucleic acid molecule comprising the nucleotide sequence of SEQ ID NO: 1-739, or fragments, analogs or derivatives thereof. An “antisense” nucleic acid comprises a nucleotide sequence that is complementary to a “sense” nucleic acid encoding a protein, e.g., complementary to the coding strand of a double-stranded cDNA molecule or complementary to an mRNA sequence. In specific aspects, antisense nucleic acid molecules are provided that comprise a sequence complementary to at least about 10, 25, 50, 100, 250 or 500 nucleotides or an entire coding strand, or to only a portion thereof. Nucleic acid molecules encoding fragments, homologs, derivatives and analogs of a protein of any of SEQ ID NO: 740-1478 or antisense nucleic acids complementary to a nucleic acid sequence of SEQ ID NO: 1-739 are additionally provided.  
       [0089] In one embodiment, an antisense nucleic acid molecule is antisense to a “coding region” of the coding strand of a nucleotide sequence of the invention. The term “coding region” refers to the region of the nucleotide sequence comprising codons which are translated into amino acid residues. In another embodiment, the antisense nucleic acid molecule is antisense to a “noncoding region” of the coding strand of a nucleotide sequence of the invention. The term “noncoding region” refers to 5′ and 3′ sequences which flank the coding region that are not translated into amino acids (i.e., also referred to as 5′ and 3′ untranslated regions).  
       [0090] Given the coding strand sequences encoding a nucleic acid disclosed herein (e.g., SEQ ID NO: 1-739 , antisense nucleic acids of the invention can be designed according to the rules of Watson and Crick or Hoogsteen base pairing. The antisense nucleic acid molecule can be complementary to the entire coding region of a mRNA, but more preferably is an oligonucleotide that is antisense to only a portion of the coding or noncoding region of a mRNA. For example, the antisense oligonucleotide can be complementary to the region surrounding the translation start site of a mRNA. An antisense oligonucleotide can be, for example, about 5, 10, 15, 20, 25, 30, 35, 40, 45 or 50 nucleotides in length. An antisense nucleic acid of the invention can be constructed using chemical synthesis or enzymatic ligation reactions using procedures known in the art. For example, an antisense nucleic acid (e.g., an antisense oligonucleotide) can be chemically synthesized using naturally occurring nucleotides or variously modified nucleotides designed to increase the biological stability of the molecules or to increase the physical stability of the duplex formed between the antisense and sense nucleic acids, e.g., phosphorothioate derivatives and acridine substituted nucleotides can be used.  
       [0091] Examples of modified nucleotides that can be used to generate the antisense nucleic acid include: 5-fluorouracil, 5-bromouracil, 5-chlorouracil, 5-iodouracil, hypoxanthine, xanthine, 4-acetylcytosine, 5-(carboxyhydroxylmethyl) uracil, 5-carboxymethylaminomethyl-2-thiouridine, 5-carboxymethylaminomethyluracil, dihydrouracil, beta-D-galactosylqueosine, inosine, N6-isopentenyladenine, 1-methylguanine, 1-methylinosine, 2,2-dimethylguanine, 2-methyladenine, 2-methylguanine, 3-methylcytosine, 5-methylcytosine, N6-adenine, 7-methylguanine, 5-methylaminomethyluracil, 5-methoxyaminomethyl-2-thiouracil, beta-D-mannosylqueosine, 5′-methoxycarboxymethyluracil, 5-methoxyuracil, 2-methylthio-N6-isopentenyladenine, uracil-5-oxyacetic acid (v), wybutoxosine, pseudouracil, queosine, 2-thiocytosine, 5-methyl-2-thiouracil, 2-thiouracil, 4-thiouracil, 5-methyluracil, uracil-5-oxyacetic acid methylester, uracil-5-oxyacetic acid (v), 5-methyl-2-thiouracil, 3-(3-amino-3-N-2-carboxypropyl) uracil, (acp3)w, and 2,6-diaminopurine. Alternatively, the antisense nucleic acid can be produced biologically using an expression vector into which a nucleic acid has been subcloned in an antisense orientation (i.e., RNA transcribed from the inserted nucleic acid will be of an antisense orientation to a target nucleic acid of interest, described further in the following subsection).  
       [0092] The antisense nucleic acid molecules of the invention are typically administered to a subject or generated in situ such that they hybridize with or bind to cellular mRNA and/or genomic DNA encoding a protein according to the invention to thereby inhibit expression of the protein, e.g., by inhibiting transcription and/or translation. The hybridization can be by conventional nucleotide complementarity to form a stable duplex, or, for example, in the case of an antisense nucleic acid molecule that binds to DNA duplexes, through specific interactions in the major groove of the double helix. An example of a route of administration of antisense nucleic acid molecules of the invention includes direct injection at a tissue site. Alternatively, antisense nucleic acid molecules can be modified to target selected cells and then administered systemically. For example, for systemic administration, antisense molecules can be modified such that they specifically bind to receptors or antigens expressed on a selected cell surface, e.g., by linking the antisense nucleic acid molecules to peptides or antibodies that bind to cell surface receptors or antigens. The antisense nucleic acid molecules can also be delivered to cells using the vectors described herein. To achieve sufficient intracellular concentrations of antisense molecules, vector constructs in which the antisense nucleic acid molecule is placed under the control of a strong pol II or pol III promoter are preferred.  
       [0093] In yet another embodiment, the antisense nucleic acid molecule of the invention is an α-anomeric nucleic acid molecule. An α-anomeric nucleic acid molecule forms specific double-stranded hybrids with complementary RNA in which, contrary to the usual β-units, the strands run parallel to each other (Gaultier et al. (1987)  Nucleic Acids Res  15: 6625-6641). The antisense nucleic acid molecule can also comprise a 2′-o-methylribonucleotide (Inoue et al. (1987)  Nucleic Acids Res  15: 6131-6148) or a chimeric RNA-DNA analogue (Inoue et al. (1987)  FEBS Lett  215: 327-330).  
       4.4 RIBOZYMES AND PNA MOIETIES  
       [0094] In still another embodiment, an antisense nucleic acid of the invention is a ribozyme. Ribozymes are catalytic RNA molecules with ribonuclease activity that are capable of cleaving a single-stranded nucleic acid, such as a mRNA, to which they have a complementary region. Thus, ribozymes (e.g., hammerhead ribozymes (described in Haselhoff and Gerlach (1988)  Nature  334:585-591)) can be used to catalytically cleave a mRNA transcripts to thereby inhibit translation of a mRNA. A ribozyme having specificity for a nucleic acid of the invention can be designed based upon the nucleotide sequence of a DNA disclosed herein (i.e., SEQ ID NO: 1-739). For example, a derivative of a Tetrahymena L-19 IVS RNA can be constructed in which the nucleotide sequence of the active site is complementary to the nucleotide sequence to be cleaved in a SECX-encoding mRNA. See, e.g., Cech et al. U.S. Pat. No. 4,987,071; and Cech et al. U.S. Pat. No. 5,116,742. Alternatively, SECX mRNA can be used to select a catalytic RNA having a specific ribonuclease activity from a pool of RNA molecules. See, e.g., Bartel et al., (1993)  Science  261:1411-1418.  
       [0095] Alternatively, gene expression can be inhibited by targeting nucleotide sequences complementary to the regulatory region (e.g., promoter and/or enhancers) to form triple helical structures that prevent transcription of the gene in target cells. See generally, Helene. (1991)  Anticancer Drug Des.  6: 569-84; Helene. et al. (1992)  Ann. N.Y Acad. Sci.  660:27-36; and Maher (1992)  Bioassays  14: 807-15.  
       [0096] In various embodiments, the nucleic acids of the invention can be modified at the base moiety, sugar moiety or phosphate backbone to improve, e.g., the stability, hybridization, or solubility of the molecule. For example, the deoxyribose phosphate backbone of the nucleic acids can be modified to generate peptide nucleic acids (see Hyrup et al. (1996)  Bioorg Med Chem  4: 5-23). As used herein, the terms “peptide nucleic acids” or “PNAs” refer to nucleic acid mimics, e.g., DNA mimics, in which the deoxyribose phosphate backbone is replaced by a pseudopeptide backbone and only the four natural nucleobases are retained. The neutral backbone of PNAs has been shown to allow for specific hybridization to DNA and RNA under conditions of low ionic strength. The synthesis of PNA oligomers can be performed using standard solid phase peptide synthesis protocols as described in Hyrup et al. (1996) above; Perry-O&#39;Keefe et al. (1996)  PNAS  93: 14670-675.  
       [0097] PNAs of the invention can be used in therapeutic and diagnostic applications. For example, PNAs can be used as antisense or antigene agents for sequence-specific modulation of gene expression by, e.g., inducing transcription or translation arrest or inhibiting replication. PNAs of the invention can also be used, e.g., in the analysis of single base pair mutations in a gene by, e.g., PNA directed PCR clamping; as artificial restriction enzymes when used in combination with other enzymes, e.g., S1 nucleases (Hyrup B. (1996) above); or as probes or primers for DNA sequence and hybridization (Hyrup et al. (1996), above; Perry-O&#39;Keefe (1996), above).  
       [0098] In another embodiment, PNAs of the invention can be modified, e.g., to enhance. their stability or cellular uptake, by attaching lipophilic or other helper groups to PNA, by the formation of PNA-DNA chimeras, or by the use of liposomes or other techniques of drug delivery known in the art. For example, PNA-DNA chimeras can be generated that may combine the advantageous properties of PNA and DNA. Such chimeras allow DNA recognition enzymes, e.g., RNase H and DNA polymerases, to interact with the DNA portion while the PNA portion would provide high binding affinity and specificity. PNA-DNA chimeras can be linked using linkers of appropriate lengths selected in terms of base stacking, number of bonds between the nucleobases, and orientation (Hyrup (1996) above). The synthesis of PNA-DNA chimeras can be performed as described in Hyrup (1996) above and Finn et al. (1996)  Nucl Acids Res  24: 3357-63. For example, a DNA chain can be synthesized on a solid support using standard phosphoramidite coupling chemistry, and modified nucleoside analogs, e.g., 5′-(4-methoxytrityl)amino-5′-deoxy-thymidine phosphoramidite, can be used between the PNA and the 5′ end of DNA (Mag et al. (1989) Nucl Acid Res 17: 5973-88). PNA monomers are then coupled in a stepwise manner to produce a chimeric molecule with a 5′ PNA segment and a 3′ DNA segment (Finn et al. (1996) above). Alternatively, chimeric molecules can be synthesized with a 5′ DNA segment and a 3′ PNA segment. See, Petersen et al. (1975)  Bioorg Med Chem Lett  5: 1119-11124.  
       [0099] In other embodiments, the oligonucleotide may include other appended groups such as peptides (e.g., for targeting host cell receptors in vivo), or agents facilitating transport across the cell membrane (see, e.g., Letsinger et al., 1989,  Proc. Natl. Acad. Sci. U.S.A.  86:6553-6556; Lemaitre et al., 1987, Proc.  Natl. Acad. Sci.  84:648-652; PCT Publication No. W088/09810) or the blood-brain barrier (see, e.g., PCT Publication No. W089/10134). In addition, oligonucleotides can be modified with hybridization triggered cleavage agents (See, e.g., Krol et al., 1988,  BioTechniques  6:958-976) or intercalating agents. (See, e.g., Zon, 1988,  Pharm. Res.  5: 539-549). To this end, the oligonucleotide may be conjugated to another molecule, e.g., a peptide, a hybridization triggered cross-linking agent, a transport agent, a hybridization-triggered cleavage agent, etc.  
       4.5 HOSTS  
       [0100] The present invention further provides host cells genetically engineered to contain the polynucleotides of the invention. For example, such host cells may contain nucleic acids of the invention introduced into the host cell using known transformation, transfection or infection methods. The present invention still further provides host cells genetically engineered to express the polynucleotides of the invention, wherein such polynucleotides are in operative association with a regulatory sequence heterologous to the host cell which drives expression of the polynucleotides in the cell.  
       [0101] Knowledge of nucleic acid sequences allows for modification of cells to permit, or increase, expression of endogenous polypeptide. Cells can be modified (e.g., by homologous recombination) to provide increased polypeptide expression by replacing, in whole or in part, the naturally occurring promoter with all or part of a heterologous promoter so that the cells express the polypeptide at higher levels. The heterologous promoter is inserted in such a manner that it is operatively linked to the encoding sequences. See, for example, PCT International Publication No. WO94/12650, PCT International Publication No. WO92/20808, and PCT International Publication No. WO91/09955. It is also contemplated that, in addition to heterologous promoter DNA, amplifiable marker DNA (e.g., ada, dhfr, and the multifunctional CAD gene which encodes carbamyl phosphate synthase, aspartate transcarbamylase, and dihydroorotase) and/or intron DNA may be inserted along with the heterologous promoter DNA. If linked to the coding sequence, amplification of the marker DNA by standard selection methods results in co-amplification of the desired protein coding sequences in the cells.  
       [0102] The host cell can be a higher eukaryotic host cell, such as a mammalian cell, a lower eukaryotic host cell, such as a yeast cell, or the host cell can be a prokaryotic cell, such as a bacterial cell. Introduction of the recombinant construct into the host cell can be effected by calcium phosphate transfection, DEAE, dextran mediated transfection, or electroporation (Davis, L. et al.,  Basic Methods in Molecular Biology  (1986)). The host cells containing one of the polynucleotides of the invention, can be used in conventional manners to produce the gene product encoded by the isolated fragment (in the case of an ORF) or can be used to produce a heterologous protein under the control of the EMF.  
       [0103] Any host/vector system can be used to express one or more of the ORFs of the present invention. These include, but are not limited to, eukaryotic hosts such as HeLa cells, Cv-1 cell, COS cells, 293 cells, and Sf9 cells, as well as prokaryotic host such as  E. coli  and  B. subtilis . The most preferred cells are those which do not normally express the particular polypeptide or protein or which expresses the polypeptide or protein at low natural level. Mature proteins can be expressed in mammalian cells, yeast, bacteria, or other cells under the control of appropriate promoters. Cell-free translation systems can also be employed to produce such proteins using RNAs derived from the DNA constructs of the present invention. Appropriate cloning and expression vectors for use with prokaryotic and eukaryotic hosts are described by Sambrook, et al., in Molecular Cloning: A Laboratory Manual, Second Edition, Cold Spring Harbor, N.Y. (1989), the disclosure of which is hereby incorporated by reference.  
       [0104] Various mammalian cell culture systems can also be employed to express recombinant protein. Examples of mammalian expression systems include the COS-7 lines of monkey kidney fibroblasts, described by Gluzman, Cell 23:175 (1981). Other cell lines capable of expressing a compatible vector are, for example, the C127, monkey COS cells, Chinese Hamster Ovary (CHO) cells, human kidney 293 cells, human epidermal A431 cells, human Colo205 cells, 3T3 cells, CV-1 cells, other transformed primate cell lines, normal diploid cells, cell strains derived from in vitro culture of primary tissue, primary explants, HeLa cells, mouse L cells, BHK, HL-60, U937, HaK or Jurkat cells. Mammalian expression vectors will comprise an origin of replication, a suitable promoter and also any necessary ribosome binding sites, polyadenylation site, splice donor and acceptor sites, transcriptional termination sequences, and 5′ flanking nontranscribed sequences. DNA sequences derived from the SV40 viral genome, for example, SV40 origin, early promoter, enhancer, splice, and polyadenylation sites may be used to provide the required nontranscribed genetic elements. Recombinant polypeptides and proteins produced in bacterial culture are usually isolated by initial extraction from cell pellets, followed by one or more salting-out, aqueous ion exchange or size exclusion chromatography steps. Protein refolding steps can be used, as necessary, in completing configuration of the mature protein. Finally, high performance liquid chromatography (HPLC) can be employed for final purification steps. Microbial cells employed in expression of proteins can be disrupted by any convenient method, including freeze-thaw cycling, sonication, mechanical disruption, or use of cell lysing agents.  
       [0105] Alternatively, it may be possible to produce the protein in lower eukaryotes such as yeast or insects or in prokaryotes such as bacteria. Potentially suitable yeast strains include  Saccharomyces cerevisiae, Schizosaccharomyces pombe , Kluyveromyces strains, Candida, or any yeast strain capable of expressing heterologous proteins. Potentially suitable bacterial strains include  Escherichia coli, Bacillus subtilis, Salmonella typhimurium , or any bacterial strain capable of expressing heterologous proteins. If the protein is made in yeast or bacteria, it may be necessary to modify the protein produced therein, for example by phosphorylation or glycosylation of the appropriate sites, in order to obtain the functional protein. Such covalent attachments may be accomplished using known chemical or enzymatic methods.  
       [0106] In another embodiment of the present invention, cells and tissues may be engineered to express an endogenous gene comprising the polynucleotides of the invention under the control of inducible regulatory elements, in which case the regulatory sequences of the endogenous gene may be replaced by homologous recombination. As described herein, gene targeting can be used to replace a gene&#39;s existing regulatory region with a regulatory sequence isolated from a different gene or a novel regulatory sequence synthesized by genetic engineering methods. Such regulatory sequences may be comprised of promoters, enhancers, scaffold-attachment regions, negative regulatory elements, transcriptional initiation sites, regulatory protein binding sites or combinations of said sequences. Alternatively, sequences which affect the structure or stability of the RNA or protein produced may be replaced, removed, added, or otherwise modified by targeting. These sequence include polyadenylation signals, mRNA stability elements, splice sites, leader sequences for enhancing or modifying transport or secretion properties of the protein, or other sequences which alter or improve the function or stability of protein or RNA molecules.  
       [0107] The targeting event may be a simple insertion of the regulatory sequence, placing the gene under the control of the new regulatory sequence, e.g., inserting a new promoter or enhancer or both upstream of a gene. Alternatively, the targeting event may be a simple deletion of a regulatory element, such as the deletion of a tissue-specific negative regulatory element. Alternatively, the targeting event may replace an existing element; for example, a tissue-specific enhancer can be replaced by an enhancer that has broader or different cell-type specificity than the naturally occurring elements. Here, the naturally occurring sequences are deleted and new sequences are added. In all cases, the identification of the targeting event may be facilitated by the use of one or more selectable marker genes that are contiguous with the targeting DNA, allowing for the selection of cells in which the exogenous DNA has integrated into the host cell genome. The identification of the targeting event may also be facilitated by the use of one or more marker genes exhibiting the property of negative selection, such that the negatively selectable marker is linked to the exogenous DNA, but configured such that the negatively selectable marker flanks the targeting sequence, and such that a correct homologous recombination event with sequences in the host cell genome does not result in the stable integration of the negatively selectable marker. Markers useful for this purpose include the Herpes Simplex Virus thymidine kinase (TK) gene or the bacterial xanthine-guanine phosphoribosyl-transferase (gpt) gene.  
       [0108] The gene targeting or gene activation techniques which can be used in accordance with this aspect of the invention are more particularly described in U.S. Pat. No. 5,272,071 to Chappel; U.S. Pat. No. 5,578,461 to Sherwin et al.; International Application No. PCT/US92/09627 (WO93/09222) by Selden et al.; and International Application No. PCT/US90/06436 (WO91/06667) by Skoultchi et al., each of which is incorporated by reference herein in its entirety.  
       4.6 POLYPEPTIDES OF THE INVENTION  
       [0109] The isolated polypeptides of the invention include, but are not limited to, a polypeptide comprising: the amino acid sequences set forth as any one of SEQ ID NO: 740-1478 or an amino acid sequence encoded by any one of the nucleotide sequences SEQ ID NO: 1-739 or the corresponding full length or mature protein. Polypeptides of the invention also include polypeptides preferably with biological or immunological activity that are encoded by: (a) a polynucleotide having any one of the nucleotide sequences set forth in SEQ ID NO: 1-739 or (b) polynucleotides encoding any one of the amino acid sequences set forth as SEQ ID NO: 740-1478 or (c) polynucleotides that hybridize to the complement of the polynucleotides of either (a) or (b) under stringent hybridization conditions. The invention also provides biologically active or immunologically active variants of any of the amino acid sequences set forth as SEQ ID NO: 740-1478 or the corresponding full length or mature protein; and “substantial equivalents” thereof (e.g., with at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, typically at least about 95%, more typically at least about 98%, or most typically at least about 99% amino acid identity) that retain biological activity. Polypeptides encoded by allelic variants may have a similar, increased, or decreased activity compared to polypeptides comprising SEQ ID NO: 740-1478.  
       [0110] Fragments of the proteins of the present invention which are capable of exhibiting biological activity are also encompassed by the present invention. Fragments of the protein may be in linear form or they may be cyclized using known methods, for example, as described in H. U. Saragovi, et al., Bio/Technology 10, 773-778 (1992) and in R. S. McDowell, et al., J. Amer. Chem. Soc. 114, 9245-9253 (1992), both of which are incorporated herein by reference. Such fragments may be fused to carrier molecules such as immunoglobulins for many purposes, including increasing the valency of protein binding sites.  
       [0111] The present invention also provides both full-length and mature forms (for example, without a signal sequence or precursor sequence) of the disclosed proteins. The protein coding sequence is identified in the sequence listing by translation of the disclosed nucleotide sequences. The mature form of such protein may be obtained by expression of a full-length polynucleotide in a suitable mammalian cell or other host cell. The sequence of the mature form of the protein is also determinable from the amino acid sequence of the full-length form. Where proteins of the present invention are membrane bound, soluble forms of the proteins are also provided. In such forms, part or all of the regions causing the proteins to be membrane bound are deleted so that the proteins are fully secreted from the cell in which they are expressed.  
       [0112] Protein compositions of the present invention may further comprise an acceptable carrier, such as a hydrophilic, e.g., pharmaceutically acceptable, carrier.  
       [0113] The present invention further provides isolated polypeptides encoded by the nucleic acid fragments of the present invention or by degenerate variants of the nucleic acid fragments of the present invention. By “degenerate variant” is intended nucleotide fragments which differ from a nucleic acid fragment of the present invention (e.g., an ORF) by nucleotide sequence but, due to the degeneracy of the genetic code, encode an identical polypeptide sequence. Preferred nucleic acid fragments of the present invention are the ORFs that encode proteins.  
       [0114] A variety of methodologies known in the art can be utilized to obtain any one of the isolated polypeptides or proteins of the present invention. At the simplest level, the amino acid sequence can be synthesized using commercially available peptide synthesizers. The synthetically-constructed protein sequences, by virtue of sharing primary, secondary or tertiary structural and/or conformational characteristics with proteins may possess biological properties in common therewith, including protein activity. This technique is particularly useful in producing small peptides and fragments of larger polypeptides. Fragments are useful, for example, in generating antibodies against the native polypeptide. Thus, they may be employed as biologically active or immunological substitutes for natural, purified proteins in screening of therapeutic compounds and in immunological processes for the development of antibodies.  
       [0115] The polypeptides and proteins of the present invention can alternatively be purified from cells which have been altered to express the desired polypeptide or protein. As used herein, a cell is said to be altered to express a desired polypeptide or protein when the cell, through genetic manipulation, is made to produce a polypeptide or protein which it normally does not produce or which the cell normally produces at a lower level. One skilled in the art can readily adapt procedures for introducing and expressing either recombinant or synthetic sequences into eukaryotic or prokaryotic cells in order to generate a cell which produces one of the polypeptides or proteins of the present invention.  
       [0116] The invention also relates to methods for producing a polypeptide comprising growing a culture of host cells of the invention in a suitable culture medium, and purifying the protein from the cells or the culture in which the cells are grown. For example, the methods of the invention include a process for producing a polypeptide in which a host cell containing a suitable expression vector that includes a polynucleotide of the invention is cultured under conditions that allow expression of the encoded polypeptide. The polypeptide can be recovered from the culture, conveniently from the culture medium, or from a lysate prepared from the host cells and further purified. Preferred embodiments include those in which the protein produced by such process is a full length or mature form of the protein.  
       [0117] In an alternative method, the polypeptide or protein is purified from bacterial cells which naturally produce the polypeptide or protein. One skilled in the art can readily follow known methods for isolating polypeptides and proteins in order to obtain one of the isolated polypeptides or proteins of the present invention. These include, but are not limited to, immunochromatography, HPLC, size-exclusion chromatography, ion-exchange chromatography, and immuno-affinity chromatography. See, e.g., Scopes,  Protein Purification: Principles and Practice , Springer-Verlag (1994); Sambrook, et al., in Molecular Cloning:  A Laboratory Manual ; Ausubel et al.,  Current Protocols in Molecular Biology . Polypeptide fragments that retain biological/immunological activity include fragments comprising greater than about 100 amino acids, or greater than about 200 amino acids, and fragments that encode specific protein domains.  
       [0118] The purified polypeptides can be used in in vitro binding assays which are well known in the art to identify molecules which bind to the polypeptides. These molecules include but are not limited to, for e.g., small molecules, molecules from combinatorial libraries, antibodies or other proteins. The molecules identified in the binding assay are then tested for antagonist or agonist activity in in vivo tissue culture or animal models that are well known in the art. In brief, the molecules are titrated into a plurality of cell cultures or animals and then tested for either cell/animal death or prolonged survival of the animal/cells.  
       [0119] In addition, the peptides of the invention or molecules capable of binding to the peptides may be complexed with toxins, e.g., ricin or cholera, or with other compounds that are toxic to cells. The toxin-binding molecule complex is then targeted to a tumor or other cell by the specificity of the binding molecule for SEQ ID NO: 740-1478.  
       [0120] The protein of the invention may also be expressed as a product of transgenic animals, e.g., as a component of the milk of transgenic cows, goats, pigs, or sheep which are characterized by somatic or germ cells containing a nucleotide sequence encoding the protein.  
       [0121] The proteins provided herein also include proteins characterized by amino acid sequences similar to those of purified proteins but into which modification are naturally provided or deliberately engineered. For example, modifications, in the peptide or DNA sequence, can be made by those skilled in the art using known techniques. Modifications of interest in the protein sequences may include the alteration, substitution, replacement, insertion or deletion of a selected amino acid residue in the coding sequence. For example, one or more of the cysteine residues may be deleted or replaced with another amino acid to alter the conformation of the molecule. Techniques for such alteration, substitution, replacement, insertion or deletion are well known to those skilled in the art (see, e.g., U.S. Pat. No. 4,518,584). Preferably, such alteration, substitution, replacement, insertion or deletion retains the desired activity of the protein. Regions of the protein that are important for the protein function can be determined by various methods known in the art including the alanine-scanning method which involved systematic substitution of single or strings of amino acids with alanine, followed by testing the resulting alanine-containing variant for biological activity. This type of analysis determines the importance of the substituted amino acid(s) in biological activity. Regions of the protein that are important for protein function may be determined by the eMATRIX program.  
       [0122] Other fragments and derivatives of the sequences of proteins which would be expected to retain protein activity in whole or in part and are useful for screening or other immunological methodologies may also be easily made by those skilled in the art given the disclosures herein. Such modifications are encompassed by the present invention.  
       [0123] The protein may also be produced by operably linking the isolated polynucleotide of the invention to suitable control sequences in one or more insect expression vectors, and employing an insect expression system. Materials and methods for baculovirus/insect cell expression systems are commercially available in kit form from, e.g., Invitrogen, San Diego, Calif., U.S.A. (the MaxBat™ kit), and such methods are well known in the art, as described in Summers and Smith, Texas Agricultural Experiment Station Bulletin No. 1555 (1987), incorporated herein by reference. As used herein, an insect cell capable of expressing a polynucleotide of the present invention is “transformed.” 
       [0124] The protein of the invention may be prepared by culturing transformed host cells under culture conditions suitable to express the recombinant protein. The resulting expressed protein may then be purified from such culture (i.e., from culture medium or cell extracts) using known purification processes, such as gel filtration and ion exchange chromatography. The purification of the protein may also include an affinity column containing agents which will bind to the protein; one or more column steps over such affinity resins as concanavalin A-agarose, heparin-toyopearl™ or Cibacrom blue 3GA Sepharose™; one or more steps involving hydrophobic interaction chromatography using such resins as phenyl ether, butyl ether, or propyl ether; or immunoaffinity chromatography.  
       [0125] Alternatively, the protein of the invention may also be expressed in a form which will facilitate purification. For example, it may be expressed as a fusion protein, such as those of maltose binding protein (MBP), glutathione-S-transferase (GST) or thioredoxin (TRX), or as a His tag. Kits for expression and purification of such fusion proteins are commercially available from New England BioLab (Beverly, Mass.), Pharmacia (Piscataway, N.J.) and Invitrogen, respectively. The protein can also be tagged with an epitope and subsequently purified by using a specific antibody directed to such epitope. One such epitope (“FLAG®”) is commercially available from Kodak (New Haven, Conn.).  
       [0126] Finally, one or more reverse-phase high performance liquid chromatography (RP-HPLC) steps employing hydrophobic RP-HPLC media, e.g., silica gel having pendant methyl or other aliphatic groups, can be employed to further purify the protein. Some or all of the foregoing purification steps, in various combinations, can also be employed to provide a substantially homogeneous isolated recombinant protein. The protein thus purified is substantially free of other mammalian proteins and is defined in accordance with the present invention as an “isolated protein.” 
       [0127] The polypeptides of the invention include analogs (variants). This embraces fragments, as well as peptides in which one or more amino acids has been deleted, inserted, or substituted. Also, analogs of the polypeptides of the invention embrace fusions of the polypeptides or modifications of the polypeptides of the invention, wherein the polypeptide or analog is fused to another moiety or moieties, e.g., targeting moiety or another therapeutic agent. Such analogs may exhibit improved properties such as activity and/or stability. Examples of moieties which may be fused to the polypeptide or an analog include, for example, targeting moieties which provide for the delivery of polypeptide to pancreatic cells, e.g., antibodies to pancreatic cells, antibodies to immune cells such as T-cells, monocytes, dendritic cells, granulocytes, etc., as well as receptor and ligands expressed on pancreatic or immune cells. Other moieties which may be fused to the polypeptide include therapeutic agents which are used for treatment, for example, immunosuppressive drugs such as cyclosporin, SK506, azathioprine, CD3 antibodies and steroids. Also, polypeptides may be fused to immune modulators, and other cytokines such as alpha or beta interferon.  
       4.6.1 DETERMINING POLYPEPTIDE AND POLYNUCLEOTIDE IDENTITY AND SIMILARITY  
       [0128] Preferred identity and/or similarity are designed to give the largest match between the sequences tested. Methods to determine identity and similarity are codified in computer programs including, but are not limited to, the GCG program package, including GAP (Devereux, J., et al., Nucleic Acids Research 12(1):387 (1984); Genetics Computer Group, University of Wisconsin, Madison, Wis.), BLASTP, BLASTN, BLASTX, FASTA (Altschul, S. F. et al., J. Molec. Biol. 215:403-410 (1990), PSI-BLAST Altschul S. F. et al., Nucleic Acids Res. vol. 25, pp. 3389-3402, herein incorporated by eference), eMatrix software (Wu et al., J. Comp. Biol., Vol. 6, pp. 219-235 (1999), wherein incorporated by reference), eMotif software (Nevill-Manning et al, ISMB-97, Vol. 4, pp. 202-209, herein incorporated by reference), pFam software (Sonnhammer et al., Nucleic Acids Res., Vol. 26(1), pp. 320-322 (1998), herein incorporated by reference) and the Kyte-Doolittle hydrophobocity prediction algorithm (J. Mol Biol, 157, pp. 105-31 (1982), incorporated herein by reference). The BLAST programs are publicly available from the National Center for Biotechnology Information (NCBI) and other sources (BLAST Manual, Altschul, S., et al. NCB NLM NIH Bethesda, Md. 20894; Altschul, S., et al., J. Mol. Biol. 215:403-410 (1990).  
       4.7 CHIMERIC AND FUSION PROTEINS  
       [0129] The invention also provides chimeric or fusion proteins. As used herein, a “chimeric protein” or “fusion protein” comprises a polypeptide of the invention operatively linked to another polypeptide. Within a fusion protein the polypeptide according to the invention can correspond to all or a portion of a protein according to the invention. In one embodiment, a fusion protein comprises at least one biologically active portion of a protein according to the invention. In another embodiment, a fusion protein comprises at least two biologically active portions of a protein according to the invention. Within the fusion protein, the term “operatively linked” is intended to indicate that the polypeptide according to the invention and the other polypeptide are fused in-frame to each other. The polypeptide can be fused to the N-terminus or C-terminus.  
       [0130] For example, in one embodiment a fusion protein comprises a polypeptide according to the invention operably linked to the extracellular domain of a second protein.  
       [0131] In another embodiment, the fusion protein is a GST-fusion protein in which the polypeptide sequences of the invention are fused to the C-terminus of the GST (i.e., glutathione S-transferase) sequences.  
       [0132] In another embodiment, the fusion protein is an immunoglobulin fusion protein in which the polypeptide sequences according to the invention comprises one or more domains are fused to sequences derived from a member of the immunoglobulin protein family. The immunoglobulin fusion proteins of the invention can be incorporated into pharmaceutical compositions and administered to a subject to inhibit an interaction between a ligand and a protein of the invention on the surface of a cell, to thereby suppress signal transduction in vivo. The immunoglobulin fusion proteins can be used to affect the bioavailability of a cognate ligand. Inhibition of the ligand/protein interaction may be useful therapeutically for both the treatment of proliferative and differentiative disorders, e,g., cancer as well as modulating (e.g., promoting or inhibiting) cell survival. Moreover, the immunoglobulin fusion proteins of the invention can be used as immunogens to produce antibodies in a subject, to purify ligands, and in screening assays to identify molecules that inhibit the interaction of a polypeptide of the invention with a ligand.  
       [0133] A chimeric or fusion protein of the invention can be produced by standard recombinant DNA techniques. For example, DNA fragments coding for the different polypeptide sequences are ligated together in-frame in accordance with conventional techniques, e.g., by employing blunt-ended or stagger-ended termini for ligation, restriction enzyme digestion to provide for appropriate termini, filling-in of cohesive ends as appropriate, alkaline phosphatase treatment to avoid undesirable joining, and enzymatic ligation. In another embodiment, the fusion gene can be synthesized by conventional techniques including automated DNA synthesizers. Alternatively, PCR amplification of gene fragments can be carried out using anchor primers that give rise to complementary overhangs between two consecutive gene fragments that can subsequently be annealed and reamplified to generate a chimeric gene sequence (see, for example, Ausubel et al. (eds.) CURRENT PROTOCOLS IN MOLECULAR BIOLOGY, John Wiley &amp; Sons, 1992). Moreover, many expression vectors are commercially available that already encode a fusion moiety (e.g., a GST polypeptide). A nucleic acid encoding a polypeptide of the invention can be cloned into such an expression vector such that the fusion moiety is linked in-frame to the protein of the invention.  
       4.8 GENE THERAPY  
       [0134] Mutations in the polynucleotides of the invention gene may result in loss of normal function of the encoded protein. The invention thus provides gene therapy to restore normal activity of the polypeptides of the invention; or to treat disease states involving polypeptides of the invention. Delivery of a functional gene encoding polypeptides of the invention to appropriate cells is effected ex vivo, in situ, or in vivo by use of vectors, and more particularly viral vectors (e.g., adenovirus, adeno-associated virus, or a retrovirus), or ex vivo by use of physical DNA transfer methods (e.g., liposomes or chemical treatments). See, for example, Anderson, Nature, supplement to vol.392, no. 6679, pp.25-20 (1998). For additional reviews of gene therapy technology see Friedmann, Science, 244: 1275-1281 (1989); Verma, Scientific American: 68-84 (1990); and Miller, Nature, 357: 455460 (1992). Introduction of any one of the nucleotides of the present invention or a gene encoding the polypeptides of the present invention can also be accomplished with extrachromosomal substrates (transient expression) or artificial chromosomes (stable expression). Cells may also be cultured ex vivo in the presence of proteins of the present invention in order to proliferate or to produce a desired effect on or activity in such cells. Treated cells can then be introduced in vivo for therapeutic purposes. Alternatively, it is contemplated that in other human disease states, preventing the expression of or inhibiting the activity of polypeptides of the invention will be useful in treating the disease states. It is contemplated that antisense therapy or gene therapy could be applied to negatively regulate the expression of polypeptides of the invention.  
       [0135] Other methods inhibiting expression of a protein include the introduction of antisense molecules to the nucleic acids of the present invention, their complements, or their translated RNA sequences, by methods known in the art. Further, the polypeptides of the present invention can be inhibited by using targeted deletion methods, or the insertion of a negative regulatory element such as a silencer, which is tissue specific.  
       [0136] The present invention still further provides cells genetically engineered in vivo to express the polynucleotides of the invention, wherein such polynucleotides are in operative association with a regulatory sequence heterologous to the host cell which drives expression of the polynucleotides in the cell. These methods can be used to increase or decrease the expression of the polynucleotides of the present invention.  
       [0137] Knowledge of DNA sequences provided by the invention allows for modification of cells to permit, increase, or decrease, expression of endogenous polypeptide. Cells can be modified (e.g., by homologous recombination) to provide increased polypeptide expression by replacing, in whole or in part, the naturally occurring promoter with all or part of a heterologous promoter so that the cells express the protein at higher levels. The heterologous promoter is inserted in such a manner that it is operatively linked to the desired protein encoding sequences. See, for example, PCT International Publication No. WO 94/12650, PCT International Publication No. WO 92/20808, and PCT International Publication No. WO 91/09955. It is also contemplated that, in addition to heterologous promoter DNA, amplifiable marker DNA (e.g., ada, dhfr, and the multifunctional CAD gene which encodes carbamyl phosphate synthase, aspartate transcarbamylase, and dihydroorotase) and/or intron DNA may be inserted along with the heterologous promoter DNA. If linked to the desired protein coding sequence, amplification of the marker DNA by standard selection methods results in co-amplification of the desired protein coding sequences in the cells.  
       [0138] In another embodiment of the present invention, cells and tissues may be engineered to express an endogenous gene comprising the polynucleotides of the invention under the control of inducible regulatory elements, in which case the regulatory sequences of the endogenous gene may be replaced by homologous recombination. As described herein, gene targeting can be used to replace a gene&#39;s existing regulatory region with a regulatory sequence isolated from a different gene or a novel regulatory sequence synthesized by genetic engineering methods. Such regulatory sequences may be comprised of promoters, enhancers, scaffold-attachment regions, negative regulatory elements, transcriptional initiation sites, regulatory protein binding sites or combinations of said sequences. Alternatively, sequences which affect the structure or stability of the RNA or protein produced may be replaced, removed, added, or otherwise modified by targeting. These sequences include polyadenylation signals, mRNA stability elements, splice sites, leader sequences for enhancing or modifying transport or secretion properties of the protein, or other sequences which alter or improve the function or stability of protein or RNA molecules.  
       [0139] The targeting event may be a simple insertion of the regulatory sequence, placing the gene under the control of the new regulatory sequence, erg., inserting a new promoter or enhancer or both upstream of a gene. Alternatively, the targeting event may be a simple deletion of a regulatory element, such as the deletion of a tissue-specific negative regulatory element. Alternatively,the targeting event may replace an existing element; for example, a tissue-specific enhancer can be replaced by an enhancer that has broader or different cell-type specificity than the naturally occurring elements. Here, the naturally occurring sequences are deleted and new sequences are added. In all cases, the identification of the targeting event may be facilitated by the use of one or more selectable marker genes that are contiguous with the targeting DNA, allowing for the selection of cells in which the exogenous DNA has integrated into the cell genome. The identification of the targeting event may also be facilitated by the use of one or more marker genes exhibiting the property of negative selection, such that the negatively selectable marker is linked to the exogenous DNA, but configured such that the negatively selectable marker flanks the targeting sequence, and such that a correct homologous recombination event with sequences in the host cell genome does not result in the stable integration of the negatively selectable marker. Markers useful for this purpose include the Herpes Simplex Virus thymidine kinase (TK) gene or the bacterial xanthine-guanine phosphoribosyl-transferase (gpt) gene.  
       [0140] The gene targeting or gene activation techniques which can be used in accordance with this aspect of the invention are more particularly described in U.S. Pat. No. 5,272,071 to Chappel; U.S. Pat. No. 5,578,461 to Sherwin et al.; International Application No. PCT/US92/09627 (WO93/09222) by Selden et al.; and International Application No. PCT/US90/06436 (WO91/06667) by Skoultchi et al., each of which is incorporated by reference herein in its entirety.  
       4.9 TRANSGENIC ANIMALS  
       [0141] In preferred methods to determine biological functions of the polypeptides of the invention in vivo, one or more genes provided by the invention are either over expressed or inactivated in the germ line of animals using homologous recombination [Capecchi, Science 244:1288-1292 (1989)]. Animals in which the gene is over expressed, under the regulatory control of exogenous or endogenous promoter elements, are known as transgenic animals. Animals in which an endogenous gene has been inactivated by homologous recombination are referred to as “knockout” animals. Knockout animals, preferably non-human mammals, can be prepared as described in U.S. Pat. No. 5,557,032, incorporated herein by reference. Transgenic animals are useful to determine the roles polypeptides of the invention play in biological processes, and preferably in disease states. Transgenic animals are useful as model systems to identify compounds that modulate lipid metabolism. Transgenic animals, preferably non-human mammals, are produced using methods as described in U.S. Pat. No 5,489,743 and PCT Publication No. WO94/28122, incorporated herein by reference.  
       [0142] Transgenic animals can be prepared wherein all or part of a promoter of the polynucleotides of the invention is either activated or inactivated to alter the level of expression of the polypeptides of the invention. Inactivation can be carried out using homologous recombination methods described above. Activation can be achieved by supplementing or even replacing the homologous promoter to provide for increased protein expression. The homologous promoter can be supplemented by insertion of one or more heterologous enhancer elements known to confer promoter activation in a particular tissue.  
       [0143] The polynucleotides of the present invention also make possible the development, through, e.g., homologous recombination or knock out strategies, of animals that fail to express polypeptides of the invention or that express a variant polypeptide. Such animals are useful as models for studying the in vivo activities of polypeptide as well as for studying modulators of the polypeptides of the invention.  
       [0144] In preferred methods to determine biological functions of the polypeptides of the invention in vivo, one or more genes provided by the invention are either over expressed or inactivated in the germ line of animals using homologous recombination [Capecchi, Science 244:1288-1292 (1989)). Animals in which the gene is over expressed, under the regulatory control of exogenous or endogenous promoter elements, are known as transgenic animals. Animals in which an endogenous gene has been inactivated by homologous recombination are referred to as “knockout” animals. Knockout animals, preferably non-human mammals, can be prepared as described in U.S. Pat. No. 5,557,032, incorporated herein by reference. Transgenic animals are useful to determine the roles polypeptides of the invention play in biological processes, and preferably in disease states. Transgenic animals are useful as model systems to identify compounds that modulate lipid metabolism. Transgenic animals, preferably non-human mammals, are produced using methods as described in U.S. Pat. No 5,489,743 and PCT Publication No. WO94/28122, incorporated herein by reference.  
       [0145] Transgenic animals can be prepared wherein all or part of the polynucleotides of the invention promoter is either activated or inactivated to alter the level of expression of the polypeptides of the invention. Inactivation can be carried out using homologous recombination methods described above. Activation can be achieved by supplementing or even replacing the homologous promoter to provide for increased protein expression. The homologous promoter can be supplemented by insertion of one or more heterologous enhancer elements known to confer promoter activation in a particular tissue.  
       4.10 USES AND BIOLOGICAL ACTIVITY  
       [0146] The polynucleotides and proteins of the present invention are expected to exhibit one or more of the uses or biological activities (including those associated with assays cited herein) identified herein. Uses or activities described for proteins of the present invention may be provided by administration or use of such proteins or of polynucleotides encoding such proteins (such as, for example, in gene therapies or vectors suitable for introduction of DNA). The mechanism underlying the particular condition or pathology will dictate whether the polypeptides of the invention, the polynucleotides of the invention or modulators (activators or inhibitors) thereof would be beneficial to the subject in need of treatment. Thus, “therapeutic compositions of the invention” include compositions comprising isolated polynucleotides (including recombinant DNA molecules, cloned genes and degenerate variants thereof) or polypeptides of the invention (including full length protein, mature protein and truncations or domains thereof), or compounds and other substances that modulate the overall activity of the target gene products, either at the level of target gene/protein expression or target protein activity. Such modulators include polypeptides, analogs, (variants), including fragments and fusion proteins, antibodies and other binding proteins; chemical compounds that directly or indirectly activate or inhibit the polypeptides of the invention (identified, e.g., via drug screening assays as described herein); antisense polynucleotides and polynucleotides suitable for triple helix formation; and in particular antibodies or other binding partners that specifically recognize one or more epitopes of the polypeptides of the invention.  
       [0147] The polypeptides of the present invention may likewise be involved in cellular activation or in one of the other physiological pathways described herein.  
       4.10.1 RESEARCH USES AND UTILITIES  
       [0148] The polynucleotides provided by the present invention can be used by the research community for various purposes. The polynucleotides can be used to express recombinant protein for analysis, characterization or therapeutic use; as markers for tissues in which the corresponding protein is preferentially expressed (either constitutively or at a particular stage of tissue differentiation or development or in disease states); as molecular weight markers on gels; as chromosome markers or tags (when labeled) to identify chromosomes or to map related gene positions; to compare with endogenous DNA sequences in patients to identify potential genetic disorders; as probes to hybridize and thus discover novel, related DNA sequences; as a source of information to derive PCR primers for genetic fingerprinting; as a probe to “subtract-out” known sequences in the process of discovering other novel polynucleotides; for selecting and making oligomers for attachment to a “gene chip” or other support, including for examination of expression patterns; to raise anti-protein antibodies using DNA immunization techniques; and as an antigen to raise anti-DNA antibodies or elicit another immune response. Where the polynucleotide encodes a protein which binds or potentially binds to another protein (such as, for example, in a receptor-ligand interaction), the polynucleotide can also be used in interaction trap assays (such as, for example, that described in Gyuris et al., Cell 75:791-803 (1993)) to identify polynucleotides encoding the other protein with which binding occurs or to identify inhibitors of the binding interaction.  
       [0149] The polypeptides provided by the present invention can similarly be used in assays to determine biological activity, including in a panel of multiple proteins for high-throughput screening; to raise antibodies or to elicit another immune response; as a reagent (including the labeled reagent) in assays designed to quantitatively determine levels of the protein (or its receptor) in biological fluids; as markers for tissues in which the corresponding polypeptide is preferentially expressed (either constitutively or at a particular stage of tissue differentiation or development or in a disease state); and, of course, to isolate correlative receptors or ligands. Proteins involved in these binding interactions can also be used to screen for peptide or small molecule inhibitors or ago: of the binding interaction.  
       [0150] Any or all of these research utilities are capable of being developed into reager grade or kit format for commercialization as research products.  
       [0151] Methods for performing the uses listed above are well known to those skilled ii the art. References disclosing such methods include without limitation “Molecular Cloning: A Laboratory Manual”, 2d ed., Cold Spring Harbor Laboratory Press, Sambrook, J., E. F. Fritsch and T. Maniatis eds., 1989, and “Methods in Enzymology: Guide to Molecular Cloning Techniques”, Academic Press, Berger, S. L. and A. R. Kimmel eds., 1987.  
       4.10.2 NUTRITIONAL USES  
       [0152] Polynucleotides and polypeptides of the present invention can also be used as nutritional sources or supplements. Such uses include without limitation use as a protein or amino acid supplement, use as a carbon source, use as a nitrogen source and use as a source of carbohydrate. In such cases the polypeptide or polynucleotide of the invention can be added to the feed of a particular organism or can be administered as a separate solid or liquid preparation, such as in the form of powder, pills, solutions, suspensions or capsules. In the case of microorganisms,the polypeptide or polynucleotide of the invention can be added to the medium in or on which the microorganism is cultured.  
       4.10.3 CYTOKINE AND CELL PROLIFERATION/DIFFERENTIATION ACTIVITY  
       [0153] A polypeptide of the present invention may exhibit activity relating to cytokine, cell proliferation (either inducing or inhibiting) or cell differentiation (either inducing or inhibiting) activity or may induce production of other cytokines in certain cell populations. A polynucleotide of the invention can encode a polypeptide exhibiting such attributes. Many protein factors discovered to date, including all known cytokines, have exhibited activity in one or more factor-dependent cell proliferation assays, and hence the assays serve as a convenient confirmation of cytokine activity. The activity of therapeutic compositions of the present invention is evidenced by any one of a number of routine factor dependent cell proliferation assays for cell lines including, without limitation, 32D, DA2, DA1G, T10, B9, B9/11, BaF3, MC9/G, M+(preB M+), 2E8, RB5, DA1, 123, T1165, HT2, CTLL2, TF-1, Mo7e, CMK, HUVEC, and Caco. Therapeutic compositions of the invention can be used in the following:  
       [0154] Assays for T-cell or thymocyte proliferation include without limitation those described in: Current Protocols in Immunology, Ed by J. E. Coligan, A. M. Kruisbeek, D. H. Margulies, E. M. Shevach, W. Strober, Pub. Greene Publishing Associates and Wiley-Interscience (Chapter 3, In Vitro assays for Mouse Lymphocyte Function 3.1-3.19; Chapter 7, Immunologic studies in Humans); Takai et al., J. Immunol. 137:3494-3500, 1986; Bertagnolli et al., J. Immunol. 145:1706-1712, 1990; Bertagnolli et al., Cellular Immunology 133:327-341, 1991; Bertagnolli, et al., I. Immunol. 149:3778-3783, 1992; Bowman et al., I. Immunol. 152:1756-1761, 1994.  
       [0155] Assays for cytokine production and/or proliferation of spleen cells, lymph node cells or thymocytes include, without limitation, those described in: Polyclonal T cell stimulation, Kruisbeek, A. M. and Shevach, E. M. In Current Protocols in Immunology. J. E. e.a. Coligan eds. Vol 1 pp. 3.12.1-3.12.14, John Wiley and Sons, Toronto. 1994; and Measurement of mouse and human interleukin-y, Schreiber, R. D. In Current Protocols in Immunology. J. E. e.a. Coligan eds. Vol 1 pp. 6.8.1-6.8.8, John Wiley and Sons, Toronto. 1994.  
       [0156] Assays for proliferation and differentiation of hematopoietic and lymphopoietic cells include, without limitation, those described in: Measurement of Human and Murine Interleukin 2 and Interleukin 4, Bottomly, K., Davis, L. S. and Lipsky, P. E. In Current Protocols in Immunology. J. E. e.a Coligan eds. Vol 1 pp. 6.3.1-6.3.12, John Wiley and Sons, Toronto. 1991; deVries et al., J. Exp. Med. 173:1205-1211, 1991; Moreau et al., Nature 336:690-692, 1988; Greenberger et al., Proc. Nati. Acad. Sci. U.S.A. 80:2931-2938, 1983; Measurement of mouse and human interleukin 6—Nordan, R. In Current Protocols in Immunology. J. E. Coligan eds. Vol 1 pp. 6.6.1-6.6.5, John Wiley and Sons, Toronto. 1991; Smith et al., Proc. Natl. Aced. Sci. U.S.A. 83:1857-1861, 1986; Measurement of human Interleukin 11—Bennett, F., Giannotti, J., Clark, S. C. and Turner, K. J. In Current Protocols in Immunology. J. E. Coligan eds. Vol 1 pp. 6.15.1 John Wiley and Sons, Toronto. 1991; Measurement of mouse and human Interleukin 9—Ciarletta, A., Giannotti, J., Clark, S. C. and Turner, K. J. In Current Protocols in Immunology. J. E. Coligan eds. Vol 1 pp. 6.13.1, John Wiley and Sons, Toronto. 1991.  
       [0157] Assays for T-cell clone responses to antigens (which will identify, among others, proteins that affect APC-T cell interactions as well as direct T-cell effects by measuring proliferation and cytokine production) include, without limitation, those described in: Current Protocols in Immunology, Ed by J. E. Coligan, A. M. Kruisbeek, D. H. Margulies, E. M. Shevach, W Strober, Pub. Greene Publishing Associates and Wiley-Interscience (Chapter 3, In Vitro assays for Mouse Lymphocyte Function; Chapter 6, Cytokines and their cellular receptors; Chapter 7, Immunologic studies in Humans); Weinberger et al., Proc. Natl. Acad. Sci. USA 77:6091-6095, 1980; Weinberger et al., Eur. J. Immun. 11:405-411, 1981; Takai et al., J. Immunol. 137:3494-3500, 1986; Takai et al., J. Immunol. 140:508-512, 1988.  
       4.10.4 STEM CELL GROWTH FACTOR ACTIVITY  
       [0158] A polypeptide of the present invention may exhibit stem cell growth factor activity and be involved in the proliferation, differentiation and survival of pluripotent and totipotent stem cells including primordial germ cells, embryonic stem cells, hematopoietic stem cells and/or germ line stem cells. Administration of the polypeptide of the invention to stem cells in vivo or ex vivo is expected to maintain and expand cell populations in a totipotential or pluripotential state which would be useful for re-engineering damaged or diseased tissues, transplantation, manufacture of bio-pharmaceuticals and the development of bio-sensors. The ability to produce large quantities of human cells has important working applications for the production of human proteins which currently must be obtained from non-human sources or donors, implantation of cells to treat diseases such as Parkinson&#39;s, AIzheimer&#39;s and other neurodegenerative diseases; tissues for grafting such as bone marrow, skin, cartilage, tendons, bone, muscle (including cardiac muscle), blood vessels, cornea, neural cells, gastrointestinal cells and others; and organs for transplantation such as kidney, liver, pancreas (including islet cells), heart and lung.  
       [0159] It is contemplated that multiple different exogenous growth factors and/or cytokines may be administered in combination with the polypeptide of the invention to achieve the desired effect, including any of the growth factors listed herein, other stem cell maintenance factors, and specifically including stem cell factor (SCF), leukemia inhibitory factor (LIF), Flt-3 ligand (Flt-3L), any of the interleukins, recombinant soluble IL-6 receptor fused to IL-6, macrophage inflammatory protein 1-alpha (MIP-1-alpha), G-CSF, GM-CSF, thrombopoietin (TPO), platelet factor 4 (PF-4), platelet-derived growth factor (PDGF), neural growth factors and basic fibroblast growth factor (bFGF).  
       [0160] Since totipotent stem cells can give rise to virtually any mature cell type, expansion of these cells in culture will facilitate the production of large quantities of mature cells. Techniques for culturing stem cells are known in the art and administration of polypeptides of the invention, optionally with other growth factors and/or cytokines, is expected to enhance the survival and proliferation of the stem cell populations. This can be accomplished by direct administration of the polypeptide of the invention to the culture medium. Alternatively, stroma cells transfected with a polynucleotide that encodes for the polypeptide of the invention can be used as a feeder layer for the stem cell populations in culture or in vivo. Stromal support cells for feeder layers may include embryonic bone marrow fibroblasts, bone marrow stromal cells, fetal liver cells, or cultured embryonic fibroblasts (see U.S. Pat. No. 5,690,926).  
       [0161] Stem cells themselves can be transfected with a polynucleotide of the invention to induce autocrine expression of the polypeptide of the invention. This will allow for generation of undifferentiated totipotential/pluripotential stem cell lines that are useful as is or that can then be differentiated into the desired mature cell types. These stable cell lines can also serve as a source of undifferentiated totipotential/pluripotential mRNA to create cDNA libraries and templates for polymerase chain reaction experiments. These studies would allow for the isolation and identification of differentially expressed genes in stem cell populations that regulate stem cell proliferation and/or maintenance.  
       [0162] Expansion and maintenance of totipotent stem cell populations will be useful in the treatment of many pathological conditions. For example, polypeptides of the present invention may be used to manipulate stem cells in culture to give rise to neuroepithelial cells that can be used to augment or replace cells damaged by illness, autoimmune disease, accidental damage or genetic disorders. The polypeptide of the invention may be useful for inducing the proliferation of neural cells and for the regeneration of nerve and brain tissue, i.e. for the treatment of central and peripheral nervous system diseases and neuropathies, as well as mechanical and traumatic disorders which involve degeneration, death or trauma to neural cells or nerve tissue. In addition, the expanded stem cell populations can also be genetically altered for gene therapy purposes and to decrease host rejection of replacement tissues after grafting or implantation.  
       [0163] Expression of the polypeptide of the invention and its effect on stem cells can also be manipulated to achieve controlled differentiation of the stem cells into more differentiated cell types. A broadly applicable method of obtaining pure populations of a specific differentiated cell type from undifferentiated stem cell populations involves the use of a cell-type specific promoter driving a selectable marker. The selectable marker allows only cells of the desired type to survive. For example, stem cells can be induced to differentiate into cardiomyocytes (Wobus et al., Differentiation, 48: 173-182, (1991); Klug et al., J. Clin. Invest., 98(1): 216-224, (1998)) or skeletal muscle cells (Browder, L. W. In:  Principles of Tissue Engineering eds . Lanza et al., Academic Press (1997)). Alternatively, directed differentiation of stem cells can be accomplished by culturing the stem cells in the presence of a differentiation factor such as retinoic acid and an antagonist of the polypeptide of the invention which would inhibit the effects of endogenous stem cell factor activity and allow differentiation to proceed.  
       [0164] In vitro cultures of stem cells can be used to determine if the polypeptide of the invention exhibits stem cell growth factor activity. Stem cells are isolated from any one of various cell sources (including hematopoietic stem cells and embryonic stem cells) and cultured on a feeder layer, as described by Thompson et al. Proc. Natl. Acad. Sci, U.S.A., 92: 7844-7848 (1995), in the presence of the polypeptide of the invention alone or in combination with other growth factors or cytokines. The ability of the polypeptide of the invention to induce stem cells proliferation is determined by colony formation on semi-solid support e.g. as described by Bernstein et al., Blood, 77: 2316-2321 (1991).  
       4.10.5 HEMATOPOIESIS REGULATING ACTIVITY  
       [0165] A polypeptide of the present invention may be involved in regulation of ematopoiesis and, consequently, in the treatment of myeloid or lymphoid cell disorders. Even marginal biological activity in support of colony forming cells or of factor-dependent cell lines indicates involvement in regulating hematopoiesis, e.g. in supporting the growth and proliferation of erythroid progenitor cells alone or in combination with other cytokines, thereby indicating utility, for example, in treating various anemias or for use in conjunction with irradiation/chemotherapy to stimulate the production of erythroid precursors and/or erythroid cells; in supporting the growth and proliferation of myeloid cells such as granulocytes and monocytes/macrophages (i.e., traditional CSF activity) useful, for example, in conjunction with chemotherapy to prevent or treat consequent myelo-suppression; in supporting the growth and proliferation of megakaryocytes and consequently of platelets thereby allowing prevention or treatment of various platelet disorders such as thrombocytopenia, and generally for use in place of or complimentary to platelet transfusions; and/or in supporting the growth and proliferation of hematopoietic stem cells which are capable of maturing to any and all of the above-mentioned hematopoietic cells and therefore find therapeutic utility in various stem cell disorders (such as those usually treated with transplantation, including, without limitation, aplastic anemia and paroxysmal nocturnal hemoglobinuria), as well as in repopulating the stem cell compartment post irradiation/chemotherapy, either in-vivo or ex-vivo (i.e., in conjunction with bone marrow transplantation or with peripheral progenitor cell transplantation (homologous or heterologous)) as normal cells or genetically manipulated for gene therapy.  
       [0166] Therapeutic compositions of the invention can be used in the following:  
       [0167] Suitable assays for proliferation and differentiation of various hematopoietic lines are cited above.  
       [0168] Assays for embryonic stem cell differentiation (which will identify, among others, proteins that influence embryonic differentiation hematopoiesis) include, without limitation, those described in: Johansson et al. Cellular Biology 15:141-151, 1995; Keller et al., Molecular and Cellular Biology 13:473-486, 1993; McClanahan et al., Blood 81:2903-2915, 1993.  
       [0169] Assays for stem cell survival and differentiation (which will identify, among others, proteins that regulate lympho-hematopoiesis) include, without limitation, those escribed in: Methylcellulose colony forming assays, Freshney, M. G. In Culture of Hematopoietic Cells. R. I. Freshney, et al. eds. Vol pp.265-268, Wiley-Liss, Inc., New York, N.Y. 1994; Hirayama et al., Proc. Natl. Acad. Sci. USA 89:5907-5911, 1992; Primitive hematopoietic colony forming cells with high proliferative potential, McNiece, I. K. and Briddell, R. A. In Culture of Hematopoietic Cells. R. I. Freshney, et al. eds. Vol pp. 23-39, Wiley-Liss, Inc., New York, N.Y. 1994; Neben et al., Experimental Hematology 22:353-359, 1994; Cobblestone area forming cell assay, Ploemacher, R E. In Culture of Hematopoietic Cells. R. I. Freshney, et al. eds. Vol pp. 1-21, Wiley-Liss, Inc., New York, N.Y. 1994; Long term bone marrow cultures in the presence of stromal cells, Spooncer, E., Dexter, M. and Allen, T. In Culture of Hematopoietic Cells. R. I. Freshney, et al. eds. Vol pp. 163-179, Wiley-Liss, Inc., New York, N.Y. 1994; Long term culture initiating cell assay, Sutherland, H. J. In Culture of Hematopoietic Cells. R I. Freshney, et al. eds. Vol pp.139-162, Wiley-Liss, Inc., New York, N.Y. 1994.  
       4.10.6 TISSUE GROWTH ACTIVITY  
       [0170] A polypeptide of the present invention also may be involved in bone, cartilage, tendon, ligament and/or nerve tissue growth or regeneration, as well as in wound healing and tissue repair and replacement, and in healing of burns, incisions and ulcers.  
       [0171] A polypeptide of the present invention which induces cartilage and/or bone growth in circumstances where bone is not normally formed, has application in the healing of bone fractures and cartilage damage or defects in humans and other animals. Compositions of a polypeptide, antibody, binding partner, or other modulator of the invention may have prophylactic use in closed as well as open fracture reduction and also in the improved fixation of artificial joints. De novo bone formation induced by an osteogenic agent contributes to the repair of congenital, trauma induced, or oncologic resection induced craniofacial defects, and also is useful in cosmetic plastic surgery.  
       [0172] A polypeptide of this invention may also be involved in attracting bone-forming cells, stimulating growth of bone-forming cells, or inducing differentiation of progenitors of bone-forming cells. Treatment of osteoporosis, osteoarthritis, bone degenerative disorders, or periodontal disease, such as through stimulation of bone and/or cartilage repair or by blocking inflammation or processes of tissue destruction (collagenase activity, osteoclast activity, etc.) mediated by inflammatory processes may also be possible using the composition of the invention.  
       [0173] Another category of tissue regeneration activity that may involve the polypeptide of the present invention is tendon/ligament formation. Induction of tendon/ligament-like tissue or other tissue formation in circumstances where such tissue is not normally formed, has application in the healing of tendon or ligament tears, deformities and other tendon or ligament defects in humans and other animals. Such a preparation employing a tendon/ligament-like tissue inducing protein may have prophylactic use in preventing damage to tendon or ligament tissue, as well as use in the improved fixation of tendon or ligament to bone or other tissues, and in repairing defects to tendon or ligament tissue. De novo tendon/ligament-like tissue formation induced by a composition of the present invention contributes to the repair of congenital, trauma induced, or other tendon or ligament defects of other origin, and is also useful in cosmetic plastic surgery for attachment or repair of tendons or ligaments. The compositions of the present invention may provide environment to attract tendon- or ligament-forming cells, stimulate growth of tendon- or ligament-forming cells, induce differentiation of progenitors of tendon- or ligament-forming cells, or induce growth of tendon/ligament cells or progenitors ex vivo for return in vivo to effect tissue repair. The compositions of the invention may also be useful in the treatment of tendinitis, carpal tunnel syndrome and other tendon or ligament defects. The compositions may also include an appropriate matrix and/or sequestering agent as a carrier as is well known in the art.  
       [0174] The compositions of the present invention may also be useful for proliferation of neural cells and for regeneration of nerve and brain tissue, i.e. for the treatment of central and peripheral nervous system diseases and neuropathies, as well as mechanical and traumatic disorders, which involve degeneration, death or trauma to neural cells or nerve tissue. More specifically, a composition may be used in the treatment of diseases of the peripheral nervous system, such as peripheral nerve injuries, peripheral neuropathy and localized neuropathies, and central nervous system diseases, such as Alzheimer&#39;s, Parkinson&#39;s disease, Huntington&#39;s disease, amyotrophic lateral sclerosis, and Shy-Drager syndrome. Further conditions which may be treated in accordance with the present invention include mechanical and traumatic disorders, such as spinal cord disorders, head trauma and cerebrovascular diseases such as stroke. Peripheral neuropathies resulting from chemotherapy or other medical therapies may also be treatable using a composition of the invention.  
       [0175] Compositions of the invention may also be useful to promote better or faster closure of non-healing wounds, including without limitation pressure ulcers, ulcers associated with vascular insufficiency, surgical and traumatic wounds, and the like.  
       [0176] Compositions of the present invention may also be involved in the generation or regeneration of other tissues, such as organs (including, for example, pancreas, liver, intestine, kidney, skin, endothelium), muscle (smooth, skeletal or cardiac) and vascular (including vascular endothelium) tissue, or for promoting the growth of cells comprising such tissues. Part of the desired effects may be by inhibition or modulation of fibrotic scarring may allow normal tissue to regenerate. A polypeptide of the present invention may also exhibit angiogenic activity.  
       [0177] A composition of the present invention may also be useful for gut protection or regeneration and treatment of lung or liver fibrosis, reperfusion injury in various tissues, and conditions resulting from systemic cytokine damage.  
       [0178] A composition of the present invention may also be useful for promoting or inhibiting differentiation of tissues described above from precursor tissues or cells; or for inhibiting the growth of tissues described above.  
       [0179] Therapeutic compositions of the invention can be used in the following:  
       [0180] Assays for tissue generation activity include, without limitation, those described in: International Patent Publication No. WO95/16035 (bone, cartilage, tendon); International Patent Publication No. WO95/05846 (nerve, neuronal); International Patent Publication No. WO91/07491 (skin, endothelium).  
       [0181] Assays for wound healing activity include, without limitation, those described in: Winter, Epidermal Wound Healing, pps. 71-112 (Maibach, H. I. and Rovee, D. T., eds.), Year Book Medical Publishers, Inc., Chicago, as modified by Eaglstein and Mertz, J. Invest. Dermatol 71:382-84 (1978).  
       4.10.7 IMMUNE STIMULATING OR SUPPRESSING ACTIVITY  
       [0182] A polypeptide of the present invention may also exhibit immune stimulating or immune suppressing activity, including without limitation the activities for which assays are described herein. A polynucleotide of the invention can encode a polypeptide exhibiting such activities. A protein may be useful in the treatment of various immune deficiencies and disorders (including severe combined immunodeficiency (SCID)), e.g., in regulating (up or down) growth and proliferation of T and/or B lymphocytes, as well as effecting the cytolytic activity of NK cells and other cell populations. These immune deficiencies may be genetic or be caused by viral (e.g., HIV) as well as bacterial or fungal infections, or may result from autoimmune disorders. More specifically, infectious diseases causes by viral, bacterial, fungal or other infection may be treatable using a protein of the present invention, including infections by HIV, hepatitis viruses, herpes viruses, mycobacteria, Leishmania spp., malaria spp. and various fungal infections such as candidiasis. Of course, in this regard, proteins of the present invention may also be useful where a boost to the immune system generally may be desirable, i.e., in the treatment of cancer.  
       [0183] Autoimmune disorders which may be treated using a protein of the present invention include, for example, connective tissue disease, multiple sclerosis, systemic lupus erythematosus, rheumatoid arthritis, autoimmune pulmonary inflammation, Guillain-Barre syndrome, autoimmune thyroiditis, insulin dependent diabetes mellitis, myasthenia gravis, graft-versus-host disease and autoimmune inflammatory eye disease. Such a protein (or antagonists thereof, including antibodies) of the present invention may also to be useful in the treatment of allergic reactions and conditions (e.g., anaphylaxis, serum sickness, drug reactions, food allergies, insect venom allergies, mastocytosis, allergic rhinitis, hypersensitivity pneumonitis, urticaria, angioedema, eczema, atopic dermatitis, allergic contact dermatitis, erythema multiforme, Stevens-Johnson syndrome, allergic conjunctivitis, atopic keratoconjunctivitis, venereal keratoconjunctivitis, giant papillary conjunctivitis and contact allergies), such as asthma (particularly allergic asthma) or other respiratory problems. Other conditions, in which immune suppression is desired (including, for example, organ transplantation), may also be treatable using a protein (or antagonists thereof) of the present invention. The therapeutic effects of the polypeptides or antagonists thereof on allergic reactions can be evaluated by in vivo animals models such as the cumulative contact enhancement test (Lastbom et al., Toxicology 125: 59-66, 1998), skin prick test (Hoffmann et al., Allergy 54: 446-54, 1999), guinea pig skin sensitization test (Vohr et al., Arch. Toxocol. 73: 501-9), and murine local lymph node assay (Kimber et al., J. Toxicol. Environ. Health 53: 563-79).  
       [0184] Using the proteins of the invention it may also be possible to modulate immune responses, in a number of ways. Down regulation may be in the form of inhibiting or blocking an immune response already in progress or may involve preventing the induction of an immune response. The functions of activated T cells may be inhibited by suppressing T cell responses or by inducing specific tolerance in T cells, or both. Immunosuppression of T cell responses is generally an active, non-antigen-specific, process which requires continuous exposure of the T cells to the suppressive agent. Tolerance, which involves inducing non-responsiveness or anergy in T cells, is distinguishable from immunosuppression in that it is generally antigen-specific and persists after exposure to the tolerizing agent has ceased. Operationally, tolerance can be demonstrated by the lack of a T cell response upon reexposure to specific antigen in the absence of the tolerizing agent.  
       [0185] Down regulating or preventing one or more antigen functions (including without limitation B lymphocyte antigen functions (such as, for example, B7)), e.g., preventing high level lymphokine synthesis by activated T cells, will be useful in situations of tissue, skin and organ transplantation and in graft-versus-host disease (GVHD). For example, blockage of T cell function should result in reduced tissue destruction in tissue transplantation. Typically, in tissue transplants, rejection of the transplant is initiated through its recognition as foreign by T cells, followed by an immune reaction that destroys the transplant. The administration of a therapeutic composition of the invention may prevent cytokine synthesis by immune cells, such as T cells, and thus acts as an immunosuppressant. Moreover, a lack of costimulation may also be sufficient to anergize the T cells, thereby inducing tolerance in a subject. Induction of long-term tolerance by B lymphocyte antigen-blocking reagents may avoid the necessity of repeated administration of these blocking reagents. To achieve sufficient immunosuppression or tolerance in a subject, it may also be necessary to block the function of a combination of B lymphocyte antigens.  
       [0186] The efficacy of particular therapeutic compositions in preventing organ transplant rejection or GVHD can be assessed using animal models that are predictive of efficacy in humans. Examples of appropriate systems which can be used include allogeneic cardiac grafts in rats and xenogeneic pancreatic islet cell grafts in mice, both of which have been used to examine the immunosuppressive effects of CTLA4Ig fusion proteins in vivo as described in Lenschow et al., Science 257:789-792 (1992) and Turka et al., Proc. Natl. Acad. Sci USA, 89:11102-11105 (1992). In addition, murine models of GVHD (see Paul ed., Fundamental Immunology, Raven Press, New York, 1989, pp. 846-847) can be used to determine the effect of therapeutic compositions of the invention on the development of that disease.  
       [0187] Blocking antigen function may also be therapeutically useful for treating autoimmune diseases. Many autoimmune disorders are the result of inappropriate activation of T cells that are reactive against self tissue and which promote the production of cytokines and autoantibodies involved in the pathology of the diseases. Preventing the activation of autoreactive T cells may reduce or eliminate disease symptoms. Administration of reagents which block stimulation of T cells can be used to inhibit T cell activation and prevent production of autoantibodies or T cell-derived cytokines which may be involved in the disease process. Additionally, blocking reagents may induce antigen-specific tolerance of autoreactive T cells which could lead to long-term relief from the disease. The efficacy of blocking reagents in preventing or alleviating autoimmune disorders can be determined using a number of well-characterized animal models of human autoimmune diseases. Examples include murine experimental autoimmune encephalitis, systemic lupus erythmatosis in MRL/lpr/lpr mice or NZB hybrid mice, murine autoimmune collagen arthritis, diabetes mellitus in NOD mice and BB rats, and murine experimental myasthenia gravis (see Paul ed., Fundamental Immunology, Raven Press, New York, 1989, pp. 840-856).  
       [0188] Upregulation of an antigen function (e.g., a B lymphocyte antigen function), as a means of up regulating immune responses, may also be useful in therapy. Upregulation of immune responses may be in the form of enhancing an existing immune response or eliciting an initial immune response. For example, enhancing an immune response may be useful in cases of viral infection, including systemic viral diseases such as influenza, the common cold, and encephalitis.  
       [0189] Alternatively, anti-viral immune responses may be enhanced in an infected patient by removing T cells from the patient, costimulating the T cells in vitro with viral antigen-pulsed APCs either expressing a peptide of the present invention or together with a stimulatory form of a soluble peptide of the present invention and reintroducing the in vitro activated T cells into the patient. Another method of enhancing anti-viral immune responses would be to isolate infected cells from a patient, transfect them with a nucleic acid encoding a protein of the present invention as described herein such that the cells express all or a portion of the protein on their surface, and reintroduce the transfected cells into the patient. The infected cells would now be capable of delivering a costimulatory signal to, and thereby activate, T cells in vivo.  
       [0190] A polypeptide of the present invention may provide the necessary stimulation signal to T cells to induce a T cell mediated immune response against the transfected tumor cells. In addition, tumor cells which lack MHC class I or MHC class II molecules, or which fail to reexpress sufficient mounts of MHC class I or MHC class II molecules, can be transfected with nucleic acid encoding all or a portion of (e.g., a cytoplasmic-domain truncated portion) of an MHC class I alpha chain protein and β 2  microglobulin protein or an MHC class II alpha chain protein and an MHC class II beta chain protein to thereby express MUC class I or MHC class II proteins on the cell surface. Expression of the appropriate class I or class II MHC in conjunction with a peptide having the activity of a B lymphocyte antigen (e.g., B7-1, B7-2, B7-3) induces a T cell mediated immune response against the transfected tumor cell. Optionally, a gene encoding an antisense construct which blocks expression of an MHC class II associated protein, such as the invariant chain, can also be cotransfected with a DNA encoding a peptide having the activity of a B lymphocyte antigen to promote presentation of tumor associated antigens and induce tumor specific immunity. Thus, the induction of a T cell mediated immune response in a human subject may be sufficient to overcome tumor-specific tolerance in the subject.  
       [0191] The activity of a protein of the invention may, among other means, be measured by the following methods:  
       [0192] Suitable assays for thymocyte or splenocyte cytotoxicity include, without limitation, those described in: Current Protocols in Immunology, Ed by J. E. Coligan, A. M. Kruisbeek, D. H. Margulies, E. M. Shevach, W. Strober, Pub. Greene Publishing Associates and Wiley-Interscience (Chapter 3, In Vitro assays for Mouse Lymphocyte Function 3.1-3.19; Chapter 7, Immunologic studies in Humans); Herrmann et al., Proc. Natl. Acad. Sci. USA 78:2488-2492, 1981; Herrmann et al., J. Immunol. 128:1968-1974, 1982; Handa et al., J. Immunol. 135:1564-1572, 1985; Takai et al., I. Immunol. 137:3494-3500, 1986; Takai et al., J. Immunol. 140:508-512, 1988; Bowman et al., J. Virology 61:1992-1998; Bertagnolli et al., Cellular Immunology 133:327-341, 1991; Brown et al., J. Immunol. 153:3079-3092, 1994.  
       [0193] Assays for T-cell-dependent immunoglobulin responses and isotype switching (which will identify, among others, proteins that modulate T-cell dependent antibody responses and that affect Th1/Th2 profiles) include, without limitation, those described in: Maliszewski, J. Immunol. 144:3028-3033, 1990; and Assays for B cell function: In vitro antibody production, Mond, J. J. and Brunswick, M. In Current Protocols in Immunology. J. E. e.a. Coligan eds. Vol 1 pp.3.8.1-3.8.16, John Wiley and Sons, Toronto. 1994.  
       [0194] Mixed lymphocyte reaction (MLR) assays (which will identify, among others, proteins that generate predominantly Th1 and CTL responses) include, without limitation, those described in: Current Protocols in Immunology, Ed by J. E. Coligan, A. M. Kruisbeek, D. H. Margulies, E. M. Shevach, W. Strober, Pub. Greene Publishing Associates and Wiley-Interscience (Chapter 3, In Vitro assays for Mouse Lymphocyte Function 3.1-3.19; Chapter 7, Immunologic studies in Humans); Takai et al., J. Immunol. 137:3494-3500, 1986; Takai et al., J. Immunol. 140:508-512, 1988; Bertagnolli et al., J. Immunol. 149:3778-3783, 1992.  
       [0195] Dendritic cell-dependent assays (which will identify, among others, proteins expressed by dendritic cells that activate naive T-cells) include, without limitation, those described in: Guery et al., J. Immunol. 134:536-544, 1995; Inaba et al., Journal of Experimental Medicine 173:549-559, 1991; Macatonia et al., Journal of Immunology 154:5071-5079, 1995; Porgador et al., Journal of Experimental Medicine 182:255-260, 1995; Nair et al., Journal of Virology 67:4062-4069, 1993; Huang et al., Science 264:961-965, 1994; Macatonia et al., Journal of Experimental Medicine 169:1255-1264, 1989; Bhardwaj et al., Journal of Clinical Investigation 94:797-807, 1994; and Inaba et al., Journal of Experimental Medicine 172:631-640, 1990.  
       [0196] Assays for lymphocyte survival/apoptosis (which will identify, among others, proteins that prevent apoptosis after superantigen induction and proteins that regulate lymphocyte homeostasis) include, without limitation, those described in: Darzynkiewicz et al., Cytometry 13:795-808, 1992; Gorczyca et al., Leukemia 7:659-670, 1993; Gorczyca et al., Cancer Research 53:1945-1951, 1993; Itoh et al., Cell 66:233-243, 1991; Zacharchuk, Journal of Immunology 145:4037-4045, 1990; Zamai et al., Cytometry 14:891-897, 1993; Gorczyca et al., International Journal of Oncology 1:639-648, 1992.  
       [0197] Assays for proteins that influence early steps of T-cell commitment and development include, without limitation, those described in: Antica et al., Blood 84:111-117, 1994; Fine et al., Cellular Immunology 155:111-122, 1994; Galy et al., Blood 85:2770-2778, 1995; Toki et al., Proc. Nat. Acad Sci. USA 88:7548-7551, 1991.  
       4.10.8 Activin/Inhibin Activity  
       [0198] A polypeptide of the present invention may also exhibit activin- or inhibin-related activities. A polynucleotide of the invention may encode a polypeptide exhibiting such characteristics. Inhibins are characterized by their ability to inhibit the release of follicle stimulating hormone (FSH), while activins and are characterized by their ability to stimulate the release of follicle stimulating hormone (FSH). Thus, a polypeptide of the present invention, alone or in heterodimers with a member of the inhibin family, may be useful as a contraceptive based on the ability of inhibins to decrease fertility in female mammals and decrease spermatogenesis in male mammals. Administration of sufficient amounts of other inhibins can induce infertility in these mammals. Alternatively, the polypeptide of the invention, as a homodimer or as a heterodimer with other protein subunits of the inhibin group, may be useful as a fertility inducing therapeutic, based upon the ability of activin molecules in stimulating FSH release from cells of the anterior pituitary. See, for example, U.S. Pat. No. 4,798,885. A polypeptide of the invention may also be useful for advancement of the onset of fertility in sexually immature mammals, so as to increase the lifetime reproductive performance of domestic animals such as, but not limited to, cows, sheep and pigs.  
       [0199] The activity of a polypeptide of the invention may, among other means, be measured by the following methods.  
       [0200] Assays for activin/inhibin activity include, without limitation, those described in: Vale et al., Endocrinology 91:562-572, 1972; Ling et al., Nature 321:779-782, 1986; Vale et al., Nature 321:776-779, 1986; Mason et al., Nature 318:659-663, 1985; Forage et al., Proc. Natl. Acad. Sci. USA 83:3091-3095, 1986.  
       4.10.9 Chemotactic/Chemokinetic Activity  
       [0201] A polypeptide of the present invention may be involved in chemotactic or chemokinetic activity for mammalian cells, including, for example, monocytes, fibroblasts, neutrophils, T-cells, mast cells, eosinophils, epithelial and/or endothelial cells. A polynucleotide of the invention can encode a polypeptide exhibiting such attributes. Chemotactic and chemokinetic receptor activation can be used to mobilize or attract a desired cell population to a desired site of action. Chemotactic or chemokinetic compositions (e.g. proteins, antibodies, binding partners, or modulators of the invention) provide particular advantages in treatment of wounds and other trauma to tissues, as well as in treatment of localized infections. For example, attraction of lymphocytes, monocytes or neutrophils to tumors or sites of infection may result in improved immune responses against the tumor or infecting agent.  
       [0202] A protein or peptide has chemotactic activity for a particular cell population if it can stimulate, directly or indirectly, the directed orientation or movement of such cell population. Preferably, the protein or peptide has the ability to directly stimulate directed movement of cells. Whether a particular protein has chemotactic activity for a population of cells can be readily determined by employing such protein or peptide in any known assay for cell chemotaxis.  
       [0203] Therapeutic compositions of the invention can be used in the following:  
       [0204] Assays for chemotactic activity (which will identify proteins that induce or prevent chemotaxis) consist of assays that measure the ability of a protein to induce the migration of cells across a membrane as well as the ability of a protein to induce the adhesion of one cell population to another cell population. Suitable assays for movement and adhesion include, without limitation, those described in: Current Protocols in Immunology, Ed by J. E. Coligan, A. M. Kruisbeek, D. H. Marguiles. E. M. Shevach, W. Strober, Pub. Greene Publishing Associates and Wiley-Interscience (Chapter 6.12, Measurement of alpha and beta Chemokines 6.12.1-6.12.28; Taub et al. J. Clin. Invest. 95:1370-1376, 1995; Lind et al. APMIS 103:140-146, 1995; Muller et al Eur. J. Immunol. 25:1744-1748; Gruber et al. J. of Immunol. 152:5860-5867, 1994; Johnston et al. J. of Immunol. 153:1762-1768, 1994.  
       4.10.10 Hemostatic and Thrombolytic Activity  
       [0205] A polypeptide of the invention may also be involved in hemostatis or thrombolysis or thrombosis. A polynucleotide of the invention can encode a polypeptide exhibiting such attributes. Compositions may be useful in treatment of various coagulation disorders (including hereditary disorders, such as hemophilias) or to enhance coagulation and other hemostatic events in treating wounds resulting from trauma, surgery or other causes. A composition of the invention may also be useful for dissolving or inhibiting formation of thromboses and for treatment and prevention of conditions resulting therefrom (such as, for example, infarction of cardiac and central nervous system vessels (e.g., stroke).  
       [0206] Therapeutic compositions of the invention can be used in the following:  
       [0207] Assay for hemostatic and thrombolytic activity include, without limitation, those described in: Linet et al., J. Clin. Pharmacol. 26:131-140, 1986; Burdick et al., Thrombosis Res. 45:413-419, 1987; Humphrey et al., Fibrinolysis 5:71-79 (1991); Schaub, Prostaglandins 35:467-474, 1988.  
       4.10.11 Cancer Diagnosis and Therapy  
       [0208] Polypeptides of the invention may be involved in cancer cell generation, proliferation or metastasis. Detection of the presence or amount of polynucleotides or polypeptides of the invention may be useful for the diagnosis and/or prognosis of one or more types of cancer. For example, the presence or increased expression of a polynucleotide/polypeptide of the invention may indicate a hereditary risk of cancer, a precancerous condition, or an ongoing malignancy. Conversely, a defect in the gene or absence of the polypeptide may be associated with a cancer condition. Identification of single nucleotide polymorphisms associated with cancer or a predisposition to cancer may also be useful for diagnosis or prognosis.  
       [0209] Cancer treatments promote tumor regression by inhibiting tumor cell proliferation, inhibiting angiogenesis (growth of new blood vessels that is necessary to support tumor growth) and/or prohibiting metastasis by reducing tumor cell motility or invasiveness. Therapeutic compositions of the invention may be effective in adult and pediatric oncology including in solid phase tumors/malignancies, locally advanced tumors, human soft tissue sarcomas, metastatic cancer, including lymphatic metastases, blood cell malignancies including multiple myeloma, acute and chronic leukemias, and lymphomas, head and neck cancers including mouth cancer, larynx cancer and thyroid cancer, lung cancers including small cell carcinoma and non-small cell cancers, breast cancers including small cell carcinoma and ductal carcinoma, gastrointestinal cancers including esophageal cancer, stomach cancer, colon cancer, colorectal cancer and polyps associated with colorectal neoplasia, pancreatic cancers, liver cancer, urologic cancers including bladder cancer and prostate cancer, malignancies of the female genital tract including ovarian carcinoma, uterine (including endometrial) cancers, and solid tumor in the ovarian follicle, kidney cancers including renal cell carcinoma, brain cancers including intrinsic brain tumors, neuroblastoma, astrocytic brain tumors, gliomas, metastatic tumor cell invasion in the central nervous system, bone cancers including osteomas, skin cancers including malignant melanoma, tumor progression of human skin keratinocytes, squamous cell carcinoma, basal cell carcinoma, hemangiopericytoma and Karposi&#39;s sarcoma  
       [0210] Polypeptides, polynucleotides, or modulators of polypeptides of the invention (including inhibitors and stimulators of the biological activity of the polypeptide of the invention) may be administered to treat cancer. Therapeutic compositions can be administered in therapeutically effective dosages alone or in combination with adjuvant cancer therapy such as surgery, chemotherapy, radiotherapy, thermotherapy, and laser therapy, and may provide a beneficial effect, e.g. reducing tumor size, slowing rate of tumor growth, inhibiting metastasis, or otherwise improving overall clinical condition, without necessarily eradicating the cancer.  
       [0211] The composition can also be administered in therapeutically effective amounts as a portion of an anti-cancer cocktail. An anti-cancer cocktail is a mixture of the polypeptide or modulator of the invention with one or more anti-cancer drugs in addition to a pharmaceutically acceptable carrier for delivery. The use of anti-cancer cocktails as a cancer treatment is routine. Anti-cancer drugs that are well known in the art and can be used as a treatment in combination with the polypeptide or modulator of the invention include: Actinomycin D, Aminoglutethimide, Asparaginase, Bleomycin, Busulfan, Carboplatin, Carmustine, Chlorambucil, Cisplatin (cis-DDP), Cyclophosphamide, Cytarabine HCl (Cytosine arabinoside), Dacarbazine, Dactinomycin, Daunorubicin HCl, Doxorubicin HCl, Estramustine phosphate sodium, Etoposide (V16-213), Floxuridine, 5-Fluorouracil (5-Fu), Flutamide, Hydroxyurea (hydroxycarbamide), Ifosfamide, Interferon Alpha-2a, Interferon Alpha-2b, Leuprolide acetate (LHRH-releasing factor analog), Lomustine, Mechlorethamine HCl (nitrogen mustard), Melphalan, Mercaptopurine, Mesna, Methotrexate (MTX), Mitomycin, Mitoxantrone HCl, Octreotide, Plicamycin, Procarbazine HCl, Streptozocin, Tamoxifen citrate, Thioguanine, Thiotepa, Vinblastine sulfate, Vincristine sulfate, Amsacrine, Azacitidine, Hexamethylmelamine, Interleukin-2, Mitoguazone, Pentostatin, Semustine, Teniposide, and Vindesine sulfate.  
       [0212] In addition, therapeutic compositions of the invention may be used for prophylactic treatment of cancer. There are hereditary conditions and/or environmental situations (e.g. exposure to carcinogens) known in the art that predispose an individual to developing cancers. Under these circumstances, it may be beneficial to treat these individuals with therapeutically effective doses of the polypeptide of the invention to reduce the risk of developing cancers.  
       [0213] In vitro models can be used to determine the effective doses of the polypeptide of the invention as a potential cancer treatment. These in vitro models include proliferation assays of cultured tumor cells, growth of cultured tumor cells in soft agar (see Freshney, (1987) Culture of Animal Cells: A Manual of Basic Technique, Wily-Liss, New York, N.Y. Ch 18 and Ch 21), tumor systems in nude mice as described in Giovanella et al., J. Natl. Can. Inst., 52: 921-30 (1974), mobility and invasive potential of tumor cells in Boyden Chamber assays as described in Pilkington et al., Anticancer Res., 17: 4107-9 (1997), and angiogenesis assays such as induction of vascularization of the chick chorioallantoic membrane or induction of vascular endothelial cell migration as described in Ribatta et al., Intl. J. Dev. Biol., 40: 1189-97 (1999) and Li et al., Clin. Exp. Metastasis, 17:423-9 (1999), respectively. Suitable tumor cells lines are available, e.g. from American Type Tissue Culture Collection catalogs.  
       4.10.12 Receptor/Ligand Activity  
       [0214] A polypeptide of the present invention may also demonstrate activity as receptor, receptor ligand or inhibitor or agonist of receptor/ligand interactions. A polynucleotide of the invention can encode a polypeptide exhibiting such characteristics. Examples of such receptors and ligands include, without limitation, cytokine receptors and their ligands, receptor kinases and their ligands, receptor phosphatases and their ligands, receptors involved in cell-cell interactions and their ligands (including without limitation, cellular adhesion molecules (such as selectins, integrins and their ligands) and receptor/ligand pairs involved in antigen presentation, antigen recognition and development of cellular and humoral immune responses. Receptors and ligands are also useful for screening of potential peptide or small molecule inhibitors of the relevant receptor/ligand interaction. A protein of the present invention (including, without limitation, fragments of receptors and ligands) may themselves be useful as inhibitors of receptor/ligand interactions.  
       [0215] The activity of a polypeptide of the invention may, among other means, be measured by the following methods:  
       [0216] Suitable assays for receptor-ligand activity include without limitation those described in: Current Protocols in Immunology, Ed by J. E. Coligan, A. M. Kruisbeek, D. H. Margulies, E. M. Shevach, W. Strober, Pub. Greene Publishing Associates and Wiley-Interscience (Chapter 7.28, Measurement of Cellular Adhesion under static conditions 7.28.1-7.28.22), Takai et al., Proc. Natl. Acad. Sci. USA 84:6864-6868, 1987; Bierer et al., J. Exp. Med. 168:1145-1156, 1988; Rosenstein et al., J. Exp. Med. 169:149-160 1989; Stoltenborg et al., J. Immunol. Methods 175:59-68, 1994; Stitt et al., Cell 80:661-670, 1995.  
       [0217] By way of example, the polypeptides of the invention may be used as a receptor for a ligand(s) thereby transmitting the biological activity of that ligand(s). Ligands may be identified through binding assays, affinity chromatography, dihybrid screening assays, BIAcore assays, gel overlay assays, or other methods known in the art.  
       [0218] Studies characterizing drugs or proteins as agonist or antagonist or partial agonists or a partial antagonist require the use of other proteins as competing ligands. The polypeptides of the present invention or ligand(s) thereof may be labeled by being coupled to radioisotopes, colorimetric molecules or a toxin molecules by conventional methods. (“Guide to Protein Purification” Murray P. Deutscher (ed) Methods in Enzymology Vol. 182 (1990) Academic Press, Inc. San Diego). Examples of radioisotopes include, but are not limited to, tritium and carbon-14. Examples of calorimetric molecules include, but are not limited to, fluorescent molecules such as fluorescamine, or rhodamine or other colorimetric molecules. Examples of toxins include, but are not limited, to ricin.  
       4.10.13 Drug Screening  
       [0219] This invention is particularly useful for screening chemical compounds by using the novel polypeptides or binding fragments thereof in any of a variety of drug screening techniques. The polypeptides or fragments employed in such a test may either be free in solution, affixed to a solid support, borne on a cell surface or located intracellularly. One method of drug screening utilizes eukaryotic or prokaryotic host cells which are stably transformed with recombinant nucleic acids expressing the polypeptide or a fragment thereof. Drugs are screened against such transformed cells in competitive binding assays. Such cells, either in viable or fixed form, can be used for standard binding assays. One may measure, for example, the formation of complexes between polypeptides of the invention or fragments and the agent being tested or examine the diminution in complex formation between the novel polypeptides and an appropriate cell line, which are well known in the art.  
       [0220] Sources for test compounds that may be screened for ability to bind to or modulate (i.e., increase or decrease) the activity of polypeptides of the invention include (1) inorganic and organic chemical libraries, (2) natural product libraries, and (3) combinatorial libraries comprised of either random or mimetic peptides, oligonucleotides or organic molecules.  
       [0221] Chemical libraries may be readily synthesized or purchased from a number of commercial sources, and may include structural analogs of known compounds or compounds that are identified as “hits” or “leads” via natural product screening.  
       [0222] The sources of natural product libraries are microorganisms (including bacteria and fungi), animals, plants or other vegetation, or marine organisms, and libraries of mixtures for screening may be created by: (1) fermentation and extraction of broths from soil, plant or marine microorganisms or (2) extraction of the organisms themselves. Natural product libraries include polyketides, non-ribosomal peptides, and (non-naturally occurring) variants thereof. For a review, see  Science  282:63-68 (1998).  
       [0223] Combinatorial libraries are composed of large numbers of peptides, oligonucleotides or organic compounds and can be readily prepared by traditional automated synthesis methods, PCR, cloning or proprietary synthetic methods. Of particular interest are peptide and oligonucleotide combinatorial libraries. Still other libraries of interest include peptide, protein, peptidomimetic, multiparallel synthetic collection, recombinatorial, and polypeptide libraries. For a review of combinatorial chemistry and libraries created therefrom, see Myers,  Curr. Opin. Biotechnol.  8:701-707 (1997). For reviews and examples of peptidomimetic libraries, see Al-Obeidi et al.,  Mol. Biotechnol,  9(3):205-23 (1998); Hruby et al.,  Curr Opin Chem Biol,  1(1):114-19 (1997); Dorner et al.,  Bioorg Med Chem,  4(5):709-15 (1996) (alkylated dipeptides).  
       [0224] Identification of modulators through use of the various libraries described herein permits modification of the candidate “hit” (or “lead”) to optimize the capacity of the “hit” to bind a polypeptide of the invention. The molecules identified in the binding assay are then tested for antagonist or agonist activity in in vivo tissue culture or animal models that are well known in the art. In brief, the molecules are titrated into a plurality of cell cultures or animals and then tested for either cell/animal death or prolonged survival of the animal/cells.  
       [0225] The binding molecules thus identified may be complexed with toxins, e.g., ricin or cholera, or with other compounds that are toxic to cells such as radioisotopes. The toxin-binding molecule complex is then targeted to a tumor or other cell by the specificity of the binding molecule for a polypeptide of the invention. Alternatively, the binding molecules may be complexed with imaging agents for targeting and imaging purposes.  
       4.10.14 Assay for Receptor Activity  
       [0226] The invention also provides methods to detect specific binding of a polypeptide e.g. a ligand or a receptor. The art provides numerous assays particularly useful for identifying previously unknown binding partners for receptor polypeptides of the invention. For example, expression cloning using mammalian or bacterial cells, or dihybrid screening assays can be used to identify polynucleotides encoding binding partners. As another example, affinity chromatography with the appropriate immobilized polypeptide of the invention can be used to isolate polypeptides that recognize and bind polypeptides of the invention. There are a number of different libraries used for the identification of compounds, and in particular small molecules, that modulate (i.e., increase or decrease) biological activity of a polypeptide of the invention. Ligands for receptor polypeptides of the invention can also be identified by adding exogenous ligands, or cocktails of ligands to two cells populations that are genetically identical except for the expression of the receptor of the invention: one cell population expresses the receptor of the invention whereas the other does not. The response of the two cell populations to the addition of ligands(s) are then compared. Alternatively, an expression library can be co-expressed with the polypeptide of the invention in cells and assayed for an autocrine response to identify potential ligand(s). As still another example, BIAcore assays, gel overlay assays, or other methods known in the art can be used to identify binding partner polypeptides, including, (1) organic and inorganic chemical libraries, (2) natural product libraries, and (3) combinatorial libraries comprised of random peptides, oligonucleotides or organic molecules.  
       [0227] The role of downstream intracellular signaling molecules in the signaling cascade of the polypeptide of the invention can be determined. For example, a chimeric protein in which the cytoplasmic domain of the polypeptide of the invention is fused to the extracellular portion of a protein, whose ligand has been identified, is produced in a host cell. The cell is then incubated with the ligand specific for the extracellular portion of the chimeric protein, thereby activating the chimeric receptor. Known downstream proteins involved in intracellular signaling can then be assayed for expected modifications i.e. phosphorylation. Other methods known to those in the art can also be used to identify signaling molecules involved in receptor activity.  
       4.10.15 Anti-Inflammatory Activity  
       [0228] Compositions of the present invention may also exhibit anti-inflammatory activity. The anti-inflammatory activity may be achieved by providing a stimulus to cells involved in the inflammatory response, by inhibiting or promoting cell-cell interactions (such as, for example, cell adhesion), by inhibiting or promoting chemotaxis of cells involved in the inflammatory process, inhibiting or promoting cell extravasation, or by stimulating or suppressing production of other factors which more directly inhibit or promote an inflammatory response. Compositions with such activities can be used to treat inflammatory conditions including chronic or acute conditions), including without limitation intimation associated with infection (such as septic shock, sepsis or systemic inflammatory response syndrome (SIRS)), ischemia-reperfusion injury, endotoxin lethality, arthritis, complement-mediated hyperacute rejection, nephritis, cytokine or chemokine-induced lung injury, inflammatory bowel disease, Crohn&#39;s disease or resulting from over production of cytokines such as TNF or IL-1. Compositions of the invention may also be useful to treat anaphylaxis and hypersensitivity to an antigenic substance or material. Compositions of this invention may be utilized to prevent or treat conditions such as, but not limited to, sepsis, acute pancreatitis, endotoxin shock, cytokine induced shock, rheumatoid arthritis, chronic inflammatory arthritis, pancreatic cell damage from diabetes mellitus type 1, graft versus host disease, inflammatory bowel disease, inflamation associated with pulmonary disease, other autoimmune disease or inflammatory disease, an antiproliferative agent such as for acute or chronic mylegenous leukemia or in the prevention of premature labor secondary to intrauterine infections.  
       4.10.16 Leukemias  
       [0229] Leukemias and related disorders may be treated or prevented by administration of a therapeutic that promotes or inhibits function of the polynucleotides and/or polypeptides of the invention. Such leukemias and related disorders include but are not limited to acute leukemia, acute lymphocytic leukemia, acute myelocytic leukemia, myeloblastic, promyelocytic, myelomonocytic, monocytic, erythroleukemia, chronic leukemia, chronic myelocytic (granulocytic) leukemia and chronic lymphocytic leukemia (for a review of such disorders, see Fishman et al., 1985, Medicine, 2d Ed., J. B. Lippincott Co., Pa.).  
       4.10.17 Nervous System Disorders  
       [0230] Nervous system disorders, involving cell types which can be tested for efficacy of intervention with compounds that modulate the activity of the polynucleotides and/or polypeptides of the invention, and which can be treated upon thus observing an indication of therapeutic utility, include but are not limited to nervous system injuries, and diseases or disorders which result in either a disconnection of axons, a diminution or degeneration of neurons, or demyelination. Nervous system lesions which may be treated in a patient (including human and non-human mammalian patients) according to the invention include but are not limited to the following lesions of either the central (including spinal cord, brain) or peripheral nervous systems:  
       [0231] (i) traumatic lesions, including lesions caused by physical injury or associated with surgery, for example, lesions which sever a portion of the nervous system, or compression injuries;  
       [0232] (ii) ischemic lesions, in which a lack of oxygen in a portion of the nervous system results in neuronal injury or death, including cerebral infarction or ischemia, or spinal cord infarction or ischemia;  
       [0233] (iii) infectious lesions, in which a portion of the nervous system is destroyed or injured as a result of infection, for example, by an abscess or associated with infection by human immunodeficiency virus, herpes zoster, or herpes simplex virus or with Lyme disease, tuberculosis, syphilis;  
       [0234] (iv) degenerative lesions, in which a portion of the nervous system is destroyed or injured as a result of a degenerative process including but not limited to degeneration associated with Parkinson&#39;s disease, Alzheimer&#39;s disease, Huntington&#39;s chorea, or amyotrophic lateral sclerosis;  
       [0235] (v) lesions associated with nutritional diseases or disorders, in which a portion of the nervous system is destroyed or injured by a nutritional disorder or disorder of metabolism including but not limited to, vitamin B 12 deficiency, folic acid deficiency, Wernicke disease, tobacco-alcohol amblyopia, Marchiafava-Bignami disease (primary degeneration of the corpus callosum), and alcoholic cerebellar degeneration;  
       [0236] (vi) neurological lesions associated with systemic diseases including but not limited to diabetes (diabetic neuropathy, Bell&#39;s palsy), systemic lupus erythematosus, carcinoma, or sarcoidosis;  
       [0237] (vii) lesions caused by toxic substances including alcohol, lead, or particular neurotoxins; and  
       [0238] (viii) demyelinated lesions in which a portion of the nervous system is destroyed or injured by a demyelinating disease including but not limited to multiple sclerosis, human immunodeficiency virus-associated myelopathy, transverse myelopathy or various etiologies, progressive multifocal leukoencephalopathy, and central pontine myelinolysis.  
       [0239] Therapeutics which are useful according to the invention for treatment of a nervous system disorder may be selected by testing for biological activity in promoting the survival or differentiation of neurons. For example, and not by way of limitation, therapeutics which elicit any of the following effects may be useful according to the invention:  
       [0240] (i) increased survival time of neurons in culture;  
       [0241] (ii) increased sprouting of neurons in culture or in vivo;  
       [0242] (iii) increased production of a neuron-associated molecule in culture or in vivo, e.g., choline acetyltransferase or acetylcholinesterase with respect to motor neurons; or  
       [0243] (iv) decreased symptoms of neuron dysfunction in vivo.  
       [0244] Such effects may be measured by any method known in the art. In preferred, non-limiting embodiments, increased survival of neurons may be measured by the method set forth in Arakawa et al. (1990, J. Neurosci. 10:3507-3515); increased sprouting of neurons may be detected by methods set forth in Pestronk et al. (1980, Exp. Neurol. 70:65-82) or Brown et al. (1981, Ann. Rev. Neurosci. 4:17-42); increased production of neuron-associated molecules may be measured by bioassay, enzymatic assay, antibody binding, Northern blot assay, etc., depending on the molecule to be measured; and motor neuron dysfunction may be measured by assessing the physical manifestation of motor neuron disorder, e.g., weakness, motor neuron conduction velocity, or functional disability.  
       [0245] In specific embodiments, motor neuron disorders that may be treated according to the invention include but are not limited to disorders such as infarction, infection, exposure to toxin, trauma, surgical damage, degenerative disease or malignancy that may affect motor neurons as well as other components of the nervous system, as well as disorders that selectively affect neurons such as amyotrophic lateral sclerosis, and including but not limited to progressive spinal muscular atrophy, progressive bulbar palsy, primary lateral sclerosis, infantile and juvenile muscular atrophy, progressive bulbar paralysis of childhood (Fazio-Londe syndrome), poliomyelitis and the post polio syndrome, and Hereditary Motorsensory Neuropathy (Charcot-Marie-Tooth Disease).  
       4.10.18 Other Activities  
       [0246] A polypeptide of the invention may also exhibit one or more of the following additional activities or effects: inhibiting the growth, infection or function of, or killing, infectious agents, including, without limitation, bacteria, viruses, fungi and other parasites; effecting (suppressing or enhancing) bodily characteristics, including, without limitation, height, weight, hair color, eye color, skin, fat to lean ratio or other tissue pigmentation, or organ or body part size or shape (such as, for example, breast augmentation or diminution, change in bone form or shape); effecting biorhythms or circadian cycles or rhythms; effecting the fertility of male or female subjects; effecting the metabolism, catabolism, anabolism, processing, utilization, storage or elimination of dietary fat, lipid, protein, carbohydrate, vitamins, minerals, co-factors or other nutritional factors or component(s); effecting behavioral characteristics, including, without limitation, appetite, libido, stress, cognition (including cognitive disorders), depression (including depressive disorders) and violent behaviors; providing analgesic effects or other pain reducing effects; promoting differentiation and growth of embryonic stem cells in lineages other than hematopoietic lineages; hormonal or endocrine activity; in the case of enzymes, correcting deficiencies of the enzyme and treating deficiency-related diseases; treatment of hyperproliferative disorders (such as, for example, psoriasis); immunoglobulin-like activity (such as, for example, the ability to bind antigens or complement); and the ability to act as an antigen in a vaccine composition to raise an immune response against such protein or another material or entity which is cross-reactive with such protein.  
       4.10.19 Identification of Polymorphisms  
       [0247] The demonstration of polymorphisms makes possible the identification of such polymorphisms in human subjects and the pharmacogenetic use of this information for diagnosis and treatment. Such polymorphisms may be associated with, e.g., differential predisposition or susceptibility to various disease states (such as disorders involving inflammation or immune response) or a differential response to drug administration, and this genetic information can be used to tailor preventive or therapeutic treatment appropriately. For example, the existence of a polymorphism associated with a predisposition to inflammation or autoimmune disease makes possible the diagnosis of this condition in humans by identifying the presence of the polymorphism.  
       [0248] Polymorphisms can be identified in a variety of ways known in the art which all generally involve obtaining a sample from a patient, analyzing DNA from the sample, optionally involving isolation or amplification of the DNA, and identifying the presence of the polymorphism in the DNA. For example, PCR may be used to amplify an appropriate fragment of genomic DNA which may then be sequenced. Alternatively, the DNA may be subjected to allele-specific oligonucleotide hybridization (in which appropriate oligonucleotides are hybridized to the DNA under conditions permitting detection of a single base mismatch) or to a single nucleotide extension assay (in which an oligonucleotide that hybridizes immediately adjacent to the position of the polymorphism is extended with one or more labeled nucleotides). In addition, traditional restriction fragment length polymorphism analysis (using restriction enzymes that provide differential digestion of the genomic DNA depending on the presence or absence of the polymorphism) may be performed. Arrays with nucleotide sequences of the present invention can be used to detect polymorphisms. The array can comprise modified nucleotide sequences of the present invention in order to detect the nucleotide sequences of the present invention. In the alternative, any one of the nucleotide sequences of the present invention can be placed on the array to detect changes from those sequences.  
       [0249] Alternatively a polymorphism resulting in a change in the amino acid sequence could also be detected by detecting a corresponding change in amino acid sequence of the protein, e.g., by an antibody specific to the variant sequence.  
       4.10.20 Arthritis and Inflammation  
       [0250] The immunosuppressive effects of the compositions of the invention against rheumatoid arthritis is determined in an experimental animal model system. The experimental model system is adjuvant induced arthritis in rats, and the protocol is described by J. Holoshitz, et at., 1983, Science, 219:56, or by B. Waksman et al., 1963, Int. Arch. Allergy Appl. Immunol., 23:129. Induction of the disease can be caused by a single injection, generally intradermally, of a suspension of killed  Mycobacterium tuberculosis  in complete Freund&#39;s adjuvant (CFA). The route of injection can vary, but rats may be injected at the base of the tail with an adjuvant mixture. The polypeptide is administered in phosphate buffered solution (PBS) at a dose of about 1-5 mg/kg. The control consists of administering PBS only.  
       [0251] The procedure for testing the effects of the test compound would consist of intradermally injecting killed  Mycobacterium tuberculosis  in CFA followed by immediately administering the test compound and subsequent treatment every other day until day 24. At 14, 15, 18, 20, 22, and 24 days after injection of Mycobacterium CFA, an overall arthritis score may be obtained as described by J. Holoskitz above. An analysis of the data would reveal that the test compound would have a dramatic affect on the swelling of the joints as measured by a decrease of the arthritis score.  
       4.11 Therapeutic Methods  
       [0252] The compositions (including polypeptide fragments, analogs, variants and antibodies or other binding partners or modulators including antisense polynucleotides) of the invention have numerous applications in a variety of therapeutic methods. Examples of therapeutic applications include, but are not limited to, those exemplified herein.  
       4.11.1 Example  
       [0253] One embodiment of the invention is the administration of an effective amount of the polypeptides or other composition of the invention to individuals affected by a disease or disorder that can be modulated by regulating the peptides of the invention. While the mode of administration is not particularly important, parenteral administration is preferred. An exemplary mode of administration is to deliver an intravenous bolus. The dosage of the polypeptides or other composition of the invention will normally be determined by the prescribing physician. It is to be expected that the dosage will vary according to the age, weight, condition and response of the individual patient. Typically, the amount of polypeptide administered per dose will be in the range of about 0.01 μg/kg to 100 mg/kg of body weight, with the preferred dose being about 0.1 μg/kg to 10 mg/kg of patient body weight. For parenteral administration, polypeptides of the invention will be formulated in an injectable form combined with a pharmaceutically acceptable parenteral vehicle. Such vehicles are well known in the art and examples include water, saline, Ringer&#39;s solution, dextrose solution, and solutions consisting of small amounts of the human serum albumin. The vehicle may contain minor amounts of additives that maintain the isotonicity and stability of the polypeptide or other active ingredient. The preparation of such solutions is within the skill of the art.  
       4.12 Pharmaceutical Formulations and Routes of Administration  
       [0254] A protein or other composition of the present invention (from whatever source derived, including without limitation from recombinant and non-recombinant sources and including antibodies and other binding partners of the polypeptides of the invention) may be administered to a patient in need, by itself, or in pharmaceutical compositions where it is mixed with suitable carriers or excipient(s) at doses to treat or ameliorate a variety of disorders. Such a composition may optionally contain (in addition to protein or other active ingredient and a carrier) diluents, fillers, salts, buffers, stabilizers, solubilizers, and other materials well known in the art. The term “pharmaceutically acceptable” means a non-toxic material that does not interfere with the effectiveness of the biological activity of the active ingredient(s). The characteristics of the carrier will depend on the route of administration. The pharmaceutical composition of the invention may also contain cytokines, lymphokines, or other hematopoietic factors such as M-CSF, GM-CSF, TNF, IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, IL-13, IL-14, IL-15, IFN, TNF0, TNF1, TNF2, G-CSF, Meg-CSF, thrombopoietin, stem cell factor, and erythropoietin. In further compositions, proteins of the invention may be combined with other agents beneficial to the treatment of the disease or disorder in question. These agents include various growth factors such as epidermal growth factor (EGF), platelet-derived growth factor (PDGF), transforming growth factors (TGF-α and TGF-β), insulin-like growth factor (IGF), as well as cytokines described herein.  
       [0255] The pharmaceutical composition may further contain other agents which either enhance the activity of the protein or other active ingredient or complement its activity or use in treatment. Such additional factors and/or agents may be included in the pharmaceutical composition to produce a synergistic effect with protein or other active ingredient of the invention, or to minimize side effects. Conversely, protein or other active ingredient of the present invention may be included in formulations of the particular clotting factor, cytokine, lymphokine, other hematopoietic factor, thrombolytic or anti-thrombotic factor, or anti-inflammatory agent to minimize side effects of the clotting factor, cytokine, lymphokine, other hematopoietic factor, thrombolytic or anti-thrombotic factor, or anti-inflammatory agent (such as IL-1Ra, IL-1 Hy1, IL-1 Hy2, anti-TNF, corticosteroids, immunosuppressive agents). A protein of the present invention may be active in multimers (e.g., heterodimers or homodimers) or complexes with itself or other proteins. As a result, pharmaceutical compositions of the invention may comprise a protein of the invention in such multimeric or complexed form.  
       [0256] As an alternative to being included in a pharmaceutical composition of the invention including a first protein, a second protein or a therapeutic agent may be concurrently administered with the first protein (e.g., at the same time, or at differing times provided that therapeutic concentrations of the combination of agents is achieved at the treatment site). Techniques for formulation and administration of the compounds of the instant application may be found in “Remington&#39;s Pharmaceutical Sciences,” Mack Publishing Co., Easton, Pa., latest edition. A therapeutically effective dose further refers to that amount of the compound sufficient to result in amelioration of symptoms, e.g., treatment, healing, prevention or amelioration of the relevant medical condition, or an increase in rate of treatment, healing, prevention or amelioration of such conditions. When applied to an individual active ingredient, administered alone, a therapeutically effective dose refers to that ingredient alone. When applied to a combination, a therapeutically effective dose refers to combined amounts of the active ingredients that result in the therapeutic effect, whether administered in combination, serially or simultaneously.  
       [0257] In practicing the method of treatment or use of the present invention, a therapeutically effective amount of protein or other active ingredient of the present invention is administered to a mammal having a condition to be treated. Protein or other active ingredient of the present invention may be administered in accordance with the method of the invention either alone or in combination with other therapies such as treatments employing cytokines, lymphokines or other hematopoietic factors. When co-administered with one or more cytokines, lymphokines or other hematopoietic factors, protein or other active ingredient of the present invention may be administered either simultaneously with the cytokine(s), lymphokine(s), other hematopoietic factor(s), thrombolytic or anti-thrombotic factors, or sequentially. If administered sequentially, the attending physician will decide on the appropriate sequence of administering protein or other active ingredient of the present invention in combination with cytokine(s), lymphokine(s), other hematopoietic factor(s), thrombolytic or anti-thrombotic factors.  
       4.12.1 Routes of Administration  
       [0258] Suitable routes of administration may, for example, include oral, rectal, transmucosal, or intestinal administration; parenteral delivery, including intramuscular, subcutaneous, intramedullary injections, as well as intrathecal, direct intraventricular, intravenous, intraperitoneal, intranasal, or intraocular injections. Administration of protein or other active ingredient of the present invention used in the pharmaceutical composition or to practice the method of the present invention can be carried out in a variety of conventional ways, such as oral ingestion, inhalation, topical application or cutaneous, subcutaneous, intraperitoneal, parenteral or intravenous injection. Intravenous administration to the patient is preferred.  
       [0259] Alternately, one may administer the compound in a local rather than systemic manner, for example, via injection of the compound directly into a arthritic joints or in fibrotic tissue, often in a depot or sustained release formulation. In order to prevent the scarring process frequently occurring as complication of glaucoma surgery, the compounds may be administered topically, for example, as eye drops. Furthermore, one may administer the drug in a targeted drug delivery system, for example, in a liposome coated with a specific antibody, targeting, for example, arthritic or fibrotic tissue. The liposomes will be targeted to and taken up selectively by the afflicted tissue.  
       [0260] The polypeptides of the invention are administered by any route that delivers an effective dosage to the desired site of action. The determination of a suitable route of administration and an effective dosage for a particular indication is within the level of skill in the art. Preferably for wound treatment, one administers the therapeutic compound directly to the site. Suitable dosage ranges for the polypeptides of the invention can be extrapolated from these dosages or from similar studies in appropriate animal models. Dosages can then be adjusted as necessary by the clinician to provide maximal therapeutic benefit.  
       4.12.2 Compositions/Formulations  
       [0261] Pharmaceutical compositions for use in accordance with the present invention thus may be formulated in a conventional manner using one or more physiologically acceptable carriers comprising excipients and auxiliaries which facilitate processing of the active compounds into preparations which can be used pharmaceutically. These pharmaceutical compositions may be manufactured in a manner that is itself known. e.g., by means of conventional mixing, dissolving, granulating, dragee-making, levigating, emulsifying, encapsulating, entrapping or lyophilizing processes. Proper formulation is dependent upon the route of administration chosen. When a therapeutically effective amount of protein or other active ingredient of the present invention is administered orally, protein or other active ingredient of the present invention will be in the form of a tablet, capsule, powder, solution or elixir. When administered in tablet form, the pharmaceutical composition of the invention may additionally contain a solid carrier such as a gelatin or an adjuvant. The tablet, capsule, and powder contain from about 5 to 95% protein or other active ingredient of the present invention, and preferably from about 25 to 90% protein or other active ingredient of the present invention. When administered in liquid form, a liquid carrier such as water, petroleum, oils of animal or plant origin such as peanut oil, mineral oil, soybean oil, or sesame oil, or synthetic oils may be added. The liquid form of the pharmaceutical composition may further contain physiological saline solution, dextrose or other saccharide solution, or glycols such as ethylene glycol, propylene glycol or polyethylene glycol. When administered in liquid form, the pharmaceutical composition contains from about 0.5 to 90% by weight of protein or other active ingredient of the present invention, and preferably from about 1 to 50% protein or other active ingredient of the present invention.  
       [0262] When a therapeutically effective amount of protein or other active ingredient of the present invention is administered by intravenous, cutaneous or subcutaneous injection, protein or other active ingredient of the present invention will be in the form of a pyrogen-free, parenterally acceptable aqueous solution. The preparation of such parenterally acceptable protein or other active ingredient solutions, having due regard to pH, isotonicity, stability, and the like, is within the skill in the art. A preferred pharmaceutical composition for intravenous, cutaneous, or subcutaneous injection should contain, in addition to protein or other active ingredient of the present invention, an isotonic vehicle such as Sodium Chloride Injection, Ringer&#39;s Injection, Dextrose Injection, Dextrose and Sodium Chloride Injection, Lactated Ringer&#39;s Injection, or other vehicle as known in the art. The pharmaceutical composition of the present invention may also contain stabilizers, preservatives, buffers, antioxidants, or other additives known to those of skill in the art. For injection, the agents of the invention may be formulated in aqueous solutions, preferably in physiologically compatible buffers such as Hanks&#39;s solution, Ringer&#39;s solution, or physiological saline buffer. For transmucosal administration, penetrants appropriate to the barrier to be permeated are used in the formulation. Such penetrants are generally known in the art.  
       [0263] For oral administration, the compounds can be formulated readily by combining the active compounds with pharmaceutically acceptable carriers well known in the art. Such carriers enable the compounds of the invention to be formulated as tablets, pills, dragees, capsules, liquids, gels, syrups, slurries, suspensions and the like, for oral ingestion by a patient to be treated. Pharmaceutical preparations for oral use can be obtained from a solid excipient, optionally grinding a resulting mixture, and processing the mixture of granules, after adding suitable auxiliaries, if desired, to obtain tablets or dragee cores. Suitable excipients are, in particular, fillers such as sugars, including lactose, sucrose, mannitol, or sorbitol; cellulose preparations such as, for example, maize starch, wheat starch, rice starch, potato starch, gelatin, gum tragacanth, methyl cellulose, hydroxypropylmethyl-cellulose, sodium carboxymethylcellulose, and/or polyvinylpyrrolidone (PVP). If desired, disintegrating agents may be added, such as the cross-linked polyvinyl pyrrolidone, agar, or alginic acid or a salt thereof such as sodium alginate. Dragee cores are provided with suitable coatings. For this purpose, concentrated sugar solutions may be used, which may optionally contain gum arabic, talc, polyvinyl pyrrolidone, carbopol gel, polyethylene glycol, and/or titanium dioxide, lacquer solutions, and suitable organic solvents or solvent mixtures. Dyestuffs or pigments may be added to the tablets or dragee coatings for identification or to characterize different combinations of active compound doses.  
       [0264] Pharmaceutical preparations which can be used orally include push-fit capsules made of gelatin, as well as soft, sealed capsules made of gelatin and a plasticizer, such as glycerol or sorbitol. The push-fit capsules can contain the active ingredients in admixture with filler such as lactose, binders such as starches, and/or lubricants such as talc or magnesium stearate and, optionally, stabilizers. In soft capsules, the active compounds may be dissolved or suspended in suitable liquids, such as fatty oils, liquid paraffin, or liquid polyethylene glycols. In addition, stabilizers may be added. All formulations for oral administration should be in dosages suitable for such administration. For buccal administration, the compositions may take the form of tablets or lozenges formulated in conventional manner.  
       [0265] For administration by inhalation, the compounds for use according to the present invention are conveniently delivered in the form of an aerosol spray presentation from pressurized packs or a nebuliser, with the use of a suitable propellant, e.g., dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas. In the case of a pressurized aerosol the dosage unit may be determined by providing a valve to deliver a metered amount. Capsules and cartridges of, e.g., gelatin for use in an inhaler or insufflator may be formulated containing a powder mix of the compound and a suitable powder base such as lactose or starch. The compounds may be formulated for parenteral administration by injection, e.g., by bolus injection or continuous infusion. Formulations for injection may be presented in unit dosage form, e.g., in ampules or in multi-dose containers, with an added preservative. The compositions may take such forms as suspensions, solutions or emulsions in oily or aqueous vehicles, and may contain formulatory agents such as suspending, stabilizing and/or dispersing agents.  
       [0266] Pharmaceutical formulations for parenteral administration include aqueous solutions of the active compounds in water-soluble form. Additionally, suspensions of the active compounds may be prepared as appropriate oily injection suspensions. Suitable lipophilic solvents or vehicles include fatty oils such as sesame oil, or synthetic fatty acid esters, such as ethyl oleate or triglycerides, or liposomes. Aqueous injection suspensions may contain substances which increase the viscosity of the suspension, such as sodium carboxymethyl cellulose, sorbitol, or dextran. Optionally, the suspension may also contain suitable stabilizers or agents which increase the solubility of the compounds to allow for the preparation of highly concentrated solutions. Alternatively, the active ingredient may be in powder form for constitution with a suitable vehicle, e.g., sterile pyrogen-free water, before use.  
       [0267] The compounds may also be formulated in rectal compositions such as suppositories or retention enemas, e.g., containing conventional suppository bases such as cocoa butter or other glycerides. In addition to the formulations described previously, the compounds may also be formulated as a depot preparation. Such long acting formulations may be administered by implantation (for example subcutaneously or intramuscularly) or by intramuscular injection. Thus, for example, the compounds may be formulated with suitable polymeric or hydrophobic materials (for example as an emulsion in an acceptable oil) or ion exchange resins, or as sparingly soluble derivatives, for example, as a sparingly soluble salt.  
       [0268] A pharmaceutical carrier for the hydrophobic compounds of the invention is a co-solvent system comprising benzyl alcohol, a nonpolar surfactant, a water-miscible organic polymer, and an aqueous phase. The co-solvent system may be the VPD co-solvent system. VPD is a solution of 3% w/v benzyl alcohol, 8% w/v of the nonpolar surfactant polysorbate 80, and 65% w/v polyethylene glycol 300, made up to volume in absolute ethanol. The VPD co-solvent system (VPD:5W) consists of VPD diluted 1:1 with a 5% dextrose in water solution. This co-solvent system dissolves hydrophobic compounds well, and itself produces low toxicity upon systemic administration. Naturally, the proportions of a co-solvent system may be varied considerably without destroying its solubility and toxicity characteristics. Furthermore, the identity of the co-solvent components may be varied: for example, other low-toxicity nonpolar. surfactants may be used instead of polysorbate 80; the fraction size of polyethylene glycol may be varied; other biocompatible polymers may replace polyethylene glycol, e.g. polyvinyl pyrrolidone; and other sugars or polysaccharides may substitute for dextrose. Alternatively, other delivery systems for hydrophobic pharmaceutical compounds may be employed. Liposomes and emulsions are well known examples of delivery vehicles or carriers for hydrophobic drugs. Certain organic solvents such as dimethylsulfoxide also may be employed, although usually at the cost of greater toxicity. Additionally, the compounds may be delivered using a sustained-release system, such as semipermeable matrices of solid hydrophobic polymers containing the therapeutic agent. Various types of sustained-release materials have been established and are well known by those skilled in the art. Sustained-release capsules may, depending on their chemical nature, release the compounds for a few weeks up to over 100 days. Depending on the chemical nature and the biological stability of the therapeutic reagent, additional strategies for protein or other active ingredient stabilization may be employed.  
       [0269] The pharmaceutical compositions also may comprise suitable solid or gel phase carriers or excipients. Examples of such carriers or excipients include but are not limited to calcium carbonate, calcium phosphate, various sugars, starches, cellulose derivatives, gelatin, and polymers such as polyethylene glycols. Many of the active ingredients of the invention may be provided as salts with pharmaceutically compatible counter ions. Such pharmaceutically acceptable base addition salts are those salts which retain the biological effectiveness and properties of the free acids and which are obtained by reaction with inorganic or organic bases such as sodium hydroxide, magnesium hydroxide, ammonia, trialkylamine, dialkylamine, monoalkylamine, dibasic amino acids, sodium acetate, potassium benzoate, triethanol amine and the like.  
       [0270] The pharmaceutical composition of the invention may be in the form of a complex of the protein(s) or other active ingredient(s) of present invention along with protein or peptide antigens. The protein and/or peptide antigen will deliver a stimulatory signal to both B and T lymphocytes. B lymphocytes will respond to antigen through their surface immunoglobulin receptor. T lymphocytes will respond to antigen through the T cell receptor (TCR) following presentation of the antigen by MHC proteins. MHC and structurally related proteins including those encoded by class I and class II MHC genes on host cells will serve to present the peptide antigen(s) to T lymphocytes. The antigen components could also be supplied as purified MHC-peptide complexes alone or with co-stimulatory molecules that can directly signal T cells. Alternatively antibodies able to bind surface immunoglobulin and other molecules on B cells as well as antibodies able to bind the TCR and other molecules on T cells can be combined with the pharmaceutical composition of the invention.  
       [0271] The pharmaceutical composition of the invention may be in the form of a liposome in which protein of the present invention is combined, in addition to other pharmaceutically acceptable carriers, with amphipathic agents such as lipids which exist in aggregated form as micelles, insoluble monolayers, liquid crystals, or lamellar layers in aqueous solution. Suitable lipids for liposomal formulation include, without limitation, monoglycerides, diglycerides, sulfatides, lysolecithins, phospholipids, saponin, bile acids, and the like. Preparation of such liposomal formulations is within the level of skill in the art, as disclosed, for example, in U.S. Pat. Nos. 4,235,871; 4,501,728; 4,837,028; and 4,737,323, all of which are incorporated herein by reference.  
       [0272] The amount of protein or other active ingredient of the present invention in the pharmaceutical composition of the present invention will depend upon the nature and severity of the condition being treated, and on the nature of prior treatments which the patient has undergone. Ultimately, the attending physician will decide the amount of protein or other active ingredient of the present invention with which to treat each individual patient. Initially, the attending physician will administer low doses of protein or other active ingredient of the present invention and observe the patient&#39;s response. Larger doses of protein or other active ingredient of the present invention may be administered until the optimal therapeutic effect is obtained for the patient, and at that point the dosage is not increased further. It is contemplated that the various pharmaceutical compositions used to practice the method of the present invention should contain about 0.01 μg to about 100 mg (preferably about 0.1 μg to about 10 mg, more preferably about 0.1 μg to about 1 mg) of protein or other active ingredient of the present invention per kg body weight. For compositions of the present invention which are useful for bone, cartilage, tendon or ligament regeneration, the therapeutic method includes administering the composition topically, systematically, or locally as an implant or device. When administered, the therapeutic composition for use in this invention is, of course, in a pyrogen-free, physiologically acceptable form. Further, the composition may desirably be encapsulated or injected in a viscous form for delivery to the site of bone, cartilage or tissue damage. Topical administration may be suitable for wound healing and tissue repair. Therapeutically useful agents other than a protein or other active ingredient of the invention which may also optionally be included in the composition as described above, may alternatively or additionally, be administered simultaneously or sequentially with the composition in the methods of the invention. Preferably for bone and/or cartilage formation, the composition would include a matrix capable of delivering the protein-containing or other active ingredient-containing composition to the site of bone and/or cartilage damage, providing a structure for the developing bone and cartilage and optimally capable of being resorbed into the body. Such matrices may be formed of materials presently in use for other implanted medical applications.  
       [0273] The choice of matrix material is based on biocompatibility, biodegradability, mechanical properties, cosmetic appearance and interface properties. The particular application of the compositions will define the appropriate formulation. Potential matrices for the compositions may be biodegradable and chemically defined calcium sulfate, tricalcium phosphate, hydroxyapatite, polylactic acid, polyglycolic acid and polyanhydrides. Other potential materials are biodegradable and biologically well-defined, such as bone or dermal collagen. Further matrices are comprised of pure proteins or extracellular matrix components. Other potential matrices are nonbiodegradable and chemically defined, such as sintered hydroxyapatite, bioglass, aluminates, or other ceramics. Matrices may be comprised of combinations of any of the above mentioned types of material, such as polylactic acid and hydroxyapatite or collagen and tricalcium phosphate. The bioceramics may be altered in composition, such as in calcium-aluminate-phosphate and processing to alter pore size, particle size, particle shape, and biodegradability. Presently preferred is a 50:50 (mole weight) copolymer of lactic acid and glycolic acid in the form of porous particles having diameters ranging from 150 to 800 microns. In some applications, it will be useful to utilize a sequestering agent, such as carboxymethyl cellulose or autologous blood clot, to prevent the protein compositions from disassociating from the matrix.  
       [0274] A preferred family of sequestering agents is cellulosic materials such as alkylcelluloses (including hydroxyalkylcelluloses), including methylcellulose, ethylcellulose, hydroxyethylcellulose, hydroxypropylcellulose, hydroxypropyl-methylcellulose, and carboxymethylcellulose, the most preferred being cationic salts of carboxymethylcellulose (CMC). Other preferred sequestering agents include hyaluronic acid, sodium alginate, poly(ethylene glycol), polyoxyethylene oxide, carboxyvinyl polymer and poly(vinyl alcohol). The amount of sequestering agent useful herein is 0.5-20 wt %, preferably 1-10 wt % based on total formulation weight, which represents the amount necessary to prevent desorption of the protein from the polymer matrix and to provide appropriate handling of the composition, yet not so much that the progenitor cells are prevented from infiltrating the matrix, thereby providing the protein the opportunity to assist the osteogenic activity of the progenitor cells. In further compositions, proteins or other active ingredients of the invention may be combined with other agents beneficial to the treatment of the bone and/or cartilage defect, wound, or tissue in question. These agents include various growth factors such as epidermal growth factor (EGF), platelet derived growth factor (PDGF), transforming growth factors (TGF-α and TGF-β), and insulin-like growth factor (IGF).  
       [0275] The therapeutic compositions are also presently valuable for veterinary applications. Particularly domestic animals and thoroughbred horses, in addition to humans, are desired patients for such treatment with proteins or other active ingredients of the present invention. The dosage regimen of a protein-containing pharmaceutical composition to be used in tissue regeneration will be determined by the attending physician considering various factors which modify the action of the proteins, e.g., amount of tissue weight desired to be formed, the site of damage, the condition of the damaged tissue, the size of a wound, type of damaged tissue (e.g., bone), the patient&#39;s age, sex, and diet, the severity of any infection, time of administration and other clinical factors. The dosage may vary with the type of matrix used in the reconstitution and with inclusion of other proteins in the pharmaceutical composition. For example, the addition of other known growth factors, such as IGF I (insulin like growth factor I), to the final composition, may also effect the dosage. Progress can be monitored by periodic assessment of tissue/bone growth and/or repair, for example, X-rays, histomorphometric determinations and tetracycline labeling.  
       [0276] Polynucleotides of the present invention can also be used for gene therapy. Such polynucleotides can be introduced either in vivo or ex vivo into cells for expression in a mammalian subject. Polynucleotides of the invention may also be administered by other known methods for introduction of nucleic acid into a cell or organism (including, without limitation, in the form of viral vectors or naked DNA). Cells may also be cultured ex vivo in the presence of proteins of the present invention in order to proliferate or to produce a desired effect on or activity in such cells. Treated cells can then be introduced in vivo for therapeutic purposes.  
       4.12.3 Effective Dosage  
       [0277] Pharmaceutical compositions suitable for use in the present invention include compositions wherein the active ingredients are contained in an effective amount to achieve its intended purpose. More specifically, a therapeutically effective amount means an amount effective to prevent development of or to alleviate the existing symptoms of the subject being treated. Determination of the effective amount is well within the capability of those skilled in the art, especially in light of the detailed disclosure provided herein. For any compound used in the method of the invention, the therapeutically effective dose can be estimated initially from appropriate in vitro assays. For example, a dose can be formulated in animal models to achieve a circulating concentration range that can be used to more accurately determine useful doses in humans. For example, a dose can be formulated in animal models to achieve a circulating concentration range that includes the IC 50  as determined in cell culture (i.e., the concentration of the test compound which achieves a half-maximal inhibition of the protein&#39;s biological activity). Such information can be used to more accurately determine useful doses in humans.  
       [0278] A therapeutically effective dose refers to that amount of the compound that results in amelioration of symptoms or a prolongation of survival in a patient. Toxicity and therapeutic efficacy of such compounds can be determined by standard pharmaceutical procedures in cell cultures or experimental animals, e.g., for determining the LD 50  (the dose lethal to 50% of the population) and the ED 50  (the dose therapeutically effective in 50% of the population). The dose ratio between toxic and therapeutic effects is the therapeutic index and it can be expressed as the ratio between LD 50  and ED 50 . Compounds which exhibit high therapeutic indices are preferred. The data obtained from these cell culture assays and animal studies can be used in formulating a range of dosage for use in human. The dosage of such compounds lies preferably within a range of circulating concentrations that include the ED 50  with little or no toxicity. The dosage may vary within this range depending upon the dosage form employed and the route of administration utilized. The exact formulation, route of administration and dosage can be chosen by the individual physician in view of the patient&#39;s condition. See, e.g., Fingl et al., 1975, in “The Pharmacological Basis of Therapeutics”, Ch. 1 p. 1. Dosage amount and interval may be adjusted individually to provide plasma levels of the active moiety which are sufficient to maintain the desired effects, or minimal effective concentration (MEC). The MEC will vary for each compound but can be estimated from in vitro data. Dosages necessary to achieve the MEC will depend on individual characteristics and route of administration. However, HPLC assays or bioassays can be used to determine plasma concentrations.  
       [0279] Dosage intervals can also be determined using MEC value. Compounds should be administered using a regimen which maintains plasma levels above the MEC for 10-90% of the time, preferably between 30-90% and most preferably between 50-90%. In cases of local administration or selective uptake, the effective local concentration of the drug may not be related to plasma concentration.  
       [0280] An exemplary dosage regimen for polypeptides or other compositions of the invention will be in the range of about 0.01 μg/kg to 100 mg/kg of body weight daily, with the preferred dose being about 0.1 μg/kg to 25 mg/kg of patient body weight daily, varying in adults and children. Dosing may be once daily, or equivalent doses may be delivered at longer or shorter intervals.  
       [0281] The amount of composition administered will, of course, be dependent on the subject being treated, on the subject&#39;s age and weight, the severity of the affliction, the manner of administration and the judgment of the prescribing physician.  
       4.12.4 Packaging  
       [0282] The compositions may, if desired, be presented in a pack or dispenser device which may contain one or more unit dosage forms containing the active ingredient. The pack may, for example, comprise metal or plastic foil, such as a blister pack. The pack or dispenser device may be accompanied by instructions for administration. Compositions comprising a compound of the invention formulated in a compatible pharmaceutical carrier may also be prepared, placed in an appropriate container, and labeled for treatment of an indicated condition.  
       4.13 Antibodies  
       [0283] Also included in the invention are antibodies to proteins, or fragments of proteins of the invention. The term “antibody” as used herein refers to immunoglobulin molecules and immunologically active portions of immunoglobulin (Ig) molecules, i.e., molecules that contain an antigen binding site that specifically binds (immunoreacts with) an antigen. Such antibodies include, but are not limited to, polyclonal, monoclonal, chimeric, single chain, F ab , F ab′  and F (ab′)2  fragments, and an F ab  expression library. In general, an antibody molecule obtained from humans relates to any of the classes IgG, IgM, IgA, IgE and IgD, which differ from one another by the nature of the heavy chain present in the molecule. Certain classes have subclasses as well, such as IgG 1 , IgG 2 , and others. Furthermore, in humans, the light chain may be a kappa chain or a lambda chain. Reference herein to antibodies includes a reference to all such classes, subclasses and types of human antibody species.  
       [0284] An isolated related protein of the invention may be intended to serve as an antigen, or a portion or fragment thereof, and additionally can be used as an immunogen to generate antibodies that immunospecifically bind the antigen, using standard techniques for polyclonal and monoclonal antibody preparation. The full-length protein can be used or, alternatively, the invention provides antigenic peptide fragments of the antigen for use as immunogens. An antigenic peptide fragment comprises at least 6 amino acid residues of the amino acid sequence of the full length protein, such as an amino acid sequence shown in SEQ ID NO: 4, and encompasses an epitope thereof such that an antibody raised against the peptide forms a specific immune complex with the full length protein or with any fragment that contains the epitope. Preferably, the antigenic peptide comprises at least 10 amino acid residues, or at least 15 amino acid residues, or at least 20 amino acid residues, or at least 30 amino acid residues. Preferred epitopes encompassed by the antigenic peptide are regions of the protein that are located on its surface; commonly these are hydrophilic regions.  
       [0285] In certain embodiments of the invention, at least one epitope encompassed by the antigenic peptide is a region of related protein that is located on the surface of the protein, e.g., a hydrophilic region. A hydrophobicity analysis of the human related protein sequence will indicate which regions of a related protein are particularly hydrophilic and, therefore, are likely to encode surface residues useful for targeting antibody production. As a means for targeting antibody production, hydropathy plots showing regions of hydrophilicity and hydrophobicity may be generated by any method well known in the art, including, for example, the Kyte Doolittle or the Hopp Woods methods, either with or without Fourier transformation. See, e.g., Hopp and Woods, 1981,  Proc. Nat. Acad. Sci. USA  78: 3824-3828; Kyte and Doolittle 1982,  J Mol. Biol.  157: 105-142, each of which is incorporated herein by reference in its entirety. Antibodies that are specific for one or more domains within an antigenic protein, or derivatives, fragments, analogs or homologs thereof, are also provided herein.  
       [0286] A protein of the invention, or a derivative, fragment, analog, homolog or ortholog thereof, may be utilized as an immunogen in the generation of antibodies that immunospecifically bind these protein components.  
       [0287] Various procedures known within the art may be used for the production of polyclonal or monoclonal antibodies directed against a protein of the invention, or against derivatives, fragments, analogs homologs or orthologs thereof (see, for example, Antibodies: A Laboratory Manual, Harlow E, and Lane D, 1988, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., incorporated herein by reference). Some of these antibodies are discussed below.  
       5.13.1 Polyclonal Antibodies  
       [0288] For the production of polyclonal antibodies, various suitable host animals (e.g., rabbit, goat, mouse or other mammal) may be immunized by one or more injections with the native protein, a synthetic variant thereof, or a derivative of the foregoing. An appropriate immunogenic preparation can contain, for example, the naturally occurring immunogenic protein, a chemically synthesized polypeptide representing the immunogenic protein, or a recombinantly expressed immunogenic protein. Furthermore, the protein may be conjugated to a second protein known to be immunogenic in the mammal being immunized. Examples of such immunogenic proteins include but are not limited to keyhole limpet hemocyanin, serum albumin, bovine thyroglobulin, and soybean trypsin inhibitor. The preparation can further include an adjuvant. Various adjuvants used to increase the immunological response include, but are not limited to, Freund&#39;s (complete and incomplete), mineral gels (e.g., aluminum hydroxide), surface active substances (e.g., lysolecithin, pluronic polyols, polyanions, peptides, oil emulsions, dinitrophenol, etc.), adjuvants usable in humans such as Bacille Calmette-Guerin and Corynebacterium parvum, or similar immunostimulatory agents. Additional examples of adjuvants which can be employed include MPL-TDM adjuvant (monophosphoryl Lipid A, synthetic trehalose dicorynomycolate).  
       [0289] The polyclonal antibody molecules directed against the immunogenic protein can be isolated from the mammal (e.g., from the blood) and further purified by well known techniques, such as affinity chromatography using protein A or protein G, which provide primarily the IgG fraction of immune serum. Subsequently, or alternatively, the specific antigen which is the target of the immunoglobulin sought, or an epitope thereof, may be immobilized on a column to purify the immune specific antibody by immunoaffinity chromatography. Purification of immunoglobulins is discussed, for example, by D. Wilkinson (The Scientist, published by The Scientist, Inc., Philadelphia Pa., Vol. 14, No. 8 (Apr. 17, 2000), pp. 25-28).  
       5.13.2 Monoclonal Antibodies  
       [0290] The term “monoclonal antibody” (MAb) or “monoclonal antibody composition”, as used herein, refers to a population of antibody molecules that contain only one molecular species of antibody molecule consisting of a unique light chain gene product and a unique heavy chain gene product. In particular, the complementarity determining regions (CDRs) of the monoclonal antibody are identical in all the molecules of the population. MAbs thus contain an antigen binding site capable of immunoreacting with a particular epitope of the antigen characterized by a unique binding affinity for it.  
       [0291] Monoclonal antibodies can be prepared using hybridoma methods, such as those described by Kohler and Milstein,  Nature,  256:495 (1975). In a hybridoma method, a mouse, hamster, or other appropriate host animal, is typically immunized with an immunizing agent to elicit lymphocytes that produce or are capable of producing antibodies that will specifically bind to the immunizing agent. Alternatively, the lymphocytes can be immunized in vitro.  
       [0292] The immunizing agent will typically include the protein antigen, a fragment thereof or a fusion protein thereof. Generally, either peripheral blood lymphocytes are used if cells of human origin are desired, or spleen cells or lymph node cells are used if non-human mammalian sources are desired. The lymphocytes are then fused with an immortalized cell line using a suitable fusing agent, such as polyethylene glycol, to form a hybridoma cell (Goding,  Monoclonal Antibodies: Principles and Practice,  Academic Press, (1986) pp. 59-103). Immortalized cell lines are usually transformed mammalian cells, particularly myeloma cells of rodent, bovine and human origin. Usually, rat or mouse myeloma cell lines are employed. The hybridoma cells can be cultured in a suitable culture medium that preferably contains one or more substances that inhibit the growth or survival of the unfused, immortalized cells. For example, if the parental cells lack the enzyme hypoxanthine guanine phosphoribosyl transferase (HGPRT or HPRT), the culture medium for the hybridomas typically will include hypoxanthine, aminopterin, and thymidine (“HAT medium”), which substances prevent the growth of HGPRT-deficient cells.  
       [0293] Preferred immortalized cell lines are those that fuse efficiently, support stable high level expression of antibody by the selected antibody-producing cells, and are sensitive to a medium such as HAT medium. More preferred immortalized cell lines are murine myeloma lines, which can be obtained, for instance, from the Salk Institute Cell Distribution Center, San Diego, Calif. and the American Type Culture Collection, Manassas, Va. Human myeloma and mouse-human heteromyeloma cell lines also have been described for the production of human monoclonal antibodies (Kozbor,  J. Immunol.,  133:3001 (1984); Brodeur et al.,  Monoclonal Antibody Production Techniques and Applications,  Marcel Dekker, Inc., New York, (1987) pp. 51-63).  
       [0294] The culture medium in which the hybridoma cells are cultured can then be assayed for the presence of monoclonal antibodies directed against the antigen. Preferably, the binding specificity of monoclonal antibodies produced by the hybridoma cells is determined by immunoprecipitation or by an in vitro binding assay, such as radioimmunoassay (RIA) or enzyme-linked immunoabsorbent assay (ELISA). Such techniques and assays are known in the art. The binding affinity of the monoclonal antibody can, for example, be determined by the Scatchard analysis of Munson and Pollard,  Anal. Biochem.,  107:220 (1980). Preferably, antibodies having a high degree of specificity and a high binding affinity for the target antigen are isolated.  
       [0295] After the desired hybridoma cells are identified, the clones can be subcloned by limiting dilution procedures and grown by standard methods. Suitable culture media for this purpose include, for example, Dulbecco&#39;s Modified Eagle&#39;s Medium and RPMI-1640 medium. Alternatively, the hybridoma cells can be grown in vivo as ascites in a mammal.  
       [0296] The monoclonal antibodies secreted by the subclones can be isolated or purified from the culture medium or ascites fluid by conventional immunoglobulin purification procedures such as, for example, protein A-Sepharose, hydroxylapatite chromatography, gel electrophoresis, dialysis, or affinity chromatography.  
       [0297] The monoclonal antibodies can also be made by recombinant DNA methods, such as those described in U.S. Pat. No. 4,816,567. DNA encoding the monoclonal antibodies of the invention can be readily isolated and sequenced using conventional procedures (e.g., by using oligonucleotide probes that are capable of binding specifically to genes encoding the heavy and light chains of murine antibodies). The hybridoma cells of the invention serve as a preferred source of such DNA. Once isolated, the DNA can be placed into expression vectors, which are then transfected into host cells such as simian COS cells, Chinese hamster ovary (CHO) cells, or myeloma cells that do not otherwise produce immunoglobulin protein to obtain the synthesis of monoclonal antibodies in the recombinant host cells. The DNA also can be modified, for example, by substituting the coding sequence for human heavy and light chain constant domains in place of the homologous murine sequences (U.S. Pat. No. 4,816,567; Morrison,  Nature  368, 812-13 (1994)) or by covalently joining to the immunoglobulin coding sequence all or part of the coding sequence for a non-immunoglobulin polypeptide. Such a non-immunoglobulin polypeptide can be substituted for the constant domains of an antibody of the invention, or can be substituted for the variable domains of one antigen-combining site of an antibody of the invention to create a chimeric bivalent antibody.  
       5.13.2 Humanized Antibodies  
       [0298] The antibodies directed against the protein antigens of the invention can further comprise humanized antibodies or human antibodies. These antibodies are suitable for administration to humans without engendering an immune response by the human against the administered immunoglobulin. Humanized forms of antibodies are chimeric immunoglobulins, immunoglobulin chains or fragments thereof (such as Fv, Fab, Fab′, F(ab′) 2  or other antigen-binding subsequences of antibodies) that are principally comprised of the sequence of a human immunoglobulin, and contain minimal sequence derived from a non-human immunoglobulin. Humanization can be performed following the method of Winter and co-workers (Jones et al.,  Nature,  321:522-525 (1986); Riechmann et al.,  Nature,  332:323-327 (1988); Verhoeyen et al.,  Science,  239:1534-1536 (1988)), by substituting rodent CDRs or CDR sequences for the corresponding sequences of a human antibody. (See also U.S. Pat. No. 5,225,539.) In some instances, Fv framework residues of the human immunoglobulin are replaced by corresponding non-human residues. Humanized antibodies can also comprise residues which are found neither in the recipient antibody nor in the imported CDR or framework sequences. In general, the humanized antibody will comprise substantially all of at least one, and typically two, variable domains, in which all or substantially all of the CDR regions correspond to those of a non-human immunoglobulin and all or substantially all of the framework regions are those of a human immunoglobulin consensus sequence. The humanized antibody optimally also will comprise at least a portion of an immunoglobulin constant region (Fc), typically that of a human immunoglobulin (Jones et al., 1986; Riechmann et al., 1988; and Presta,  Curr. Op. Struct. Biol.,  2:593-596 (1992)).  
       5.13.3 Human Antibodies  
       [0299] Fully human antibodies relate to antibody molecules in which essentially the entire sequences of both the light chain and the heavy chain, including the CDRs, arise from human genes. Such antibodies are termed “human antibodies”, or “fully human antibodies” herein. Human monoclonal antibodies can be prepared by the trioma technique; the human B-cell hybridoma technique (see Kozbor, et al., 1983 Immunol Today 4: 72) and the EBV hybridoma technique to produce human monoclonal antibodies (see Cole, et al., 1985 In: MONOCLONAL ANTIBODIES AND CANCER THERAPY, Alan R. Liss, Inc., pp. 77-96). Human monoclonal antibodies may be utilized in the practice of the present invention and may be produced by using human hybridomas (see Cote, et al., 1983. Proc Natl. Acad Sci USA 80: 2026-2030) or by transforming human B-cells with Epstein Barr Virus in vitro (see Cole, et al., 1985 In: MONOCLONAL ANTIBODIES AND CANCER THERAPY, Alan R. Liss, Inc., pp. 77-96).  
       [0300] In addition, human antibodies can also be produced using additional techniques, including phage display libraries (Hoogenboom and Winter,  J. Mol. Biol.  227:381 (1991); Marks et al.,  J. Mol. Biol.,  222:581 (1991)). Similarly, human antibodies can be made by introducing human immunoglobulin loci into transgenic animals, e.g., mice in which the endogenous immunoglobulin genes have been partially or completely inactivated. Upon challenge, human antibody production is observed, which closely resembles that seen in humans in all respects, including gene rearrangement, assembly, and antibody repertoire. This approach is described, for example, in U.S. Pat. Nos. 5,545,807; 5,545,806; 5,569,825; 5,625,126; 5,633,425; 5,661,016, and in Marks et al. ( Bio/Technology  10 779-783 (1992)); Lonberg et al. ( Nature  368 856-859 (1994)); Morrison ( Nature  368, 812-13 (1994)); Fishwild et al,( Nature Biotechnology  14, 845-51 (1996)); Neuberger ( Nature Biotechnology  14, 826 (1996)); and Lonberg and Huszar ( Intern. Rev. Immunol.  13 65-93 (1995)).  
       [0301] Human antibodies may additionally be produced using transgenic nonhuman animals which are modified so as to produce fully human antibodies rather than the animal&#39;s endogenous antibodies in response to challenge by an antigen. (See PCT publication WO94/02602). The endogenous genes encoding the heavy and light immunoglobulin chains in the nonhuman host have been incapacitated, and active loci encoding human heavy and light chain immunoglobulins are inserted into the host&#39;s genome. The human genes are incorporated, for example, using yeast artificial chromosomes containing the requisite human DNA segments. An animal which provides all the desired modifications is then obtained as progeny by crossbreeding intermediate transgenic animals containing fewer than the fill complement of the modifications. The preferred embodiment of such a nonhuman animal is a mouse, and is termed the Xenomouse™ as disclosed in PCT publications WO 96/33735 and WO 96/34096. This animal produces B cells which secrete fully human immunoglobulins. The antibodies can be obtained directly from the animal after immunization with an immunogen of interest, as, for example, a preparation of a polyclonal antibody, or alternatively from immortalized B cells derived from the animal, such as hybridomas producing monoclonal antibodies. Additionally, the genes encoding the immunoglobulins with human variable regions can be recovered and expressed to obtain the antibodies directly, or can be further modified to obtain analogs of antibodies such as, for example, single chain Fv molecules.  
       [0302] An example of a method of producing a nonhuman host, exemplified as a mouse, lacking expression of an endogenous immunoglobulin heavy chain is disclosed in U.S. Pat. No. 5,939,598. It can be obtained by a method including deleting the J segment genes from at least one endogenous heavy chain locus in an embryonic stem cell to prevent rearrangement of the locus and to prevent formation of a transcript of a rearranged immunoglobulin heavy chain locus, the deletion being effected by a targeting vector containing a gene encoding a selectable marker; and producing from the embryonic stem cell a transgenic mouse whose somatic and germ cells contain the gene encoding the selectable marker.  
       [0303] A method for producing an antibody of interest, such as a human antibody, is disclosed in U.S. Pat. No.5,916,771. It includes introducing an expression vector that contains a nucleotide sequence encoding a heavy chain into one mammalian host cell in culture, introducing an expression vector containing a nucleotide sequence encoding a light chain into another mammalian host cell, and fusing the two cells to form a hybrid cell. The hybrid cell expresses an antibody containing the heavy chain and the light chain.  
       [0304] In a further improvement on this procedure, a method for identifying a clinically relevant epitope on an immunogen, and a correlative method for selecting an antibody that binds immunospecifically to the relevant epitope with high affinity, are disclosed in PCT publication WO 99/53049.  
       5.13.4 F ab  Fragments and Single Chain Antibodies  
       [0305] According to the invention, techniques can be adapted for the production of single-chain antibodies specific to an antigenic protein of the invention (see e.g., U.S. Pat. No. 4,946,778). In addition, methods can be adapted for the construction of F ab  expression libraries (see e.g., Huse, et al., 1989 Science 246: 1275-1281) to allow rapid and effective identification of monoclonal F ab  fragments with the desired specificity for a protein or derivatives, fragments, analogs or homologs thereof. Antibody fragments that contain the idiotypes to a protein antigen may be produced by techniques known in the art including, but not limited to: (i) an F (ab′)2  fragment produced by pepsin digestion of an antibody molecule; (ii) an F ab  fragment generated by reducing the disulfide bridges of an F (ab′)2  fragment; (iii) an F ab  fragment generated by the treatment of the antibody molecule with papain and a reducing agent and (iv) F v  fragments.  
       5.13.5 Bispecific Antibodies  
       [0306] Bispecific antibodies are monoclonal, preferably human or humanized, antibodies that have binding specificities for at least two different antigens. In the present case, one of the binding specificities is for an antigenic protein of the invention. The second binding target is any other antigen, and advantageously is a cell-surface protein or receptor or receptor subunit.  
       [0307] Methods for making bispecific antibodies are known in the art. Traditionally, the recombinant production of bispecific antibodies is based on the co-expression of two immunoglobulin heavy-chain/light-chain pairs, where the two heavy chains have different specificities (Milstein and Cuello,  Nature,  305:537-539 (1983)). Because of the random assortment of immunoglobulin heavy and light chains, these hybridomas (quadromas) produce a potential mixture of ten different antibody molecules, of which only one has the correct bispecific structure. The purification of the correct molecule is usually accomplished by affinity chromatography steps. Similar procedures are disclosed in WO 93/08829, published May 13, 1993, and in Traunecker et al., 1991  EMBO J.,  10:3655-3659.  
       [0308] Antibody variable domains with the desired binding specificities (antibody-antigen combining sites) can be fused to immunoglobulin constant domain sequences. The fusion preferably is with an immunoglobulin heavy-chain constant domain, comprising at least part of the hinge, CH2, and CH3 regions. It is preferred to have the first heavy-chain constant region (CH1) containing the site necessary for light-chain binding present in at least one of the fusions. DNAs encoding the immunoglobulin heavy-chain fusions and, if desired, the immunoglobulin light chain, are inserted into separate expression vectors, and are co-transfected into a suitable host organism. For further details of generating bispecific antibodies see, for example, Suresh et al.,  Methods in Enzymology  121:210 (1986).  
       [0309] According to another approach described in WO 96/27011, the interface between a pair of antibody molecules can be engineered to maximize the percentage of heterodimers which are recovered from recombinant cell culture. The preferred interface comprises at least a part of the CH3 region of an antibody constant domain. In this method, one or more small amino acid side chains from the interface of the first antibody molecule are replaced with larger side chains (e.g. tyrosine or tryptophan). Compensatory “cavities” of identical or similar size to the large side chain(s) are created on the interface of the second antibody molecule by replacing large amino acid side chains with smaller ones (e.g. alanine or threonine). This provides a mechanism for increasing the yield of the heterodimer over other unwanted end-products such as homodimers.  
       [0310] Bispecific antibodies can be prepared as full length antibodies or antibody fragments (e.g. F(ab′) 2  bispecific antibodies). Techniques for generating bispecific antibodies from antibody fragments have been described in the literature. For example, bispecific antibodies can be prepared using chemical linkage. Brennan et al.,  Science  229:81 (1985) describe a procedure wherein intact antibodies are proteolytically cleaved to generate F(ab′) 2  fragments. These fragments are reduced in the presence of the dithiol complexing agent sodium arsenite to stabilize vicinal dithiols and prevent intermolecular disulfide formation. The Fab′ fragments generated are then converted to thionitrobenzoate (TNB) derivatives. One of the Fab′-TNB derivatives is then reconverted to the Fab′-thiol by reduction with mercaptoethylamine and is mixed with an equimolar amount of the other Fab′-TNB derivative to form the bispecific antibody. The bispecific antibodies produced can be used as agents for the selective immobilization of enzymes.  
       [0311] Additionally, Fab′ fragments can be directly recovered from  E. coli  and chemically coupled to form bispecific antibodies. Shalaby et al.,  J. Exp. Med.  175:217-225 (1992) describe the production of a fully humanized bispecific antibody F(ab′) 2  molecule. Each Fab′ fragment was separately secreted from  E. coli  and subjected to directed chemical coupling in vitro to form the bispecific antibody. The bispecific antibody thus formed was able to bind to cells overexpressing the ErbB2 receptor and normal human T cells, as well as trigger the lytic activity of human cytotoxic lymphocytes against human breast tumor targets.  
       [0312] Various techniques for making and isolating bispecific antibody fragments directly from recombinant cell culture have also been described. For example, bispecific antibodies have been produced using leucine zippers. Kostelny et al.,  J. Immunol.  148(5):1547-1553 (1992). The leucine zipper peptides from the Fos and Jun proteins were linked to the Fab′ portions of two different antibodies by gene fusion. The antibody homodimers were reduced at the hinge region to form monomers and then re-oxidized to form the antibody heterodimers. This method can also be utilized for the production of antibody homodimers. The “diabody” technology described by Hollinger et al.,  Proc. Natl. Acad. Sci. USA  90:6444-6448 (1993) has provided an alternative mechanism for making bispecific antibody fragments. The fragments comprise a heavy-chain variable domain (V H ) connected to a light-chain variable domain (V L ) by a linker which is too short to allow pairing between the two domains on the same chain. Accordingly, the V H  and V L  domains of one fragment are forced to pair with the complementary V L  and V H  domains of another fragment, thereby forming two antigen-binding sites. Another strategy for making bispecific antibody fragments by the use of single-chain Fv (sFv) dimers has also been reported. See, Gruber et al.,  J. Immunol.  152:5368 (1994).  
       [0313] Antibodies with more than two valencies are contemplated. For example, trispecific antibodies can be prepared. Tutt et al.,  J. Immunol.  147:60 (1991). Exemplary bispecific antibodies can bind to two different epitopes, at least one of which originates in the protein antigen of the invention. Alternatively, an anti-antigenic arm of an immunoglobulin molecule can be combined with an arm which binds to a triggering molecule on a leukocyte such as a T-cell receptor molecule (e.g. CD2, CD3, CD28, or B7), or Fc receptors for IgG (FcγR), such as FcγRI (CD64), FcγRII (CD32) and FcγRIII (CD16) so as to focus cellular defense mechanisms to the cell expressing the particular antigen. Bispecific antibodies can also be used to direct cytotoxic agents to cells which express a particular antigen. These antibodies possess an antigen-binding arm and an arm which binds a cytotoxic agent or a radionuclide chelator, such as EOTUBE, DPTA, DOTA, or TETA. Another bispecific antibody of interest binds the protein antigen described herein and further binds tissue factor (TF).  
       5.13.6 Heteroconjugate Antibodies  
       [0314] Heteroconjugate antibodies are also within the scope of the present invention. Heteroconjugate antibodies are composed of two covalently joined antibodies. Such antibodies have, for example, been proposed to target immune system cells to unwanted cells (U.S. Pat. No. 4,676,980), and for treatment of HIV infection (WO 91/00360; WO 92/200373; EP 03089). It is contemplated that the antibodies can be prepared in vitro using known methods in synthetic protein chemistry, including those involving crosslinking agents. For example, immunotoxins can be constructed using a disulfide exchange reaction or by forming a thioether bond. Examples of suitable reagents for this purpose include iminothiolate and methyl-4-mercaptobutyrimidate and those disclosed, for example, in U.S. Pat. No. 4,676,980.  
       5.13.7 Effector Function Engineering  
       [0315] It can be desirable to modify the antibody of the invention with respect to effector function, so as to enhance, e.g., the effectiveness of the antibody in treating cancer. For example, cysteine residue(s) can be introduced into the Fc region, thereby allowing interchain disulfide bond formation in this region. The homodimeric antibody thus generated can have improved internalization capability and/or increased complement-mediated cell killing and antibody-dependent cellular cytotoxicity (ADCC). See Caron et al., J. Exp Med., 176: 1191-1195 (1992) and Shopes, J. Immunol., 148: 2918-2922 (1992). Homodimeric antibodies with enhanced anti-tumor activity can also be prepared using heterobifunctional cross-linkers as described in Wolff et al. Cancer Research, 53: 2560-2565 (1993). Alternatively, an antibody can be engineered that has dual Fc regions and can thereby have enhanced complement lysis and ADCC capabilities. See Stevenson et al., Anti-Cancer Drug Design, 3: 219-230 (1989).  
       5.13.8 Immunoconjugates  
       [0316] The invention also pertains to immunoconjugates comprising an antibody conjugated to a cytotoxic agent such as a chemotherapeutic agent, toxin (e.g., an enzymatically active toxin of bacterial, fungal, plant, or animal origin, or fragments thereof), or a radioactive isotope (i.e., a radioconjugate).  
       [0317] Chemotherapeutic agents useful in the generation of such immunoconjugates have been described above. Enzymatically active toxins and fragments thereof that can be used include diphtheria A chain, nonbinding active fragments of diphtheria toxin, exotoxin A chain (from Pseudomonas aeruginosa), ricin A chain, abrin A chain, modeccin A chain, alpha-sarcin, Aleurites fordii proteins, dianthin proteins,  Phytolaca americana  proteins (PAPI, PAPII, and PAP-S), momordica charantia inhibitor, curcin, crotin, sapaonaria officinalis inhibitor, gelonin, mitogellin, restrictocin, phenomycin, enomycin, and the tricothecenes. A variety of radionuclides are available for the production of radioconjugated antibodies. Examples include  212 Bi,  131 I,  131 In,  90 Y, and  186 Re.  
       [0318] Conjugates of the antibody and cytotoxic agent are made using a variety of bifunctional protein-coupling agents such as N-succinimidyl-3-(2-pyridyldithiol) propionate (SPDP), iminothiolane (IT), bifunctional derivatives of imidoesters (such as dimethyl adipimidate HCL), active esters (such as disuccinimidyl suberate), aldehydes (such as glutareldehyde), bis-azido compounds (such as bis (p-azidobenzoyl)hexanediamine), bis-diazonium derivatives (such as bis-(p-diazoniumbenzoyl)-ethylenediamine), diisocyanates (such as tolyene 2,6-diisocyanate), and bis-active fluorine compounds (such as 1,5-difluoro-2,4-dinitrobenzene). For example, a ricin immunotoxin can be prepared as described in Vitetta et al., Science, 238: 1098 (1987). Carbon-14-labeled 1-isothiocyanatobenzyl-3-methyldiethylene triaminepentaacetic acid (MX-DTPA) is an exemplary chelating agent for conjugation of radionucleotide to the antibody. See WO94/11026.  
       [0319] In another embodiment, the antibody can be conjugated to a “receptor” (such streptavidin) for utilization in tumor pretargeting wherein the antibody-receptor conjugate is administered to the patient, followed by removal of unbound conjugate from the circulation using a clearing agent and then administration of a “ligand” (e.g., avidin) that is in turn conjugated to a cytotoxic agent.  
       4.14 Computer Readable Sequences  
       [0320] In one application of this embodiment, a nucleotide sequence of the present invention can be recorded on computer readable media. As used herein, “computer readable media” refers to any medium which can be read and accessed directly by a computer. Such media include, but are not limited to: magnetic storage media, such as floppy discs, hard disc storage medium, and magnetic tape; optical storage media such as CD-ROM; electrical storage media such as RAM and ROM, and hybrids of these categories such as magnetic/optical storage media. A skilled artisan can readily appreciate how any of the presently known computer readable mediums can be used to create a manufacture comprising computer readable medium having recorded thereon a nucleotide sequence of the present invention. As used herein, “recorded” refers to a process for storing information on computer readable medium. A skilled artisan can readily adopt any of the presently known methods for recording information on computer readable medium to generate manufactures comprising the nucleotide sequence information of the present invention.  
       [0321] A variety of data storage structures are available to a skilled artisan for creating a computer readable medium having recorded thereon a nucleotide sequence of the present invention. The choice of the data storage structure will generally be based on the means chosen to access the stored information. In addition, a variety of data processor programs and formats can be used to store the nucleotide sequence information of the present invention on computer readable medium. The sequence information can be represented in a word processing text file, formatted in commercially-available software such as WordPerfect and Microsoft Word, or represented in the form of an ASCII file, stored in a database application, such as DB2, Sybase, Oracle, or the like. A skilled artisan can readily adapt any number of data processor structuring formats (e.g. text file or database) in order to obtain computer readable medium having recorded thereon the nucleotide sequence information of the present invention.  
       [0322] By providing any of the nucleotide sequences SEQ ID NO: 1-739 or a representative fragment thereof, or a nucleotide sequence at least 95% identical to any of the nucleotide sequences of SEQ ID NO: 1-739 in computer readable form, a skilled artisan can routinely access the sequence information for a variety of purposes. Computer software is publicly available which allows a skilled artisan to access sequence information provided in a computer readable medium. The examples which follow demonstrate how software which implements the BLAST (Altschul et al., J. Mol. Biol. 215:403-410 (1990)) and BLAZE (Brutlag et al., Comp. Chem. 17:203-207 (1993)) search algorithms on a Sybase system is used to identify open reading frames (ORFs) within a nucleic acid sequence. Such ORFs may be protein encoding fragments and may be useful in producing commercially important proteins such as enzymes used in fermentation reactions and in the production of commercially useful metabolites.  
       [0323] As used herein, “a computer-based system” refers to the hardware means, software means, and data storage means used to analyze the nucleotide sequence information of the present invention. The minimum hardware means of the computer-based systems of the present invention comprises a central processing unit (CPU), input means, output means, and data storage means. A skilled artisan can readily appreciate that any one of the currently available computer-based systems are suitable for use in the present invention. As stated above, the computer-based systems of the present invention comprise a data storage means having stored therein a nucleotide sequence of the present invention and the necessary hardware means and software means for supporting and implementing a search means. As used herein, “data storage means” refers to memory which can store nucleotide sequence information of the present invention, or a memory access means which can access manufactures having recorded thereon the nucleotide sequence information of the present invention.  
       [0324] As used herein, “search means” refers to one or more programs which are implemented on the computer-based system to compare a target sequence or target structural motif with the sequence information stored within the data storage means. Search means are used to identify fragments or regions of a known sequence which match a particular target sequence or target motif. A variety of known algorithms are disclosed publicly and a variety of commercially available software for conducting search means are and can be used in the computer-based systems of the present invention. Examples of such software includes, but is not limited to, Smith-Waterman; MacPattern (EMBL), BLASTN and BLASTA (NPOLYPEPTIDEIA). A skilled artisan can readily recognize that any one of the available algorithms or implementing software packages for conducting homology searches can be adapted for use in the present computer-based systems. As used herein, a “target sequence” can be any nucleic acid or amino acid sequence of six or more nucleotides or two or more amino acids. A skilled artisan can readily recognize that the longer a target sequence is, the less likely a target sequence will be present as a random occurrence in the database. The most preferred sequence length of a target sequence is from about 10 to 300 amino acids, more preferably from about 30 to 100 nucleotide residues. However, it is well recognized that searches for commercially important fragments, such as sequence fragments involved in gene expression and protein processing, may be of shorter length.  
       [0325] As used herein, “a target structural motif,” or “target motif,” refers to any rationally selected sequence or combination of sequences in which the sequence(s) are chosen based on a three-dimensional configuration which is formed upon the folding of the target motif. There are a variety of target motifs known in the art. Protein target motifs include, but are not limited to, enzyme active sites and signal sequences. Nucleic acid target motifs include, but are not limited to, promoter sequences, hairpin structures and inducible expression elements (protein binding sequences).  
       4.15 Triple Helix Formation  
       [0326] In addition, the fragments of the present invention, as broadly described, can be used to control gene expression through triple helix formation or antisense DNA or RNA, both of which methods are based on the binding of a polynucleotide sequence to DNA or RNA. Polynucleotides suitable for use in these methods are preferably 20 to 40 bases in length and are designed to be complementary to a region of the gene involved in transcription (triple helix—see Lee et al., Nucl. Acids Res. 6:3073 (1979); Cooney et al., Science 15241:456 (1988); and Dervan et al., Science 251:1360 (1991)) or to the mRNA itself (antisense—Olmno, J. Neurochem. 56:560 (1991); Oligodeoxynucleotides as Antisense Inhibitors of Gene Expression, CRC Press, Boca Raton, Fla. (1988)). Triple helix-formation optimally results in a shut-off of RNA transcription from DNA, while antisense RNA hybridization blocks translation of an mRNA molecule into polypeptide. Both techniques have been demonstrated to be effective in model systems. Information contained in the sequences of the present invention is necessary for the design of an antisense or triple helix oligonucleotide.  
       4.16 Diagnostic Assays and Kits  
       [0327] The present invention further provides methods to identify the presence or expression of one of the ORFs of the present invention, or homolog thereof, in a test sample, using a nucleic acid probe or antibodies of the present invention, optionally conjugated or otherwise associated with a suitable label.  
       [0328] In general, methods for detecting a polynucleotide of the invention can comprise contacting a sample with a compound that binds to and forms a complex with the polynucleotide for a period sufficient to form the complex, and detecting the complex, so that if a complex is detected, a polynucleotide of the invention is detected in the sample. Such methods can also comprise contacting a sample under stringent hybridization conditions with nucleic acid primers that anneal to a polynucleotide of the invention under such conditions, and amplifying annealed polynucleotides, so that if a polynucleotide is amplified, a polynucleotide of the invention is detected in the sample.  
       [0329] In general, methods for detecting a polypeptide of the invention can comprise contacting a sample with a compound that binds to and forms a complex with the polypeptide for a period sufficient to form the complex, and detecting the complex, so that if a complex is detected, a polypeptide of the invention is detected in the sample.  
       [0330] In detail, such methods comprise incubating a test sample with one or more of the antibodies or one or more of the nucleic acid probes of the present invention and assaying for binding of the nucleic acid probes or antibodies to components within the test sample.  
       [0331] Conditions for incubating a nucleic acid probe or antibody with a test sample vary. Incubation conditions depend on the format employed in the assay, the detection methods employed, and the type and nature of the nucleic acid probe or antibody used in the assay. One skilled in the art will recognize that any one of the commonly available hybridization, amplification or immunological assay formats can readily be adapted to employ the nucleic acid probes or antibodies of the present invention. Examples of such assays can be found in Chard, T., An Introduction to Radioimmunoassay and Related Techniques, Elsevier Science Publishers, Amsterdam, The Netherlands (1986); Bullock, G. R. et al., Techniques in Immunocytochemistry, Academic Press, Orlando, Fla. Vol. 1 (1982), Vol. 2 (1983), Vol. 3 (1985); Tijssen, P., Practice and Theory of immunoassays: Laboratory Techniques in Biochemistry and Molecular Biology, Elsevier Science Publishers, Amsterdam, The Netherlands (1985). The test samples of the present invention include cells, protein or membrane extracts of cells, or biological fluids such as sputum, blood, serum, plasma, or urine. The test sample used in the above-described method will vary based on the assay format, nature of the detection method and the tissues, cells or extracts used as the sample to be assayed. Methods for preparing protein extracts or membrane extracts of cells are well known in the art and can be readily be adapted in order to obtain a sample which is compatible with the system utilized.  
       [0332] In another embodiment of the present invention, kits are provided which contain the necessary reagents to carry out the assays of the present invention. Specifically, the invention provides a compartment kit to receive, in close confinement, one or more containers which comprises: (a) a first container comprising one of the probes or antibodies of the present invention; and (b) one or more other containers comprising one or more of the following: wash reagents, reagents capable of detecting presence of a bound probe or antibody.  
       [0333] In detail, a compartment kit includes any kit in which reagents are contained in separate containers. Such containers include small glass containers, plastic containers or strips of plastic or paper. Such containers allows one to efficiently transfer reagents from one compartment to another compartment such that the samples and reagents are not cross-contaminated, and the agents or solutions of each container can be added in a quantitative fashion from one compartment to another. Such containers will include a container which will accept the test sample, a container which contains the antibodies used in the assay, containers which contain wash reagents (such as phosphate buffered saline, Tris-buffers, etc.), and containers which contain the reagents used to detect the bound antibody or probe. Types of detection reagents include labeled nucleic acid probes, labeled secondary antibodies, or in the alternative, if the primary antibody is labeled, the enzymatic, or antibody binding reagents which are capable of reacting with the labeled antibody. One skilled in the art will readily recognize that the disclosed probes and antibodies of the present invention can be readily incorporated into one of the established kit formats which are well known in the art.  
       4.17 Medical Imaging  
       [0334] The novel polypeptides and binding partners of the invention are useful in medical imaging of sites expressing the molecules of the invention (e.g., where the polypeptide of the invention is involved in the immune response, for imaging sites of inflammation or infection). See, e.g., Kunkel et al., U.S. Pat. No. 5,413,778. Such methods involve chemical attachment of a labeling or imaging agent, administration of the labeled polypeptide to a subject in a pharmaceutically acceptable carrier, and imaging the labeled polypeptide in vivo at the target site.  
       4.18 Screening Assays  
       [0335] Using the isolated proteins and polynucleotides of the invention, the present invention further provides methods of obtaining and identifying agents which bind to a polypeptide encoded by an ORF corresponding to any of the nucleotide sequences set forth in SEQ ID NO: 1-739, or bind to a specific domain of the polypeptide encoded by the nucleic acid. In detail, said method comprises the steps of:  
       [0336] (a) contacting an agent with an isolated protein encoded by an ORF of the present invention, or nucleic acid of the invention; and  
       [0337] (b) determining whether the agent binds to said protein or said nucleic acid.  
       [0338] In general, therefore, such methods for identifying compounds that bind to a polynucleotide of the invention can comprise contacting a compound with a polynucleotide of the invention for a time sufficient to form a polynucleotide/compound complex, and detecting the complex, so that if a polynucleotide/compound complex is detected, a compound that binds to a polynucleotide of the invention is identified.  
       [0339] Likewise, in general, therefore, such methods for identifying compounds that bind to a polypeptide of the invention can comprise contacting a compound with a polypeptide of the invention for a time sufficient to form a polypeptide/compound complex, and detecting the complex, so that if a polypeptide/compound complex is detected, a compound that binds to a polynucleotide of the invention is identified.  
       [0340] Methods for identifying compounds that bind to a polypeptide of the invention can also comprise contacting a compound with a polypeptide of the invention in a cell for a time sufficient to form a polypeptide/compound complex, wherein the complex drives expression of a receptor gene sequence in the cell, and detecting the complex by detecting reporter gene sequence expression, so that if a polypeptide/compound complex is detected, a compound that binds a polypeptide of the invention is identified.  
       [0341] Compounds identified via such methods can include compounds which modulate the activity of a polypeptide of the invention (that is, increase or decrease its activity, relative to activity observed in the absence of the compound). Alternatively, compounds identified via such methods can include compounds which modulate the expression of a polynucleotide of the invention (that is, increase or decrease expression relative to expression levels observed in the absence of the compound). Compounds, such as compounds identified via the methods of the invention, can be tested using standard assays well known to those of skill in the art for their ability to modulate activity/expression.  
       [0342] The agents screened in the above assay can be, but are not limited to, peptides, carbohydrates, vitamin derivatives, or other pharmaceutical agents. The agents can be selected and screened at random or rationally selected or designed using protein modeling techniques.  
       [0343] For random screening, agents such as peptides, carbohydrates, pharmaceutical agents and the like are selected at random and are assayed for their ability to bind to the protein encoded by the ORF of the present invention. Alternatively, agents may be rationally selected or designed. As used herein, an agent is said to be “rationally selected or designed” when the agent is chosen based on the configuration of the particular protein. For example, one skilled in the art can readily adapt currently available procedures to generate peptides, pharmaceutical agents and the like, capable of binding to a specific peptide sequence, in order to generate rationally designed antipeptide peptides, for example see Hurby et al., Application of Synthetic Peptides: Antisense Peptides,” In Synthetic Peptides, A User&#39;s Guide, W. H. Freeman, NY (1992), pp. 289-307, and Kaspczak et al., Biochemistry 28:9230-8 (1989), or pharmaceutical agents, or the like.  
       [0344] In addition to the foregoing, one class of agents of the present invention, as broadly described, can be used to control gene expression through binding to one of the ORFs or EMFs of the present invention. As described above, such agents can be randomly screened or rationally designed/selected. Targeting the ORF or EMF allows a skilled artisan to design sequence specific or element specific agents, modulating the expression of either a single ORF or multiple ORFs which rely on the same EMF for expression control. One class of DNA binding agents are agents which contain base residues which hybridize or form a triple helix formation by binding to DNA or RNA. Such agents can be based on the classic phosphodiester, ribonucleic acid backbone, or can be a variety of sulfhydryl or polymeric derivatives which have base attachment capacity.  
       [0345] Agents suitable for use in these methods preferably contain 20 to 40 bases and are designed to be complementary to a region of the gene involved in transcription (triple helix—see Lee et al., Nucl. Acids Res. 6:3073 (1979); Cooney et al., Science 241:456 (1988); and Dervan et al., Science 251:1360 (1991)) or to the mRNA itself (antisense—Okano, J. Neurochem. 56:560 (1991); Oligodeoxynucleotides as Antisense Inhibitors of Gene Expression, CRC Press, Boca Raton, Fla. (1988)). Triple helix-formation optimally results in a shut-off of RNA transcription from DNA, while antisense RNA hybridization blocks translation of an mRNA molecule into polypeptide. Both techniques have been demonstrated to be effective in model systems. Information contained in the sequences of the present invention is necessary for the design of an antisense or triple helix oligonucleotide and other DNA binding agents.  
       [0346] Agents which bind to a protein encoded by one of the ORFs of the present invention can be used as a diagnostic agent. Agents which bind to a protein encoded by one of the ORFs of the present invention can be formulated using known techniques to generate a pharmaceutical composition.  
       4.19 Use of Nucleic Acids as Probes  
       [0347] Another aspect of the subject invention is to provide for polypeptide-specific nucleic acid hybridization probes capable of hybridizing with naturally occurring nucleotide sequences. The hybridization probes of the subject invention may be derived from any of the nucleotide sequences SEQ ID NO: 1-739. Because the corresponding gene is only expressed in a limited number of tissues, a hybridization probe derived from of any of the nucleotide sequences SEQ ID NO: 1-739 can be used as an indicator of the presence of RNA of cell type of such a tissue in a sample.  
       [0348] Any suitable hybridization technique can be employed, such as, for example, in situ hybridization. PCR as described in U.S. Pat. Nos. 4,683,195 and 4,965,188 provides additional uses for oligonucleotides based upon the nucleotide sequences. Such probes used in PCR may be of recombinant origin, may be chemically synthesized, or a mixture of both. The probe will comprise a discrete nucleotide sequence for the detection of identical sequences or a degenerate pool of possible sequences for identification of closely related genomic sequences.  
       [0349] Other means for producing specific hybridization probes for nucleic acids include the cloning of nucleic acid sequences into vectors for the production of mRNA probes. Such vectors are known in the art and are commercially available and may be used to synthesize RNA probes in vitro by means of the addition of the appropriate RNA polymerase as T7 or SP6 RNA polymerase and the appropriate radioactively labeled nucleotides. The nucleotide sequences may be used to construct hybridization probes for mapping their respective genomic sequences. The nucleotide sequence provided herein may be mapped to a chromosome or specific regions of a chromosome using well known genetic and/or chromosomal mapping techniques. These techniques include in situ hybridization, linkage analysis against known chromosomal markers, hybridization screening with libraries or flow-sorted chromosomal preparations specific to known chromosomes, and the like. The technique of fluorescent in situ hybridization of chromosome spreads has been described, among other places, in Verma et al (1988) Human Chromosomes: A Manual of Basic Techniques, Pergamon Press, New York N.Y.  
       [0350] Fluorescent in situ hybridization of chromosomal preparations and other physical chromosome mapping techniques may be correlated with additional genetic map data. Examples of genetic map data can be found in the 1994 Genome Issue of Science (265:1981f). Correlation between the location of a nucleic acid on a physical chromosomal map and a specific disease (or predisposition to a specific disease) may help delimit the region of DNA associated with that genetic disease. The nucleotide sequences of the subject invention may be used to detect differences in gene sequences between normal, carrier or affected individuals.  
       4.20 Preparation of Support Bound Oligonucleotides  
       [0351] Oligonucleotides, i.e., small nucleic acid segments, may be readily prepared by, for example, directly synthesizing the oligonucleotide by chemical means, as is commonly practiced using an automated oligonucleotide synthesizer.  
       [0352] Support bound oligonucleotides may be prepared by any of the methods known to those of skill in the art using any suitable support such as glass, polystyrene or Teflon. One strategy is to precisely spot oligonucleotides synthesized by standard synthesizers. Immobilization can be achieved using passive adsorption (Inouye &amp; Hondo, (1990) J. Clin. Microbiol. 28(6) 1469-72); using UV light (Nagata et al., 1985; Dahlen et al., 1987; Morrissey &amp; Collins, (1989) Mol. Cell Probes 3(2) 189-207) or by covalent binding of base modified DNA (Keller et al., 1988; 1989); all references being specifically incorporated herein.  
       [0353] Another strategy that may be employed is the use of the strong biotin-streptavidin interaction as a linker. For example, Broude et al. (1994) Proc. Natl. Acad. Sci. USA 91(8) 3072-6, describe the use of biotinylated probes, although these are duplex probes, that are immobilized on streptavidin-coated magnetic beads. Streptavidin-coated beads may be purchased from Dynal, Oslo. Of course, this same linking chemistry is applicable to coating any surface with streptavidin. Biotinylated probes may be purchased from various sources, such as, e.g., Operon Technologies (Alameda, Calif.).  
       [0354] Nunc Laboratories (Naperville, Ill.) is also selling suitable material that could be used. Nunc Laboratories have developed a method by which DNA can be covalently bound to the microwell surface termed Covalink NH. CovaLink NH is a polystyrene surface grafted with secondary amino groups (&gt;NH) that serve as bridge-heads for further covalent coupling. CovaLink Modules may be purchased from Nunc Laboratories. DNA molecules may be bound to CovaLink exclusively at the 5′-end by a phosphoramidate bond, allowing immobilization of more than 1 pmol of DNA (Rasmussen et al., (1991) Anal. Biochem. 198(1) 138-42).  
       [0355] The use of CovaLink NH strips for covalent binding of DNA molecules at the 5′-end has been described (Rasmussen et al., (1991). In this technology, a phosphoramidate bond is employed (Chu et al., (1983) Nucleic Acids Res. 11 (8) 6513-29). This is beneficial as immobilization using only a single covalent bond is preferred. The phosphoramidate bond joins the DNA to the CovaLink NH secondary amino groups that are positioned at the end of spacer arms covalently grafted onto the polystyrene surface through a 2 nm long spacer arm. To link an oligonucleotide to CovaLink NH via an phosphoramidate bond, the oligonucleotide terminus must have a 5′-end phosphate group. It is, perhaps, even possible for biotin to be covalently bound to CovaLink and then streptavidin used to bind the probes.  
       [0356] More specifically,the linkage method includes dissolving DNA in water (7.5 ng/ul) and denaturing for 10 min. at 95° C. and cooling on ice for 10 min. Ice-cold 0.1 M 1-methylimidazole,pH 7.0 (1-MeIm 7 ), is then added to a final concentration of 10 mM 1-MeIm 7 . A ss DNA solution is then dispensed into CovaLink NH strips (75 ul/well) standing on ice.  
       [0357] Carbodiimide 0.2 M 1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide (EDC), dissolved in 10 mM 1-MeIm 7 , is made fresh and 25 ul added per well. The strips are incubated for 5 hours at 50° C. After incubation the strips are washed using, e.g., Nunc-Immuno Wash; first the wells are washed 3 times, then they are soaked with washing solution for 5 min., and finally they are washed 3 times (where in the washing solution is 0.4 N NaOH, 0.25% SDS heated to 50° C.).  
       [0358] It is contemplated that a further suitable method for use with the present invention is that described in PCT Patent Application WO 90/03382 (Southern &amp; Maskos), incorporated herein by reference. This method of preparing an oligonucleotide bound to a support involves attaching a nucleoside 3′-reagent through the phosphate group by a covalent phosphodiester link to aliphatic hydroxyl groups carried by the support. The oligonucleotide is then synthesized on the supported nucleoside and protecting groups removed from the synthetic oligonucleotide chain under standard conditions that do not cleave the oligonucleotide from the support. Suitable reagents include nucleoside phosphoramidite and nucleoside hydrogen phosphorate.  
       [0359] An on-chip strategy for the preparation of DNA probe for the preparation of DNA probe arrays may be employed. For example, addressable laser-activated photodeprotection may be employed in the chemical synthesis of oligonucleotides directly on a glass surface, as described by Fodor et al. (1991) Science 251(4995) 767-73, incorporated herein by reference. Probes may also be immobilized on nylon supports as described by Van Ness et al. (1991) Nucleic Acids Res. 19(12) 3345-50; or linked to Teflon using the method of Duncan &amp; Cavalier (1988) Anal. Biochem. 169(1) 104-8; all references being specifically incorporated herein.  
       [0360] To link an oligonucleotide to a nylon support, as described by Van Ness et al. (1991), requires activation of the nylon surface via alkylation and selective activation of the 5′-amine of oligonucleotides with cyanuric chloride.  
       [0361] One particular way to prepare support bound oligonucleotides is to utilize the light-generated synthesis described by Pease et al., (1994) PNAS USA 91(11) 5022-6, incorporated herein by reference). These authors used current photolithographic techniques to generate arrays of immobilized oligonucleotide probes (DNA chips). These methods, in which light is used to direct the synthesis of oligonucleotide probes in high-density, miniaturized arrays, utilize photolabile 5′-protected N-acyl-deoxynucleoside phosphoramidites, surface linker chemistry and versatile combinatorial synthesis strategies. A matrix of 256 spatially defined oligonucleotide probes may be generated in this manner.  
       4.21 Preparation of Nucleic Acid Fragments  
       [0362] The nucleic acids may be obtained from any appropriate source, such as cDNAs, genomic DNA, chromosomal DNA, microdissected chromosome bands, cosmid or YAC inserts, and RNA, including mRNA without any amplification steps. For example, Sambrook et al. (1989) describes three protocols for the isolation of high molecular weight DNA from mammalian cells (p. 9.14-9.23).  
       [0363] DNA fragments may be prepared as clones in M13, plasmid or lambda vectors and/or prepared directly from genomic DNA or cDNA by PCR or other amplification methods. Samples may be prepared or dispensed in multiwell plates. About 100-1000 ng of DNA samples may be prepared in 2-500 ml of final volume.  
       [0364] The nucleic acids would then be fragmented by any of the methods known to those of skill in the art including, for example, using restriction enzymes as described at 9.24-9.28 of Sambrook et al. (1989), shearing by ultrasound and NaOH treatment.  
       [0365] Low pressure shearing is also appropriate, as described by Schriefer et al. (1990) Nucleic Acids Res. 18(24) 7455-6, incorporated herein by reference). In this method, DNA samples are passed through a small French pressure cell at a variety of low to intermediate pressures. A lever device allows controlled application of low to intermediate pressures to the cell. The results of these studies indicate that low-pressure shearing is a useful alternative to sonic and enzymatic DNA fragmentation methods.  
       [0366] One particularly suitable way for fragmenting DNA is contemplated to be that using the two base recognition endonuclease, CviJI, described by Fitzgerald et al. (1992) Nucleic Acids Res.20(14)3753-62. These authors described an approach for the rapid fragmentation and fractionation of DNA into particular sizes that they contemplated to be suitable for shotgun cloning and sequencing.  
       [0367] The restriction endonuclease CviJI normally cleaves the recognition sequence PuGCPy between the G and C to leave blunt ends. Atypical reaction conditions, which alter the specificity of this enzyme (CviJI**), yield a quasi-random distribution of DNA fragments form the small molecule pUC19 (2688 base pairs). Fitzgerald et al. (1992) quantitatively evaluated the randomness of this fragmentation strategy, using a CviJI** digest of pUC19 that was size fractionated by a rapid gel filtration method and directly ligated, without end repair, to a lac Z minus M13 cloning vector. Sequence analysis of 76 clones showed that CviJI** restricts pyGCPy and PuGCPu, in addition to PuGCPy sites, and that new sequence data is accumulated at a rate consistent with random fragmentation.  
       [0368] As reported in the literature, advantages of this approach compared to sonication and agarose gel fractionation include: smaller amounts of DNA are required (0.2-0.5 ug instead of 2-5 ug); and fewer steps are involved (no preligation, end repair, chemical extraction, or agarose gel electrophoresis and elution are needed  
       [0369] Irrespective of the manner in which the nucleic acid fragments are obtained or prepared, it is important to denature the DNA to give single stranded pieces available for hybridization. This is achieved by incubating the DNA solution for 2-5 minutes at 80-90° C. The solution is then cooled quickly to 2° C. to prevent renaturation of the DNA fragments before they are contacted with the chip. Phosphate groups must also be removed from genomic DNA by methods known in the art.  
       4.22 Preparation of DNA Arrays  
       [0370] Arrays may be prepared by spotting DNA samples on a support such as a nylon membrane. Spotting may be performed by using arrays of metal pins (the positions of which correspond to an array of wells in a microtiter plate) to repeated by transfer of about 20 nl of a DNA solution to a nylon membrane. By offset printing, a density of dots higher than the density of the wells is achieved. One to 25 dots may be accommodated in 1 mm 2 , depending on the type of label used. By avoiding spotting in some preselected number of rows and columns, separate subsets (subarrays) may be formed. Samples in one subarray may be the same genomic segment of DNA (or the same gene) from different individuals, or may be different, overlapped genomic clones. Each of the subarrays may represent replica spotting of the same samples. In one example, a selected gene segment may be amplified from 64 patients. For each patient, the amplified gene segment may be in one 96-well plate (all 96 wells containing the same sample). A plate for each of the 64 patients is prepared. By using a 96-pin device, all samples may be spotted on one 8×12 cm membrane. Subarrays may contain 64 samples, one from each patient. Where the 96 subarrays are identical, the dot span may be 1 mm 2  and there may be a 1 mm space between subarrays.  
       [0371] Another approach is to use membranes or plates (available from NUNC, Naperville, Ill.) which may be partitioned by physical spacers e.g. a plastic grid molded over the membrane, the grid being similar to the sort of membrane applied to the bottom of multiwell plates, or hydrophobic strips. A fixed physical spacer is not preferred for imaging by exposure to flat phosphor-storage screens or x-ray films.  
       [0372] The present invention is illustrated in the following examples. Upon consideration of the present disclosure, one of skill in the art will appreciate that many other embodiments and variations may be made in the scope of the present invention. Accordingly, it is intended that the broader aspects of the present invention not be limited to the disclosure of the following examples. The present invention is not to be limited in scope by the exemplified embodiments which are intended as illustrations of single aspects of the invention, and compositions and methods which are functionally equivalent are within the scope of the invention. Indeed, numerous modifications and variations in the practice of the invention are expected to occur to those skilled in the art upon consideration of the present preferred embodiments. Consequently, the only limitations which should be placed upon the scope of the invention are those which appear in the appended claims.  
       [0373] All references cited within the body of the instant specification are hereby incorporated by reference in their entirety. 
     
    
    
     5.0 EXAMPLES  
     5.1 Example 1  
     [0374] Novel Nucleic Acid Sequences Obtained from Various Libraries  
     [0375] A plurality of novel nucleic acids were obtained from cDNA libraries prepared from various human tissues and in some cases isolated from a genomic library derived from human chromosome using standard PCR, SBH sequence signature analysis and Sanger sequencing techniques. The inserts of the library were amplified with PCR using primers specific for the vector sequences which flank the inserts. Clones from cDNA libraries were spotted on nylon membrane filters and screened with oligonucleotide probes (e.g., 7-mers) to obtain signature sequences. The clones were clustered into groups of similar or identical sequences. Representative clones were selected for sequencing.  
     [0376] In some cases, the 5′ sequence of the amplified inserts was then deduced using a typical Sanger sequencing protocol. PCR products were purified and subjected to fluorescent dye terminator cycle sequencing. Single pass gel sequencing was done using a 377 Applied Biosystems (ABI) sequencer to obtain the novel nucleic acid sequences. In some cases RACE Random Amplification of cDNA Ends) was performed to further extend the sequence in the 5′ direction.  
     5.2 Example 2  
     [0377] Novel Contigs  
     [0378] The novel contigs of the invention were assembled from sequences that were obtained from a cDNA library by methods described in Example 1 above, and in some cases sequences obtained from one or more public databases. Chromatograms were base called and assembled using a software suite from University of Washington, Seattle containing three applications designated PHRED, PHRAP, and CONSED. The sequences for the resulting nucleic acid contigs are designated as SEQ ID NO: 1-739 and are provided in the attached Sequence Listing. The contigs were assembled using an EST sequence as a seed. Then a recursive algorithm was used to extend the seed EST into an extended assemblage, by pulling additional sequences from different databases (i.e., Hyseq&#39;s database containing EST sequences, dbEST version 120, gb pri 120, UniGene version 120, and Genpept 120) that belong to this assemblage. The algorithm terminated when there was no additional sequences from the above databases that would extend the assemblage. Inclusion of component sequences into the assemblage was based on a BLASTN hit to the extending assemblage with BLAST score greater than 300 and percent identity greater than 95%.  
     [0379] The nearest neighbor result for the assembled contig was obtained by a FASTA version 3 search against Genpept release 120, using FASTXY algorithm. FASTXY is an improved version of FASTA alignment which allows in-codon frame shifts. The nearest neighbor result showed the closest homologue for each assemblage from Genpept (and contains the translated amino acid sequences for which the assemblage encodes). The nearest neighbor results for SEQ ID NO: 1-739 are shown in Table 2.  
     [0380] Tables 1, 2, and 3 follow. Table 1 shows the various tissue sources of SEQ ID NO: 1-739. Table 2 shows the nearest neighbor result for the assembled contig. The nearest neighbor result shows the closest homologue for each assemblage and contains the translated amino acid sequences for which the assemblage encodes. Table 2 also shows homologues with identifiable functions for SEQ ID NO: 1-739. The polypeptides were predicted using a software program called FASTY (available from http://fasta.bioch.virginia.edu) which selects a polypeptide based on a comparison of translated novel polynucleotides to known polynucleotides (W. R. Pearson, Methods in Enzymology, Vol. 183: pp. 63-98, (1990), herein incorporated by reference). Table 3 shows the predicted amino acid sequence corresponding to the novel nucleic acid contig sequences.  
               TABLE 1                          Tissue Sources                                     Hyseq           Tissue       Library       Origin   RNA Source   Name   SEQ ID NOS:               adult brain   GIBCO   AB3001   28 46 54 62 95 117 134 175 188-189                   324 330 337 356 369 371 378 386                   389 396 432 435-436 468 472-473                   476-477 483 486 518 538-539 543                   545 557 565 571 573 578 582 598                   613-614 619 627 632 634 639 687                   709       adult brain   GIBCO   ABD003   5 12 46 52 57 66 79 91 97 134 144                   148 150 162 164 172 175-176 181                   186 193 250 323 325-327 330 334                   338 362 367 369 371 378-379 386                   388-389 392 396-397 399-401 403                   416 422 435 444 449 451 454 461                   463-464 468 472-473 483 486 494                   506 511 513 516 520 523-524 526                   529 533 536-537 539 545 548 552                   556 558-559 562-563 565 567 569                   573-574 576 579-580 582-584 590                   593-594 598 602 606 613-614 619-621                   623-624 627 634 637 641 646                   648 659 675 688-689 694 696-698                   703 714 729       adult brain   Clontech   ABR001   57 162 164 227 266 316 334 356 367                   385 438 468 512 524 528 557 582                   590 621 627 631 634 689 714       adult brain   Clontech   ABR006   189 228 385 438 571 584 632 650                   677       adult brain   Clontech   ABR008   1 3 5 11-25 31-32 46-47 55-57 59                   61 65-67 69 75 79 91 103 108 111                   113-114 126 132 150 160 162 164                   171-172 186 188-189 193 202-203                   206 210-212 220 222-224 227-229                   233 235-236 243-247 251-252 257                   264-266 268 275 313 324 328-331                   334-335 338-339 343 346-347 351                   355 357 359-361 365 367 370-371                   378 380 382 386-389 391 396 399-400                   402 406 413 419-420 423 426                   432 434 437-438 442 446 448-449                   459-460 465 468 470 472-473 475                   481-483 487 489-490 495-497 499                   501 503-504 507-509 511 520 524                   526 528 532-533 536 539-540 543-546                   551-552 556-557 563 565-567                   569 572-573 576-577 579-580 582                   584 586 590-591 593 595-597 599-602                   604 610-616 620-621 624-625                   627-628 632 634 637-638 641 643-644                   646-647 650 653-657 660-662                   668 672 675 677-678 680-681 688-689                   691 693 695-696 698 706-707                   709 711 713-727 729 731 733-734                   736 738-739       adult brain   Clontech   ABR011   334 476 634 677       adult brain   BioChain   ABR012   379 587       adult brain   Invitrogen   ABR013   334 634       adult brain   Invitrogen   ABT004   3 19 57 62 66 75 110 122 150 160                   162 167 171 176 186 197 203 211                   230 232 259 328-331 334 369 382                   389 394 400 406 417 426 429 442                   457 472 483-484 492 511 514 529                   531 534 537 540 553 558 562 572                   580 582-584 590 604 611 613 615                   622 637 639 643-644 648 688-689                   692 695       cultured   Strategene   ADP001   16 37-39 66 109 120 141 144 193       preadipocytes           273 316 331 333 338 389 415 429                   442 444 464-465 475 489 501 511                   513 531 534 539-540 545-546 557                   583-584 590 596 602 607 613 615                   619 622 629 632 634 643       adrenal   Clontech   ADR002   4-5 12 48 53 57 162 164 172 186       gland           188 192 196 203 207 213 258 316                   330-331 333 339 354 356-357 369                   383 385 388 392 395 402 406 411                   415 434 454-455 465 468 473 475                   477 491 498 501 509 511 517 528-529                   532 537-539 542 545 558 560                   565 567 576-577 586 600 606 615                   621 624 627 632 634 647 653 660                   667 683 689 696 714       adult heart   GIBCO   AHR001   28 39 57 64-65 75 79 89 97-98 108                   117 134 144 157 159-160 164-166                   169 171 174 184 192-193 203 207                   220 243 256 258 266-267 281 314                   316 318 328-329 331 338-339 341                   346 348 354 356-357 366-367 369                   371 377-379 382 385-386 388 393                   395-396 399-401 403 415 420 422                   425 431-432 435-436 445 451 459                   465 472-473 477 483 486 488 490                   496 501 503 508 515 519-520 526                   528 531 533-534 537-538 540-541                   544 546 552 556-557 562-563 566-571                   573 576-581 583-584 586-587                   594 602 606 608 611 613-615 618                   620-621 626-628 632 634 641 643                   646 648 653 659 667 676 678 687                   689 696 703-704 708 711 714 729-730       adult   GIBCO   AKD001   3 28-29 48 56-57 67 79 84 93 106       kidney           117 134 138 140 144 156 160-164                   168-170 172 177 183 188-189 192-193                   199 203 207 235 251 257 275                   319 321-323 328-330 337 346-347                   349 354-356 360 367-369 371 375                   378-381 383-386 388-389 392 396-397                   399 401 404 407 409 411-412                   415-416 420-422 427 432 436-437                   439-440 444 451-456 458-459 464-465                   468 470 472-473 477 481 483                   486-487 492 496 501 503 505-506                   508 511 513-516 518 524 526 529                   533 535 537-541 543 545-546 548                   552 557 559-560 562-563 565-569                   572-574 576-577 579-587 589-591                   593-594 602 604-607 613-614 617-618                   620-624 627-628 630 632-635                   637-638 640-642 644-645 652 662                   664 667-668 677 682 685 687 689                   694-696 698 703 716 723 728-729                   732 734       adult   Invitrogen   AKT002   92 136 154 160 164 178 271 314 347       kidney           353 360 367 376 378-379 386 391                   402 409 423 432 449 451 477 490                   494 503 526 528 531 534 538-539                   541 545-546 559 566 579 584 588                   594 602 613 621 624 632 647 652                   689       adult lung   GIBCO   ALG001   56-57 67 69 98 113 134 144 164 172                   191-192 270 321 328 338 369 371                   374 378 380 388-389 396 405 411                   416 424 443-444 456 473-474 482-483                   497 508 518 529 531 534 536                   540 552 556 559 563 568 573 579-580                   585-586 588-589 593 601-602                   606 612-613 618 634 662 667 685                   696 702 726 729-730       lymph node   Clontech   ALN001   28 57 79 113 164 172 179 193 240                   325 332 367 378-379 386 388 402                   485 526 580 586 603 613-614 621-622                   628 634 662 667 686 734       young liver   GIBCO   ALV001   3 24 28 54 60 117 134 137 154 160                   193 196 242 273 316 328-329 334                   351 354 370-371 388 392 395-396                   401 406 411 415 432 435 439 448                   454-455 477 483 486-487 495 506                   509 514 518 523-524 526 529 531                   534 537-538 540 544 548 566 568                   571 573 579 587-588 591 594 602                   621 641 645 686 713 723       adult liver   Invitrogen   ALV002   3 24 27 56-57 65-66 71 79 92 97                   106 134 140 164 192 200 214 220                   232 240 242 271-272 291 313 316                   328 347 349-350 353 355 357 368-369                   371-372 378-379 381-382 385                   397 430 435 448 457 459 471-472                   475 485 487 502 505-506 511 520                   530-531 533-534 537 540-541 543                   548 566 574-575 579 582 588 590                   612 623 640 648-649 681 687 689                   710 714       adult ovary   Invitrogen   AOV001   3 10 14 28 54 56-58 62 65-66 68 73                   75 79 98 127 144 154 162 164-165                   172-174 182 186 188-189 192-196                   206 213 224 234-235 241 243 248                   253 261 273 275 289 314 316 321-322                   325-327 329-331 333-334 336-338                   340 343 345-348 354-357 367                   369 371-372 378 382 386 388 395-397                   399-402 404 407 411 415-416                   419-420 425 427 429 431 435-437                   441 444 451 453-459 465 468-470                   472-475 481 485 490 494 496 501                   503 509-510 513 517-518 522-524                   526 528-529 531-534 537-542 545-546                   548 552 554 556-557 559-560                   562-563 565 567-569 572-579 581-582                   584-588 590-591 593-598 602-604                   606 611-615 618 620-623 627                   629 631-632 635-638 643 647 652-654                   657 659 661-662 667 674-675                   677-678 682 684 689 693 695-698                   703 705-707 714 717-718 723 729                   731 738       adult   Clontech   APL001   172 224 239 363 371 392 437 531       placenta           534 622 690 696       placenta   Invitrogen   APL002   57 66 122 161 172 241 326 329 334                   369 388 407 427 429 436 459 464                   506 508 511 539 541 545 566 573                   575 590 597 637 648 690       adult   GIBCO   ASP001   28 57 65 78 93 95 117 134 156-157       spleen           172 186 188 194 214 273 314 319                   331 334 338 344 354 371 374 392                   436 457 471-473 478-479 481 483                   515 526 528-529 541 548 557 559                   563 565 569 573 585-587 603 606                   613 615 618 621-622 627 632 634                   637 643 654 671 689 696-698 701                   712 739       testis   GIBCO   ATS001   3 67 134 160 192 235 327 329 337                   342 371 375 378 380-381 396 399                   415 431 436 441 451 472 477-478                   483 486 494 496 503 522 524 526                   531 533-534 538 541-542 546 548                   557 568 573 577 579 581 584 594                   596 618 641 658 662 689 700 714                   729-730       adult   Invitrogen   BLD001   28 57 112 161 164 172 192 194 250       bladder           334 354 370 397 404 487 513 526                   531 534 545 572 599 602 620 634                   651 659 672 689 713 725       bone marrow   Clontech   BMD001   10-11 28 31 54 57 62 75 78-83 88                   131-133 135-137 141-143 157 159                   164 171-173 176-177 187-189 192                   195 200 202 205 207 218 225 282                   314-318 325 330 334-335 337 346-348                   367 369 372 378 383 386 388                   395 401 405 412-413 416 422 436                   442-443 447 449 455 465 472 475                   477 503 516 523 528-529 533-534                   539 545 551 556 559 563 565-567                   571 573-574 576 579-586 594 601-602                   606 613 620-623 628-629 634                   638 642-643 646 656 659 666 686                   689 691 696 698-699 703 705 714                   720 726 729       bone marrow   Clontech   BMD002   2 15 23 35 49 54 57 59 78 81 114                   156-157 164 171-172 189-190 202                   223 240 325 334 346 357 367 379                   381-382 388 397 412 454 465 482                   490 509 516 526 535 537 563 566                   579 595 600 638 640-641 654-655                   676 689 714       adult colon   Invitrogen   CLN001   48 79 94 138 162 167 189 333 368-369                   375 386 404 409 414 435-436                   455 470 525 541 548 553 567 603                   634 656 659 689 694 721       adult   BioChain   CVX001   3 28 35 54 57 79 83 95 97 113 117       cervix           154 162 164 172 176 220 235 248-249                   249 321 327 329 333 338 346 348                   354 356 362 367-368 371 374-375                   378-379 386 388-389 395 401-402                   404 407 420 429 431 437 443 451                   459 468 475 477 479 483 485 490                   493-494 496 506 508 511 517 526                   528 531 534 544 550 552 559 566                   569 571-573 575-576 581-583 588                   590 593-594 604 606 614 622 628                   631-635 639 661-662 675 689 692                   695 715 718 738       endothelial   Strategene   EDT001   3 28 31 39 54 58 65-66 79 89 144       cells           160 173 187 189 191 193 197-199                   207 220 230 267 273 314 324 326                   329-331 336 347 354 369 372 378-379                   384 386 388 391-394 396-397                   399 401 407 420 422 429 431-432                   435-437 444 449 451 455 459 465                   472 474-475 481-482 486 490 499-501                   503 506 511 513 515-517 520                   522-524 528 531-534 538-539 541                   545-546 548 550 552 557 559-560                   563 565 567 569 571 573 577 579-580                   583-584 587-590 593-594 596-597                   599 602 611 614-615 618 620-621                   624 630 632-634 637-638 642-643                   647-648 651 675 677 680 682                   694 696-698 703 708 714 719 724-725                   728-730 734       Genomic   Genomic   EPM001   38 41-45 118-121 164 198 292-312       clones from   DNA from       the short   Genetic       arm of   Research       chromosome 8       Genomic   Genomic   EPM003   43 164 295       clones from   DNA from       the short   Genetic       arm of   Research       chromosome 8       Genomic   Genomic   EPM004   121 164 306 482       clones from   DNA from       the short   Genetic       arm of   Research       chromosome 8       Genomic   Genomic   EPM006   293       clones from   DNA from       the short   Genetic       arm of   Research       chromosome 8       esophagus   BioChain   ESO002   513 526       fetal brain   Clontech   FBR001   57 468 563 634       fetal brain   Clontech   FBR004   162 186 254 265 491 582       fetal brain   Clontech   FBR006   1-2 5-6 11-12 22-23 49 57 62 73 94                   103 114 162 164 172 189 193 203                   218 240 244 251-252 259 279 330-331                   334-335 346-347 351 367 378                   386 388-389 399 413 420 422 424                   434 442 444 448 465 468 470 472-473                   490 496 501 503-504 511 520                   524 528 532-533 539 544-546 548                   551 553 563 571 573 576 587 591                   601 613 615-616 620-621 628 634                   641 644 648 653 657 662 672-673                   689 691 698 706 714 718 725-728                   733 735-739       fetal brain   Clontech   FBRs03   444 587       fetal brain   Invitrogen   FBT002   17 66 157 162 164 186 190 193 250                   270 324 331 334-335 338 346 354-355                   374 382 389-390 426 429-430                   437 442 453 467 471 475 481 485                   491 507-508 513-514 526 528 532                   540 544 548 550 552-553 557-558                   563 565-566 590 593 602 612 615                   637 641 648 654 662 672 676 692                   703       fetal heart   Invitrogen   FHR001   57 75 164 547       fetal   Clontech   FKD001   57 164 172 179 188 194 208 218 230       kidney           240 250 330 334 369 388 401 413                   439 454 465 529 546 550 573 576                   581 583 594-596 602 634 648 667                   676 689 698 706       fetal   Clontech   FKD002   2 560       kidney       fetal   Invitrogen   FKD007   565 596-597       kidney       fetal lung   Clontech   FLG001   75 164 355 386 428 455 513 524 528                   631 689       fetal lung   Invitrogen   FLG003   30 157 162 169 188 243 253 256 283                   330 392 400-401 404 407 424 428                   435-436 479 506 508 520 530-531                   534 572 578 584 602 611 613 631                   654 658 662 676 689 701 716       fetal lung   Clontech   FLG004   371       fetal   Columbia   FLS001   2-3 5 26 29 31 35 48 54-58 60 62       liver-   University       65 67 70 74-77 79-80 84-87 89 92       spleen           96 98-100 104 117 122-130 138 140                   144-158 160 162 164 172-173 185-186                   188-189 192-194 196 199-200                   207 214 218-219 237-238 241 269                   273 280 282 314-316 318-322 324                   327 329-331 334-335 337 340 345                   348-350 354-358 363-364 367-371                   373 375 377-380 382-383 385-386                   388 394-396 399 402 409 411-412                   418 420-422 424 427 431 435-437                   440 442 448-451 453 455 459 461                   464-465 470 472-473 475 477-478                   480-485 488-490 501 503 505-506                   509 511-513 515-518 520 522-524                   526-534 538-539 541 543-547 549-550                   552-553 556-557 559-564 566-567                   569 571 573 576 578-580 582-587                   589 591-594 596-597 599-600                   602 611-615 618 620-625 627-628                   631-636 638 641-642 646 648 651                   659-660 662-664 667-668 675-678                   680-681 684 689-690 696-698 709                   714 723 738       fetal   Columbia   FLS002   15 31-32 39-40 47-49 52 56 60 65       liver-   University       69 72 75 78 84 97-98 100 104 115       spleen           123 138 140 144 146 152-153 157                   161 164 172-173 182 188 194 196                   199 220 241-242 246 249 253 255                   266 273-275 280-281 288-291 314-316                   318-319 321-322 324 329-331                   336-339 343 347-350 353-354 357-358                   363 367 369-370 372 374 378-380                   382-383 386 388-389 393-397                   399 405 407 409-410 412 421 424                   432 435 439 448 450-451 453-457                   459 461 464-465 470 472-475 477                   479-481 483 485 488 490 497 501                   503 506 509 511-513 516-518 520                   524 527-528 531-532 534 539 541-546                   556 559-560 565-566 569 571                   574 576 579 582-586 588 590 597-599                   602-604 606 615 618 620-621                   623 625 627 632-634 639 641 644                   648 666-668 675-676 681 684 689-690                   696-697 701 703 714 719 723                   734-735       fetal   Columbia   FLS003   60 79 157 190 690       liver-   University       spleen       fetal liver   Invitrogen   FLV001   3 27 35 48 50 56-57 66 75 92 94                   105 157 161 164 176 189 209 220                   243 272 324 328 333 335 353 369-370                   381 392 396 429-430 435 439-440                   442 444 465 471 483 487 502                   506 513-514 519 534-535 537 548                   554 566 568 576-577 580 582 590                   613 621 645 648-649 689       fetal liver   Clontech   FLV002   343       fetal   Invitrogen   FMS001   51 79 97 108-110 166 194 196 266       muscle           341 352 380 389 402 407 444 464                   475 501 513 524 546 552 554 560                   570 572 598 605 628 634 649 675                   703-704 714 737       fetal   Invitrogen   FMS002   524       muscle       fetal skin   Invitrogen   FSK001   31 33 35 48 57 63 67 75 112-114                   117 157 162 164 172 178 180 188                   196 220 243 254 319 324 328 330                   333-334 367 369 371 375 379-383                   386 388-389 400 404 407 412 419-420                   429 444 455 472-473 491 499                   503 508 511 514 517 522-524 529                   531 534 537 540 542 547 552 554                   556-557 560 563 565 567 571-572                   574 576 579 590 596 599 616 621                   625 627 631-632 634 639-640 648                   653-654 662 689 708 714       fetal skin   Invitrogen   FSK002   501 537       fetal   BioChain   FSP001   465 729       spleen       umbilical   BioChain   FUC001   27-28 35 57 68 83 105 136 157 159-160       cord           164 188 191 225 279 315-316                   321 328 334 363 367 369 378-379                   383 386 388-389 392 397 406-407                   413 415-416 427 440 449 455 458                   461 464-465 468 473-475 479 485-486                   488 490 496 514 517 522 524                   526 528-529 531 533-534 538 540                   546 550 552 556-558 572 582 584-585                   587-588 594-597 602 606 613                   616 618-619 631 634 637 651 689                   696 698 706 729       fetal brain   GIBCO   HFB001   3 5 22 26 46 53 66 73 94 117 134                   139 164 172-173 188-189 212 215                   230-231 248 251 262 288-289 316                   325 329-331 334 337-338 348 352                   365-367 369 371 377-379 385-386                   388 392 394 396 400 403 420 422                   429 437 444-446 449 451 455 459                   461-463 466-468 472-473 475 477                   481 483 485-486 488 490-491 496                   503-504 506 513 523-524 529 532-533                   539-541 545 548 550 552 557-560                   563 565-566 569 571 576-577                   579-580 583-584 586 590 593-594                   596-599 601-602 604 606 611 613                   615 618 621-623 627-628 634-635                   637 641 643 647 662 664-665 667                   675 677 680 689 695-697 703 726       macrophage   Invitrogen   HMP001   97 518 532 569       infant   Columbia   IB2002   28 46 56-57 59 67 75 78 109 117       brain   University       122 129 144 157 162 164-165 172                   176 180 190 193 212 220 226 236-237                   251 261-262 316 318 324 328-330                   334-335 337 340 354-356 361                   364-365 367 369 371-373 377-380                   382 385-386 389 392 395 397 400                   411 416 421-422 429 432 436 438                   444 448 451 456 464-465 469 471-475                   484 486 496 504-506 511 520                   524 526 529 531 533-534 537-540                   544-546 548 553 556 558 562 565                   567 576 579-580 582 584 586 589-590                   593 597-598 602 613-614 618                   620-621 627-628 632 634 636 641                   650 654 659 662 667 683 689 721                   730       infant   Columbia   IB2003   46 54 75 109 156 164 220 244 251       brain   University       314 324-325 331 335 340 361-362                   367 369 377-379 400 408 438 442                   456 460 464 469 472 496 506 523-524                   526 529 538 540 544-545 547                   558 560-562 565 567 569 579 584                   598 602 613 615 621 627 632 634                   637 639 650 738       infant   Columbia   IBM002   262 340 432 436 438 472 531 534       brain   University       569 613 634       infant   Columbia   IBS001   162 231 283 331 369 385 438 444       brain   University       472 506 513 523 531 534 580 615                   636 689       lung,   Strategene   LFB001   28 54 57 65 172 188 233 321 331       fibroblast           340 347 367 369 378-379 388 401                   451 459 475 479 503 511 522 524                   532 534 559-560 573 580 583 587                   597 615 632 634 638 686 689 708       lung tumor   Invitrogen   LGT002   3 7 21 24 26 28 31 54 56-57 62-63                   66 92-93 101 109 112 162 164 171-172                   176 183 188-189 192-193 196                   201-202 223 230 235 259 273-274                   316 321 329-331 333-334 338 345                   347-348 356 367 369 371-372 378-379                   381-382 386 388-390 396 399-404                   406 409 416 424-425 427 429                   432 436-437 439 451 455-456 459                   464-465 467 473 475 484-486 490                   499 502-503 506 508 511 513-514                   517-518 522 524 526 528 531-532                   534-535 538-539 541 543-546 553                   557-559 563 567-568 571 573 575-576                   579-580 585-588 590-591 593-594                   598 601-604 609 611-613 615                   621 627-628 631-632 636-637 645                   648 651-652 654 662 667 672 677                   681 683 689 698 701-702 714 718                   724 726 729 734       lymphocytes   ATCC   LPC001   4 31-32 35 57 65-66 70 110 116 156                   162 164 230 243 250 282 287 326                   328-330 334 336 346-347 359 378                   386 388 397 407 414 416 419 472                   497 520 525 539 545 549 551 582                   590 606 615 618 621 631 634 686                   692 698 701 714       leukocyte   GIBCO   LUC001   4 7 9-11 23 28 31 35 39 54 65 75-76                   79 90 97 110 117 134 152 157                   159 162 164-167 171 173 176 188                   193 199 204 207 220 244 253 255                   314 316 318 321 324 326 329-330                   337-339 346-347 352 354 356 367                   369 371 378-379 382 388-389 392                   396-397 400-402 405 415-416 420                   422 429 432 435-436 443-444 449                   454-455 457-459 465 479 481-486                   491 497 501 503-504 506 508 511                   514 516 520 523-525 529 532-533                   535 538-539 545 548 552-554 556                   559-560 562-563 565-566 569 571-573                   576 579 581 585-587 590 593-594                   598 600-602 604 606-609 613-614                   618 620-622 624 627 630 632-634                   636 638 643 645 660-662 667                   678 682 684 686 689 691 693 696-698                   714 726       leukocyte   Clontech   LUC003   11 54 97 152 164 330 479 546 564-565                   593 613 627 634 646 696 729       melanoma   Clontech   MEL004   2 57 67 79 164 171-173 188 193 196       from cell           232 321 337 341 346 367 379-380       line ATCC           388 407 427 454 472 477 482 501       #CRL 1424           520 539 545 552 556 579 588 593                   598 611 621 631 648 665 714 730       mammary   Invitrogen   MMG001   3 20-21 29 31 54 56-57 63-66 79 94       gland           109 112-113 117 122 125 138 141                   154 160 162 164 172 176 186 189                   192 204 214 220-221 232 238 251                   255 257 273 276-278 324 326 328-331                   333 335 337 341-343 347 354-355                   357 367-371 374-375 379 382-386                   388-392 397 399-400 404 406-408                   410-411 425 431 435-436 444                   451 455 457 459 461 464-465 470-471                   475 479 483 485 487-488 491                   501 506-508 511 513-519 523-524                   526 529 531-532 534-535 537 539-540                   542-545 552-554 557-560 563                   566 569 572 577 580 584 587-588                   590 597-598 602 604-605 609 611                   613 615 624 627 631-634 637 639-640                   643 648-649 654 664 669-670                   672-673 676-679 681 689 691-695                   697-698 706 714 731 734 737       induced   Strategene   NTD001   36 57 164 284 388 397 420 481 485       neuron           501 524 528-529 539 542 545 560       cells           571 579 582 595 602 620 637 654                   667 689 730       retinoid   Strategene   NTR001   524 584 693       acid       induced       neuronal       cells       neuronal   Strategene   NTU001   36-38 120 204 331 351 354 357 386       cells           388 399 411 442 459 516 533 539                   545 565 586 606 615 621 637-638                   642 646 648 714 730       placenta   Clontech   PLA003   503 579 690       prostate   Clontech   PRT001   15 40 65 164 187 207 229 337 348                   367 375 377-378 395 406 416 428                   458 468 476 511 524 526 531 534                   538 555 559 563 576 584 597 613                   622 624 631 642 667 672 677 684                   724 734       rectum   Invitrogen   REC001   57 67 164 260 331 343 370-371 380                   382 384 404 409 436 444 475 485                   498 513 524 526 540 542 552 554                   581 615 619 624 627 634 654 659                   671 689 714       salivary   Clontech   SAL001   21 84 106-107 152 179 238 246 255       gland           273 287 371 378 383 401 407 420                   455 475 477 509 512 515 521 541                   548 565 570-571 573-574 589 606                   628 634 636 652 689 703 738       skin   ATCC   SFB002   192       fibroblast       skin   ATCC   SFB003   464       fibroblast       small   Clontech   SIN001   57 66 71 98 116 150 164 172 327       intestine           336 343 362 367 379 388 397 401-402                   417 429 433 436 496 526 528                   533 590 602 620 631 634 667 678                   711       skeletal   Clontech   SKM001   3 57 66 101 164 172 256 266 325       muscle           379 385 449 468 485 487 518 552                   554 566-567 570 582 584 590 606                   611 628 631 738       spinal cord   Clontech   SPC001   10 54 57 66 75 100 102 114 144 164                   175 193 199 215-216 325 334 337                   367 370 380 385-386 406 411-413                   419 429 466 470 486 518 526 529                   531 534 574 579 585 587 590 604                   620-621 631-632 634 642 644 648                   659 688-689 691 693 695       adult   clontech   SPLc01   478 572       spleen       stomach   Clontech   STO001   26 90 164 218 358 369 386 468 475                   485 526 532 569 576 579 581 586                   603 631 634 677 682 689       thalamus   Clontech   THA002   17 31 57 66 109 127 164 217-218                   262 315-316 324 330 357 369 386                   388 400 406 435 456 459 464 468-469                   515-516 537 540-541 556 566                   574 590 611 622 631 634 644 648                   656 677-678 680       thymus   Clontech   THM001   6 15 26 54 79 164 172 187 193 201                   264 291 315 329 331 351 356 367                   397-398 401 407 412 424 427 429                   435-436 443 451 474 478 482 549                   563 565 567 569 576 578 581-582                   610 615 621 631-632 634 648 662                   667 669 679 689 693 696       thymus   Clontech   THMc02   3-6 8 11 16 18 34 58-59 67 132 149                   162 164 167 172-173 186 188-189                   193 200 203 216 223 232 239 255                   263 265 319-320 331 333-334 355                   359 370 373 377-380 382 387-390                   393 395 398-399 402 404 408 420                   427 434 436 467 475-476 503 508                   518 524 526 532 540 560 563 565                   571-572 576-577 579 582 598 601                   603 612-613 615 621 627 632 634                   639 641 648 651 657 659 662 672                   677-678 684-686 689 696 699 706                   714-716 722 726-729 732       thyroid   Clontech   THR001   5 29-30 40 54 57 66 72 79 117 144       gland           160 164 166 170 172 176 183 188-189                   208-209 219 230 285-286 314                   318 327 331 335 338 344 347 354                   363 367 375 377-380 382 384-386                   388 393 397 399 401-403 419 422                   429 436 442 444 451 456 458-461                   464 467-468 470 472-473 476-477                   481 488 494 503 508-509 511 516                   519-521 524 528-529 533 537-538                   543 548 557 559-560 563 565-566                   571-574 576 582 585 587 590-591                   593-594 596-597 606 614-615 620-621                   623-624 627 631-634 640 650-651                   653 662 667 669-670 675 679                   689 708 712 714       trachea   Clontech   TRC001   156 164 171 240 375 378 390 400                   422 468 484 565 574 581 585 587                   631 654 689 714       uterus   Clontech   UTR001   65 77 79 101 164 220 367 369 451                   468 526 530 533 548 554 559 562                   568 573 582 594 637 648 689                  
 
     [0381]               TABLE 2                          Nearest Neighbor Results                                             SEQ                               ID           NO:           in               Simth-       SEQ   USSN               Water       ID   09/   Accession           man   %       NO:   488,725   No.   Species   Description   Score   Identity                                                 1   1000   gi7021484     Mus Musculus     secretory   567   85                       carrier                       membrane                       protein 4       2   10017   R06463     Homo sapiens     Derived   848   100                       protein of                       clone ICA13                       (ATCC 40553).       3   10020   gi1065967     Caenorhabditis     similar to   325   36                     elegans     other protein                       phosphatases                       1, 2A and 2B       4   10024   G03460     Homo sapiens     Human   439   98                       secreted                       protein,       5   10032   Y12505     Homo sapiens     Human 5′ EST   136   87                       secreted                       protein       6   10042   Y29511     Homo sapiens     Human lung   701   100                       tumour protein                       SAL-25 1st                       predicted                       amino acid                       sequence.       7   1006   Y92324     Homo sapiens     Human alpha-   763   100                       2-delta-D                       polypeptide                       from splice                       variant 1.       8   10064   gi4589375     Homo sapiens     Gab2   425   58       9   1007   gi7018398     Homo sapiens         151   75       10   1008   gi896065     Homo sapiens     protein that   1226   99                       is immuno-                       reactive with                       anti-PTH                       polyclonal                       antibodies       11   10088   gi3779244     Homo sapiens     Metalloprotease 1   1512   98       12   10089   gi2947232     Homo sapiens     membrane   523   100                       associated                       guanylate                       kinase 2       13   10091   gi3347863     Mus Musculus     cAMP-specific   223   54                       cyclic                       nucleotide                       phosphodiesterase                       PDE8;                       MMPDE8       14   10098   gi6979311     Homo sapiens     cysteine-rich   1068   100                       repeat-                       containing                       protein S52                       precursor       15   10102   G01395     Homo sapiens     Human   297   88                       secreted                       protein,       16   10103   gi854733     Rattus     casein kinase 1   293   84                     norvegicus     gamma 1                       isoform       17   10104   Y60017     Homo sapiens     Human   154   100                       endometrium                       tumour EST                       encoded                       protein 77.       18   10108   G03290     Homo sapiens     Human   215   97                       secreted                       protein,       19   10110   gi7292299     Drosophila     CG1271 gene   208   46                     melanogaster     product       20   10111   gi4512334     Rattus     Ca/calmodulin-   822   89                     norvegicus     dependent                       protein kinase                       kinase alpha,                       CaM-kinase                       kinase alpha       21   10113   Y41694     Homo sapiens     Human PRO382   633   97                       protein                       sequence.       22   10114   gi349075     Rattus     calmodulin-   531   99                     norvegicus     binding                       protein       23   10116   gi162981     Bos taurus     endozepine-   937   87                       related                       protein                       precursor       24   10121   gi8979743     Canis     Band4.1-like5   643   100                     familiaris     protein       25   10126   Y99420     Homo sapiens     Human PRO1486   607   100                       (UNQ755) amino                       acid sequence       26   1013   gi804750     Homo Sapiens     protein   614   73                       tyrosine                       phosphatase       27   10136   W02105     Homo sapiens     Human L-   1243   98                       asparaginase.       28   10142   Y35924     Homo sapiens     Extended   862   89                       human secreted                       protein                       sequence,       29   10148   gi3334982     Homo sapiens     R27216_1   329   98       30   1015   G02485     Homo sapiens     Human   120   72                       secreted                       protein,       31   10154   gi10798804     Homo sapiens     sperm antigen   2607   98       32   10175   Y96864     Homo sapiens     SEQ. ID. 37   536   100                       from                       WO0034474.       33   10196   gi553621     Homo sapiens     profilaggrin   346   39       34   10198   gi1419016     Mus Musculus     odorant   281   53                       receptor       35   10200   Y57903     Homo sapiens     Human   448   100                       transmembrane                       protein HTMPN-                       27.       36   10208   gi4062492     Escherichia         505   100                     coli         37   10212   gi882529     Escherichia     ORF_f141   625   96                     coli         38   10213   gi4062778     Escherichia     Hypothetical   773   98                     coli     protein HI0761       39   10214   gi6693832     Rattus     opioid growth   661   44                     norvegicus     factor                       receptor       40   10227   G01360     Homo sapiens     Human   384   100                       secreted                       protein,       41   10236   gi1651257     Escherichia         373   100                     coli         42   10241   gi2769262     Escherichia     catabolite   178   96                     coli     gene activator                       protein       43   10245   gi1789539     Escherichia     orf,   679   98                     coli     hypothetical                       protein       44   10246   gi882492     Escherichia     ORF_o179   488   97                     coli         45   10247   gi1742149     Escherichia     Sn-glycerol-   323   100                     coli     3-phosphate                       transport                       system                       permease                       protein UgpA.       46   10282   Y29817     Homo sapiens     Human synapse   521   96                       related                       glycoprotein 2.       47   1031   gi6435130     Mus Musculus     putative E1-E2   990   86                       ATPase       48   1040   gi854124     Homo sapiens     Human giant   471   63                       larvae                       Homologue       49   1043   gi3882285     Homo sapiens     KIAA0782   154   61                       protein       50   1051   gi178216     Homo sapiens     anion   172   100                       exchange                       protein 1       51   1053   Y76748     Homo sapiens     Human protein   180   92                       kinase                       Homologue,                       PKH-1.       52   1062   gi965014     Mus Musculus     ADAM 4   492   65                       protein                       precursor       53   1063   gi2393880     Drosophila     A-kinase   580   60                     melanogaster     anchor protein                       DAKAP550       54   1066   gi2746788     Caenorhabditis     contains   607   35                     elegans     similarity to                       transacylases       55   107   G00357     Homo sapiens     Human   183   77                       secreted                       protein,       56   1071   gi9105937     Xylella     Acetylglutamate   505   36                     fastidiosa     kinase       57   1085   R95913     Homo sapiens     Neural thread   257   55                       protein.       58   1086   Y76332     Homo sapiens     Fragment of   387   58                       human secreted                       protein                       encoded by                       gene 38.       59   1088   gi4589642     Homo sapiens     KIAA0999   873   99                       protein       60   109   gi763431     Homo sapiens     KIAA0999   360   85                       protein       61   1095   Y94907     Homo sapiens     Human   701   97                       secreted                       protein clone                       ca106_19x                       protein                       sequence       62   1102   Y07096     Homo sapiens     Colon cancer   1982   100                       associated                       antigen                       precursor                       sequence.       63   1105   Y84907     Homo sapiens     A human   983   91                       proliferation                       and apoptosis                       related                       protein.       64   1108   gi1398903     Mus Musculus     Ca2+ dependent   1307   89                       activator                       protein for                       secretion       65   1109   Y91524     Homo sapiens     Human   2400   99                       secreted                       protein                       sequence                       encoded by                       gene 74       66   1113   gi1657462     Sus scrofa     calcium/calmodulin-   1348   94                       dependent                       protein kinase                       II isoform                       gamma-E       67   1117   Y32169     Homo sapiens     Human growth-   2831   97                       associated                       protease                       inhibitor                       heavy chain                       precursor.       68   1118   gi3063517     Homo sapiens         1138   98       69   1125   gi8248285     Homo sapiens     sphingosine   1290   98                       kinase type 2                       isoform       70   1132   Y94918     Homo sapiens     Human   437   59                       secreted                       protein clone                       dd504_18                       protein                       sequence       71   1143   gi45806     Homo sapiens     prepro-major   209   40               77       basic protein                       Homolog       72   1146   gi182395     Homo sapiens     focal   131   87                       adhesion                       kinase       73   1161   W90962     Homo sapiens     Human CSGP-2   931   100                       protein.       74   117   W69428     Homo sapiens     Human   159   93                       secreted                       protein                       bp537_4.       75   1170   gi34339     Homo sapiens         586   87       76   1175   gi7960243     Homo sapiens     SNARE protein   308   100                       kinase SNAK       77   118   gi5360093     Homo sapiens     NY-REN-18   178   96                       antigen       78   1183   gi292037     Homo sapiens     helix-loop-   361   91                       helix                       phosphoprotein       79   1193   gi1899186     Rattus     polysialyltransferase   171   76                     norvegicus         80   1195   gi1399462     Homo sapiens     serine/threonine-   208   71                       protein                       kinase PRP4h       81   1198   gi181535     Homo sapiens     defensin   150   71                       precursor       82   1201   gi5668935     Rattus     plasma   244   73                     norvegicus     membrane Ca2+                       ATPase isoform                       1 kb       83   1207   gi6224868     Homo sapiens     TANK binding   716   86                       kinase TBK1       84   1210   gi179646     Homo sapiens     complement   242   61                       component Cls       85   1211   gi1483187     Homo sapiens         296   65       86   1214   gi7800638     Streptococcus     PspA   121   37                     pneumoniae         87   123   Y44810     Homo sapiens     Human   218   93                       Aspartic                       Protease-2                       (NHAP-2).       88   1259   gi2116672     Homo sapiens     EAR-1r   128   70       89   1266   gi7243125     Homo sapiens     KIAA1372   403   53                       protein       90   1270   gi1289445     Homo sapiens     diacylglycerol   125   96                       kinase epsilon                       DGK       91   1290   gi1429371     Drosophila     ubiquitin-   470   41                     melanogaster     specific                       protease       92   1291   Y66755     Homo sapiens     Membrane-bound   993   100                       protein                       PRO1185.       93   1296   gi9652087     Homo sapiens     scavenger   1183   99                       receptor                       cysteine-rich                       type 1 protein                       M160                       precursor       94   1299   gi7300398     Drosophila     CG7683 gene   397   40                     melanogaster     product       95   1317   gi3695115     Rattus     CL1AA   216   100                     norvegicus         96   132   gi187171     Homo sapiens     12-   176   97                       lipoxygenase       97   1330   Y12482     Homo sapiens     Human 5′ EST   65   44                       secreted                       protein       98   1336   gi10798814     Homo sapiens     MLTK-beta   2366   99       99   135   gi456090     Homo sapiens     effector cell   190   74                       protease                       receptor 1       100   1356   gi193057     Mus Musculus     envelope   131   36                       polyprotein                       precursor       101   1369   gi458657     Homo sapiens     glucocorticoid   596   89                       receptor                       alpha-2       102   1392   gi8493519     Mus Musculus     nuclear   145   59                       localization                       signal binding                       protein       103   1408   gi3127051     Rattus     potassium   176   84                     norvegicus     channel                       regulatory                       protein KChAP       104   141   gi6453613     Mus Musculus     putative   204   33                       protein kinase       105   1424   gi2982501     Homo sapiens     neuropathy   769   100                       target                       esterase       106   143   W50033     Homo sapiens     Human immunity   1201   98                       related                       factor.       107   1431   gi10644565     Heterodera     hypothetical   133   36                     glycines     esophageal                       gland cell                       secretory                       protein 10       108   1441   gi3044086     Myxococcus     unknown   149   32                     xanthus         109   1444   gi7248381     Homo sapiens     adaptor   1615   97                       protein                       p130Cas       110   1447   Y65168     Homo sapiens     Human 5′ EST   403   97                       related                       polypeptide       111   1457   W19919     Homo sapiens     Human Ksr-1   227   77                       (kinase                       suppressor of                       Ras).       112   1471   G02532     Homo sapiens     Human   97   59                       secreted                       protein,       113   1473   gi6062874     Homo sapiens     candidate   581   100                       tumor                       suppressor                       protein DICE1       114   1474   Y64896     Homo sapiens     Human 5′ EST   197   100                       related                       polypeptide       115   1483   gi436218     Homo sapiens     KIAA0037   295   76       116   1486   gi5852834     Homo sapiens     bridging   133   64                       integrator-2       117   149   gi3327162     Homo sapiens     KIAA0674   2243   98                       protein       118   1503   gi1736785     Escherichia     .   1270   97                     coli         119   1506   gi4062298     Escherichia     YhhI protein   612   90                     coli         120   1513   gi4062346     Escherichia     .   556   94                     coli         121   1514   gi216609     Escherichia     PhoQ protein   661   90                     coli         122   1523   gi5712756     Rattus     calcium   1178   90                     norvegicus     transporter                       CaT1       123   1527   gi1853980     Mus Musculus     glucocorticoid   171   84                       receptor                       interacting                       protein 1       124   1536   Y17227     Homo sapiens     Human   452   100                       secreted                       protein (clone                       ya1-1).       125   154   gi8515090     Pinus taeda     putative   81   40                       arabinogalactan                       protein       126   1544   gi3879933     Caenorhabditis     Similarity to   134   34                     elegans     Xenopus F-                       spondin                       precursor (PIR                       Acc. No.                       comes from                       this gene       127   1554   gi6523817     Homo sapiens     S1R protein   255   84       128   1555   gi6635205     Homo sapiens     beta-   210   90                       ureidopropionase       129   1556   Y39286     Homo sapiens     Phosphodiesterase   161   61                       10 (PDE10)                       clone FB93a.       130   1564   gi8977945     Streptomyces     putative   231   45                     coelicolor     secreted                   A3(2)   serine                       protease       131   1576   gi3025828     Rattus     signal   183   97                     norvegicus     transducer and                       activator of                       transcription 4       132   1578   gi5106572     Homo sapiens     transcriptional   758   98                       activator                       SRCAP       133   1579   gi8575527     Homo sapiens     toll-like   595   99                       receptor 8       134   158   gi406058     Mus Musculus     protein kinase   168   70       135   1580   gi63340     Gallus gallus     c-Rmil   231   90       136   1588   gi2217931     Homo sapiens     PKU-alpha   127   92       137   1589   gi1272422     Mus Musculus     Phosphoinositide   720   99                       3-kinase       138   159   gi2224629     Homo sapiens     KIAA0344   215   43       139   1600   gi1016012     Rattus     neural cell   543   93                     norvegicus     adhesion                       protein BIG-2                       precursor       140   161   gi6649583     Homo sapiens     kidney and   1651   98                       liver proline                       oxidase 1       141   1612   gi406113     Rattus     protein kinase I   125   89                     norvegicus         142   1615   gi219992     Homo sapiens     phSR2   150   78       143   1620   gi5714636     Homo sapiens     serine/threonine   126   71                       protein                       kinase Kp78                       splice variant                       CTAK75a       144   1644   Y13352     Homo sapiens     Amino acid   2542   100                       sequence of                       protein                       PRO228.       145   1647   Y99444     Homo sapiens     Human PRO1575   704   100                       (UNQ781) amino                       acid sequence       146   1650   gi3789765     Homo sapiens     transmembrane   271   100                       receptor UNC5C       147   1663   W75258     Homo sapiens     Fragment of   163   96                       human secreted                       protein                       encoded by                       gene 26.       148   1665   gi10432431     Homo sapiens     secreted   1428   99                       modular                       calcium-                       binding                       protein       149   1671   gi6708169     Mus Musculus     inositol   169   97                       phosphatase                       eSHIPD183       150   1672   Y68773     Homo sapiens     Amino acid   1030   99                       sequence of a                       human                       phosphorylation                       effector                       PHSP-5.       151   1678   gi6063017     Homo sapiens     tousled-like   132   86                       kinase 1       152   1680   gi3510603     Homo sapiens     nuclear   278   80                       receptor co-                       repressor N-                       CoR       153   1692   gi1546084     Homo sapiens     farnesol   165   100                       receptor HRR-1       154   1698   gi520469     Oryctolagus     597 aa   177   94                     cuniculus     protein                       related to                       Na/glucose                       cotransporters       155   1702   gi10432382     Homo sapiens         519   95       156   1704   Y91668     Homo sapiens     Human   214   75                       secreted                       protein                       sequence                       encoded by                       gene 73       157   1708   gi3080757     Mus Musculus     growth factor   457   78                       independence-                       IB       158   1716   gi29653     Homo sapiens     putative   220   92                       oncogene       159   173   gi3452473     Rattus     serine/threonine   699   100                     norvegicus     protein                       kinase TAO1       160   1731   Y27581     Homo sapiens     Human   774   100                       secreted                       protein                       encoded by                       gene No. 15.       161   1732   gi9652087     Homo sapiens     scavenger   1025   98                       receptor                       cysteine-rich                       type 1 protein                       M160                       precursor       162   174   Y35923     Homo sapiens     Extended   1691   100                       human secreted                       protein                       sequence,       163   1740   Y53014     Homo sapiens     Human   337   60                       secreted                       protein clone                       fn189_13                       protein                       sequence       164   1748   gi7770237     Homo sapiens     PRO2822   218   93       165   1751   gi8979825     Homo sapiens         306   50       166   1755   R95332     Homo sapiens     Tumor   1184   62                       necrosis                       factor                       receptor 1                       death domain                       ligand (clone                       3TW).       167   1762   gi7380947     Homo sapiens     Gem-   1545   99                       interacting                       protein       168   1776   gi5912265     Homo sapiens     hypothetical   224   100                       protein       169   1777   Y70461     Homo sapiens     Human   413   95                       membrane                       channel                       protein-11                       (MECHP-11).       170   1781   R26060     Homo sapiens     Growth Factor   398   98                       Receptor Bound                       protein GRB-1.       171   1796   gi10312169     Homo sapiens     serine   1381   99                       carboxypeptidase 1                       precursor                       protein       172   180   gi3002527     Homo sapiens     neuronal   477   61                       thread protein                       AD7c-NTP       173   182   gi7385131     Homo sapiens     HBV pX   2066   82                       associated                       protein-8;                       XAP-8       174   1820   G03249     Homo sapiens     Human   370   97                       secreted                       protein,       175   1822   gi473969     Oryctolagus     one of the   1048   90                     cuniculus     members of                       sodium-glucose                       cotransporter                       family       176   1829   gi10440355     Homo sapiens     FLJ00012   310   96                       protein       177   1832   gi165650     Oryctolagus     phosphorylase   146   96                     cuniculus     kinase beta-                       subunit       178   1834   W75132     Homo sapiens     Human   423   47                       secreted                       protein                       encoded by                       gene 11 clone                       HCENJ40.       179   1837   gi60369     Saimiriine     ORF   615   71                     herpesvirus 2     48˜EDLF5˜sim.                       to EBV BRRF2       180   1859   gi9989696     Homo sapiens     ROR2 protein   645   87       181   1880   gi7340847     Mus Musculus     chondroItin   275   40                       4-                       sulfotransferase       182   1881   gi7573291     Homo sapiens         298   100       183   1890   gi3149950     Homo sapiens     ST1C2   183   94       184   1899   gi2143260     Homo sapiens     Phosphoinositide   346   98                       3-                       kinase       185   19   gi1808582     Homo sapiens     U2AF1-RS2   224   46       186   192   G03192     Homo sapiens     Human   267   86                       secreted                       protein,       187   1922   gi485858     Mus Musculus     IB3/5-   1206   78                       polypeptide       188   1945   gi37261     Homo sapiens         1402   97       189   195   W67863     Homo sapiens     Human   551   98                       secreted                       protein                       encoded by                       gene 57 clone                       HFEBF41.       190   1957   gi406738     Homo sapiens     Shb   263   44       191   1969   Y41701     Homo sapiens     Human PRO708   975   98                       protein                       sequence.       192   1970   gi3979817     Caenorhabditis     Weak   254   49                     elegans     similarity to                       Human                       tyrosine-                       protein kinase                       CSK       193   1973   G00796     Homo sapiens     Human   365   98                       secreted                       protein,       194   1985   gi4558637     Homo sapiens     Putative   1420   99                       Homolog of                       hypoxia                       inducible                       factor three                       alpha       195   1986   gi4455015     Homo sapiens     host cell   367   50                       factor Homolog                       LCP       196   2   G02532     Homo sapiens     Human   106   85                       secreted                       protein,       197   2004   gi10503935     Homo sapiens     type A   961   100                       calpain-like                       protease       198   2023   gi1651341     Escherichia         1075   97                     coli         199   2025   Y71069     Homo sapiens     Human   540   100                       membrane                       transport                       protein,                       MTRP-14.       200   2038   gi8572543     Homo sapiens     membrane-   686   98                       associated                       lectin type-C       201   2041   gi37400     Homo sapiens     trk-2h   228   89                       polypeptide       202   2043   W75096     Homo sapiens     Human   290   38                       secreted                       protein                       encoded by                       gene 40 clone                       HNEDJ57.       203   2068   G03394     Homo sapiens     Human   595   97                       secreted                       protein,       204   2072   gi2116552     Rattus     cationic   1025   85                     norvegicus     amino acid                       transporter 3       205   2076   gi157409     Drosophila     fat protein   369   39                     melanogaster         206   2078   gi1054940     Gallus gallus     cSH-PTP2   605   94       207   2084   gi9663128     Homo sapiens     hypothetical   874   99                       protein       208   2088   gi10567590     Homo sapiens     sodium   609   100                       bicarbonate                       cotransporter-                       like protein       209   2089   gi1789001     Escherichia     putative ATP-   961   98                     coli     binding                       component of a                       transport                       system       210   2097   Y70460     Homo sapiens     Human   258   96                       membrane                       channel                       protein-10                       (MECHP-10).       211   2108   gi3207508     Rattus     hexokinase   767   74                     norvegicus         212   2111   gi6330233     Homo sapiens     KIAA1176   3710   99                       protein       213   2118   W74797     Homo sapiens     Human   156   96                       secreted                       protein                       encoded by                       gene 68 clone                       HKIXR69.       214   2134   gi1780991     Homo sapiens     branched   209   97                       chain acyl-CoA                       oxidase       215   2146   gi7688148     Homo sapiens     hypothetical   1038   100                       protein       216   2149   gi2280485     Homo sapiens     KIAA0376   917   100       217   2153   gi1842429     Rattus     ankyrin   592   88                     norvegicus     binding cell                       adhesion                       molecule                       neurofascin       218   2155   gi6526791     Homo sapiens     Eps15R   1126   100       219   2161   gi7300427     Drosophila     CG7709 gene   200   33                     melanogaster     product       220   2163   Y52296     Homo sapiens     Human   186   91                       isomerase                       Homologue-3                       (HIH-3).       221   2173   W34526     Homo sapiens     hTCP protein   164   93                       fragment.       222   2178   gi3360512     Rattus     Citron-K   299   94                     norvegicus     kinase       223   2180   Y74008     Homo sapiens     Human   261   41                       prostate tumor                       EST fragment                       derived                       protein #195.       224   2184   gi53041     Mus Musculus         130   41       225   2186   gi401774     Homo sapiens     ribosomal   142   64                       protein S6                       kinase 3       226   2190   gi577295     Homo sapiens     The ha1225   176   100                       gene product                       is related to                       human alpha-                       glucosidase.       227   2210   gi2055392     Rattus     transmembrane   620   90                     norvegicus     receptor                       UNC5H1       228   2214   gi7861733     Homo sapiens     low density   1360   98                       lipoprotein                       receptor                       related                       protein-                       deleted in                       tumor       229   2223   gi7959189     Homo sapiens     KIAA1464   884   99                       protein       230   223   W88627     Homo sapiens     Secreted   300   77                       protein                       encoded by                       gene 94 clone                       HPMBQ32.       231   2233   gi7839587     Homo sapiens     organic anion   1092   99                       transporting                       polypeptide 14       232   2237   gi10440400     Homo sapiens     FLJ00033   1212   99                       protein       233   2251   gi5923786     Homo sapiens     zinc metallo-   277   44                       protease                       ADAMTS6       234   2256   W63698     Homo sapiens     Human secreted   516   100                       protein 18.       235   2259   gi4678722     Homo sapiens     hypothetical   387   36                       protein       236   2262   Y33741     Homo sapiens     Beta-   793   99                       secretase.       237   2265   gi7018545     Homo sapiens     hypothetical   608   94                       protein       238   2271   gi4186183     Homo sapiens     unknown   684   53       239   2273   gi7243035     Homo sapiens     KIAA1327   1031   100                       protein       240   2280   gi5809678     Homo sapiens     sperm membrane   342   95                       protein BS-63       241   2286   gi6224691     Homo sapiens     Na+/sulfate   1221   99                       cotransporter                       SUT-1       242   2291   gi207621     Rattus     uromodulin   345   50                     norvegicus         243   2292   gi7296304     Drosophila     CG5274 gene   272   35                     melanogaster     product       244   2294   Y28503     Homo sapiens     HGFH3 Human   320   98                       Growth Factor                       Homologue 3.       245   2296   W88799     Homo sapiens     Polypeptide   223   86                       fragment                       encoded by                       gene 45.       246   2303   gi7110160     Homo sapiens     guanine   1212   99                       nucleotide                       exchange                       factor       247   2306   gi6434874     Mus Musculus     calcium/calmodulin   576   84                       dependent                       protein kinase                       kinase alpha       248   2309   Y95433     Homo sapiens     Human calcium   1203   99                       channel SOC-                       2/CRAC-1 C-                       terminal                       polypeptide.       249   2313   gi7300943     Drosophila     CG4677 gene   689   79                     melanogaster     product       250   2318   W48351     Homo sapiens     Human breast   202   59                       cancer related                       protein                       BCRB2.       251   2329   G01772     Homo sapiens     Human   311   84                       secreted                       protein,       252   2330   Y41729     Homo sapiens     Human PRO1071   886   99                       protein                       sequence.       253   2342   gi3786430     Caenorhabditis         268   42                     elegans         254   2350   gi930104     Homo sapiens     protein-   571   79                       tyrosine                       phosphatase       255   2359   gi9392591     Homo sapiens     CC chemokine   679   99                       CCL28       256   2361   gi1666689     Mus Musculus     alpha-NAC,   357   41                       Muscle-                       specific form                       gp220       257   2374   G03172     Homo sapiens     Human   112   78                       secreted                       protein,       258   2387   gi1399197     Homo sapiens     pyruvate   201   85                       dehydrogenase                       kinase isoform 4       259   2401   G01757     Homo sapiens     Human   612   99                       secreted                       protein,       260   2409   gi181123     Homo sapiens     cleavage   194   86                       signal 1                       protein       261   2431   gi7018547     Homo sapiens     hypothetical   473   50                       protein       262   2432   gi4826496     Homo sapiens         327   39       263   2467   G03667     Homo sapiens     Human   640   97                       secreted                       protein,       264   2471   gi7688148     Homo sapiens     hypothetical   1284   91                       protein       265   2478   gi790819     Homo sapiens     polycystic   615   90                       kidney                       disease-                       associated                       protein       266   2484   gi3327080     Homo sapiens     KIAA0633   1747   99                       protein       267   249   G03793     Homo sapiens     Human   139   65                       secreted                       protein,       268   2490   gi6467371     Homo sapiens     thyrotropin-   757   98                       releasing                       hormone                       degrading                       ectoenzyme       269   25   G03203     Homo sapiens     Human   137   65                       secreted                       protein,       270   2504   gi4097712     Homo sapiens     HBV   166   74                       associated                       factor       271   2506   gi2072784     Homo sapiens     Na+/nucleoside   201   95                       cotransporter       272   2507   gi5924007     Homo sapiens         335   38       273   2510   gi7717385     Homo sapiens     beta-site   383   89                       APP-cleaving                       enzyme 2, EC                       3.4.23.       274   2523   gi339709     Homo sapiens         150   96       275   253   gi36615     Homo sapiens     serine/threonine   391   77                       protein                       kinase       276   2533   gi4589614     Homo sapiens     KIAA0985   191   61                       protein       277   2536   gi2088685     Caenorhabditis     strong   419   55                     elegans     similarity to                       the CDC2/CDX                       subfamily of                       ser/thr                       protein                       kinases       278   2544   gi1002425     Mus Musculus     YSPL-1 form 2   280   80       279   2568   Y41738     Homo sapiens     Human PRO541   379   49                       protein                       sequence.       280   2580   gi3004482     Rattus     putative   382   49                     norvegicus     integral                       membrane                       transport                       protein       281   2593   gi7300049     Drosophila     CG4525 gene   582   50                     melanogaster     product       282   2600   gi4530437     Homo sapiens     thyroid   334   90                       hormone                       receptor-                       associated                       protein                       complex                       component                       TRAP240       283   2625   gi8099652     Homo sapiens     toll-like   761   96                       receptor 9                       form A       284   2641   gi148019     Escherichia     tolA   692   100                     coli         285   2667   gi1750387     Pseudomonas     Carbamoyl-   143   76                     aeruginosa     phosphate                       synthetase                       large subunit       286   2670   gi4883437     Mus Musculus     RNA binding   139   92                       protein       287   2673   Y66656     Homo sapiens     Membrane-   1869   98                       bound protein                       PRO943.       288   2676   gi3885978     Mus Musculus     mismatch-   123   88                       specific                       thymine-DNA                       glycosylate       289   2680   gi6453438     Homo sapiens     hypothetical   465   82                       protein       290   2682   gi1841756     Mus Musculus     GATA-5   527   77                       cardiac                       transcription                       factor       291   2684   gi9844920     Homo sapiens     nicotinic   294   88                       acetylcholine                       receptor                       subunit alpha                       10       292   2695   gi1789764     Escherichia     putative   879   98                     coli     transport       293   2697   gi349229     Escherichia     peripheral   936   99                     coli     membrane                       protein       294   2698   gi4062194     Escherichia         737   100                     coli         295   2700   gi529240     Escherichia     Homoserine   578   100                     coli     kinase       296   2704   gi1552831     Escherichia     hypothetical   420   100                     coli         297   2712   gi1789672     Escherichia     putative ATP-   262   100                     coli     binding                       component of a                       transport                       system       298   2716   gi4062409     Escherichia     Transmembrane   382   100                     coli     protein dppC       299   2719   gi304976     Escherichia     matches   921   95                     coli     PS00017:                       ATP_GTP_A and                       PS00301:                       EFACTOR_GTP;                       similar       300   2724   gi145856     Escherichia     nmpC   647   97                     coli         301   2725   gi1789473     Escherichia     putative   312   100                     coli     transport                       protein       302   2728   gi1805561     Escherichia         222   97                     coli         303   2729   gi43248     Escherichia         655   91                     coli         304   2744   gi396299     Escherichia     similar to  E.     675   100                     coli       coli  pyruvate                       formate-lyase                       activating                       enzyme       305   2749   gi1742648     Escherichia         592   100                     coli         306   2752   gi40622     Escherichia     Sensor kinase   357   100               36     coli     CitA       307   2762   gi1787795     Escherichia     putative   342   100                     coli     LACI-type                       transcriptional                       regulator       308   2764   gi1799743     Escherichia     putative   151   84                     coli     LACI-type                       transcriptional                       regulator       309   27684   gi405964     Escherichia     yohG   534   94                     coli         310   2774   gi4062338     Escherichia     .   387   97                     coli         311   2790   gi4062338     Escherichia     .   420   86                     coli         312   2800   gi1789805     Escherichia     putative   572   100                     coli     transport       313   2811   gi5305333     Mus Musculus     protein   421   49                       kinase Myak-S       314   2827   gi10047251     Homo sapiens     KIAA1588   531   97                       protein       315   2830   G02872     Homo sapiens     Human   185   62                       secreted                       protein,       316   2836   gi191175     Cricetulus     cAMP-   1677   97                     sp.     dependent                       protein kinase                       alpha-                       catalytic                       subunit       317   2851   gi558846     Homo sapiens     BCL2/adeno-   220   61                       virus E1B                       19 kD-                       interacting                       protein 3       318   2856   gi3882211     Homo sapiens     KIAA0745   232   93                       protein       319   2866   gi6329708     Homo sapiens     KIAA1119   1331   91                       protein       320   2874   gi2853033     Mus Musculus     tousled-like   203   82                       kinase       321   2882   gi10185134     Schizosaccharomyces     hypothetical   318   42                     pombe     zinc-finger                       protein       322   2886   G03797     Homo sapiens     Human   140   69                       secreted                       protein,       323   2899   gi4240325     Homo sapiens     KIAA0918   170   53                       protein       324   2906   Y94988     Homo sapiens     Human   1738   100                       secreted                       protein v11_1,       325   2920   gi9453735     Homo sapiens         1926   100       326   2925   gi6434876     Homo sapiens     CDK4-binding   1210   100                       protein                       p34SEI1       327   2930   gi3941320     Schistosoma     myosin   208   28                     japonicum         328   2934   Y31645     Homo sapiens     Human   642   63                       transport-                       associated                       protein-7                       (TRANP-7).       329   2955   G01165     Homo sapiens     Human   528   99                       secreted                       protein,       330   2967   gi7263960     Homo sapiens         466   100       331   2980   gi4589530     Homo sapiens     KIAA0943   1849   94                       protein       332   2994   G03812     Homo sapiens     Human   124   61                       secreted                       protein,       333   2996   gi9857400     Homo sapiens     tumor   2666   98                       endothelial                       marker 1                       precursor       334   2999   Y66697     Homo sapiens     Membrane-   2254   100                       bound protein                       PRO1383.       335   3   gi6289072     Homo sapiens     JM24 protein   930   100       336   3008   Y45219     Homo sapiens     Human CASB47   557   92                       protein.       337   3013   gi5262678     Homo sapiens     hypothetical   1747   100                       protein       338   3041   Y73335     Homo sapiens     HTRM clone   1315   99                       1850120                       protein                       sequence.       339   306   gi4868443     Mesocricetus     Mx-   1867   95                     auratus     interacting                       protein kinase                       PKM       340   3061   gi433338     Homo sapiens     protein-   3934   94                       tyrosine                       kinase       341   309   Y76145     Homo sapiens     Human   1313   99                       secreted                       protein                       encoded by                       gene 22.       342   3095   gi7300159     Drosophila     CG14899 gene   190   57                     melanogaster     product       343   3098   gi532056     Homo sapiens     protein-   2641   86                       tyrosine-                       phosphatase       344   3105   gi285987     Homo sapiens     mitochondrial   192   71                       outer membrane                       protein 19       345   3118   gi9929935     Macaca     hypothetical   180   61                     fascicularis     protein       346   3124   gi8131903     Mus Musculus     transient   226   100                       receptor                       potential-                       related                       protein       347   3126   Y02370     Homo sapiens     Polypeptide   261   100                       identified by                       the signal                       sequence trap                       method.       348   3166   gi7290860     Drosophila     CG1531 gene   534   42                     melanogaster     product       349   3175   gi6649583     Homo sapiens     kidney and   1752   95                       liver proline                       oxidase 1       350   3176   gi7208438     Homo sapiens     long-chain 2-   1048   95                       hydroxy acid                       oxidase HAOX2       351   3188   Y02693     Homo sapiens     Human   243   57                       secreted                       protein                       encoded by                       gene 44 clone                       HTDAD22.       352   3191   gi7105926     Homo sapiens     calcium   300   96                       channel                       alpha2-delta3                       subunit       353   3208   gi10334774     Homo sapiens     MUCDHL-FL   613   98       354   3226   Y87209     Homo sapiens     Human   3147   99                       secreted                       protein                       sequence       355   3235   gi6715135     Homo sapiens     Fanconi   1947   99                       anemia,                       complementation                       group F       356   3257   gi5441615     Canis     zinc finger   326   42                     familiaris     protein       357   3282   G03002     Homo sapiens     Human   211   61                       secreted                       protein,       358   3289   gi3288457     Homo sapiens     PI3-kinase   5832   97       359   3296   gi7770139     Homo sapiens     PRO1722   293   64       360   3298   gi2198815     Ambystoma     electrogenic   1278   52                     tigrinum     Na+ bicarbonate                       cotransporter;                       NBC       361   3303   gi4028015     Homo sapiens     potassium   1881   92                       channel       362   3305   gi5902966     Homo sapiens     very large G-   1770   100                       protein                       coupled                       receptor-1       363   3308   gi219944     Homo sapiens     The first in-   3967   86                       frame ATG                       codon is                       located at                       nucleotides                       NPPase.       364   3325   gi3510234     Homo sapiens     R31237_1,   192   94                       partial CDS       365   3341   W78899     Homo sapiens     Human UNC-5   1614   90                       Homologue                       UNC5H-1.       366   3342   gi1478205     Mus Musculus     PNG protein   341   70       367   3350   gi2739460     Bos taurus     regulator of   2263   98                       G-protein                       signaling 7       368   3372   gi7671663     Homo sapiens         375   79       369   338   Y84322     Homo sapiens     A human   2606   100                       cardiovascular                       system                       associated                       protein                       kinase-3.       370   3383   gi10441382     Homo sapiens     protein   1127   100                       kinase       371   3395   gi530823     Homo sapiens     epidermal   402   47                       growth factor                       receptor                       kinase                       substrate       372   3405   Y29332     Homo sapiens     Human   1220   94                       secreted                       protein clone                       pe584_2                       protein                       sequence.       373   3408   gi3334741     Homo sapiens     shal-type   2888   90                       potassium                       channel       374   345   gi4539527     Homo sapiens     NAALADase L   600   72                       protein       375   346   Y95434     Homo sapiens     Human calcium   1802   99                       channel SOC-                       3/CRAC-2 C-                       terminal                       polypeptide.       376   3470   gi9798452     Homo sapiens     putative   277   100                       capacitative                       calcium                       channel       377   3482   gi3818572     Homo sapiens     cAMP-specific   2353   96                       phosphodiester                       ase 8B;                       PDE8B1; 3′,5′-                       cyclic                       nucleotide                       phosphodiesterase       378   3492   gi1665825     Homo sapiens         3878   99       379   3530   gi505100     Homo sapiens     KIAA0066   3637   100       380   3533   Y32169     Homo sapiens     Human growth-   2860   99                       associated                       protease                       inhibitor                       heavy chain                       precursor.       381   3545   gi6624133     Homo sapiens         449   98       382   3549   gi1469193     Homo sapiens     The KIAA0135   5374   99                       gene is                       related to                       pim-1                       oncogene.       383   3595   gi6330190     Homo sapiens     KIAA1169   1893   100                       protein       384   3601   gi808915     Homo sapiens     tumor   992   99                       necrosis                       factor                       receptor type                       1 associated                       protein       385   3612   gi5305448     Mus Musculus     SH2-B PH   1439   92                       domain                       containing                       signaling                       mediator 1                       gamma isoform       386   3613   Y32194     Homo sapiens     Human   1438   100                       receptor                       molecule (REC)                       encoded by                       Incyte clone                       266775.       387   3621   gi897849     Mus Musculus     ubiquitinating   393   68                       enzyme E2-230 kDa       388   3624   R47858     Homo sapiens     Human LDL   2895   100                       receptor                       Domains 1 and                       2.       389   3625   Y57949     Homo sapiens     Human   1868   100                       transmembrane                       protein HTMPN-                       73.       390   3626   W69342     Homo sapiens     Secreted   442   94                       protein of                       clone CJ424_9.       391   3627   gi6537136     Homo sapiens     putative   982   92                       organic anion                       transporter       392   3630   Y06886     Homo sapiens     HWHHJ20   1109   91                       polypeptide.       393   3642   gi4886467     Homo sapiens     hypothetical   570   52                       protein       394   3645   gi9588402     Homo sapiens         598   98       395   3647   Y12050     Homo sapiens     Human 5′ EST   517   98                       secreted                       protein       396   3653   Y70018     Homo sapiens     Human   2232   99                       Protease and                       associated                       protein-12                       (PPRG-12).       397   3676   W67818     Homo sapiens     Human   338   100                       secreted                       protein                       encoded by                       gene 12 clone                       HMSJJ74.       398   3677   gi32093     Homo sapiens     HGMP07J   650   52       399   3681   Y48443     Homo sapiens     Human   803   93                       prostate                       cancer-                       associated                       protein 140.       400   3682   gi4691726     Homo sapiens     ARF GTPase-   2435   91                       activating                       protein GIT1       401   3688   gi6693824     Homo sapiens     ubiquitin-   1995   99                       specific                       protease       402   3689   Y94927     Homo sapiens     Human   530   81                       secreted                       protein clone                       ck213_12                       protein                       sequence       403   3690   gi1871612     Oryctolagus     ryanodine   594   95                     cuniculus     receptor       404   3706   gi6002714     Homo sapiens     membrane-type   2630   94                       serine                       protease 1       405   3714   gi2695708     Homo sapiens     SPOP   553   81       406   3720   gi9309293     Homo sapiens     asc-type   566   95                       amino acid                       transporter 1       407   3726   gi10440381     Homo sapiens     FLJ00026   1023   69                       protein       408   373   gi5714696     Mus Musculus     alpha 2 delta   243   95                       calcium                       channel                       subunit       409   3788   gi6911219     Homo sapiens     type II   841   100                       membrane                       serine                       protease       410   3789   Y45023     Homo sapiens     Human sensory   1084   95                       transduction                       G-protein                       coupled                       receptor-B3.       411   3790   gi1524088     Homo sapiens     Polio virus   1508   99                       receptor                       protein       412   3801   gi6723675     Homo sapiens     mitotic   2035   99                       kinase-like                       protein-1       413   3803   gi968973     Homo sapiens     mitotic   332   86                       kinase-like                       protein-1       414   3820   gi1770478     Homo sapiens     NK receptor   1988   99       415   3831   gi2781386     Homo sapiens         1493   99       416   3837   gi9367840     Homo sapiens     neuronal   2243   99                       apoptosis                       inhibitory                       protein 2       417   385   gi1526978     Homo sapiens     ryanodine   149   96                       receptor 2       418   3856   gi995654     Homo sapiens     interleukin-   147   100                       11 receptor       419   386   gi4960038     Mus Musculus     T2K protein   669   66                       kinase Homolog       420   3861   Y74129     Homo sapiens     Human   842   98                       prostate tumor                       EST fragment                       derived                       protein #316.       421   3883   gi6635205     Homo sapiens     beta-   1576   100                       ureidopropionase       422   3898   gi37231     Homo sapiens     DNA   8436   99                       topoisomerase                       II       423   3921   gi8648881     Homo sapiens     putative   131   100                       organic anion                       transporter       424   3932   gi8575775     Homo sapiens     KRAB zinc   1935   99                       finger protein       425   3934   gi4689128     Homo sapiens     SIH003   127   92       426   3963   gi3212996     Homo sapiens         339   64       427   3974   G03790     Homo sapiens     Human   232   63                       secreted                       protein,       428   3983   gi181971     Homo sapiens     vascular   433   85                       endothelial                       growth factor       429   3999   gi1657464     Sus scrofa     calcium/calmodulin-   484   75                       dependent                       protein kinase                       II isoform                       gamma-G       430   4001   gi6572230     Homo sapiens         329   100       431   4009   gi2143260     Homo sapiens     phosphoinositide   521   99                       3-kinase       432   401   gi6572379     Homo sapiens         1372   56       433   4020   gi2815624     Homo sapiens     tumor   1252   100                       necrosis                       factor                       superfamily                       member LIGHT       434   4024   Y21166     Homo sapiens     Human bcl2   84   40                       proto-oncogene                       mutant protein                       fragment 14.       435   4040   Y57285     Homo sapiens     Human GPCR   1726   99                       protein                       (HGPRP)                       sequence                       (clone ID                       2214673).       436   4057   W74873     Homo sapiens     Human   531   100                       secreted                       protein                       encoded by                       gene 145                       clone HFXHL79.       437   4066   G03714     Homo sapiens     Human   92   70                       secreted                       protein,       438   4067   gi8331760     Homo sapiens     LU1 protein   1077   92       439   4078   Y57900     Homo sapiens     Human   996   100                       transmembrane                       protein HTMPN-                       24.       440   4120   gi1871539     Homo sapiens     mitogen-   927   100                       activated                       protein kinase                       phosphatase 4       441   4123   gi5360125     Homo sapiens     NY-REN-58   140   100                       antigen       442   4130   gi6289072     Homo sapiens     JM24 protein   604   100       443   4133   gi8575527     Homo sapiens     toll-like   755   100                       receptor 8       444   4166   gi6118555     Homo sapiens     DEAD-box   2512   100                       protein                       abstrakt       445   4167   gi3800830     Rattus     putative four   615   93                     norvegicus     repeat ion                       channel       446   4172   gi7209676     Homo sapiens     potassium   369   100                       channel Kv8.1       447   4185   gi5305405     Homo sapiens     Na+/H+   1769   100                       exchanger                       isoform 2       448   4197   gi2811122     Xenopus     NaDC-2   524   69                     laevis         449   4203   Q89840_aa1     Homo sapiens     Human death   198   97                       associated                       protein DAP-                       3.       450   4262   gi5901478     Marmota     olfactory   209   92                     marmota     receptor       451   4276   gi32456     Homo sapiens     protein-   3270   99                       tyrosine                       phosphatase       452   4283   R41231     Homo sapiens     GAT-2   477   100                       transporter                       gene.       453   4331   gi3171912     Homo sapiens     RAMP2   443   98       454   4340   gi8118223     Homo sapiens     unknown   1330   100       455   4351   gi1754515     Rattus     aminopeptidase-B   2050   92                     norvegicus         456   4354   Y57906     Homo sapiens     Human   1402   100                       transmembrane                       protein HTMPN-                       30.       457   4385   gi5596433     Homo sapiens     candidate   509   97                       tumor                       suppressor                       protein NOC2       458   4388   W78140     Homo sapiens     Human   100   94                       secreted                       protein                       encoded by                       gene 15 clone                       HSDES04.       459   4405   Y48226     Homo sapiens     Human   1246   99                       prostate                       cancer-                       associated                       protein 12.       460   441   gi291536     Bovine     BICP4   106   35                     herpesvirus 1         461   4417   gi6562533     Homo sapiens     sialin   939   100       462   4419   gi1841555     Homo sapiens     NG5   146   33       463   4443   gi496139     Mus Musculus     AMPA   262   94                       selective                       glutamate                       receptor       464   4470   gi7248381     Homo sapiens     adaptor   2592   100                       protein                       p130Cas       465   4482   gi7329979     Homo sapiens     apoptosis   2071   100                       regulator       466   4487   gi6706659     Homo sapiens         405   100       467   4491   gi9837341     Homo sapiens     CamKI-like   1044   100                       protein kinase       468   4492   Y42751     Homo sapiens     Human calcium   586   99                       binding                       protein 2                       (CaBP-2).       469   4497   gi6179740     Homo sapiens     paraneoplastic   352   37                       cancer-testis-                       brain antigen       470   4502   gi6329742     Homo sapiens     KIAA1124   327   100                       protein       471   4519   Y99426     Homo sapiens     Human PRO1604   1563   100                       (UNQ785) amino                       acid sequence       472   4526   Y08008     Homo sapiens     Human HLIG-1   4023   99                       protein.       473   4547   gi4589562     Homo sapiens     KIAA0959   4165   99                       protein       474   4554   gi1381029     Mus Musculus         1164   77       475   4555   gi2792366     Homo sapiens     unknown   4461   99                       protein IT12       476   457   Y70551     Homo sapiens     Human latent   1825   100                       transforming                       growth                       factor-beta                       binding                       protein 3 (I).       477   4571   gi5360115     Homo sapiens     NY-REN-45   869   100                       antigen       478   4613   Y05868     Homo sapiens     Human Toll   2413   100                       protein                       PRO358.       479   4614   Y27129     Homo sapiens     Human bone   1815   100                       marrow-derived                       polypeptide                       (clone OAF038-                       Leu).       480   4622   G03789     Homo sapiens     Human   173   53                       secreted                       protein,       481   4667   gi7673638     Danio rerio     Deddl   446   48       482   4670   gi402649     Homo sapiens     c-rel   2309   100       483   4683   Y68773     Homo sapiens     Amino acid   2234   99                       sequence of a                       human                       phosphorylation                       effector                       PHSP-5.       484   4698   Y73470     Homo sapiens     Human   746   100                       secreted                       protein clone                       yd141_1                       protein                       sequence       485   4724   gi6456846     Homo sapiens     hypothetical   1101   99                       protein       486   4734   gi3334982     Homo sapiens     R27216_1   1151   80       487   4814   gi6274473     Homo sapiens     pregnancy-   1348   100                       induced growth                       inhibitor       488   4819   Y07825     Homo sapiens     Human   117   67                       secreted                       protein                       fragment #4                       encoded from                       gene 28.       489   4821   Y81498     Homo sapiens     Human foetal   1200   100                       bone-derived                       growth                       factor-like                       protein.       490   4851   gi5689491     Homo sapiens     KIAA1077   4364   99                       protein       491   4872   gi5911953     Homo sapiens     hypothetical   3723   99                       protein       492   4902   B08917     Homo sapiens     Human   717   100                       secreted                       protein                       sequence                       encoded by                       gene 27       493   5006   gi435774     Homo sapiens     receptor   385   100                       tyrosine                       kinase isoform                       FLT4 long,                       FLT41 {C-                       terminal}       494   5007   Y93951     Homo sapiens     Amino acid   804   100                       sequence of a                       Brainiac-5                       polypeptide.       495   5027   gi3548791     Homo sapiens     R33590_1   1606   100       496   5029   gi5689527     Homo sapiens     KIAA1095   5722   99                       protein       497   5033   Y14482     Homo sapiens     Fragment of   166   66                       human secreted                       protein                       encoded by                       gene 17.       498   5040   Y95019     Homo sapiens     Human   258   92                       secreted                       protein vq1_1,       499   5061   gi1304434     Pseudorabies     EP0   85   38                     virus         500   5081   gi4038081     Homo sapiens     vascular   134   100                       endothelial                       cell growth                       inhibitor       501   5129   gi3169158     Homo sapiens     BC269730_2   2340   99       502   5139   gi4062856     Homo sapiens     HEXIM1   293   47                       protein       503   5174   gi9368540     Homo sapiens     140up gene   576   90                       product       504   524   G00329     Homo sapiens     Human   565   100                       secreted                       protein,       505   5291   Y92515     Homo sapiens     Human OXRE-   1271   98                       12.       506   5335   gi7296158     Drosophila     CG3862 gene   753   46                     melanogaster     product       507   5346   Y94987     Homo sapiens     Human   849   100                       secreted                       protein vj1_1,       508   5379   gi7144506     Homo sapiens     cytokine-   1353   99                       inducible SH2-                       containing                       protein       509   5441   gi8096551     Homo sapiens     similar to   1516   100                       mouse Ehm2       510   549   Y22113     Homo sapiens     Human ZSMF-3   294   62                       protein                       sequence.       511   5542   Y76267     Homo sapiens     Fragment of   1066   100                       human secreted                       protein                       encoded by                       gene 11.       512   5560   G03790     Homo sapiens     Human   103   36                       secreted                       protein,       513   5696   gi7920398     Homo sapiens     PTOV1   1904   91       514   5704   B08930     Homo sapiens     Human   987   100                       secreted                       protein                       sequence                       encoded by                       gene 2       515   5758   W18878     Homo sapiens     Human protein   368   100                       kinase C                       inhibitor,                       IPKC-1.       516   5760   gi6562176     Homo sapiens     hypothetical   425   100                       protein       517   5763   Y41706     Homo sapiens     Human PRO381   441   100                       protein                       sequence.       518   5787   Y57907     Homo sapiens     Human   952   100                       transmembrane                       protein HTMPN-                       31.       519   5823   gi9800242     rat     pr5   153   36                     cytomegalovirus                     Maastricht       520   5886   gi1781037     Mus Musculus     neuronal   1135   52                       tyrosine                       threonine                       phosphatase 1       521   5924   W69221     Homo sapiens     Human parotid   710   96                       secretory                       protein.       522   5960   Y91529     Homo sapiens     Human   1300   99                       secreted                       protein                       sequence                       encoded by                       gene 79       523   5962   W69784     Homo sapiens     Protein   395   100                       Kinase C                       Inhibitor-like                       Protein                       (IPKC-2).       524   5969   Y79141     Homo sapiens     Human   1205   79                       haemopoietic                       stem cell                       regulatory                       protein                       SCM113.       525   5976   gi780310     Homo sapiens     natural   1808   91                       killer                       associated                       transcript 4       526   6002   gi2104553     Homo sapiens         4367   67       527   6008   Y66765     Homo sapiens     Membrane-   822   100                       bound protein                       PRO1384.       528   6020   gi1911548     Homo sapiens     cytochrome c-   322   50                       like                       polypeptide       529   6036   W71362     Homo sapiens     Human   353   51                       cytokine/steroid                       receptor                       protein.       530   6070   Y42750     Homo sapiens     Human calcium   626   100                       binding                       protein 1                       (CaBP-1).       531   6075   gi10732648     Homo sapiens     angiopoietin-   2164   100                       like protein                       PP1158       532   6106   gi2217970     Homo sapiens     p40   1349   96       533   6420   W82000     Homo sapiens     Human adult   929   100                       brain secreted                       protein                       dm26_2.       534   6434   gi10732648     Homo sapiens     angiopoietin-   2164   100                       like protein                       PP1158       535   6439   gi189701     Homo sapiens     endothelial   376   100                       cell growth                       factor       536   6463   Y41720     Homo sapiens     Human PRO792   360   82                       protein                       sequence.       537   6466   gi4884084     Homo sapiens     hypothetical   538   100                       protein       538   6508   gi5442030     Homo sapiens     aminopeptidase   2317   96       539   6570   gi5921491     Homo sapiens         1591   99       540   6719   gi31847     Homo sapiens     glypican   1625   87       541   6772   Y65432     Homo sapiens     Human 5′ EST   180   53                       related                       polypeptide       542   6789   gi537292     Homo sapiens     ICH-1L   1556   100       543   6805   gi4454702     Homo sapiens     HSPC007   634   84       544   6833   gi1890660     Homo sapiens     protein   5726   87                       tyrosine                       phosphatase                       receptor                       omicron       545   6834   gi5921491     Homo sapiens         1746   88       546   6851   gi2407641     Homo sapiens     neuropilin   3968   98       547   6868   gi6714641     Drosophila     MAP kinase   218   49                     melanogaster     phosphatase       548   6876   Y13138     Homo sapiens     Human   414   76                       secreted                       protein                       encoded by 5′                       EST       549   688   Y73463     Homo sapiens     Human   701   98                       secreted                       protein clone                       yk199_1                       protein                       sequence       550   6897   gi5815180     Homo sapiens     unknown   509   97       551   690   gi10645186     Homo sapiens     meningioma-   522   100                       expressed                       antigen 5s                       splice variant       552   6909   W78149     Homo sapiens     Human   485   100                       secreted                       protein                       encoded by                       gene 24 clone                       HSVBF78.       553   6924   Y35923     Homo sapiens     Extended   514   99                       human secreted                       protein                       sequence,       554   6937   G03798     Homo sapiens     Human   281   70                       secreted                       protein,       555   6951   gi511857     Homo sapiens     prostate-   364   95                       specific                       antigen       556   7008   G03200     Homo sapiens     Human   548   98                       secreted                       protein,       557   7009   Y22213     Homo sapiens     Human V201   856   100                       protein                       sequence.       558   7057   gi6003654     Homo sapiens     brain   1814   100                       specific                       membrane-                       anchored                       protein BSMAP       559   7098   W27291     Homo sapiens     Human H1075-1   712   100                       secreted                       protein 5′                       end.       560   7114   gi3212110     Homo sapiens     prefoldin   534   98                       subunit 1       561   712   gi4558641     Homo sapiens     P85B_HUMAN;   470   74                       PTDINS-3-                       KINASE P85-                       BETA       562   7215   gi4868366     Homo sapiens     delta-6 fatty   2437   100                       acid                       desaturase       563   7244   Y12445     Homo sapiens     Human 5′ EST   428   100                       secreted                       protein       564   7248   gi311376     Homo sapiens     Humig   633   100       565   7252   gi5689531     Homo sapiens     KIAA1097   5240   100                       protein       566   7292   gi5106998     Homo sapiens     HSPC040   580   100                       protein       567   7306   Y32201     Homo sapiens     Human   1974   95                       receptor                       molecule (REC)                       encoded by                       Incyte clone                       2057886.       568   7338   Y73880     Homo sapiens     Human   1566   100                       prostate tumor                       EST fragment                       derived                       protein #67.       569   736   gi10178317     Homo sapiens         1468   100       570   737   G00851     Homo sapiens     Human   522   98                       secreted                       protein,       571   740   W85610     Homo sapiens     Secreted   1115   87                       protein clone                       eh80_1.       572   7400   Y93948     Homo sapiens     Amino acid   1982   98                       sequence of a                       lectin ss3939                       polypeptide.       573   7415   gi3043670     Homo sapiens     KIAA0573   2392   100                       protein       574   7429   Y40864     Homo sapiens     A human   1183   99                       glutathione-S-                       transferase                       (hGST)                       protein.       575   7458   Y53643     Homo sapiens     A bone marrow   554   99                       secreted                       protein                       designated                       BMS6.       576   7516   gi4468311     Homo sapiens         1146   99       577   7526   gi4138922     Homo sapiens     promyelocytic   3571   99                       leukemia zinc                       finger                       protein;                       kruppel-like                       zinc finger                       protein; PLZF       578   7571   G02915     Homo sapiens     Human   209   100                       secreted                       protein,       579   7614   W74726     Homo sapiens     Human   1879   100                       secreted                       protein                       fg949_3.       580   7663   gi5912548     Homo sapiens         1634   100       581   7686   gi4929711     Homo sapiens     CGI-121   870   100                       protein       582   7714   gi388765     Homo sapiens     phospholipase D   4428   99       583   7724   G03933     Homo sapiens     Human   570   100                       secreted                       protein,       584   7834   gi8919166     Homo sapiens     mesenchymal   1133   100                       stem cell                       protein DSC92       585   7855   Y48505     Homo sapiens     Human breast   684   100                       tumour-                       associated                       protein 50.       586   7870   Y13372     Homo sapiens     Amino acid   2559   100                       sequence of                       protein                       PRO223.       587   7871   Y91689     Homo sapiens     Human   768   100                       secreted                       protein                       sequence                       encoded by                       gene 93       588   7892   gi34659     Homo sapiens     macrophage   532   100                       inflammatory                       protein-2alpha                       precursor       589   7927   gi32575     Homo sapiens         183   91       590   7944   gi1657458     Sus scrofa     calcium/calmodulin-   2744   100                       dependent                       protein kinase                       II isoform                       gamma-B       591   7947   G01131     Homo sapiens     Human   574   96                       secreted                       protein,       592   800   gi3021428     Homo sapiens     neutral   167   68                       sphingomyelinase       593   8055   gi4929637     Homo sapiens     CGI-84   1038   100                       protein       594   8082   gi4679014     Homo sapiens     HSPC014   715   100       595   8127   gi9955693     Homo sapiens     twisted   905   95                       gastrulation                       protein       596   8174   gi5532294     Homo sapiens     MUM2   767   100       597   8178   gi4530587     Homo sapiens     TADA1 protein   1132   100       598   8215   R66278     Homo sapiens     Therapeutic   830   100                       polypeptide                       from                       glioblastoma                       cell line.       599   8263   Y48371     Homo sapiens     Human   713   98                       prostate                       cancer-                       associated                       protein 68.       600   827   gi3172337     Cavia     phospholipase B   955   73                     porcellus         601   828   Y29517     Homo sapiens     Human lung   833   94                       tumour protein                       SAL-82                       predicted                       amino acid                       sequence.       602   8294   gi4929767     Homo sapiens     CGI-149   1085   100                       protein       603   8313   gi5771420     Homo sapiens     group IID   852   100                       secretory                       phospholipase                       A2       604   832   Y86260     Homo sapiens     Human   319   78                       secreted                       protein                       HELHN47,       605   8357   gi4191358     Mus Musculus     claudin-7   164   47       606   8373   gi1945271     Homo sapiens     protein   1666   100                       phosphatase 6       607   8379   gi5852981     Homo sapiens         1226   100                       cardiotrophin-                       like cytokine                       CLC       608   8380   gi3402216     Homo sapiens     protein   974   100       609   8386   gi386988     Homo sapiens     oncostatin M   1297   99       610   8418   Y70210     Homo sapiens     Human TANGO   722   98                       130 protein.       611   8442   G01895     Homo sapiens     Human   490   95                       secreted                       protein,       612   8457   G04048     Homo sapiens     Human   450   98                       secreted                       protein,       613   8458   W97119     Homo sapiens     S-adenosyl-L-   1484   100                       methyltransfer                       ase (SAM-MT)                       protein.       614   8469   gi7159799     Homo sapiens         255   100       615   8480   gi4589530     Homo sapiens     KIAA0943   1998   100                       protein       616   8521   gi5726235   multiple   unknown   250   82                   sclerosis   protein U5/2                   associated                   retrovirus                   element       617   857   gi9663958     Homo sapiens     cysteinyl   612   99                       leukotriene                       CysLT2                       receptor       618   8574   gi6841260     Homo sapiens     HSPC305   1049   100       619   8606   gi3367707     Homo sapiens     scrapie   544   100                       responsive                       protein 1       620   8632   G01158     Homo sapiens     Human   502   100                       secreted                       protein,       621   8646   gi3882249     Homo sapiens     KIAA0764   2175   100                       protein       622   8666   Y66196     Homo sapiens     Human bladder   1080   95                       tumour EST                       encoded                       protein 54.       623   8675   gi9963908     Homo sapiens     NPD009   432   96       624   8683   G04018     Homo sapiens     Human   469   98                       secreted                       protein,       625   8708   gi1633564     Homo sapiens     C8   364   98       626   8720   gi8248465     Homo sapiens     hepatocellular   191   69                       carcinoma-                       associated                       antigen 56A       627   8756   Y94984     Homo sapiens     Human   369   97                       secreted                       protein                       ve11_1,       628   8765   Y00346     Homo sapiens     Fragment of   1068   97                       human secreted                       protein                       encoded by                       gene 2.       629   8783   Y27918     Homo sapiens     Human   1051   95                       secreted                       protein                       encoded by                       gene No. 123.       630   8804   Y25426     Homo sapiens     Human SIGIRR   887   100                       protein.       631   8838   Y99409     Homo sapiens     Human PRO1343   1279   100                       (UNQ698) amino                       acid sequence       632   8851   W74785     Homo sapiens     Human   454   100                       secreted                       protein                       encoded by                       gene 56 clone                       HSAXS65.       633   8853   W75116     Homo sapiens     Human   245   95                       secreted                       protein                       encoded by                       gene 60 clone                       HILCJ01.       634   8857   gi2565196     Homo sapiens     non-   479   74                       functional                       folate binding                       protein       635   8859   Y02690     Homo sapiens     Human   600   100                       secreted                       protein                       encoded by                       gene 41c lone                       HSZAF47.       636   8901   Y86491     Homo sapiens     Human gene   548   99                       59-encoded                       protein                       fragment,       637   8907   W88745     Homo sapiens     Secreted   2004   99                       protein                       encoded by                       gene 30 clone                       HTSEV09.       638   8934   W75088     Homo sapiens     Human   421   98                       secreted                       protein                       encoded by                       gene 32 clone                       HAGBB70.       639   8960   Y02693     Homo sapiens     Human   267   72                       secreted                       protein                       encoded by                       gene 44 clone                       HTDAD22.       640   8979   Y76143     Homo sapiens     Human   1374   98                       secreted                       protein                       encoded by                       gene 20.       641   8980   Y11433     Homo sapiens     Human 5′ EST   466   100                       secreted                       protein       642   8986   G02626     Homo sapiens     Human   306   100                       secreted                       protein,       643   8987   G02093     Homo sapiens     Human   486   97                       secreted                       protein,       644   8995   Y12908     Homo sapiens     Human 5′ EST   181   100                       secreted                       protein       645   9035   Y71108     Homo sapiens     Human   800   100                       Hydrolase                       protein-6                       (HYDRL-6).       646   9062   gi8886005     Homo sapiens     lysophosphatidic   523   100                       acid                       acyltransferase-                       delta       647   9074   Y25761     Homo sapiens     Human   1366   99                       secreted                       protein                       encoded from                       gene 51.       648   9075   Y73336     Homo sapiens     HTRM clone   1591   100                       1852290                       protein                       sequence.       649   9098   Y57878     Homo sapiens     Human   516   100                       transmembrane                       protein HTMPN-2.       650   9109   gi23903     Homo sapiens     63 kDa protein   1141   97                       kinase       651   911   gi32456     Homo sapiens     protein-   2591   100                       tyrosine                       phosphatase       652   912   gi1136743     Homo sapiens     human P5   212   46       653   9163   Y34129     Homo sapiens     Human   377   71                       potassium                       channel                       K + Hnov28.       654   9164   Y41324     Homo sapiens     Human   1083   99                       secreted                       protein                       encoded by                       gene 17 clone                       HNFIY77.       655   9173   gi6851256     Mus Musculus     protein   631   93                       tyrosine                       phosphatase-                       like protein                       PTPLB       656   9187   Y66721     Homo sapiens     Membrane-   1173   95                       bound protein                       PRO511.       657   9190   W40378     Homo sapiens     Human breast   792   81                       cancer protein                       CH14-2a16-1                       from 2.0 kB                       DNA fragment                       #2.       658   9194   Y02781     Homo sapiens     Human   462   70                       secreted                       protein.       659   9210   G02994     Homo sapiens     Human   166   80                       secreted                       protein,       660   9222   G02520     Homo sapiens     Human   186   43                       secreted                       protein,       661   9230   gi6706554     Homo sapiens     inositol   1315   95                       1,4,5-                       trisphosphate                       3-kinase B       662   9258   gi522145     Homo sapiens     B-cell growth   120   56                       factor       663   9260   G04072     Homo sapiens     Human   138   51                       secreted                       protein,       664   9271   gi6690095     Homo sapiens     tetraspanin   317   67                       protein       665   9272   gi163042     Bos taurus     factor   444   72                       activating                       exoenzyme S       666   9275   gi401774     Homo sapiens     ribosomal   424   81                       protein S6                       kinase 3       667   930   G02355     Homo sapiens     Human   167   41                       secreted                       protein,       668   9304   gi8979743     Canis     Band4.1-like5   1493   93                     familiaris     protein       669   9346   gi2738989     Mus Musculus     high mobility   384   89                       group protein                       Homolog HMG4       670   9347   gi36613     Homo sapiens     serine/threonine   199   91                       protein                       kinase       671   935   gi5541870     Homo sapiens     QA79 membrane   334   57                       protein,                       allelic                       variant airm-                       1b       672   9350   gi3327124     Homo sapiens     KIAA0655   757   87                       protein       673   9351   W57260     Homo sapiens     Human   573   95                       semaphorin Y.       674   9356   gi59977   Human   tripartite   127   59                   endogenous   fusion                   retrovirus   transcript                       PLA2L       675   9363   Y17834     Homo sapiens     Human PRO361   968   92                       protein                       sequence.       676   9366   gi72431     Homo sapiens     KIAA1374   649   96                       protein       677   9369   G03793     Homo sapiens     Human   222   69                       secreted                       protein,       678   9378   gi4468311     Homo sapiens         163   39       679   9393   gi2738989     Mus Musculus     high mobility   384   89                       group protein                       Homolog HMG4       680   9444   G01399     Homo sapiens     Human   157   93                       secreted                       protein,       681   9467   gi4454702     Homo sapiens     HSPC007   230   71       682   9486   gi10047243     Homo sapiens     KIAA1584   605   93                       protein       683   949   Y30895     Homo sapiens     Human   704   99                       secreted                       protein                       fragment                       encoded from                       gene 25.       684   9499   W36002     Homo sapiens     Human Fchd531   2173   96                       gene product.       685   9510   gi1665799     Homo sapiens         867   83       686   9523   Y53022     Homo sapiens     Human   1252   89                       secreted                       protein clone                       qf116_2                       protein                       sequence       687   9534   Y66670     Homo sapiens     Membrane-   998   100                       bound protein                       PRO1180.       688   9539   Y76144     Homo sapiens     Human   633   100                       secreted                       protein                       encoded by                       gene 21.       689   954   G02490     Homo sapiens     Human   160   78                       secreted                       protein,       690   9546   gi181121     Homo sapiens     chorionic   616   96                       somatomammotropin       691   955   gi7243103     Homo sapiens     KIAA1361   2042   100                       protein       692   9551   gi1772345     Homo sapiens     ras-related   341   57                       GTP-binding                       protein       693   9558   W88403     Homo sapiens     Human adult   2252   100                       testis                       secreted                       protein                       ga63_6.       694   9561   gi6690017   Herpesvirus   NTR   100   30                   papio       695   957   Y86260     Homo sapiens     Human   319   78                       secreted                       protein                       HELHN47,       696   9572   gi972940     Mus Musculus     Elf-1   806   92       697   9576   gi3249005     Homo sapiens     geminin   448   98       698   9586   gi2887288     Homo sapiens     mRNA cleavage   208   100                       factor I 25 kDa                       subunit       699   9587   G00995     Homo sapiens     Human   726   99                       secreted                       protein,       700   9592   gi495273     Rattus     ribosomal   202   78                     norvegicus     protein S15a       701   9595   gi7799912     Homo sapiens     UBASH3A   453   47                       protein       702   9610   Y07875     Homo sapiens     Human   574   100                       secreted                       protein                       fragment                       encoded from                       gene 24.       703   9634   Y73325     Homo sapiens     HTRM clone   820   99                       001106 protein                       sequence.       704   9639   G00805     Homo sapiens     Human   155   67                       secreted                       protein,       705   9647   G03786     Homo sapiens     Human   196   73                       secreted                       protein,       706   9653   gi3882341     Homo sapiens     KIAA0810   523   100                       protein       707   9654   G01924     Homo sapiens     Human   469   100                       secreted                       protein,       708   9678   Y99376     Homo sapiens     Human PRO1244   474   100                       (UNQ628) amino                       acid sequence       709   9709   Y11825     Homo sapiens     Human 5′ EST   657   100                       secreted                       protein       710   9722   gi7677422     Mus Musculus     GTPase Rab37   189   75       711   9731   Y12424     Homo sapiens     Human 5′ EST   207   100                       secreted                       protein       712   9742   Y57954     Homo sapiens     Human   484   100                       transmembrane                       protein HTMPN-                       78.       713   9749   gi3687829     Homo sapiens     hT41   386   65       714   9755   gi2055295     Homo sapiens     Similar to a   2583   100                         C. elegans                         protein in                       cosmid C14H10       715   9762   G03436     Homo sapiens     Human   176   61                       secreted                       protein,       716   9763   gi6180011     Homo sapiens     anaphase-   1016   100                       promoting                       complex                       subunit 4       717   9784   G03570     Homo sapiens     Human   401   96                       secreted                       protein,       718   9794   G00803     Homo sapiens     Human   333   69                       secreted                       protein,       719   9795   gi2516242     Mus Musculus     Rab33B   669   94       720   9798   gi558599     Homo sapiens     ZID, zinc   605   96                       finger protein                       with                       interaction                       domain       721   9805   Y25881     Homo sapiens     Human   566   96                       secreted                       protein                       fragment                       encoded from                       gene 61.       722   9816   gi532056     Homo sapiens     protein-   384   100                       tyrosine-                       phosphatase       723   9830   G00857     Homo sapiens     Human   539   96                       secreted                       protein,       724   9836   G00914     Homo sapiens     Human   527   100                       secreted                       protein,       725   9837   gi2662099     Homo sapiens     KIAA0409   230   67       726   984   Y29517     Homo sapiens     Human lung   833   94                       tumour protein                       SAL-82                       predicted                       amino acid                       sequence.       727   9849   gi7229305     Homo sapiens     ZNF264,   140   90                       partial cds       728   9851   gi5262560     Homo sapiens     hypothetical   369   64                       protein       729   9859   gi3881976     Homo sapiens     hypothetical   167   93                       protein       730   9863   gi7295707     Drosophila     CG15433 gene   837   78                     melanogaster     product       731   9888   gi3319677     Homo sapiens         209   72       732   989   gi4557143     Rattus     zinc finger   604   92                     norvegicus     protein RIN ZF       733   9919   G01843     Homo sapiens     Human   586   100                       secreted                       protein,       734   9922   W67869     Homo sapiens     Human   551   93                       secreted                       protein                       encoded by                       gene 63 clone                       HHGDB72.       735   9947   W78239     Homo sapiens     Fragment of   251   78                       human secreted                       protein                       encoded by                       gene 3.       736   9956   Y36203     Homo sapiens     Human   273   77                       secreted                       protein #75.       737   9961   Y99357     Homo sapiens     Human PRO1190   650   99                       (UNQ604) amino                       acid sequence       738   9972   Y12149     Homo sapiens     Human 5′ EST   284   100                       secreted                       protein       739   9977   gi10039439     Homo sapiens     osteoblast   822   98                       differentiation                       promoting                       factor                    
     [0382]               TABLE 3                          Amino Acids                                         Predicted   Predicted                   beginning   end               nucleotide   nucleotide               location   location               corre-   corre-               sponding   sponding   Amino acid segment containing signal peptide (A = Alanine,               to first   to first   C = Cysteine, D = Aspartic Acid, E = Glutamic Acid,       SEQ   SEQ   amino   amino   F = Phenylalanine, G= Glycine, H = Histidine, I = Isoleucine,       ID   ID   acid   acid   K = Lysine, L = Leucine, M = Methionine, N = Asparagine,       NO:   NO:   residue   residue   P = Proline, Q = Glutamine, R = Arginine, S = Serine,       of   of   of amino   of amino   T = Threonine, V = Valine, W = Tryptophan, Y = Tyrosine,       Nucleic   Amino   acid   acid   X = Unknown, * = Stop Codon, / = possible nucleotide deletion,       Acids   Acids   sequence   sequence   \ = possible nucleotide insertion)                                         1   740   2   557   FVGRLLRLGEALRLRPDPSGGCRLQPALVGETEMSEKENNFPP                               LPKFIPVKPCFYQNFSDEIPVEHQVLVKRIYRLWMFYCATLGV                               NLIACLAWWIGGGSGTNFGLAFVWLLLFTPCGYVCWFRPVYKA                               FRADSSFNFMAFFFIFRSPVCPDRHPGDWLLRLGRVRLAVGNW                               ILPVQPGRCRGHA               2   741   305   838   FLGAGADIFCAYLRMSSKQATSPFACAADGEDAMTQDLTSREK                               EEGSDQHVASHLPLHPIMHNKPHSEELPTLVSTIQQDADWDSV                               LSSQQRMESENNKLCSLYSFRNTSTSPHKPDEGSRDREIMTSV                               TFGTPERRKGSLADVVDTLKQKKLEEMTRTEQEDSSCMEKLLS                               KDWKE               3   742   12   1315   EGYLTGRPTRPVAVRGKSTADLRMMGRSPGFAMQHIVGVPHVL                               VRRGLLGRDLFMTRTLCSPGPSQPGEKRPEEVALGLHHRLPAL                               GRALGHSIQQRATSTAKTWWDRYEEFVGLNEVREAQGKVTEAE                               KVFMVARGLVREAREDLEVHQAKLKEVRDRLDRVSREDSQYLE                               LATLEHRMLQEEKRLRTAYLRAEDSEREKFSLFSAAVRESHEK                               ERTRAERTKNWSLIGSVLGALIGVAGSTYVNRVRLQELKALLL                               EAQKGPVSLQEAIREQASSYSRQQRDLHNLMVDLRGLVHAAGP                               GQDSGSQAGSPPTRDRDVDVLSAALKEQLSHSRQVHSCLEGLR                               EQLDGLEKTCSQMAGVVQLVKSAAHPGLVEPADGAMPSFLLEQ                               GSMILALSDTEQRLEAQVNRNTIYSTLVTCVTFVATLPVLYML                               FKAS               4   743   112   745   NLPPLTPQPGPRLAGSGPSHWFSPLSLPVASKAPGTMAQALGE                               DLVQPPELQDDSSSLGSDSELSGPGPYRQADRYGFIGGSSAEP                               GPGHPPADLIRQREMKWVEMTSHWEKTMSRRYKKVKMQCRKGI                               PSALRARCWPLLCGAHVCQKNSPGTYQELAEAPGDPQWMETIG                               RDLHRQFPLHEMFVSPQGHGQQGLLQVLKAYTLYRPEQG               5   744   99   265   LRGMAAAAAGPAASQRFFQSFSDALIDQDPQAALEVGEPFLLP                               PLPAPPPPSSTA               6   745   210   758   WACFRSAHCSRHLRNRIFMYLYWDKTRSPVCKGPALREERPQP                               RLKLEDYKDRLKSGEHLNPDQLEAVEKYEEVLHNLEFAKELQK                               TFSGLSLDLLKAQKKAQRREHMLKLEAEKKKLRTILQVQYVLQ                               NLTQEHVQKDFKGGLNGAVYLPSKELDYLIKFSKLTCPERNES                               LRQTLEGSTV               7   746   48   450   XAGVQMKLEFLQRKFWAATRQCSTVDGPCTQSCEDSDLDCFVI                               DNNGFILISKRSRETGRFLGEVDGAVLTQLLSMGVFSQVTMYD                               YQAMCKPSSHHHSAAQPLVSPISAFLTATRWLLQELVLFLLEW                               SVWGSX*               8   747   1   469   CRGRLAQLEEAAVAATMSAGDAVCTGWLVKSPPERKLQRYAWR                               KRWFVLRRGRMSGNPDVLEYYRNKHSSKPIRVIDLSECAVWKH                               VGPSFVRKEFQNNFVFIVKTTSRTFYLVAKTEQEMQVWVHSIS                               QVCNLGHYLEDGAADSMESLSYTRSYLQ               9   748   242   409   IPAVPLTSCVTVGSYSLSVRDYDPRQGDTVKHYKIRTL\DKRG                               FYISP\RSTFSTLQ               10   749   1   1146   KDSVLNIARGKKYGEKTKRVSSRKKPALKC/TSQKQPALKAIC                               DKEDSVPNTATEKKDEQISGTVSSQKQPALKATSDKKDSVSNI                               PTEIKDGQQSGTVSSQKQPAWKATSVKKDSVSNIATEIKDGQI                               \RGTVSSQRQPALKA\TGDEKDSVSNIAREIKDGEKSGTVSPQ                               KQSAQKVIFKKKVSLLNIATRITGGWKSGTEYPENLPTLKATI                               ENKNSVLNTATKMKDVQTSTPEQDLEMASEGEQKRLEEYENNQ                               PQVKNQIHSRDDLDDIIQSSQTVSEDGDSLCCNCKNVILLIDQ                               HEMKCKDCVHLLKIKKTFCLCKRLTELKDNHCEQLRVKIRKLK                               NKASVLQKRLSEKEEIKSQLKHETLELEKELCSLRAFAIQQ               11   750   3   892   SPLRYRAGQSGSTISSSSCAMWRCGGRQGLCVLRRLSGGHAHH                               RAWRWNSNRACERALQYKLGDKIHGFTVNQVTSVPELFLTAVK                               LTHDDTGARYLHLAREDTNNLFSVQFRTTPMDSTGVPHILEHT                               VLCGSQKYPCRDPFFKMLNRSLSTFMNAFTASDYTLYPFSTQN                               PKDFQNLLSVYLDATFFPCLRELDFWQEGWRLEHENPSDPQTP                               LVFKGVVFNEMKGAFTDNERIFSQHLQNRLLPDHTYSVVSGGD                               PLCIPELTWEQLKQFHATHYHPSNARFFTYGNFPLDQH               12   751   367   856   RGAKAKSAVLPPGPPCSSILILSPPAPLTPRSPGTEATRPTAM                               SKSLKKKSHWTSKVHESVIGRNPEGQLGFELKGGAENGQFPYL                               GEVKPGKVAYESGSKLVSEELLLEVNETPVAGLTIRDVLAVIK                               HCKDPLRLKCVKQGESSGLLSVLPGGGTARGAGQ               13   752   144   442   SHRPQPDAWRQGNAFQCVQKEKMQVSSAEVRIGPMRLTQDPIQ                               VLLIFAKEDSQSDGFWWACDRAGYRCNIARTPESALECFLDKH                               HEIIVIDHRQTQN               14   753   1   581   FRLAGCGHLLVSLLGLLLLLARSGTRALVCLPCDESKCEEPRN                               CPGSIVQGVCGCCYTCASQRNESCGGTFGIYGTCDRGLRCVIR                               PPLNGDSLTEYEAGVCEDENWTDDQLLGFKPCNENLIAGCNII                               NGKCECNTIRTCSNPFEFPSQDMCLSALKRIEEEKPDCSKARC                               EVQFSPRCPEDSVLIEGYAPP               15   754   1   219   FRMAANVGSMFQYWKRFDLQQLQRELDATATVLANRQDESEQS                               RKRLIEQSREFKKNTPEVRRVTIVFALKGS               16   755   313   562   ETLSCRIMDHPSREKDERQRTTKPMAQRSAHCSRPSGSSSSSG                               VLMVGPNFRVGKKIGCGNFGELRLGEGLPQVYYFGPCGKY               17   756   273   574   GCCKD*HSGVIGRSWAMLFASGGFQVKLYDIEQQQIRNALENI                               RWASRRSPEGMEVGLFLSVGLVCHILKAMRICDVTFSSDGYCS                               ASELVKARPTVAGM               18   757   3   390   NSRVDDFVSARPKPRPLPRARGMVVVTGREPDSRRQDGAMSSS                               DAEDDFLEPATPTATQAGHAL/PPAAT/GSFLRLFPLTSEGLT                               SLHACPHCGATKTPCWQPCSVGGTTSPRTPRAGTSSTEMAHTL                               EMC               19   758   98   461   RALWVGGCSGEACGIGMSGLLTDPEQPAQEPRYPGFVLGLDVG                               SSVIRCHVYDRAARVCGSSVQKVENLYPQIGWVEIDPDVLWIQ                               FVAVIKEAVAGIQNNQIVGLGISTQRATFITWN               20   759   100   731   GLAAEQSMQFVKLWCGCSGEFPTRLRRRTPLTEAMEGGPAVCC                               QDPRAELVERVAAIDVTHLEEADGGPEPTRNGVDPPPRARAAS                               VIPGSTSRLLPARPSLSARKISLQERPAGSYLEAQAGPYATGP                               ASHISPRAWRRPTIESHHVAISDAEDCVQLNQYKLQSEIGKGA                               YGVVRLAYNESEDPRYAMKVLSKKKLLXQYGFPRRPPP               21   760   2   520   FVYGKPVTLWPTISSVVPSTFLGLGNYEVEVEAEPDVRGPEIV                               TMGENDPPAVEAPFSFRSLFGLDDLKISPVAPDADAVAAQILS                               LLPLKFFPIIVIGIIALILALAIGLGIHFDCSGKYRCRSSFKC                               IELIARCDGVSDCKGEDEYRCVRVGGQNAALQVFTAASRKTKM               22   761   158   470   SLAMPFGCVTLGDKKNYNQPSEVTDRYDLGQVIKTEEFCEIFR                               AKDKTTGKLHTCKKFQKRDGRKVRKAAKNEIGILKMVKHPNIL                               QLVDVFVTRKEYFIFLEL               23   762   1   749   QRRRFRAGLWGGHGLTDGLRRNGGCGCSARVPRVGERLRGHRC                               PDPLCLLLDMLFLSFHAGSWESWCCCCLIPADRPWDRGQHWQL                               EMADTRSVHETRFEAAVKVIQSLPKNGSFQPTNEMMLKFYSFY                               KQATEGPCKLSRPGFWDPIGRYKWDAWSSLGDMTKEEAMIAYV                               EEMKKIIETMPMTEKVEELLRVIGPFYEIVEDKKSGRSSDITS                               DLGNVLTSTPNAKTVNGICAESSDSGAESEEEEAC               24   763   3   558   SCFKGRTGGRSGSSGDSSRWARCGRHFSASTEEPPLSQPCSAL                               PRSGRRGCAVPSSVTKMLSFFRRTLGRRSMRKHAEKERLREAQ                               RAATHIPAAGDSKSIITCRVSLLDGTDVSVDLPKXAKGQELFD                               QIMYHLDLIESDYFGLRFMDSAQVAHWLDGTKSIKKQVKIGSP                               YCLHLRVKFYSS               25   764   9   424   ESRERSGNRRGAEDRGTCGLQSPSAMLGAKPHWLPGPLHSPGL                               PLVLVLLALGAGNAQEGSEPVLLEGECLVVCEPGRAAAGGPGG                               AALGEAPPGRVAFAAVRSHHHEPAGETGNGTSGAIYFDQVLVN                               EGGGFDRAS               26   765   2   507   EDVKSYYTVHLPQLENINSGETRTISHFHYTTWPDFGVPQSPA                               SFLNFLFKVRESGSLNPDHGPVVIHRSAGTGRSSTFSVVHTCL                               VLMEKGDDINIKQVLLNIRKFQMGLI\QTPDQLRFSYMAITEG                               AKCVKGDSSIQKRWKELSKE/DLPPAFDHSPNKIMTEKYNR               27   766   84   852   LNRQRCGDQVLVPGTGLAAILRTLPMFHDEEHARARGLSEDTL                               VLPPASRNQRILYTVLECQPLFDSSDMTIAEWVCLAQTIKRHY                               EQYHGFVVIHGTDTMAFAASMLSFMLENLQKTVILTGAQVPIH                               ALWSDGRENLLGALLMAGQYVIPEVCLFFQNQLFRGNRATKVD                               ARRFAAFCSPNLLPLATVGADITINRELVRKVDGKAGLVVHSS                               MEQDVGLLRLYPGIPAALVRAFLQPPLKGVVMETFGSGNG               28   767   992   210   LFRLAPGFLRSLARQGYHQIWAFPFLPSGATATWPAASRSRSL                               AARSLPRSPARPGPNDALLGEHDFRGQGVPAQRFRFSEEPGPG                               ADGAVLEVHVPQIGAGVSLPGILAAKCGAEVILSDSSELPHCL                               EVCRQSCQMNNLPHLQVVGLTWGHISWDLLAIPPQDIILASDV                               FFEPEDFEDILATIYFLMHKNPKVQLWSTYQVRSADWSLEALL                               YKWDMKCVHIPLESFDADKEDIAESTLPGRHTVEMLVISFAKD                               SL               29   768   23   624   SFIYKHTHRARFGPRAIVASPALTAGPHVSLTASCRVGMWVSC                               SPSPFLHPTNTLVAVLERDTLGIREVRLFNAVVRWSEAECQRQ                               QLQVTPENRRKVLGKALGLIRFPLMTIEEFAAGNRAPAQGLVW                               EGSGTQVGIW\CTEDSAPEFTAESLADAWHIQIGRNLACEDAS                               T\WAIC*PRPGSVPTVRTARPRLSCLSSCF               30   769   100   2   MASTQDAELAVSRXRAIALXPGXQSXXPSQKKK               31   770   158   1957   LLKSCGVLLSGVCIPCEGKGPTVLVIQTAVPQDRPTKSSMRSA                               AKPWNPAIRAGGHGPDRVRPLPAASSGMKSSKSSTSLAFESRL                               SRLKRASSEDTLNKPGSTAASGVVRLKKTATAGAISELTESRL                               RSGTGAFTTTKRTGIPAPREFSVTVSRERSVPRGPSNPPKSVS                               SPTSSNTPTPTKHLRTPSTKPKQENEGGEIC\VRLSPK/FRELL                               AEAKAKDSEINRLRSELKKYKEKRTLNAEGTDALGPNVDGTSV                               SPGDTEPMIRALEEKNKNFQKELSDLEEENRVLKEKLIYLEHS                               PNSEGAASHTGDSSCPTSITQESSFGSPTGNQLSSDIDEYKKN                               IHGNALRTSGSSSSDVTKASLSPDASDFEHITAETPSRPLSST                               SNPFKSSKCSTAGSSPNSVSELSLASLTBKIQKMEENHHSTAE                               ELQATLQELSDQQQMVQELTAENEKLVDEKTILETSFHQHRER                               AEQLSQENEKLMNLLQERVKNEEPTTQEGKIIELEQKCTGILE                               QGRFEREKLLNIQQQLTCSLRKVEEENQGALEMIKRLKEENEK                               LNEFLELERHNNNNMAKTLEECRVTLEGLKMENGSLKSHLQG               32   771   203   514   SQMHRLIFVYTLICANFCSCRDTSATPQSASIKALRNANLRRD                               ESNHLTDLYRRDETIQVKGNGYVQSPRFPNSYPRNLLLTWPLH                               SQENTRIQLVPDNQFGL               33   772   59   713   PFKKMTDLLRSVVTVIDVFYKYTKQDGECGTLSKGELKELLEK                               ELHPVLKNPDDPDTVDVIMHMLDRDHDRRLDFTEFLLMIFKLT                               MACNKVLSKEYCKASGSKKHRRGHRHQEEESETEEDEEDTPGH                               KSGYRHSSWSEGEEHGYSSGHSRGTVKCRHGSNSRRLGRQGNL                               SSSGNQEGSQKRYHRSSCGHSWSGGKDRHGSSSVELRERINKS                               HIK               34   773   209   601   VPKISGPDHIDFIPWDQLFMASSSSVTEFLVLGFSSLGELQLV                               LFAVFLCLYLIILSGNIIIISVIHLDHSLHTPMYFFLGILSIS                               EIFYTTVILPKMLINLFSVFRTLSFVSCATQMFYEIVGPGTQE                               R               35   774   373   987   DHSTETPGIPAAEPVSHGTGKLERAPTLPAGAELPAPAAVPCP                               TL*VC/LYPQLLGLSVATMVTLTYFGAHFAVIRRASLEKNPYQ                               AVHQWGTQQRLIQHPESGSEGQSLLGPLRAFSAFLSLVGLLTL                               GAVLSAAATVREQQGLMAGGFLCFSLAFCAQVQVVFWRLHSPT                               QVEDAMLDTYDLVYEQAMKGTSHVRRQELAAIQ               36   775   102   466   QPGYSEYDKNRGQGMLLNMMCGRQLSAISLCLAVTFAPLFNAQ                               ADEPEVIPGDSPVAVSEQGEALPQAQATAIMAGIQPLPEGAAE                               KARTQIESQLPAGYKPVYLNQLQLLYAARGISCSV               37   776   2   430   RTRAADVYVFSLTGKSRNVSSSTVRRSAVGGMSALALFDLLKP                               NYALATQVEFTDPEIVAEYITYPSPNGHGEVRGYLVKPAKMSG                               KTPAVVVVHENRGLNPYIEDVARRVAKAGYIALAPDGLSSVGG                               YPGNDIKVVSAAA               38   777   106   556   VKQRHGNSLLTTETKCISCRLGVPLSPQRRFQAIRIEEVKLRW                               FAFLIVLLAGCSSKHDYTNPPWNAKVPVQRAMQWMPISQKAGA                               AWGVDPQLITAIIAIESGGNPNAVSKSNAIGLMQLKASTSGRD                               VYRRMGWSGEPTTSEILKNSSR               39   778   3   892   HAAGIRHEAKPKRSFYAARDLYKYRHQYPNFKDIRYQNDLSNL                               RFYKNKIPFKPDGVYIEEVLSKWKGDYEKLEHNHTYIQWLFPL                               REQGLNFYAKELTTYEIEEFKKTKEAIRRFLLAYKMMLEFFGI                               KLTDKTGNVARAVNWQERFQHLNESQHNYLRITRILKSLGELG                               YESFKSPLVKFILHEALVENTIPNIKQSALEYFVYTIRDRRER                               RKLLRFAQKHYTPSENFIWGPPRKEQSEGSKAQKMSSPLASSH                                NSQTSMHKKAKDSKNSSSAVHLNSKTAEDKKVAPKEPV                40   779   123   395   ELQVFQPIGGMSDSGSQLGSMGSLTMKSQLQITVISAKLKENK                               KNWFGPSPYVEVTVDGQSKKTEKCNNTNSPKWKQPLTVIVTPV                                SKLH               41   780   173   438   IETLSFVIRNWNTHAMSKPIVMERGVKYRDADKMALIPVKNVA                               TEREALLRKPEWMKIKLPADSTRIQGIKAAMRKNGLHSVCEEA                               SC               42   781   287   393   PRMVLGKPQTDPTLEWFLSHCHIHKYPSKSTLIPQ               43   782   119   556   GLRISVQERIKACFTESIQTQIAAAEALPDAISRAAMTLVQSL                               LNGNKILCCGNGTSAANAQHFAASMINRFETERPSLPAIALNT                               DNVVLTAIANDRLHDEVYAKQVRALGHAGDVLLAISTRGNSRD                               IVKAVEAAVTRDTTIV               44   783   248   554   KQTQHAPGMMKKYLALALIAPLLISCSTTKKGDTYNEAWVKDT                               NGFDILMGQFAHNIENIWGFKEVVIAGPKDYVKYTDQYQTRSH                               INFDDGTITIEPIPGT                45   784   77   311   TDRTALNPGQESAMNRLFSGRSDMPFALLLLAPSLLLLGGLVA                               WPMVSNIEISFLRLPLNPNIESTFVGVSNYVRILS               46   785   184   627   KELVDEKSERGRAMDPVSQLASAGTFRVLKEPLAFLRALELLF                               AIFAFATCGGYSGGLRLSVDCVNKTESNLSIDIAFAYPFRLHQ                               VTFEVPTCEGKERQKLALIGDSSSSAEFFVTVAVFAFLYSLAA                               TGRYIFFHNKNRENNRGPL               47   786   3   742   LGTVSYGADTMDEIQSHVRDSYSQMQSQAGGNNTGSTPLRKAQ                               SSAPKVRKSVSSRIHEAVKAIVLCHNVTPVYESRAGVTEETEF                               AEADQDFSDENRTYQASSPDEVALVQWTESVGLTLVSRDLTSM                               QLKTPSGQVLSFCILQLFPFTSESKRMGVIVRDESTAEITFYM                               KGADVAMSPIVQYNDWLEEECGNMAREGLRTLVVAKKAITEEQ                               YQDFEVSRLPGIPSSYDGAFLTLKLVLPVFV               48   787   864   335   EGPHR\RLFQMVKA/LQEAPEDPNQILIGYSRGLVVIWDLQGS                               RVLYHFLSSQQLENIWWQRDGRLLVSCHSDGSYCQW\PVSSEA                               QQPEPLRSLVPYGPFPCKAITRILWLTTRQGLPFTIFQGGMPR                               ASYGDRHCISVIHDGQQTAFDFTSRVIGFTVLTEADPAASRRA                               SGVGAQG               49   788   410   951   KQGLEVRDLHFKEITSGRALLRVACKRPSMVPGGQLQPAGAGA                               QARITGLSPALWGARVHGWIPELPAGLPPGACLWPLIPACPSR                               HWGWVSAPVKG/WAQAILGLALCL/RGEHRGLGAGVSKVRSLK                               MDRKVWTETLIEVGMPLLATDTWGLPHSTAVIVSQPPPYLSDH                               STLELERDPLS               50   789   1   437   LSCNSEQALLSLVPVQRELLRRRYQSSPAXPDSSFYKGLGTCP                               SQLRLSEPPPTPRHLSVASVSHHMFPSHRSLCPHLPDPFAAPF                               PSDNLPYTLQSPFPSPPPATPSDHALILHH\DLNGGPDDPLQQ                               TGQLFGGLVRDIRRRYP               51   790   1   198   SPSSKLVGMWWAGRAGSSRTTSVSLLCPL/SAPFGASNLLVNP                               LEPQNADKIKIKIADLGNACWVV               52   791   3   435   RVDPRVRAPRCGDKIKNHMY\KCDCGSLKDCASDRCCETSCTL                               SLGSVCNTGLCCHKCKYAAPGVVCRDLGGICDLPEYCDGKKEE                               CPNDIYIQDGTPCSAVSVCIRGNCSDRDMQCQALFGYQVKDGS                               PACYRKLNRIGNRFGT               53   792   1   728   PGRPTRPDASLAQ/DPRTTMFRIPEFKWSPMHQRLLTDLLFAL                               ETDVHVWRS\HSTKSVMDFVNSNENIIFVHNTIHLISQMVDNI                               IIACGGILPLLSAATSPTGSKTELENIEVTQGMSAETAVTFLS                               RLMAMVDVLVFASSLNFSEIEAEKNMSSGGLMRQCLKLVCCVA                               VRNCLECRQRQRDRGNKSSHGSSKPQEVPQSVTATAASKTPLE                               NVPGNLSPIKDPDRLLQDVDINRLRAVVF               54   793   2230   990   NSSGVKLLQALGLSPGNGKDHSILHSRNDLEEAFIHFMGKGAA                               AERFFSDKETFHDIAQVASEFPGAQHYVGGNAALIGQKFAANS                               DLKVLLCGPVGPKLHELLDDNVFVPPESLQEVDEFHLILEYQA                               GEEWGQLKAPHANRFIFSHDLSNGAMNMLEVFVSSLEEFQPDL                               GGLSGLHMMEGQSKELQRKRLLEVVTSISDIPTGIPV\HLELG                               \SMTNRELMSSIV\LQQVFPAVTSLGLNEQELLFLTQSASGPH                               SSLSSWNGVPDVGMVSDILFWILKEHGRSKSRASDLTRIHFHT                               LVYHILATVDGHWANQLAAVAAGARVAGTQACATETIDTSRVS                               LRAPQEFMTSHSEAGSRIVLNPNKPVVEWHREGISFHFTPVLV                               CKDPIRTVGLGDAISAEGLFYSEVHPHY               55   794   249   3   DDSSGWGLEQLVVRWSLALWPRLECSGMISAHCNLCL/LGSSD                               SPASAPRVAGITDVCHHAWLVFVFLVVMGFPHVGHVGLELL               56   795   2   1176   LGEVLKCQQGVSSLAFALAFLQRMDMKPLVVLGLPAPTAPSGC                               LSFWEAKAQLAKSCKVLVDALRHNAAAAVPFFGGGSVLRAAEP                               APHASYGGIVSVETDLLQWCLESGSIPILCPIGETAARRSVLL                               DSLEVTASLAKALRPTKIIFLNNTGGLRDSSHKVLSNVNLPAD                               LDLVCNAEWVSTKERQQMRLIVDVLSRLPHHSSAVITAASTLL                               TELFSNKGSGTLFKNAERMLRVRSLDKLDQGRLVDLVNASFGK                               KLRDDYLASLRPRLHSIYVSEGYNAAAILTMEPVLGGTPYLDK                               FVVSSSRQGQGSGWMLWECLRRDLQTLFWRSRVTNPINPWYFK                               HSDGSFSNKQWIFFWFGLADIRDSYELVNHAKGLPDSFHKPAS                               DPGS               57   796   755   374   YHAPALQPGQQSKTLSQEKKNFFRPGAVAHTCNPSTLGGRGGR                               ITRSGDRDHPG*HGETPSLLKIQKKLAGRDGGRL*SQLLGRLR                               QENGVNPGGGGCSEPRLRHCTPAW*QSETISRKKRKKERKY               58   797   2   476   FRPIGIIRQALCSADGHQRRILTLRLGLLVIPFLPASNLFFRV                               GFVVPSVGCCVMLLFGFG/ALRKHTEKKKLIAAVVLGILLS/N                               DAERLRCAVRGGEWRSE/EAVFRGAVSVCPLSAEVRCNIGRNL                               AAKGNQTGAIRYHREAVSLNPKTKSSTREFRPC               59   798   3   711   KIADFGFSNLFTPGQLLKTWCGSPPYAAPELFEGKEYDGPKVD                               IWSLGVVLYVLVCGALPFDGSTLQNLRARVLSGKFRIPFFMST                               ECEHLIRHMLVLDPNKRLSMEQICKHKWMKLGDADPNFDRLIA                               ECQQLKEERQVDPLNEDVLLAMEDMGLDKEQTLQSLRSDAYDH                               YSAIYSLLCDRHKRHKTLRLGALPSMPRALGLSSTSQYP\AEQ                               AGTAMNISVPQVQLINPENQIV               60   799   2   344   AREFLGHRASITWS*ARVHHRFPKAEVA*P/SLLRTDLTEDRT                               KCCHGDLLECADDRADLVEDIWENQDSISTILIECCEKPLLEK                               SHCIAEVENDEMPADLPSLAADFVESKDV               61   800   142   594   VPPKMKRGTSLHSRRGKPEAPKGSPQINRKSGQEMTAVMQSGR                               PRSSSTTDAPTGSAMMEIACAAAAAAAACLPGEEGTAERIERL                               EVSSLAQTSSAVASSTDGSIHTDSVDGTPDPQRTKAAIAHLQQ                               KILKLTEQIKIAQTARRNRRPGS*KDCTP*KCLRKSDEALNRV                               LQQI\RVPPKMKRGTSLHSRRGKPEAPKGSPQINRKSGQEMTA                               VMQSGRPRSSSTTDAPTGSAMMEIACAAAAAAAACLPGEEGTA                               ERIERLEVSSLAQTSSAVASSTDGSIHTDSVDGTPDPQRTKAA                               IAHLQQKILKLTEQIKIAQTARRNRRPG               62   801   232   1299   MQTIERLVKERDDLMSALVSVRSSLADTQQREASAYEQVKQVL                               QISEEANFEKTKALIQCDQLRKELERQAERLEKELASQQEKRA                               IEKDMMKKEITKEREYMGSKMLILSQNIAQLEAQVERVTKEKI                               SAINQLEEIQSQLASREMDVTKVCGEMRYQLNKTNMEKDEAEK                               EHREFRAKTNRDLEIKDQEIEKLRIELDESKQHLEQEQQKAAL                               AREECLRLTELLGESEHQLHLTRQEKDSIQQSFSKEAKAQALQ                               AQQREQELTQKIQQMEAQHDKTENEQYLLLTSQNTFLTKLKEE                               CCTLAKKLEQISQKTRSEIAQLSQEKRYTYDKLGKLQRRNEEL                               EEQCVQHGRST*               63   802   3   334   SYPVWWNSPLTAEVPPELLAAAGFFHTGHQDKVRCFFCYGGLQ                               SWKRGDDPWTEHAKWFPSCQFLLRSKGRDFVHSVQETHSQLLG                               SWDPWEEPEDAAPVAPSVPASGYPELPTPRREVQSESAQEPGG                               VSPAEAQRAWWVLEPPGARDVEAQLRRLQEERTCKVCLDRAVS                               IVFVPCGHLVC\AECAPGLQLCPI\CRSPCGPLRPCLWVP               64   803   70   456   MCSYREKKAEPQELLQLDGYTVDYTDPQPGLEGGRAFFNAVKE                               GDTVIFASDDEQDRILWVQAMYRATGQSHKPVPPTQVQKLNAK                               GGNVPQLDAPISQFYADRAQKHGMDEFISSNPCNFDHASLFEM                               *               65   804   2   1376   KQLIVLGNKVDLLPQDAPGYRQRLRERLWEDCARAGLLLAPGH                               QGPQRPVKDEPQDGENPNPPNWSRTVVRDVRLISAKTGYGVEE                               LISALQRSWRYRGDVYLVGATNAGKSTLFNTLLESDYCTAKGS                               EAIDRATISPWPGTTLNLLKFPICNPTPYRMFKRHQRLKKDST                               QAEEDLSEQEQNQLNVLKKHGYVVGRVGRTFLYSEEQKDNIPF                               EFDADSLAFDMENDPVMGTHKSTKQVELTAWDVKDAHWFYDTP                               GITKENCILNLLTEKEVNIVLPTQSIVPRTFVLKPGMVLFLGA                               IGRIDFLQGNQSAWFTVVASNILPVHITSLDRADALYQKHAGH                               TLLQIPMGGKERMAGFPPLVAEDIMLKEGLGASEAVADIKFSS                               AGWVSVTPNFKDRLHLRGYTPEGTVLTVRPPLLPYIVNIKGQR                               IKKSVAYKTKKPPSLMYNVRKKKGKINV               66   805   1   874   STVASMMHRQETVECLRKFNARRKLKGAILTTMLVSRNFSAAK                               SLLNKKSDGGVKPQSNNKNSLVSPAQEPAPLQTAMEPQTTVVH                               NATDGIKGSTESCNTTTEDEDLKAAPLRTGNGSSVPEGRSSRD                               RTAPSAGMQPQPSLCSSAMRKQEIIKITEQLIEAINNGDFEAY                               TKICDPGLTSFEPEALGNLVEGMDFHKFYFENLLSKNSKPIHT                               TILNPHVHVIGEDAACIAYIRLTQYIDGQGRPSNPAKSE\TR                               VWH\RR\DGKWLNVHYHCSGAPCPHRCSELSHRGF               67   806   3   1714   LPKNVVFVLDSSASMVGTKLRQTKDALFTILHDLRPQDRFSII                               GFSNRIKVWKDHLISVTPDSIRDGKVYIHHMSPTGGTDINGAL                               QRAIRLLNKYVAHSGIGDRRVSLIVFLTDGKPTVGETHTLKIL                               NNTREAARGQVCIFTIGIGNDVDFRLLEKLSLENCGLTRRVHE                               EEDAGSQLIGFYDEIRTPLLSDIRIDYPPSSVVQATKTLFPNY                               FNGSEIIIAGKLVDRKLDHLHVEVTASNSKKFIILKTDVPVRP                               QKAGKDVTGSPRPGGDGEGDTNHIERLWSYLTTKELLSSWLQS                               DDEPEKERLRQRAQALAVSYRFLTPFTSMKLRGPVPRMDGLEE                               AHGMSAAMGPEPVVQSVRGAGTQPGPLLKKPYQPRIKISKTSV                               DGDPHFVVDFPLSRLTVCFNIDGQPGDILRLVSDHRDSGVTVN                               GELIGAPAPPNGHKKQRTYLRTITILINKPERSYLEITPSRVI                               LDGGDRLVLPCNQSVVVGSWGLEVSVSANANVTVTIQGSIAFV                               ILIHLYKKPAPFQRHHLGFYIANSEGLSSNCRVFCESGILIQE                               LTQQSVAVAGR               68   807   2   841   FFLEQVSQYTFAMCSYREKKSEPQELMQLEGYTVDYTDPHPGL                               QGGCMFFNAVKEGDTVIFASDDEQDRILWVQAMYRATGQSYKP                               VPAIQTQKLNPKGGTLHADAQLYADRFQKHGMDEFISANPCKL                               DHAFLFRILQRQTLDHRLNDSYSCLGWFSPGQVFVLDEYCARY                               GVRGCHRHLCYLAELMEHSENGAVIDPTLLHYSFAFCAS\HVH                               GNRPDGIGTVSVEEKERFEEIKERLSSLLENQISHFRYCFPFG                               RPEGALKATLSLLERVLMKDIA               69   808   2   757   DGLLHEVLNGLLDRPDWEEAVKMPVGILPCGSGNALAGAVNQH                               GGFEPALGLDLLLNCSLLLCRGGGHPLDLLSVTLASGSRCFSF                               LSVAWGFVSDVDIQSERFRALGSARFTLGTVLGLATLHTYRGR                               LSYLPATVEPASPTPAHSLPRAKSELTLTPDPAPPMAHSPLHR                               SVSDLPLPLPQPALASPGSPEPLPILSLNGGGPELAGDWGGAG                               DAPLSPDPQLSSPPGSPKAALHSPV*KKAPVIPPDM               70   809   3   530   KGVPTLLMAAGSFYDILAITGFNTCLGIAFSTGSTVFNVLRGV                               LEVVIGVATGSVLGFFIQYFPSRDQDKLVCKRTFLVLGLSVLA                               VFSSVHFGFPGSGGLCTLVMAFLAGMGWTSEKAEVEKIIAVAW                               DIFQPLLFGLIG\AEVSI\SSLRPETVGLCVATVGI\AVLIRI                               FDYIF               71   810   228   541   LLKEVVVQASPVCKTCCSQLVRTPVTFTEVQNV/CRCSAGYLI                               SVCSYTSSDHNQCYAGTASLALLWIGGILKGCLLWKQFRWTER                               SHWNFGYWALWSPGNGNGC               72   811   173   404   ICTSTYLQIFPGKPSCFMCKGRLMCIYFILWYLGHYTSLHWNW                               CRYISDPNVD/ACPDPRNAEVSMTHTVPALMELID               73   812   2   586   LESLPGFKEIVSRGVKVDYLTPDFPSLSYPNYYTLMTGRHCEV                               HQMIGNYMWDPTTNKSFDIGVNKDSLMPLWWNGSEPLWVTLTK                               AKRKVYMYYWPGCEVEILGVRPTYCLEYKNVPTDINFANAVSD                               ALDSFKSGRADLAAIYHERIDVEGHHYGPASPQRKDALKA\VD                               TVLKYMTKWIQERGLQDRLNVII               74   813   2   348   ARDFHPKQTLDFLRSDMANSKITEEVKRSIAQQYLDLTVA/LE                               QVDPDAEVDAAPSTTSSCGH*DSHAGS*RVLSLLGD*GPA*TG                               ANSMAGKLLLVAWLGFPDPFWGKELSDPAFK               75   814   2   366   KQSGDVTCNCTDGRLAPSCLTCVGHCIFGGYCTMNSKMMPECQ                               SPPHMTGPRCEEHVFSQHQPGHITSILIPML*LLLLVLVAGVI                               FCHKRRVQGAKGFQHQRMTNGAMNAQIANPTKYMY               76   815   420   681   TVENAGRWL*EEAEIQAELERLERVRNLHIRELKRINNEDNSQ                               FKDHPTLNERYLLLHLLGRGGFSEVYKVMYGLFWFFYTNVARI               77   816   37   428   MCEEFLVMGKGCSCVF*ILLSNPQMWWLNDSNPETDNRQESPS                               QENIDRVSD/MAFVPSAWTASGGVAWGNLGESGSRTGGVRAET                               LAPRLQV*PAHLRGHPRSNRGQGRPPWKAGKLGKCQEVLFRFA                               AF               78   817   1   358   FRAMFLAVQHDCRPMDKSAGSGHKSEEKREKMKRTLLKDWKTR                               LSYFLQNSSTPGKPKTGKKSKQQAFIK*VENPELANINS*LLN                               *KGEL**A*ANIQNLSCRPSPEEAQLWSEAFDE               79   818   1   169   GFFNFSSPKLKGWKINSSLVLEIRKNILRFLDAERDVSVVKSS                               FPSKDARHSSVHR*FTQLHWGPPSHTPARP*RGFFNFSSPKLK                               GWKINSSLVLEIRKNILRFLDAERDVSVVKSSFPSKDARHSSV                               HR               80   819   55   310   RIDDQQELKRVT*YSQKEYTKKKLHKKCNIIQADIKPDNILDN                               ESITILKLSDFGSASHVADNDITPSSSQTTSAASSPPRTLRR               81   820   1   134   SSKPWD*SLAPKHSG*TKNMDCYCIIPTCIGRERCYGTCIGDT                               V               82   821   187   360   NSSKKLVMEHQWKKYLRRNYQRMLNRLITLIGSCGVL*LISTI                               PTSRLKFLKETGHGTPMEEIPEEELSEDVEQIDHADRELRRGQ                               NLRCKGIHRLPTHIQVGQN               83   822   208   723   KWMLLHSFKIFCLSLYPQL*CPFEFFSHSATIFHELVYKQTKI                               ISSNQELIYEGRRLVLEPGRLAQHFPKTTEENPIFVVSREPLN                               TIGLIYEKISLPKVHPRYDLDGDASMAKAITGVVCYACRIAST                               LLLYQELMRKGIRWLIELIKDDYNETVHKKTEVVITLGFLVSR               84   823   1   314   GTRKMGPTVSPICLPGTWGDYNLMDGDLGLISGWGRTEKRDRA                               DRLKAGRSPAAG*RKWEPGRDDPTWEESEEDVHKSKWTRCVDE                               KGA*C*TDNKRPLRCGVT               85   824   3   302   HELENLIKSAHSYSLY*G*YLHGA*TAEPEASFCPRRGWNRQA                               GAAGSRMNFRPGVLSSRQLGLPGPPDGPDYTVYYPFHRLAMVT                               AASRLEREHLTHL               86   825   87   422   PVPLPHPILEVCPGQ*EPQSAISLTAFQVQAGASRASPGPPAP                               SSSKPGRKAKVASPCPDRPAPPPT*PRPAAAPGSESSPRPPRP                               RTGRRQQRAHARRAAARTAPWRPSC               87   826   3   289   HEGRRRGWASASQRFLRNWAFLTPSKVRRLKGQKAFGKLPSHS                               DTSLTSDLGFHHRFNPNASSSFKPSGTKFAIQYGTGRVDGILS                               EDKLTVSGL               88   827   3   101   GRNIMHYPNGHAICIANGHCIIL*NSHNIKVWV               89   828   1   535   INLGNTCYMNSVI*ALFMATDFRRQVLSLNLNGCNSLMKKLQH                               LFAFLAHTQREAYAPRIFFEASRPPWFTPRSQQDCSEYLRFLL                               DRLHEEEKILKVQASHKPSEILECSETSLQEVASKAAVLTETP                               RTSDGEKTLIEKMFGGKLRTHIRCLNCTSTSQKVEAFTDLSLA                               FWPSSS               90   829   1   434   ARDDPRVRLSLSPNFF*LASKLGKQWTPLIILANSLSGTNMGE               91   830   3   782   MHRIKLNDRMTFPEELDMSTFIDVEDEKSPQTESCTDSGAENE                               GSCHSDQMSNDFSNDDGVDEGICLETNSGTEKISKSGLEKNSL                               IYELFSVMVHSGSAAGGHYYACIKSFSDEQWYSFNDQHVSRIT                               QEDIKKTHGGSSGSRGYYSSAFASSTNAYMLIYRLKDPARNAK                               FLEVDEYPEHIKNLVQKERELEEQEKRQREIERNTCKIKLFCL                               HPTKQVMMED*IEVHKDKTLKEAVEMAYKMMDLEEVIPLDCCR                               L               92   831   2   604   SVMPVPALCLLWALAMVTRPASAAPMGGPELAQHEELTLLFHG                               TLQLGQALNGVYRTTEGRLTKARNSLGLYGRTIELLGQEVSRG                               RDAAQELRASLLETQMEEDILQLQAEATAEVLGEVAQAQKVLR                               DSVQRLEVQLRSAWLGPAYREFEVLKAHADKQSHILWALTGHV                               QRQRREMVAQQHRLRQIQERLHTAALPA               93   832   16   690   ITSVDPRVRGNASTGYGKIWLDDVSCDGDESDLWSCRNSGWGN                               NDCSHSEDVGVICSDASDMELRLVGGSSRCAGKVEVNVQGAVG                               ILCANGWGMNIAEVVCRQLECGSAIRVSREPHFTERTLHILMS                               NSGCAGGEASLWDCIRWEWKQTACHLNMEASLICSAHRQPRLV                               GADMPCSGRVEVKHAHTWRSVCDSDFSLHAANVLCRELNCGDA                               ISLSVGDHFG               94   833   108   727   SNYPSSRFRVAGITGVKLGMRSIPIATACTIYHKFFCETNLDA                               YDPYLIAMSSIYLAGKVEEQHLRTRDIINVSNRYFNPSGEPLE                               LDSRFWELRDSIVQCELLMLRVLRFQVSFQHPHKYLLHYLVSL                               QNWLNRHSWQRTPVAVTAWALLRDSYHGALCLRFQAQHIAVAV                               LYLALQVYGVEVPAEVEA/DEAVGWQIYAMDTEIP               95   834   118   376   RGSRHAVHGWAFGLLFINKESVVMAYLFTTFNAFQGVFIFVFH                               CALQKKVRSRRGPGSQPPLETFPGYPGEGGEGGGDSGAPSSPQ               96   835   3   333   ARKDDLPPNMRFHEEKRLDFEWTLKAG*EKG*PSK*NKGWEGQ                               E***TVRD*GIS**VKPQHLS*\ALQMALKRVTLLSSWNCLE                               DFDQIFWGQKSALAGQWFPEVSIIP               97   836   740   951   GKQQRETLRRPSPTISVQRAGSPEHSSASH*HSPCPAPGQRVL                               PTALCTLMTSKHFHGCPLAGQGRAVTL               98   837   81   1503   GVCGLPRFCGSIILCHYEMSSLGASFVQXKFDDLQFFENCGGG                               SFGSVYRAKWISQDKEVAVKKLLKIEKEAEILSVLSHRNIIQF                               YGVILEPPNYGIVTEYASLGSLYDYINSNRSEEMDMDHIMTWA                               TDVAKGMHYLHMEAPVKVIHRDLKSRNVVIAADGVLKICDFGA                               SRFHNHTTHMSLVGTFPWMAPEVIQSLPVSETCDTYSYGVVLW                               EMLTREVPPKGLEGLQVAWLVVEKNERLTIPSSCPRSFAELLH                               QCWEADAKRRPSFKQIISILESMSNDTSLPDKCNSFLHNKAEW                               RCEIEATLERLKKLERDLSFKEQELKERERRLKMWEQKLTEQS                               NTPLLLPLAARMSEESYFESKTEESNSAEMSCQITATSNGEGH                               GMNPSLQAMMLMGFGDIFSMNKAGAVMHSGMQINMQAKQNSSK                               TTSKRRGKKVNMALGFSDFDLSEGDDDDDDDGEEEYNDMDNSE               99   838   185   328   MIWETGCSAACRVTVSPTVTFATFSTRGIDAMRPGPSFLWRQQ                               LSQG*               100   839   1   348   PTLGDQPDLHSITRASRPKLCTRKNcNPLTITVHDPNSTQ*YY                               GMSWELRFYIPGFDVGTMFTIQKILVSWSPPKPIGPLTDLGDP                               MFQKPPNKVDLTVPPPFLVIKDTLQKFEKI               101   840   1   416   SLNNVTLPQAKTEKDFIQLCTPGVIKQEKLGTVYCQASSPGAN                               MIGNKMSAISVHGVSTSGGQMYHYDMNTASLSQQ*DQKPIFNV                               IPPIPVGSENWNRCQGSGDDNITSLGTLNFPGRTVSFSFEMES                               RSVAQAGVQ               102   841   105   354   RHTQECRCPHTHIHTHTHSHTHSHTHSHSHSHTTPRCSHTQPP                               HAQAPALC*S*EDRGQPTWKLCAHRPRLKVIKEGGWLGG               103   842   171   347   NYSLSVYLVRQLTAGTLLQKLRAKGIRNPDHSRALSE*HLSSL                               PHLIWIQVFLALQPS               104   843   2   690   ATYIVDFGFSTTFREGQMLTAPCGMYPYVAPERSLGQACQ*PA                               RDIQSLSVILYFRNTVGRRARTLPFYS/AFASKLQEKILTGRY                               HAPPLLALQLDSL/IKLLMLNARKCPSL*LMKNPWVKSSQKMP                               LIPYEEPL/RGPPQTIQLMVAMGFQAKNISVAIIERKFNYPMA                               TYLILEHTKQERKCSTIRELSLPPGVPTSPSPSTELSTFPLSL                               MRAHREPAFNVQPPEESQ               105   844   2   777   AKQELAKLMRIEDPSLLNSRVLLHHAKAGTIIARQGDQDVSLH                               FVLWGCLHVYQRMIDKAEDVCLFVAQPGELVGQLAVLTGEPLI                               FTLRAQRDCTFLRISKSDFYEIMRAQPSVVLSAAHTVAARMSP                               FVRQMDFAIDWTAVEAGRALYRCSSHRAAQARPRGGDLGVVRP                               C*PPRPLRQGDRSDCTYIVLNGRLRSVIQRGSGKKELVGEYGR                               GDLIGVVSATPTH*PLAFSRPVPRQLTRIIPGNPGSGEVFPGA               106   845   3   709   HASGWTPGTTQTLGQGTAWDTVASTPGTSETTASAEGRRTPGA                               TRPAAPGTGSWAEGSVKAPAPIPESPPSKSRSMSNTTEGVWEG                               TRSSVTNRARASKDRREMTTTKADRPREDIEGVRIALDAAKKV                               LGTIGPPALVSETLAWEILPQATPVSKQQSQGSIGETTPAAGM                               WTLGTPAADVWILGTPAADVWTSMEAASGEGSAAGDLDAATGD                               RGPQATLSQTPAV*PWGPPG               107   846   3   406   AGTSGTGDTGPGNTAVSGTPVVSPGATPGAPGSSTPGEADIGN                               TSFGKSGTPTVSAASTTSSPVSKHTDAASATAVTISGSKPGTP                               GTPGGATSGGKITPGIA*PTLDQKSPCFSGYGGYFPVNPHQNP                               CADSL               108   847   1   565   RAHRCCLPLPSLSCEIQIGFS*SSIFPGQ*ACPCSCCRSCRRN                               WPQSPRCPHHPPAPCSLLLSSCLPPPLSCSWRGTSGKPPSQSP                               AASRSMRPRCSPRTSSLRGASCRGPGGSAPAAASGPRCRGCSR                               SPRRCSRSGCAAASPPRSQRRSPPLSPPPFPTSGTLLLKTSRF                               GSATRE*SSPRPRPRP               109   848   2   987   DDVPPPAPDLYDVPPGLRRPGPGTLYDVPRERVLPPEVADGGV                               VDSGVYAVPPPAEREAPAEGKRLSASSTGSTRSSQSASSLEVA                               GPGREPLELEVAVEALARLQQGVSATVAHLLDLAGSAGATGSW                               RSPSEPQEPLVQDLQAAVAAVQSAVHELLEFARSAVGNAAHTS                               DRALHAKLSRQLQKMEDVHQTLVAHGQALDAGRGGSGATLEDL                               DRLVACSRAVPEDAKQLASFLHGNASLLFRRTKATAPGPEGGG                               TLHPNPTDKTSSIQSRPLPSPPKFTSQDSPDGQYENSEGGWME                               DYDYVHLTGGRRSF*KTQKELLGKRAA               110   849   84   372   MATDEENVYGLEENAQSRQESTRRLILVGRTGAGKSATGNSIL                               GQRRFFSRLGATSVTRACTTGSRRWDKCHVEVVDTPDIFSSQV                               SKTDPGCEERX*               111   850   2   47   TLGLRSLTKEGGGGGDVAAFEVGTGAAASRALGQCGQLQKLIV                               IFIGSLCGLCTKCAVSNDLTQQEIQTPEIQQRNA*CDSRVTFT                               NEGGRWWG               112   851   1192   1040   FFFLVETRFEHIGQAGLELLTLSIK*SARLGLPKCWDDRREPP                               YLAGFMI               113   852   791   362   RRSPPPAPPPLPSPLSPPPRAPVSPASTMPILLFLIDTSASMN                               QRSHLGTTYLDTAKGAVETFMKLRARDPASRGDRYMLVTFEEP                               PYAIKAGWKENHATFMNELKNLQAEGLTTLGQSLRTAFDLLNL                               NRLVTGIDNYGQVG               114   853   812   348   NCRTYVFCFVLVFRLLFLHGSPLSPSLLSRAGLLCGSAENPTP                               FLCGITMAAGVSLLALVVRVILSTAILCPSGASRRQRSSEVEW                               GTDSGVYRLYCWRVGFLGPGGELRLGLSEARGGRVWGRGEKRC                               RVWAVRSLRKGFGSVAALRRGIWAG               115   854   93   170   VTPTPPQYYTCSCVLGFIACSIFLQMSLKPKVMLLTVALVACL                               VLFNLSQCWQRDCCSQGLGNLTEPSGTNR*GPAAVSWASLPAP                               SSCR               116   855   1   183   GKAGGAAGLFAKQVQKKFSRAQEK*TRRFGKTCQPEERAREER                               QEGPEIEFGFSFFSLSLY               117   856   53   2400   PKRLFLFQDVNTLQGGGQPVVTPSVQPSLQPAHPALPQMTSQA                               PQPSVTGLQAPSAALMQVSSLDSHSAVSGNAQSFQPYAGMQAY                               AYPQASAVTSQLQPVRPLYPAPLSQPPHFQGSGDMASFLMTEA                               RQHNTEIRMAVSKVADKMDHLMTKVEELQKHSAGNSMLIPSMS                               VTMETSMIMSNIQRIIQENERLKQEILEKSNRIEEQNDKISEL                               IERNQRYVEQSNLMMEKRNNSLQTATENTQARVLHAEQEKAKV                               TEELAAATAQVSHLQLKMTAHQKKETELQMQLTESLKETDLLR                               GQLTKVQAKLSELQETSEQAQSKFKSEKQNRKQLELKVTSLEE                               ELTDLRVEKESLEKNLSERKKKSAQERSQAEEEIDEIRKSYQE                               ELDKLRQLLKKTRVSTDQAAAEQLSLVQAELQTQWEAKCEHLL                               ASAKDEHLQQYQEVCAQRDAYQQKLVQLQEKSVCFA\CLALQA                               QITALTKQNEQHIKELEKNKSQMSGVEAAASDPSEKVKKIMNQ                               VFQSLRREFELEESYNGRTILGTIMNTIRMVTLQLLNQQEQEK                               EESSSEEEEEKAEERPRRPSQEQSASASSGQPQAPLNRERPES                               PMVPSEQVVEEAVPLPPQALTTSQDGHRRKGDSEAEALSEIKD                               GSLPPELSCIPSHRVLGPPTSIPPEPLGPVSMDSECEESLAAS                               PMAAK\PDNPSGK\VCVQGK*APDGPTYKE\SSTRLFPGFQDP                               E\EGDPLALGLE\SPG\EPQPPQLQGKVDVH*VPPVPHKGAFQ                               EQEGRFPQFCRE               118   857   1   791   SETAQQIIDRLRVKLAKEPGANLFLMAVQDIRVGGRQSNASYQ                               YTLLSDDLAALREWEPKIRKKLATLPELADVNSDQQDNGAEMN                               LVYDRDTMARLGIDVQAANSLLNNAFGQRQISTIYQPMNQYKV                               VMEVDPRYTQDISALEKMFVINNEGKAIPLSYFAKWQPANAPL                               SVNHQGLSAALTISFNLPTGKSLSDASAAIDRAMSQLGVPSTV                               RGSFAGPAQVFQETMNSQVILIIAAIATVYIVLOIPYERYVHP                               PTILL*RPGANLFLMAVQDIRVGGRQSNASYQYTLLSDDLAAL                               REWEPKIRKKLATLPELADVNSDQQDNGAEMNTVYDRDTMARL                               GIDVQAANSLLNNAFGQRQISTIYQPMNQYKVVMEVDPRYTQD                               ISALEKMFVINNEGKAIPLSYFAKWQPANAPLSVNHQGLSAAL                               TISFNLPTGKSLSDASAAIDRAMSQLGVPSTVRGSFAGPAQVF                               QETMNSQVILIIAAIATVYIVLGIPYERYVHPPTILL               119   858   3   417   IITPDAMGCQKDIAEKIQKQGGDYLFAVKGNQGRLNKAFEEKF                               PLKELNNPEHDSYAISEKSHGREEIRLHIVCDVPDELIDFTFE                               WKGLKKLCVAVSFRSIIAEQKKEPEMTVRYNIS*LGIAGDISV                               TAISGTDD               120   859   2   373   HYLKMLTQARREVIIANAYFFPGYRFLHAIRKAARRGVRIKLI                               IQGEPDMPIVRVGARLLYNYLVKGGVQVFEYRRRPLHGKVALM                               DDHWATVGSSNLHPVS*SGNLQANILHVLRVPTLNP               121   860   286   495   CWSKSAAFHSKLATTCIVPVCAAGHCSAAW*SLRPIEALAKEV                               RELK*HTR*LLNPATTRELTSLGRNLNRLLKSERERYDKYRTT                               LTDLTHSLKTPLAVLQSTLRSLRSEKMSVSDAEPVMLEQISRI                               SQQIGYYLHRASMRGGTLLSRELHPVAPLLDNLTSALIKGKPR                               KGGNVTVFPFTAMYRDGH               122   861   2   725   GNTVMFQHLMQKRKHTQWTYGPLTSTLYDLTEIDSSGDEQSLL                               ELIITTKKREARQILDQTPVKELVSLKWKRYGRPYFCMLGAIY                               LLYIICFTMCCIYRPLKPRTNNRTSPRDNTLLQQKLLQEAYMT                               PKDDIRLVGELVTVIGAIIILLVEVPDIFRMGVTRFFGQTILG                               GPFHVLIITYAFMVLVTMVMRLISASGEVVPMSFALVLGWCNV                               MYFARGFQMLGPFTIMIQKMIFGDLM               123   862   1   135   EKAAAANIDEVQKSDVSSTGQGVIDKDALGPMMLEVAHLHFSA                               VF               124   863   2   364   LEVPSEVTPLGFAMQATKTLLLRTCCLQEFNIMEKNKGWALLG                               GKDGHLQGLFLLANALLERNQLLAQKVMYLLVPLLNRGNDKHK                               LTSAGFFVELLRSPVAKRLPSIYSVARFKDWLQD               125   864   1   374   RPAPAPSAAPEEAPSP\GVKGRGMAKRRVPAPVWGGAGGGTKS                               ARRAAAAKPDTERSEEGGRAVKEAYPSSRQPPPSP*PLRCARR                               CHPNLAPSMPISNREGKGKRREEKIRPLSPASTHTSARA               126   865   3   364   LQGVHGSSSTFCSSLSSDFDPLEYCSPKGDPQRVDMQPSVTSR                               PRSLDSEVPTGETQVSSHVHYHRHRHHHYKKRFQRHGRKPGPE                               TGVPQSRPPIPRTQPQPEPPSPDQQVTRSNSAAP               127   866   2   250   MADPDPRYPRSSIEDDFNYGSSEASDTVHIRMAFLRRVYSILS                               LQDLLATVTSTDNLAFEDGRTDWLQRPDCVSFKIHVLPM               128   867   194   375   AGMSVVVVPPIGSSYLGLISQEHFPNEFTSGDGKKAHQDFGYF                               YGSSYVAASDSSRTPGL               129   868   104   339   VAAALTLFPQQLSPPGAWGLGLSACFCCAEGFSRLNQQVLSSS                               LLLLSRTNCPCKYSFLDNLKKLTPRRDVPTYPKVR               130   869   2   360   RDDACLYSPASAPEVITVGATNAQDQPVTLGTLGTNFGRCVDL                               FAPGEDIIGASSDCSTCFVSQSGTSQAAAHVAGIAANMISAEP                               ELTLAELRQRLIHFSAKDVINEAWFPEDQRVLT               131   870   2   105   LEIKFLEQVDQFYDDNFPMEIRHLLAQWIENQDW               132   871   2   466   EAGDADEDEADANSSDCEPEGPVEAEEPPQEDSSSQSDSVEDR                               SEDEEDEHSEEEETSGSSASEESESEESEDAQSQSQADEEEED                               DDFGVEYLLARDEEQSEADAGSGPPTPGPTTLGPKKEITDIAA                               AAESLQPKGYTLATTQVKTPIPLLL               133   872   1   354   LKNLRELLLEDNQLPQIPSGLPESLTELSLIQTNIYNITKEGI                               SRLINLKNLYLAWNCYFNKVCEKTNIEDGVFETLTNLELLSLS                               FNSLSHVPPKLPSSLRKLFLSNTQIKYISEED               134   873   59   184   MRSQALGQSAPSLTASLKELSLPRRGSFPVCPNAGRTSPLG*               135   874   1   210   LLCVCLPVGACPSLSLLTAPLNQLMRCLRKYQSRTPSPLLHSV                               PSEIVFDFEPGPVFRGSWALLSWSTRP               136   875   131   254   QTPDKKQNDQRNRKRKAEPYETSQGSNNFVSTKVLNSNVLR               137   876   84   504   YFIIKGMVELVPASDTLRKIQVEYGVTGSFKDKPLAEWLRKYN                               PSEEEYEKASENFIYSCAGCCVATYVLGICDRHNDNIMLRSTG                               HMFHIDFGKFLGHAQMFGSFKRDRAPFVLTSDMAYVINGGEKP                               TIRFQLFVDL               138   877   3   215   PSPLPSLSLPPPVAPGGQESPSPHTAEVESEASPPPARPLPGE                               ARLAPISEEGKPQLVGRF\QVTSSK\NRLSLFPCSQHPPLSLV                               LQNLQPLSSLQRAQIQRTV/PGGGPETREALAESDRAAEGLGA                               GVEEEGDDGKEPQVGGSPQPLSHPSPVWMNYSYSSLCLSSEES                               ESSGEDEEFWAELQSLRQKRLSEVETLQTLQKKEIEDLYSRLG                               KQPPPGIVAPAAMLSSRQRRLSKGSFPTSRRNSLQRSEPPGPG                               ETA/GHPASIFSLRPLSVDCFSPGPGGLPRGNRPPLPTSPFLT                               *CSPSP&amp;TAEVESEASPPPARPLPGEARLAPISEEGKPQLVGR                               FPSDFIQGTG               139   878   1   337   RRFVSQETGNLYIAKVEKSDVGNYTCVVTNTVTNHKVLGPPTP                               LILRNDGVMGEYEPKIEVQFPETVPTAKGATVKLECFALGNPV                               PTIIWRRADGKKPIARKARRHKSRVGK               140   879   72   917   MLRTCYVLCSQAGPRSRGWQSLSFDGGAFHLKGTGELTRALLV                               LRLCAWPPLVTHGLLLQAWSRRLLGSRLSGAFLRASVYGQFVA                               GETAEEVKGCVQQLRTLSLRPLLAVPTEEEPDSAAKSGEAWYE                               GNLGAMLRCVDLSRGLLEPPSLAEASLMQLKVTALTSTRLCKE                               LASWVRRPGASLELSPERLAEAMDSGQNLQVSCLNAEQNQHLR                               ASLSRLHRVAQYARAQHVRLLVDAEYTSLNPALSLLVAALAVR                               WNSPGEGGPNVNNTYQACLKDTF*               141   880   219   308   PHHRIAGDTAIDKNIHQSVSEQIKKNFAK               142   881   182   317   QMTNPFFLCFTTMISNCNFFKGPPGPPGEKGDRGPTGESGPRG                               FP               143   882   177   341   NGIIASFFLRTFIFCFIHIQGCQAGQTIKVQVSFDLLSLMFTF                               VSPCTNDLIIH               144   883   3   1441   KLSVNHRRTHLTKLMHTVEQATLRISQSFQKTTEFDTNSTDIA                               LKVFFFDSYNMKHIHPHMNMDGDYINIFPKRKAAYDSNGNVAV                               AFLYYKSIGPLLSSSDNFLLKPQNYDNSEEEERVISSVISVSM                               SSNPPTLYELEKITFTLSHRKVTDRYRSLCAFWNYSPDTMNGS                               WSSEGCELTYSNETHTSCRCISLTHFAILMSSGPSIGIKDYNI                               LTRITQLGIIISLICLAICIFTFWFFSEIQSTRTTIHKNLCCS                               LFLAELVFLVGINTNTNKLFCSIIAGLLHYFFLAAFAWMCIEG                               IHLYLIVVGVIYNKGFLHKNFYIFGYLSPAVVVGFSAALGYRY                               YGTTKVCWLSTENNFIWSFIGPACLIILVNLLAFGVIIYKVFR                               HTAGLKPEVSCFENIRSCARGALALLFLLGTTWIFGVLHVVHA                               SVVTAYLPTVSNAPQGMFIFLFLCVLSRKIQEEYYRLFKNVPC                               CFGCLR               145   884   1   429   GTREAAPSRFMFLLFLLTCELAAEVAAEVEKSSDGPGAAQEPT                               WLTDVPAAMEFIAATEVAVIGFFQDLEIPAVPILHSMVQKFPG                               VSFGISTDSEVLTHYNITGNTICLFRLVDNEQINTEDEDIESI                               DATKLSRFIEINSL               146   885   1   156   DETSGLIVREVSIELSRQQVEELFGPEDYWCQCVAWSSAGTTK                               SRKAYVRIA               147   886   1   121   GTRSIHVKLDVGKLHTQPKLAAQLRMVDDGSGKVEGLPGI               148   887   128   652   XCGEDGSFTQVQCHTYTGYCWCVTPDGKPISGSSVQNKTPVCS                               GSVTDKPLSQGNSGRKDDGSKPTPTMETQPVFDGDEITAPTLW                               IKHLVIKDSKLNNTNIRNSEKVYSCDQERQSALEEAQQNPREG                               IVIPECAPGGLYKPVQCHQSTGYCWCVLVDTGRPLPGTSTRYV                               MPSX*               149   888   128   273   VLQLIKSQKFLNKLVILVETEKEKILRKEYVFADSKVSDSKLL                               KWAVR               150   889   1   948   RRLSLLDLQLGPLGRDPPQECSTFSPTDSGEEPGQLSPGVQFQ                               RRQNQRRFSMEDVSKILSLPMDIRLPQEFLQKLQMESPDLPKP                               LSRMSRRASLSDIGFGKLETYVKLDKLGEGTYATVFKGRSKLT                               ENLVALKEIRLEHEEGAPCTAIREVSLLKNLKHANIVTLHDLI                               HTDRSLTLVFEYLDSDLKQYLDHCGNLMSMHNVKVRPRGQGPP                               ILAATCPEAQCGDPLSPPGIRLLRWLKPSHVGKRERAMPSTSP                               GTGLSALPQEQTHTVCHCLAVGIKPTLNSEHQFPSLSNGSVSY                               LPKCREASGEARGYE               151   890   3   108   HERHEPSPTALAFGDHPIVQPKQLSFKIIQVNDN               152   891   2   208   ARGPSLLSEFHPGSDRPQERRTSYEPIHPGPSPVDHDSLESKR                               PRLEQASDSHYQGHITGESLPGRVH               153   892   1   116   GTRKEEFSAEENFLILTEMATNHVQVLVEFTKKLPGIF               154   893   74   661   HTHKLVAPRPGLPPTSQWPRDAGRQASGGLPSLSTGPPKGPRD                               GLARGHPAWELAGSPGNNSPTQGSLPPQLDLYAGALFVHICLG                               WNFYLSTILTLGITALYTIAGMVPAAGRSTQGTCKGVRRPPPP                               TGPREQPRKWPQQEPQKFLPVSLLPGARAPSSNLASTGRGPGC                               CNLHGRPADAHHGGGGCHPDNQR               155   894   55   312   MVNHSLQETSEQNVILQHTLQQQQQMIQQETIRNGELEDTQTK                               LEKQVSKLEQELQKQRESSAEKLRKMEEKCESAAHEADLKRQK                               *               156   895   38   185   VCPKWCRFLTMLGHCCYFWHVWPAS*AISAGPTPTSRSFSPSP                               LRSIST               157   896   37   462   MRGPPVLLLQAAPMECPVPQGIPAGSSPEPAPDPPGPHFLRQE                               RSFECRMCGKAFKRSSTLSTHLLIHSDTRPYPCQFCGKRFHQK                               SDMKKHTYIHTGEKPHKCQTQREPTMVLSPADKTNVKAAWX*               158   897   3   175   HEQLTNNTATAPSATPVFGQVAASTAPSLFGQQTGITASTAVA                               TPQVISSRFINTLDF               159   898   187   677   VSVFKNCPMY*ICIFLTKMFCVLLII\*NKF*VHKKPLQEVEIA                               AITHGALQGLAYLHSHTMIHRDIKAGNILLTEPGQVKLADFGS                               ASMASPANSFVGTPYWMAPEVILANDEGQYDGKVDVWSLGITC                               IELAERKPPLFNMNAMSALYHIAQNESPTLQSNEW               160   899   2   1060   RHARPGGGGHSNQRKMSLEQEEETQPGRLLGRRDAVPAFIEPN                               VRFWITERQSFIRRFLQWTELLDPTNVFISVESIENSRQLLCT                               NEDVSSPASQDQRIQEAWKRSLATVHPDSSNLIPKLFRPAAFL                               PFMAPTVFLSMTPLKGIKSVILPQVFLCAYMAAFNSINGNRSY                               TCKPLERSLLMAGAVASSTFLGVIPQFVQMKYGLTGPWIKRLL                               PVIFLVQASGMNVYMSRSLESIKGIAVMDKEGNVLGHSRIAGT                               KAVRETLASRIVLFGTSALIPEVFTYFFKRTQYFRKNPGSLWI                               LKLSCTVLAMGLMVPFSFSIFPQIGQIQYCSLEEKIQSPTEET                               EIFYHRGV               161   900   3   564   HASGRLEVFYNGTWGSVGRRNITTAIAGIVCRQLGCGENGVVS                               LAPLSKTGSGFMWVDDIQCPKTHISIWQCLSAPWERRISSPAE                               ETWITCEDRIRVRGGDTECSGRVEIWHAGSWGTVCDDSWDLAE                               AEVVCQQLGCGSALAALRDASFGQGTGTIWLDDMRCKGNESFL                               WDCHAKPWGQSDCG               162   901   1099   2   LGDFPQPQRQRRPGASDLPPHLAGARQWEVRFFRHLPARTLPP                               SLRMPEGPELHLASQFVNEACRALVFGGCVEKSSVSRNPEVPF                               ESSAYRISASARGKELRLILSPLPGAQPQQEPLALVFRFGMSG                               SFQLVPREELPRHAHLRFYTAPPGPRLALCFVDIRRFGRWDLG                               GKWQPGRGPCVLQEYQQFRENVLRNLADKAFDRPICEALLDQR                               FFNGIGNYLRAEILYRLKIPPFEKARSVLEALQQHRPSPELTL                               SQKIRTKLQNPDLLELCHSVPKEVVQLGGRGYGSESGEEDFAA                               FRAWLRCYGMPGMSSLQDRHGRTIWFQGDPGPLAPKGRKSRKK                               KSKATQLSPEDRVEDALPPSK               163   902   3   335   LTWSACYWRDILRIQLWIAADILLRMLEKALLYSEHQNISNTG                               LSSQGLLIFAELIPAIKRTLARLLVIIASLDYGIEKPHLGTGM                               HRVIGLMLLYLIFANAESVIRVIG               164   903   2   135   FFFEMESRSAAQAGVQWCNLGSLQALPPRFTPFSCLSLPSSWD                               Y               165   904   74   645   YECEELAKKLENSQRDGISRNKLALAELYEDEVKCKSSKSNRP                               KATVFKSPRTPPQRFYSSEHEYSGLNIVRPSTGKIVNELFKEA                               REHGAVPLNEATRASGDDKSKSFTGGGYRLGSSFCKRSEYIYG                               ENQLQDVQILLKLWSNGFSLDDGELRPYNEPTNAQFLESVKRG                               VTLIACMPEIQQLMLEIF               166   905   14   1257   WPCGAAPGLTHASERMFTLTTMIQALAPVMGWDRKPLKMFSSE                               EMRGHLHHHHKCLTKILKVEGQVPDLPSCLPLTDNTRMLASIL                               INMLYDDLRCDPERDHFRKICEEYITGKFDPQDMDKNLNAIQT                               VSGILQGPFDLGNQLLGLKGVMEMMVALCGSERETDQLVAVEA                               LIHASTKLSRATFIITNGVSLLKQIYKTTKNEKIKIRTLVGLC                               KLGSAGGTDYGLRQFAEGSTEKLAKQCRKWLCNMSIDTRTRRW                               AVEGLAYLTLDADVKDDFVQDVPALQAMFELAKTSDKTILYSV                               ATTLVNCTNSYDVKEVIPELVQLAKFSKQHVPEEHPKDKKDFI                               DMRVKRLLKAGVISALACMVKADSAILTDQTKELLARVFLALC                               DNPKDRGTIVAQGGGKALIPLALEGTD               167   906   3   894   VDSVGGGSESRSLDSPTSSPGAGTRQLVKASSTGTESSDDFEE                               RDPDLGDGLENGLGSPFGKWTLSSAAQTHQLRRLRGPAKCREC                               EAFMVSGTECEECFLTCHKRCLETLLILCGHRRLPARTPLFGY                               DFLQLPRDFPEEVPFVVTKCTAEIEHRALDVQGIYRVSGSRVR                               VERLCQAFENGRALVELSGNSPHDVSSVLKRFLQELTEPVIPF                               HLYDAFISLAKTLHADPGDDPGTPSPSPEVIRSLKTLLVQLPD                               SNYNTLRHLVAHLFRVAARFMENKMSANNLGIVFGPTL               168   907   1   394   GLHVISLHSADGRHWEDPLSELDSERVSAFLVTETLVFYLFCL                               LADETVVPPDVPSYLSSQGTLSDRQETVVRTEGGPQANGHIES                               NGKASVTVKQSSAVTVSLGAGGGLQVFTGQVPGIRWGKLGEAH                               AS               169   908   179   551   KIKHRPEEEPRWAAAGAQSAGPGAAEVAPPRPGTVAPGANGMT                               DSATANGDDRDPEIELFVKAGIDGESIGNCPFSQRLFMILWLK                               GVVFNVTTVDLKRKPADLRNLAPGTHPPFLAFNWYVKT               170   909   1   335   LGFSDGQEARPEEIGWLNGYNETTGERGDFPGTYVEYIGRKKI                               SPPTPKPRPPRPLPVAPGSSKTEADVEQQVLYKYRKKPSSSHR                               PQTPHNGKSKNFLHKQGLKKKKASL               171   910   1   895   RTRGVMELALRRSPVPRWLLLLPLLLGLNAGAVIDWPTEEGKE                               VWDYVTVRKDAYMFWWLYYATNSCKNFSELPLVMWLQGGPGGS                               STGFGNFEEIGPLDSDLKPRKTTWLQAASLLFVDNPVGTGFSY                               VNGSGAYAKDLAMVASDMMGLLKTFFSCHKEFQTVPFYIFSES                               YGGKMAAGIGLELYKAIQRGTIKCNFAGVALGDSWISPVDSVL                               SWGPYLYSMSLLEDKGLAEVSKVAEQVLNAVNKGLYREATELW                               GKAEMIIEQVKRGNTQRRACLAFSGGYRAHGWCCQTWSLH               172   911   553   194   PGWSRSPDLVIRLPRPPKVLGLQYYHFFFFLRWSL/DSVAQAE                               VQWHDLRSLQAPPPGFTPFSCLSLPGSWDYRCPPPRPANFLYF                               **RRGFTVLARMVSIS*PRDPPASASQSAGITVLSLFFFFEME                               SCSVAGAGVQWRYLGSLQALPPGFTPFSCLSLPSSWDYRRPPP                               RPANFFVFLVETGVSPC*PGWSRSPDLVIRLPQPPKVLGLQV               173   912   1761   1   PSMKTGELEKETAPLRKDADSSISVLEIHSQKAQIEEPDPPEM                               ETSLDSSEMAKDLSSKTALSSTESCTMKGEEKSPKTKKDKRPP                               ILECLEKLEKSKKTFLDKDAQRLSPIPEEVPKSTLESEKPGSP                               EAAETSPPSNIIDHCEKLASEKEVVECQSTSTVGGQSVKKVDL                               ETLKEDSEFTKVEMDNLDNAQTSGIEEPSETKGSMQKSKFKYK                               LVPEEETTASENTEITSERQKEGIKLTIRISSRKKKPDSPPKV                               LEPENKQEKTEKEEEKTNVGRTLRRSPRISRPTAKVAEIRDQK                               ADKKRGEGEDEVEEESTALQKTDKKEILKKSEKDTNSKVSKVK                               PKGKVRWTGSRTRGRWKYSSNDESEGSGSEKSSAASEEEEEKE                               SEEAILADDDEPCKKCGLPNHPELILLCDSCDSGYHTALPFAP                               PLMIHPQMGGW\F\CPTFCPTLNLLLLEKLEDQF\QDL\DVAL                               KKERALPERRK\ERLVYVGI\SIENIIPPQ\EPDFSEDQEEKK                               KDSKKSKANLL\ERRSTRTRKCISYRFDEFDEAIDEAIEDDIK                               EADGGGVGRGKDISTITGHRGKDISTILDEER               174   913   3   539   KRRGSFKMAELDQLPDESSSAKALVSLKEGSLSNTWNEKYSSL                               QKTPVWKGRNTSSAVEMPFRNSKRSRLFSDEDDRQINTRSPKR                               NQRVAMVPQKFTATMSTPDKKASQKIGFRLRNLLKLPKAHKWC                               IYEWFYSNIDKPLFEGDNDFCVCLKESFPNLKTRKLTRVEWGK                               IRRLMG               175   914   166   635   MPEYLRKRFGGIRIPIILAVLYLFIYIFTKISVDMYAGAIFIQ                               QSLHLDLYLAIVGLLAITAVYTVAGGLAAVIYTDALQTLIMLI                               GALTLMGYSFAAVGGMEGLKEKYFLALASNRSENSSCGLPRED                               AFHIFRDPLTSDLPWPGVLFGMSIPSLX*               176   915   673   1025   XSASATSLTLSHCVDVVKGLLDFKKRRGHSIGGAPEQRYQIIP                               VMCCSLLATGGADRLIHLWNVVGSRLEANQTLEGAGGSITSVD                               FDPSGYQVLAATYNQVAQFWK*               177   916   3   139   QKRFPSNCGRDGKLFLWGQALHIIAKLLGKWRRLGMVFFSLLL                               SY               178   917   1   541   VHVCSSKMGALSTERLQYYTQELGVRERSGHSVSLIDLWGLLV                               EYLLYQEENPAKLSDQQEAVRQGQNPYPIYTSVNVRTNLSGED                               FAEWCEFTPYEVGFPKYGAYVPTELFGSELFMGRLLQLQPEPR                               ICYLQGMWGSAFATSLDEIFLKTAGSGLSFLEWYRGSVNITDD                               CQKPQLHN               179   918   1   628   EFLGRPTRPAKDEGNDEGKDEGKDEGKDEGKDEGKDEGKDERK                               DEGKDEGKDERKDEGKDEGKDEGKDEGKDEGKDEGKDEGKDEG                               NDEGKDEGKDEGKDEGKDEGKDEGKDERKDEGKDEGKDERKDE                               GKDEGKDEGKDEGKDEGKDEGKDEGKDEGNDEGKDEGKDEGKD                               EGKDEGKDEGKDEGNDEGNDEGNDEGKDEGKDERNDEGKDEGK                               DEGKDEGKDERNDEGKDERKDEGKDEGKDEGKDEGKDEGKDEG                               NDEGKDERKDEGKDEGKDEGKDK               180   919   27   471   PSLRPAWHEGEDFSYGLQPYCGYSFQVVGEMIRNREVLPCPDD                               CPAWAYALMIEGWNEFPSRRARFKDIHSRLRAWGNLSNYNSSE                               QTSGGRNTTQTSSLSTSPLCNVSNAPYVGPKQKVPPFPQTQVI                               PMKGQIRPMVPPPQLYVP               181   920   2   454   RNSGRHPRVRWILEERKRVMQEACAKYRASSSRRAVTPRHVSR                               IFVEDRHRVLYCEVPKAGCSNWKRVLMVLAGLASSTADIQHNT                               VHYGSALKRLDTFDRQGILHRLSTYTKMLFVREPFERLVSAFR                               DKFEHPNSYYHPVFCMAILAR               182   921   2   378   IMYSISPANSEEGQELYVCTVKDDVNLDTVLLLPFLKEIAVSQ                               LDQLSPEEQLLVKCAAIIGHSFHIDLLQHLLPGWDKNKLLQVL                               RALVDIHVLCWSDICSQELPAEPILMPSSIDIIDGTKEKK               183   922   181   513   GPHVVLVLRRCFLLSYFKGVEKAKAMPSPRILKTHLSTQLLPP                               SFWENNCKVRYQQLPVTEGKVSQPKRVLQTPTQSIRDHLCLST                               VSDAYQQRENIKFYIQQDIHLNSFK               184   923   32   239   FYYICRLSKEDKAFLWEKRYYCFKHPNCLPKILASAPNWKWVN                               LAKTYSLIMQWPALYPLIALELLDSK               185   924   3   361   KMMI*GLFEIQQCPIGKHCNFLQVLRN/PNRDL/WLVSSFGKS                               SKGRERMGHHDEYYRLRGR/HNPSPDHSYKRNGESERKRKKSH                               *HMSKSQERHNSPSRGRNSDRSGGRCSRSDNGRSRYR               186   925   443   1412   PLSLFARVAGSRVEMPEPPGLGDEGRPLLHPGRREAVGSWVSA                               FAGDSTPCGPGDLSVPRREPFRLTAL*PHRSPVVRTSLIGLLL                               GPSVKEELRGVGWAARTPLGIR               187   926   2   917   FDKRQHEARIQQMENEIKYIQENLKSMEEIQGLTDLQLQEADE                               EKERILAQLRELEKKKKLEDAKSQEQVFGLDKELKKLKKAVAT                               SDKLATAELTIAKDQLKSLHGTVMKINQEPAEELQEAERFSRK                               AAQAARDLTRAEAEIELLQNLLRQKGEQFRLEMEKTGVGTGAN                               SQVLEIEKLNETMERQRTEIARLQNVLYLTGSDNKGGFENVLE                               EIAELRREGSYQNDYISSMADPFKRRGYWYFMPPPPSSKVSSH                               SSQATKDSGVGLKYSASTPVRKPRPGQQDGKEGSQPPPASGYW                               VYSP               188   927   171   1082   SDASSFKTRVIVVPRPRVFPLGSAITENSLESDSQIGQFGVGF                               YSAFLVADKVIVTSKHNNDTQHIWESDSNEFSVIADPRGNTLG                               RGTTITLVLKEEASDYLELDTIKNLVKKYSQFINFPIYVWSSK                               TETVEEPMEEEEAAMEEKEESDDEAAVEEEEEEKKPKTKKVEK                               TVWDWELMNDIKPIWQRPSKEVEEDEYKAFYKSFSKESDDPMA                               YIHFTAEGEVTFKSILFVPTSAPRGLFDEYGSKKSDYIKLYVR                               RVFITDDFHDMMPKYLNFVVKGWDSDDLPLNVSRETLQQHKLL                               KV               189   928   718   275   CGSWMRRALIPPCRGGPSASDRCCSCSPSGPSAGRGRCPVQGC                               LRPHRVQLLRRWGPGSPAGQRLSKGFQLLRWWGPGSPAPEPRK                               GPFPPPDPPWPVTAVTVMAGSVPSAQSVDALESPGPLALEGPS                               SPRNLLWREMSIFLPGIF               190   929   1   550   PGPTPPPRHGSPPHRLIRVETPGPPAPPADERISGPPASSDRL                               AILEDYADPFDVQETGEGSAGASGAPEKVPENDGYMEPYEAQK                               MMAEIRGSKETATQPLPLYDTPYEPEEDGATPEGEGAPWPRES                               RLPEDDERPPEEYDQPWEWKKERISKAFAVDIKVIKDLPWPPP                               VGQLDSSPSLP               191   930   1   562   QFFSLFLRYQIHTGLQHSIIRPTQPNCLPLDNATLPQKLKEVG                               YSTHMVGKWHLGFYRKECMPTRRGFDTFFGSLLGSGDYYTHYK                               CDSPGMCGYDLYENDNAAWDYDNGIYSTQMYTQRVQQILASHN                               PTKPIFLYIAYQAVHSPLQAPGRYFEHYRSIININRRRYAAML                               SCLDEAINNVTLALK               192   931   3   580   RVRKGRGGERLQSPLRVPQKPERPPLPPKPQFLNSGAYPQKPL                               RNQGVVRTLSSSAQEDIIRWFKEEQLPLRAGYQKTSDTIAPWF                               HGILTLKKANELLLSTGMPGSFLIRVSERIKGYALSYLSEDGC                               KHFLIDASADAYSFLGVDQLQHATLADLVEYHKEEPITSLGKE                               LLLYPCGQQDQLPDYLELFE               193   932   3   1641   GSLEKALFQLLKVWGQWAEQTRRLQRLDVSLSVARVRSAGPSC                               QNKGDLVMEALLEGIQNRGHGGGFLTSCEAELQELMKQIDIMV                               AHKKSEWEGRTHALETCLKIREQELKSLRSQLDVTHKEVGMLH                               QQVEEHEKIKQEMTMEYKQELKKLHEELCILKRSYEKLQKKQM                               REFRGNTKNHREDRSEIERLTAKIEEFRQKSLDWEKQRLIYQQ                               QVSSLEAQRKALAEQSEIIQAQLVNRKQKLESVELSSQSEIQH                               LSSKLERANDTICANELEIERLTNRVNDLVGTSMTVLQEQQQK                               EEKLRESEKLLEALQEEKRELKAALQSQENLIHEARIQKEKLQ                               EKVKATNTQHAVEAISLESVSATCKQLSQELMEKYEELKRMEA                               HNNEYKAEIKKLKEQILQGEQSYSSALEGMKMEISHLTQELHQ                               RDITIASTKGSSSDMEKRLRAEMQKAEDKAVEHKEILDQLESL                               KLENRHLSEMVMKLELGLHECSLPVSPLGSIATRFLEEEELRS                               HHILERLDAHIEELKRESEKTVRQFTALK               194   933   159   1053   TGFLGWSQGPSLTPTSLSALYPSQVEETGVVLSLEQTEQHSRR                               PIQRGAPSQKDTPNPGDSLDTPGPRILAFLHPPSLSEAALAAD                               PRRFCSPDLRRLLGPILDGASVAATPSTPLATRHPQSPLSADL                               PDELPVGTENVHRLFTSGKDTEAVETDLDIAQDADALDLEMLA                               PYISMDDDFQLNASEQLPRAYHRPLGAVPRPRARSFHGLSPPA                               LEPSLLPRWGSDPRLSCSSPSRGDPSASSPMAGARKRTLAQSS                               KDEDEGVELLGVRPPKRSPSPEHENFLLFPLSLSFLLTG               195   934   3   425   ELQDCFDVHDASWEEQIFWGWHNDVHIFDTKTQTWFQPEIKGG                               VPPQPRAAHTCAVLGNKGYIFGGRVLQTRMNDLHYLNLDTWTW                               SGRITINGESPKHRSWHTLTPIADDKLFLCGGLNAYNMPLSDG                               WIHNVTTHCWK               196   935   2   295   FFFLRTRSHSVTPRWECSDDITAHWQPQPWGSSDPLTFS/RPQ                               VVVPPRHTTLCP\ANFFVFCIFCRNRISPCWPGWSRTPWAQLI                               RLPRPPKVLGLQV               197   936   2   737   PREGQVKQGLLGDCWFLCACAALQKSRHLLDQVIPPGQPSWAD                               QEYRGSFTCRIWQFGRWVEVTTDDRLPCLAGRLCFSRCQREDY                               FWLPLLEKVYAKVHGSYEHLWAGQVADALVDLTGGLAERWNLK                               GVAGSGGQQDRPGRWEHRTCRQLLHLKDQCLISCCVLSPRAGE                               ARGQHGRAAASVPPTARPQAHCSFLCDWLHSPVRTKWEEVSLF                               SRVVSSVCDLPLLSSSRGTWPFSPLTSPFH               198   937   3   638   AECLEASIARYAHRVANSRYTFDGETVTLSPSQGVNQLHGGPE                               GFDKRRWQIVNQNDRQVLFALSSDDGDQGFPGNLGATVQYRLT                               DDNRISITYRATVDKPCPVNMTNHVYFNLDGEQSDVRNHKLQI                               LADEYLPVDEGGIPHDGLKSVAGTSFDFRSAKIIASEFLADDD                               QRKVKGYDHAFLLQAXGDGKKVAAHVWSADEKLQLKVYT               199   938   69   425   PLSRFLSKESQEDWGMERQSRVMSEKDEYQFQHQGAVELLVFN                               FLLILTILTIWLFKNHRFRFLHETGGAMVYDKPPKFAMSREQM                               SQSCSHTAHNASLLTDAGPLSCGESRASCLPL               200   939   3   435   DSKEPRLQQLGLLEEEQLRGLGFRQTRGYKSLAGCLGHGPLVL                               QLLSFTLLAGLLVQVSKVPSSISQEQSRQDAIYQNLTQLKAAV                               GELSEKSKLQEIYQELTQLKAAVGELPEKSKLQEIYQELTWLK                               AAVGELPEKSKMQE               201   940   657   469   MQSIAWGHRRDRGESPLGWGQESEASPSALTEAPKAAHTTRLG                               FLAANNIPNGHSQPQDSFLL*               202   941   1   714   FETLSMRGIPHMLALGPQQLLAQDEEGDTLLHLFAARGLRWAA                               YAAAEVLQVYRRLDIREHKGKTPLLVAAAANQPLIVEDLLNLG                               AEPNAADHQGRSVLHVAATYGLPGVLLAVLNSGVQVDLEARDF                               EGLTPLHTAILALNVAMRPSDLCPRVLSTQARDRLDCVHMLLQ                               MGANHTIQVSGDVGGQTLGDCVEWGHLDVRELQANADFASSLL                               RALEHVTSLLCALRVFCLFLCQL               203   942   3   479   DAWADAWVGTKMADLDSPPKLSGVQQPSEGVGGGRCSEISAEL                               IRSLTELQELEAVYERLCGEEKVVERELDALLEQQNTIESKMV                               TLHRMGPNLQLIEGDAKQLAGMITFTCNLAENVSSKVRQLDLA                               KNRLYQAIQRADDILDLKFCMDGVQTALR               204   943   1   706   AVEFRVPRSGSAYLYSYVTVGELWAFTTGWNLILSYVIGTASV                               ARAWSSAFDNLIGNHISKTLQGSIALHVPHVLAEYPDFFALGL                               VLLLTGLLALGASESALVTKVFTGVNLLVLGFVMISGFVKGDV                               HNWKLTEEDYELAMAELNDTYSLGPLGSGGFVPFGFEGILRGA                               ATCFYAFVGFDCIATTGEEAQNPQRSIPMGIGISLSVCFLADF                               AVSSALTLMMPYYQLQPESP               205   944   1   852   GFHPNTTHYRARAAARAGAGSFVGEVSAVDKDFGPNGEVRYSF                               EMVQPDFELHAISGEITNTHQFDRESLMRRRGTAVFSFTVIAT                               DQGIPQPLKDQATVHVYMKDINDNAPKFLKDFYQATISESAAN                               LTQVLRVSASDVDEGNNOLIHYSIIKGNEERQFAIDSTSGQVT                               LIGKLDYEATPAYSLVIQAVDSGTIPLNSTCTLNIDILDENDN                               TPFF/LLNQHFFVDVLENMRIGELGASGTATDS\DSGDIADLY                               YKFTGTKHPPGTFSISPKHLGVFFLAQK               206   945   3   363   GDCYDLYGGEKFATLAELVQYYMEHHGQLKEKNGDVIELKNPL                               NCADPTSQRWFHGHLSGKEAEKLLTEKGKHSSFLVRESQSHPG                               DFVLSVCTGDDKGESNDGKSKVTHVMIHCQELK               207   946   218   717   IDSGNQNGGNDDKTKNAERNYLNVLPGEFYITRHSNLSEIHVA                               FHLCVDDHVKSGNITARDPAIMGLRNILKVCCTHDITTISIPL                               LLVHDMSEEMTIPWCLRRAELVFKCVKGFMMEMASWDGGISRT                               VQFLVPQSISEEMFYQLSNMLPQIFRVSSTLTLTSKH               208   947   3   368   SILPALLVTILIFMDQQITAVIVNRKENKLKKAAGYHLDLFWV                               GILMALCSFMGLPWYVAATVISIAHIDSLKMETETSAPGEQPQ                               FLGVREQRVTGIIVFILTGISVFLAPILKCIPLPV               209   948   2   575   GASRVEAGSANGMLIDGGSQIVKVQGHADGTTINKSGSQDVVQ                               GSLATNTTINGGRQYVEQSTVETTTIKNGGEQRVYESRALDTT                               IEGGTQSLNSKSTAKNTHIYSGGTQIVDNTSTSDVIEVYSGGV                               LDVRGGTATNVTQHDGAILKTNTNGTTVSGTNSEGAFSIHNHV                               ADNVLLENGGHLDINAYGS               210   949   1   296   FFSSIQLTDDQGPVLMTTVAMPVFSKQNETRSKGILLGVVGTD                               VPVKELLKTIPKYKVMNDLIPEIKATEMPRALFSQSSGFKLYF                               GAMFLLTTITAC               211   950   3   594   SCSGTGTNACYMEDMSNIDLVEGDEGRMCINTEWGAFGDDGAL                               EDIRTEFDRELDLGSLNPGKQLFEKMISGLYLGELVRLILLKM                               AKAGLLFGGEKSSALHTKGKIETRHVAAMEKYKEGLANTREIL                               VDLGLEPSEADCIAVQHVCTIVSFRSANLCAAALAAILTRLRE                               NKKVERLRTTVGMDGTLYKIHPQY               212   952   2   2167   FVAIATNGVVPAGGSYYMISRSLGPEFGGAVGLCFYLGTTFAG                               AMYILGTIEELLAYLFPAMAIFKAEDASGEAAAMLNNMRVYGT                               CVLTCMATVVFVGVKYVNKFALVFLGCVILSILAIYAGVIKSA                               FDPPNFPICLLGNRTLSRHGFDVCAKLAWEGNETVTTRLWGLF                               CSSRFLNATCDEYFTRNNVTEIQGIPGAASGLIKENLWSSYLT                               KGVIVERSGMTSVGLADGTPIDMDHPYVFSDMTSYFTLLVGIY                               FPSVTGIMAGSNRSGDLRDAQKSIPTGTILAIATTSAVYISSV                               VLFGACIEGVVLRDKFGEAVNGNLVVGTLAWPSPWVIVIGSFF                               STCGAGLQSLTGAPRLLQAISRDGIVPFLQVFGHGKANGEPTW                               ALLLTACICEIGILIASLDEVAPILSMFFLMCYMFVNLACAVQ                               TLLRTPNWRPRFRYYHWTLSFLGMSLCLALMFICSWYYALVAM                               LIAGLIYKYIEYRGAKKEWGDGIRGLSLSAARYALLRLEEGPP                               HTKNWRPQLLVLVRVDQDQNVVHPQLLSLTSQLKAGKGLTIVG                               SVLEGTFLENHPQAQRAEESIRRLMEAEKVKGFCQVVISSNLR                               DGVSHLIQSGGLGGLQHNTVLVGWPRNWRQKEDHQTWRNFIEL                               VRETTAGHLALLVTKNVSMFPGNPERFSEGSIDRWGIGHDGGM                               LMLVPFLLRHHKVWRKCKMRIFTVAQMVDMHAM               213   952   1   128   FYLRLLSFFCFQEHEKRCWSVDFNLMDPKLLASGSDDAKGTV               214   953   3   244   RNSKAMHRSSCDGPLLSLPSVGRSATHALVQAQLICSGARRGM                               HAFIVPIRSLQDHTPLPGKPIMLPQGTLPGGEPRWPP               215   954   2   609   CGTLILQARAYVGPHVLAVVTRTGFCTAKGGLVSSILHPRPIN                               FKFYKHSMKFVAALSVLALLGTIYSIFILYRNRVPLNEIVIRA                               LDLVTVVVPPALPAAMTVCTLYAQSRLRRQGIFCIHPLRINLG                               GKLQLVCFDKTGTLTEDGLDVMGVVPLKGQAFLPLVPEPRRLP                               VGPLLRALATCHALSRLQDTPVGDPMDLKM               216   955   292   855   QIEYFRSLLDEHHISYVIDEDVKSGRYMELEQRYMDLAENARF                               EREQLLGVQQHLSNTLKMAEQDNKEAQEMIGALKERSHHMERI                               IESEQKGKAALAATLEEYKATVASDQIEMNRLKAQLENEKQRV                               AELYSIHNSGDKSDIQDLLESVRLDKEKAETLASSLQEDLAHT                               RNDANRLQDAIAKGRG               217   956   2   400   ARYRFTLSARTQVGSGEAVTEESPAPPNEATPTAAPPTLPPTT                               VGATGAVSSTDATAIAATTEATTVPIIPTVAPTTMATTTTVAT                               TTTTTAAATTTTESPPTTTSGTKIHESAPDEQSIWNVTVLPNS                               KWA               218   957   1   662   LKSTQDEINQARSKLSQLHESRQEAHRSLEQYDQVLDGAHGAS                               LTDLANLSEGVSLAERGSFGAMDDPFKNKALLFSNNTQELHPD                               PFQTEDPFKSDPFKGADPFKGDPFQNDPFAEQQTTSTDPFGGD                               PFKESDPFRGSATDDFFKKQTKNDPFTSDPFTKNPSLPSKLDP                               FESSDPFSSSSVSSKGSDPFGTLDPFGSGSFNSAEGFADFSTI                               EGRRG               219   958   1   752   RTRGGSGNSSQPSLREGHDKPVFNGAGKPHSSTSSPSVPKTSA                               SRTQKSAVEHKAKKSLSHPSHSRPGPMVTPHNKAKSPGVRQPG                               SSSSSAPGQPSTGVARPTVSSGPVPRRQNGSSSSGPERSISGS                               KKPTNDSNPSRRTVSGTCGPGQPASSSGGPGRPISGSVSSARP                               LGSSRGPGRPVSSPHELRRPVSGLGPPGRSVSGPGRSISGSIP                               AGRTVSNSVPGRPVSSLGPGQTVSSSGPTIKPKCT               220   959   439   582   RGKGITPRYHLCISDPHNLKICCRVNGEVVQSSNTNQMVFKTE                               DLIAW               221   960   230   420   VVAVTRWLCENGVSYLRKCVCSACRHGTRCAGEVAAAANNSHC                               TVGIAFNAKIGGMGNQLTWM               222   961   311   490   GAPPPFVPTLKSDDDTSNFDEPKKNSWVSSSPCQLSPSGFSGE                               ELPFVGFSYSKALGIL               223   962   2   422   FVERLAHLHAACAPRRKVALLLEVCRDVYAGLARGENQDPLGA                               DAFLPALTEELIWSPDIGDTQLDVEFLMELLDPDELRGEAGYY                               LTTWFGALHHIAHYQPETDRAPRGLSSEARASLHQWHRRRTLH                               RKDHPRAQQLD               224   963   385   844   FWMDPYNPLNFKAPFQTSGENEKGCRDSKTPSESIVAISECHT                               LLSCKVQLLGSQESECPDSVQRDVLSGGRHTHVKRKKVTFLEE                               VTEYYISGDEDRKGPWEEFARDGCRFQKRIQETEDAIGYCLTF                               EHRERMFNRLQGTCFKGLNVLKQC               225   964   3   166   AASTAYSFFGTVENMAPKVVNRPGHTQSADWGSFGGLMGRFEF                               GIFLKGKEIVK               226   965   1   118   GFVFLPGPMSVGLDFSLPGMEHVYGIPEHADNLRLKVTE               227   966   1   390   GSECQGTDLDTRNCTSDLCVHTASGPEDVALYVGLIAVAVCLV                               LLLLVLILVYCRKKEGLDSDVADSSILTSGFQPVSIKPSKADN                               PHLLTIQPDLSTTTTTYQGSLCPRQDGPSPKFQLTNGHLLSPL                               G               228   967   1   777   LIYNEDMICWIESRESSNQLKCIQITKAGGLTDEWTINILQSF                               HNVQQMAIDWLTRNLYFVDHVGDRIFVCNSNGSVCVTLIDLEL                               HNPKAIAVDPIAGKLFFTDYGNVAKVERCDMDGMNRTRIIDSK                               TEQPAALALDLVNKLVYNVDLYLDYVGVVDYQGKNRHAVIQGR                               QVRHLYGITVFEDYLYATNSDSYNIVRISRFNGTDIHSLIKIE                               NAWGIRIYQKRTQPTVRSHACEVDPYGMPGGCSHICLLSSSYT                               K               229   968   3   488   SSGNPQPGDSSGGGAGGGLPSPGEQELSRRLQRLYPAVNQQET                               PLPRSWSPKDKYNYIGLSQGNLRVHYKGHGKNHKDAASVRATH                               PIPAACGIYYFEVKIVSKGRDGYMGIGLSAQGVNMNRLPGWDK                               HSYGYHGDDGHSFCSSGTGQPYGPTFTTGDVI               230   969   1   228   FFFFKMGSRSVTQAGVQWCDVSSLQAPPPRFTLFCLSLPSSWD                               YRCVPPCPANFFVFLVETGFHRVSQYGLDLLTS               231   970   2   119   QLSLARGKVFLCALSFVYFAKALAEGYLKSTITQIERRVDIPS                               SLVGVIDGSFEIGNLLVITFVSYFGAKLBRPKIIGAGCVIMGV                               GTLLIAMPQFFMEQYKYERYSPSSNSTLSISPCLLESSSQLPV                               SVMEKSKSKISNECEVDTSSSMWIYVFLGNLLRGIGETPIQPL                               GIAYLDDFASEDNAAFYIGCVQTVAIIGPIFGFLLGSLCAKLY                               VDIGFVNL/DHF*VSAQLGTRKGVLVCLVFCLLCQSIGRRLSE                               EHHHSDREKG               232   971   221   1068   QPAGRVEAFCKFHMWAEGMTSLMKAALDLTYPITSMFSGAGFN                               SSIFSVFKDQQIEDLWIPYFAITTDITASAMRVHTDGSLWRYV                               RASMSLSGYMPPLCDPKDGHLLMDGGYINNLPADVARSMGAKV                               VIAIDVGSRDETDLTNYGDALSGWWLLWKRWNPLATKVKVLNM                               AEIQTRLAYVCCVRQLEVVKSSDYCEYLRPPIDSYSTLDFGKF                               NEICEVGYQHGRTVFDIWGRSGVLEKMLRDQQGPSKKPASAVL                               TCPNASFTDLAEIVSRIEPAKPAM               233   972   133   635   LWVIMFVSYLILTLLHVQTAVLARPGGESIGCDDYLGSDKVVD                               KCGVCGGDNTGCQVVSGVFKHALTSLGYHRVVEIPEGATKINI                               TEMYKSNNYLALRSRSGRSIINGNWAIDRPGKYEGGGTMFTYK                               RPNEISSTAGESFLAEGPTNEILDVYVSLDVSGLFFGF               234   973   1   420   ISGGTRSAGPLRRNYNFIAAVVEKVAPSVVHVQLWGRNQQWIE                               VVLQNGARYEAVVKDIDLKLDLAVIKIESNAELPVLMLGRSSD                               LRAGEFVVALGSPFSLQNTATAGIVSTKQRGGKELGMKDSDMD                               YVQIDATINYG               235   974   2   860   PRVRELKEILDRKGHFSENETRWIIQSLASAIAYLHNNDIVHR                               DLKLENIMVKSSLIDDNNEINLNIKVTDFGLAVKKQSRSEAML                               QATCGTPIYMAPEVISAHDYSQQCDIWSIGVVMYMLLRGEPPF                               LASSEEKLFELIRKGELHFENAVWNSISDCAKSVLKQLMKVDP                               AHRITAKELLDNQWLTGNKLSSVRPTNVLEMMKEWKNNPESVE                               ENTTEEKNKPSTEEKLKSYQPWGNVPETNYTSDEEEEKQVGRI                               IAAFLPSVKYPHHTWNIFLQICLFVVSL               236   975   1   467   LSISVSDVSLSDEGQYTCSLFTMPVKTSKAYLTVLGVPEKPQI                               SGFSSPVMEGDLMQLTCKTSGSKPAADIRWFKNDKEIKDVKYL                               KEEDANRKTFTVSSTLDFRVDRSDDGVAVICRVDHESLNATPQ                               VAMQVLEMHYTPSVKIIPSTPFPQEG               237   976   3   417   YNQKVDLFSLGIIFFEMSYHPMVTASERIFVLNQLRDPTSPKF                               PEDFDDGEHAXQKSVISWLLNHDPAKRPTATELLKSELLPPPQ                               MEESELHEVLHHTLTNVDGKAYRTIDGPRSFRQRISPAIA\YT                               YD\SDILKGN               238   977   2   740   DQDYKYDSTSDDSNFLNPPRGWDHTAPGHRTFETKDQPEYDST                               DGEGDWSLWSVCSVTCGNGNQKRTRSCGYACTATESRTCDRPN                               CPGIEDTFRTAATEVSLLAGSEEFNATKLFEVDTDSCERWMSC                               KSEFLKKYMHKVMNDLPSCPCSYPTEVAYSTADIFDRIKRKDF                               RWKDASGPKEKLEIYKPTARYCIRSMLSLESTTLAAQHCCYGD                               NMQLITRGKGAGTPNLISTEFSAELHYKVDV               239   978   2   612   ESEENGESANDSTVAXEGTNVPLVAAGPCDDEGIVTSTGAKEE                               DEEGEDVVTSTGRGNEIGHASTCTGLGEESEGVLICESAEGDS                               QIGTVVEHVEAEAGAAIMNANENNVDSMSGTEKGSKDTDICSS                               AKGIVESSVTSAVSGKDEVTPVPGGCEGPMTSAASDQSDSQLE                               KVEDTTISTGLVGGSYDVLVSGEVPECEVAH               240   979   79   361   VCIICLIFSYYSFDSALQSAKSSLGGNDELSATFLEMKGHFYM                               YAGSLLLKMGQHGNNVQWRALSELAALCYLIAFQVSLPLGAID                               ISRSLDVF               241   980   2   681   QHPSQEKPQVLTPSPRKQKLNRKYRSHHDQMICKCLSLSISYS                               ATIGGLTTIIGTSTSLIFLEHFNNQYPASEVVNFGTWFLFSFP                               ISLIMLVVSWFWMHWLFLGCNFKETCSLSKKKKTKREQLSEKR                               IQEEYEKLGDISYPEMVTGFFFILMTVLWFTREPGFVPGWDSF                               FEKKGYRTDATVSVFLGFLLFLIPAKKPCFGKKNDGENQEHSL                               GTEPIITWKDF               242   981   1   491   LEREGDKGTPVLRGFSSVSGSWSRRMPPFLLLTCLFITGTSVS                               PVAKDPCSAYISLNEPWPNTDHQLDESQGPPLCDNHVNGEWYH                               FTGMAGDAMPTFCIPENHCGTHAPVWKNGSHPLEGDGIVQRQA                               CASFNGNCCLWNTTVEVKACPGGYYVYRLTKPSV               243   982   1   983   CGRTMSDIRHSLLRRDALSAAKEVLYHLDIYFSSQLQSAPLPI                               VDKGPVELLEEFVFQVPKERSAQPKRLNSLQELQLLEIMCNYF                               QEQTKDSVRQIIFSSLFSPQGNKADDSRMSLLGKLVSMAVAVC                               RIPVLECAASWLQRTPVVYCVRLAXALVDDYCCLVPGSIQTLK                               QIFSASPRFCCQFITSVTALYDLSSDDLIPPMDLLEMIVTWIF                               EDPRLILITFLNTPIAANLPIGFLELTPLVGLIRWCVKAPLAY                               KRKKKPPLSNGHVSNKVTKDGPVGMDRDSHLLYSKLHLSVLQV                               LMTLQLHLTEKNLYGPPGADPKRPEG               244   983   32   362   SACSTGPELPGRATRSLTRPANQKGCDGDRLYYDGCAMIAMNG                               SVFAQGSQFSLDDVEVLTATLDLEDVRSYRAEISSRNLAVSAP                               VDTCVGCSSKTWKVAPFVRAWWRP               245   984   158   398   APLSRLCFPQVLVNEGGGFDRASGSFVAPVRGVYSFRFHVVKV                               YNRQTVQVTSALAPIPGSGGWGGGRRGAQLTSGWTLH                       246   985   2   707   PHIIGAEDDDFGTEHEQINGQCSCFQSIELLKSRPAHLAVFLR                               HVVSQFDPATLLCYLYSDLYKHTNSKETRRIFLEFHQFFLDRS                               AHLKVSVPDEMSADLEKRRPELIPEDLHRHYIQTMQERVHPEV                               QRHLEDFRQKRSMGLTLAESELTKLDAERDKDRLTLEKERTCA                               EQIVAKIEEVLMTAQAVEEDKSSTMQYVILMYMKRLGVKVKEP                               RNLEHKRGRIGFLPKIKQSM               247   986   18   441   SPGTGRGPGPTSFVCLPTPQCPFIDDFILALHRKIKNEPVVFP                               EGPEISEELKDLILKMLDKNPETRIGVPDIKLHPWVTKNGEEP                               LPSEEEHCSVVEVTEEEVKNSVRLIPSWTTVILVKSMLRKRSF                               GNPFEPQARMA               248   987   3   732   HASGIKIDKTSDGPKLFLTEEDQKKLHDFEEQCVEMYFNEKDD                               KFHSGSEERIRVTFERVEQMCIQIKEVGDRVNYIKRSLQSLDS                               QIGHLQDLSALTVDTLKTLTAQKASEASKVHNEITRELSISKH                               LAQNLIDDGPVRPSVWKKHGVVNTLSSSLPQGDLESNNPFHCN                               ILMKDDKDPQCNIFGQDLPAVPQRKEFNFPEAGSSSGALFPSA                               VSPPELRQRLHGVELLKIFNKKQKKRA               249   988   3   468   CCRWIDCFALYDQQEELVRHIEKVHIDQRKGEDFTCFWAGCPR                               RYKPFNARYKLLIHMRVHSGEKPNKCTFEGCEKAFSRLENLKI                               HLRSHTGEKPYLCQHPGCQKAFSNSSDRAKHQRTHLDTKPYAC                               QIPGCTKRYTDPSSLRKHVKAHSSK               250   989   356   553   LPLLWTLSDFGGTMDQSGMEIPVTLIIKAPNQKYSDQTISCFL                               NWTVGKKKTHLSNVYPSKPVSV               251   990   1   895   AGTRMCVVAAAEELVCGA\RGLWMRRTRRPRFVLMNKMDDLNL                               HYRFLNWRRRIREIREVRAFRYQERFKHILVDGDTLSYHGNSG                               EVGCYVASRPLTKDSNYFEVSIVDSGVRGTIAVGLVPQYYSLD                               HQPGWLPDSVAYHADDGKLYNGRAKGRQFGSKCNSGDRIGCGI                               EPVSFDVQTAQIFFTKNGKRVGSTIMPMSPDGLFPAVGMHSLG                               EEVRLHLNAELGREDDSVMMVDSYEDEWGRLHDVRVCGTLLEY                               LGKGKSIVDVGLAQARHPLSTRSHYFEVEIVDPGEKCYIA               252   991   51   674   QQAEEHLAAYSVSDSDSGKDPSMECCRRATPGTLLLFLAFLLL                               SSRTARSEEDRDGLWDAWGPWSECSRTCGGGASYSLRRCLSSK                               SCEGRNIRYRTCSNVDCPPEAGDFRAQQCSAHNDVKHHGQFYE                               WLPVSNDPDNPCSLKCQAKGTTLVVELAPKVLDGTRCYTESLD                               MCISGLCQVSADLFSFNLSRGFQCLCVNGLHSLTL               253   992   2   554   RLLRQELVVLCHLHHPSLISLLAAGIRPRMLVMELASKGSLDR                               LLQQDKASLTRTLQHRIALHVADGLRYLHSAMIIYRDLKPHNV                               LLFTLYPNAAIIAKIADYGIAQYCCRMGIKTSEGTPGFRAPEV                               ARGNVIYNQQADVYSFGLLLYDILTTGGRIVEGLKFPNEFDEL                               EIQGKLPDPVKE               254   993   3   437   KASNSTHEFRIGLPEGWESEKKAVIPLGIGPPLTLICLGVLGG                               ILIYGRKGFQTAHFYLKDSPSPKVISTPPPPIFPISKEVGPIP                               IKHFPKHVANLHASRGFTEKFETLKKFYQEGQSCTVDLGITAN                               SSNHPDNRHRNRSLI               255   994   3   445   SFPDRTASLVLLSVPVGQAGMQQRGLAIVALAVCAALHASPAI                               LPIASSCCTEVSHHISRRLLERVNMCRIQRADGDCDLAAVILH                               VKRRRICVSPHNHTVKQWMKVQAAKKNGKGNVCHRKKHHGKRN                               SNRAHQGKHETYGHKTPY               256   995   2   737   FEQPGNPGDPRVRTPPPWGPHFFALIPSSPKEVPATPSSRRDP                               IAPTATLLSKKTPATLAPKEALIPPAMTVPSPKKTPAIPTPKE                               APATPSSKEASSPPAVTPSTYKGAPSPKELLIPPAVTSPSPKE                               APTPPAVTPPSPEKGPATPAPKGTPTSPPVTPSSLKDSPTSPA                               SVTCKMGATVPQASKGLPAKKGPTALKEVLVAPAPESTPIITA                               PTRKGPQTKKSSATSPPICPDPSAKNGSKG               257   996   79   3   FFLKIQGLGWARWLTPVIPVLWEAE               258   997   307   475   AGFGYGLPISRLYAKYFQGDLNLYSLSGYGTDAIIYLKVSLEF                               NSKILFLKPLLLL               259   998   26   622   WMRAPMLQKQQAPRMDTPPPEERLEKQNEKLNNQEEETEFKEL                               DGLREALANLRGLSEEERSEKAMLRSRIEEQSQLICILKRRSD                               EALERCQILELLNAELEEKMMQEAEKLKAQGEYSRKLEERFMT                               LAANHELMLRFKDEYKSENIKLREENEKLRLENNSLFSQALKD                               EEAKVLQLTVRCEAKTGELETLKERC               260   999   2   241   DPGASHASVQVQVLKEQLFAGRMPSPFRSCALMGMCGSRSADN                               LSCPSPLNVMEPVSFFPLKSLGKGMIQHFRHIVSLV               261   1000   1   620   VTTTTHSVGRGHELQLLNEELRNIELECQNIMQAHRLQKVTDQ                               YGDIWTLHDGGFRNYNTSIDMQRGKLDDIMEHPEKSDKDSSSA                               YNTAESCRSTPLTVDRSPDSSLPRVINLTNKKNLRSTMAATQS                               SSGQSSKESTSTKAKTTEQGCSAESKEKVLEGSKLPDQEKAVS                               EHIPYLSPYHSSSYRYANIPAHARHYQSYMQLIQ               262   1001   3   420   VWGCLATVSTHKKIQGLPFGNCLPVSDGPFNNSTGIPFFYMTA                               KDPVVADLMKNPMASLMLPESEGEFCRKNIVDPEDPRCVQLTL                               TGQMIAVSPEEVEFAKQAMFSRHPGMRKWPRQYEWFFMKMRIE                               HIWLQKWYG               263   1002   43   441   QAANMAVARVDAALPPGEGSVVNWSGQGLQKLGPNLPCEADIH                               TLILDKNQIIKLENLEKCKRLIQLSVANNRLVRMMGVAKLTLL                               RVLNLPHNSIGCVEGLKELVHLEWLNLAGNNLIAMEQINSCTA                               LQHL               264   1003   3   834   FRAAVGAVPEGAWKDTAQLHKSEEAKRVLRYYLFQGQRYIWIE                               TQQAFYQVSLLDHGRSCDDVHRSRHGLSLQDQMERKAIYGPNV                               ISIPVKSYPQLLVDEAFSLALWLADHYYWYALCIFLISSISIC                               LSLYKTRKQSQTLRDMVKLSMRVCVCRPGGEEEWVDSSELVPG                               DCLVLSQEGGLMPCDAALVAGECMVNDSSLTGESIPVLKTALP                               EGLGPYCAETHRRHTLFCGTLILHARAYVGPHVLAVVTRTGMS                               REAGLERDPGSAPLKRWS               265   1004   2   670   FVGGGLHLHLCLLLCFMLPEDAAMAVLTASNHVSNVTVNYNIT                               VERMNRMQGLRVSTVPAVLSPNATLALTAGVLVDSAVEVAFLW                               TFGDGEQALHQFQPPYNESFPVPDPSVAQVLVEHNVTHTYAAP                               GEYVLTVLASNAFENRTQQVLIRSGRVPIVSLECVSCKAQAVY                               EVSRSSYVYLEGRCLNCSSGSKRGRWAARTFSNKTLVLDETTT                               STGSASM               266   1005   2   1093   PEFLGRLFRGKAATLHVHSDQKPLHDGALGSQQNLVRMKEALR                               ASTMDVTVVLPSGLEKRSVLNGSHAMMDLLVELCLQNHLNPSH                               HALEIRSSETQQPLSFKPNTLIGTLNVHTVFLKEKVPEEKVKP                               GPPKVPEKSVRLVVNYLRTQKAVVRVSPEVPLQNILPVICAKC                               EVSPEHVVLLRDNIAGEELELSKSLNELGIKELYAWDNRRETF                               RKSSLGNDETDKEKKKFLGFFKVNKRSNSKGCLTTPNSPSMHS                               RSLTLGPSLSLGSISGVSVKSEMKKRRAPPPPGSGPPVQDKAS                               EKVSLGSQIDLQKKKRRAPAPPPPQPPPPSPLIPNRTEDKEEN                               RKSTMVYCCASFPTQAKRF               267   1006   686   400   VQWHNLHSLQPLPAGFK*FLCFSLPSSWDYRCAPPLP/APFFF                               YFLFLVELGFHHIG*AGLELTSTDLPASAS/ESAGITGMSHRA                               RPMDFFLLKIL               268   1007   1   453   GRRFRPPSDEEREPWEPWTQLRLSGHLKPLHYNLMLTAFMENF                               TFSGEVNVEIACRNATRYVVLHASRVAVEKVQLAEDRAFGAVP                               VAGFFLYPQTQVLVVVLNRTLDAQRNYNLKIIYNALIENELLG                               FFRSSYVKHGERRFLGVTQFSP               269   1008   333   526   KELDPFYNS*RKIKYLRIYLTKEVKDLYKENYKTLLKEITDDT                               N/KKHIPSSWTGRINTVKMTIL               270   1009   699   882   VPHPLQAIHEQMNCKEYQEDLALRAQNDAAARRPSEMFKVRLA                               QGRGLASLSSGIQSGVG               271   1010   16   148   RWNSLTCVVLTFLGHRLLKRFLVPKLRRFLKPQGHPRLLLWFK                               R               272   1011   1   659   YGEFVTYQGVAVTRSRKEGIAHNYKNETEWRANIDTVMAWFTE                               EDLDLVTLYFGEPDSTGHRYGPESPERREMVRQVDRTVGYLRE                               SIARNHLTDRLNLIITSDHGMTTVDKRAGDLVEFHKFPNFTFR                               DIEFELLDYGPNGMLLPKEGRLEKVYDALKDAHPKLHVYKKEA                               FPEAFHYANNPRVTPLLMYSDLGYVIHGVSRLLEAPPPGAPSP                               GSGS               273   1012   146   413   RIPLLRLRSSTYRSKGFDVTVKHSHGSWTGFGGEDLATIPKGL                               NTYFLVNIATIFESKNFFLPGIKWNGILGLSYATLAKPSSSLE                               TFF               274   1013   3   251   IKSYSGPNGRSCQIWQRLRWGSRELLLGWKLSHSFSTCPFQFP                               DIVEFCEAMANAGKTVIVAALDGTFQRKVRRLIQVWSWD               275   1014   326   651   YCFCFDLLH*CIHRDVKPENILITKHSVIKLCDFGFARLLTGP                               SDYYTDYVATRWYRSPELPVGDTQ\GPPV\DVW\AIGCVSAE                               \LLSGKCLWWPGKS/DMLDQLYLIRK               276   1015   224   435   RGWALDWIGADLSLHLQEEVETEVAWEECGHVLLSLCYSSQQG                               GLLVGVLRCAHLAPMDANGYSDPFVRL               277   1016   2   429   GGILAMEYAPGGTLAEFIQKRCNSLLEEETILHFFVQILLALH                               HVHTHLILHRDLKTQNILLDKHRMVVKIGDFGISKILSSKSKA                               YTVVGTPCYISPELCEGKPYNQKSDIWALGCVLYELASLKRAF                               EAANLPALVLKIM               278   1017   1   262   VQCGGIHQVSGAVVVSGLLQGMMGLLGSPGHVFPHCGPLVLAP                               SLVVAGLSAHREVAQFCFTHWGLALLYVSPERRGMVPSGGVWG                               D               279   1018   1   480   PRMTGSTHASAPSYGGSCRNNLFYREETYTPKAETDEMNEVET                               APIPEENHVWLQPRVMRPTKPKKTSAVNYMTQVVRCDTKMKDR                               CIGSTCNRYQCPAGCLNHXAKIFGSLFYESFASICRAAIHYGI                               LDDICGGLVDITRNGKVPFFVKSERHGVQSLR               280   1019   271   792   VPQNIICAFFCVPCRFASTIPFWGLTLHLQHLGNNVFLLQTLF                               GAVTLLANCVAPWALNHMSRRLSQMLLMFLLATCLLAIIFVPQ                               EMQTLRVVLATLGVGAASLGITCSTAQENELIPSIIRGRATGI                               TGNFANIGGALASLVMILSIYSRPLPWIIYGVFAILSGLVVLL                               LP               281   1020   2   679   VLVSRDHMKSAQQFFQLVGGSASECDTIPGRQCMASCFFLLKQ                               FDDVLIYLNSFKSHFYNDDIFNFNYAQAKAATGNTSEGEEAFL                               LIQSEKMKNDYIYLSWLARGYIMNKKPRLAWELYLKMETSGES                               FSLLQLIANDCYKMGQFYYSAKAFDVLERLDPNPEYWEGKRGA                               CVGIFQMIIAGREPKETLREVLHLLRSTGNTQVEYMIRIMKKW                               AKENRVSILK               282   1021   3   359   LKVSDELVQQYQIKNQCLSAIASDAEQEPKIDPYAFVEGDEEF                               LFPDKKDRQNSEREAGKKHKVREITVHQRVTVDFVALHIVTLL                               LPQLSHFFCLRIERVIIYLEKPIFARLRWLMP               283   1022   3   538   GVPRNLPSSLEYLLLSYNRIVKLAPEDLANLTALRVLDVGGNC                               RRCDHAPNPCMECPRHFPQLHPDTFSHLSRLEGLVLKDSSLSW                               LNASWFRGLGNLRVLDLSENFLYKCITKTKAFQGLTQLRKLNL                               SFNYQKRVSFAHLVSGPPFLRGSLGRPLKGAGTWRGNLSFPLH                               FEWGKT               284   1023   3   442   ILFAALIWSSFDENIEASAGGGGGSSIDAVMVDSGAVVBQYKR                               MQSQESSAKRSDEQRKMKEQQAAEELREKQAAEQERLKQLEKE                               RLAAQEQKKQAEEAAKQAELKQKQAEEAAAKAAADAKAKAEAD                               AKAAEEAAKKAAADAKK               285   1024   1   119   AMEIVHEPRDLERYIVIREAVKVSNDSPVLLDRFLNDAIEC               286   1025   67   227   MLSPGYDYGYVCVEPSLLEDAIGCMEANQVALYFGQMMLEGYI                               FLYMGREGFK               287   1026   2   1101   PRVRSSGGQEDPASQQWARPRFTQPSKMRRRVIARPVGSSVRK                               KCVASGHPRPDITWMKDDQALTRPEAAEPRKKKWTLSLKNLRP                               EDSGKYTCRVSNRAGAINATYKVDVIQRTRSKPVLTGTHPVNT                               TVDFGGTTSFQCKVRSDVKPVIQWLKRVEYGAEGRHNSTIDVG                               GQKFVVLPTGDVWSRPDGSYLNKLLITRARQDDAGMYICLGAN                               TMGYSFRSAFLTVLPDPKPPGPPVASSSSATSLPWPVVIGIPA                               GAVFILGTLLLWLCQAQKKPCTPAPAPPLPGHRPPGTARDRSG                               DKDLPSLAALSAGPGVGLCEEHGSPAAPQHLLGPGPVAGPKLY                               PKLYT\DIPHHTHTHTPHPPAN               288   1027   3   96   NFHFTGKCLFMSGLSEVQLTHMDDHTLPGY               289   1028   95   407   SPRKRKTRHSTNPPLECHVGWVMDSRDHGPGTSSVSTSNASPS                               EGAPLAGSYGCTPHSFPKFQHPSHELLKENGFTQQVYHKYRRR                               CLSERKRLGIGQSQEMNT               290   1029   1   359   PGSGGSAGGRDGSAYQGALLPREQFAAPLGRPVGTSYSATYPA                               YVSPDVAQSWTAGPFDGSVLHGLPGRRPTFVSDFLEEFPGEGR                               ECVNCGALSTPLWRRDGTGHYLCNACGLYHKMN               291   1030   2   513   PDHRHGALWWWYSCGVLPVTVSRNEGDERNQVLTLYLWIRQEW                               TDAYLRWDPNAYGGLDAIRIPSSLVWRPDIVLYNKYCLS/AAP                               PLSYPSLDLPLAVGV**SPLPTT*PGCHAAKEAFPQDPSKLPS                               TQPLHGTPTLGYPRPAQAERLLGTYCVVQGRCLNHKGLSRAHP               292   1031   1   595   YALTGALVIVTGMVMGNIADYFNLPVSSMSNTFTFLNAGILIS                               IFLNAWLMEIVPLKTQLRFGFLLMVLAVAGLMFSHSLALFSAA                               MFILGVVSGITMSIGTFLVTQMYEGRQRGSRLLFTDSFFSMAG                               MIFPMIAAFLLARSIEWYWVYACIGLVYVAIFILTFGCEFPAL                               CSHATKLGTASSYPSLDVVQLRTLNA               293   1032   71   479   MAKVGLKTEHYDRYPHMFSGGQRQRIAIARGLMLDPDVVIADE                               PVSALDVSVRAQVLNLMMDLQQELGLSYVFISHDLSVVEHIAD                               EVMVMYLGRCVEKGTKDQIFNNPRHPYTQALLSATPRLNPDDR                               RERIKLSX*               294   1033   2   427   SATLERVLNHPDETQARRLMTLEDIVSGYSNVLISLADSQGKT                               VYHSPGAPDIREFTRDAIPDKDAQGGEVYLLSGPTMMMPGHGH                               GHMEHSNWRMINLPVGPLVDGKPIYTLYIALSIDFHLHYINDL                               MNKLIMTASVII               295   1034   3   342   VLAYPGIKVSTAEARAILPAQYRRQDCIAHGRHLAGFIHACYS                               RQPELAAKLMKDVIAEPYRERLLPGFRQARQAVAEIGAVASGI                               SGSGPTLFALCDKPETAQRVADWLGK               296   1035   2   279   GQQQRVALARALILKPKVLLFDEPLSNLDANLRRSMRDKIREL                               QKQFDITSLYVTHDQSEAFAVSDTVLVMNKGHIMQIGSPQDLR                               VRRLNW               297   1036   3   157   AVHYLERVRIAEHAHKFPGQISGGQQQRVAIARSLCMKPKIML                               FDEPTSAL               298   1037   1   217   APYDAENYFDYDNLNNGPSLQHWFGVDSLGRDIFSRVLVGAQI                               SLAAGVFAVFIGAAIGTLLGLLAGYYEGW               299   1038   3   570   VFCLIADLDPIDELVDFPIVYASALNGIAGLDHEDMAEDMTPL                               YQAIVDHVPAPDVDLDGPFQMQISQLDYNSYVGVIGIGRIKRG                               KVKPNQQVTIIDSEGKTRNAKVGKVLGHLGLERIETDLAEAGD                               IVAITGLGELNISDTVCDTQNVEALPALSVDEPTVSMFFCVNT                               SPFCGKEGKFVTSRQI               300   1039   1   366   QGTRAESQGSSKDKTRLAFAGLKFGDYGSIDYGRNYGVAYDIG                               AWTDVLPEFGGDTWTQTDVFMTQRATGVATYRNNDFFGLVDGL                               NFAAQYQGKNDRSDFDNYTEGNGHGFGFSATYEYEG               301   1040   3   201   DTYSVSIPLGATINMAGAAITITVLTLAAVNTLGIPVDLPTAL                               LLSVVASLCACGASGVAGGSLL               302   1041   1   140   ANAQQGLPSGITLKLNNLVDKGLVDRLYAASSSGVPVNLLVRG                               TCS               303   1042   2   442   ARMTLIPGTHLLENIHNIWVNGVGTNSAPFWRMLLNSFVMAFS                               ITLGKITVSMLSAFAIVWFRFPLRNLFFWMIFITLMLPVEVRI                               FPTVEVIANLQMLDSYAGLTLPLMASATATFLFRKLNMSGPDK                               VVPAARISGYGPRVRKQ               304   1043   2   403   CAKCLRDADECPSGAFERIGRDISLDALEREVMKDDIFFRTSG                               GGVTLSGGEVLMQAEFATRFLQRLRLWGVSCAIETAGDAPASK                               LLPLAKLCDEVLFDLKIMDATQARDVVKMNLPRVLENLRLLVS                               EGVN               305   1044   1   346   YLLLFVCFLVMSLLVGLVYKFTAERAGKQSLDDLMNSSLYLMR                               SELREIPPHDWGKTLKEMDLNLSFDLRVEPLSKYHLDDISMHR                               LRGGEIVALDDQYTFLQRIPRSHYVLAVG               306   1045   1   207   VELFLSDEGDDVVIEVADQGCGVPESLRDKIFEQGVSTRADEP                               GEHGIGLYLIASYVTRCGGVITLEDN               307   1046   3   213   DAIIAPDANALPAAAQAAENLKNDKVAIVGFSTPNVMRPYVER                               GTVKEFGLWDVVQQGKISVYVADALQ               308   1047   1   129   YIVVTGKTHCGTPLTTVTGDATQSGYLTLNLPEMWEVSGYNRV               309   1048   271   46   XEGVEPDINASKTRQQLNDVAGKMKIIEARLSALTNNQTKSLK                               LNPVALPKVASQLLDELGYSLLARRADLQSAHX*               310   1049   16   253   ENIAEEYATKRYRSNVINWGMLPLQMAEVPTFEVGDYIYIPGI                               KAALDNPGTTFKGYVIHEDAPVTEITLYMESQEART               311   1050   2   299   LQTEIGSMVYAVKPGDGSAREQAASCQRVIGGLANIAEEYATK                               RYRSNVINWGMLPLQMAEVPTFEVGDYIYILGFKAAKYSPGTA                               FTVYAISGYGPRI               312   1051   1   344   TLEDLLMALDGEQHLQQQVSEKVLADNVLIAPGSVKPDATFWS                               ALIQDRYNVMTCIEKDACVLVEQDLNSDGQAERILFAFNDDRV                               IVYGFDSDRKEWDALDMSLLPNEITKEK               313   1052   2   630   ENSSRCRKMPGERCRGGPARLSLLLDLPTRPLPHPRQVIDFGS                               ASIFSEVRYVKEPYIQSRFYRAPEILLGLPFCEKVDVWSLGCV                               MDELHLGWPLYPGNNEYDQVRYICETQGLPKPHLLHAACKAHH                               FFKRNPHPDAANPWQLKSSADYLAETKVRPLERRKYMLKSLDQ                               IETVNGGSVASRLTFPDREALAEHADLKSMVEL/MKRLL               314   1053   1   302   RLVKKRVECRQCGKAGRNQSTLKTHMRSHTGEKPYECDHCGKA                               FSIGSNLNVHRRIHTGEKPYECLVCGEAFSDHSSLRSHVKTHR                               GEKLFVSSVWKRKQ               315   1054   1318   730   CGPGFSLSFFFLRWSF\ALVAQAGVQWHDLGSLQPPAPGFKRF                               SSLSLLSRWDYRHAHARLIFVFLVEMGFLHVGQAGLEIPTSGD                               PPTSASQSARITGVTTPLGTFFFFLRWSFALVAQAGGQCLDLG                               SLQLPPPGFKRLVCHFQTPQKHRCSCQAPGDCLQESFVMTGCV                               LRTVSESVQRANAGAGAETVQGL               316   1055   2486   1429   MGNAAAAKKGSEQESVKEFLAKAKEDFLKKWESPAQNTAHLDQ                               FERIKTLGTGSFGRVMLVKHKETGNHYAMKILD*QKVGKLKQI                               EHTLNEKRILQAVNFPFLVKLEFSFKDNSNLYMVMEYVPGGEM                               FSHLRRIGRFSEPHARFYAAQIVLTFEYLHSLDLIYRDLKPEN                               LLIDQQGYIQVTDFGFAKRVKGRTWTLCGTPEYLAPEIILSKG                               YNKAVDWWALGVLIYEMAAGYPPFFADQPIQIYEKIVSGKVRF                               PSHFSSDLKDLLRNLLQVDLTKRFGNLKNGVNDIKNHKWFATT                               DWIAIYQRKVEAPFIPKFKGPGDTS\NFDDYEEEEIRV\SINE                               KFG\KEFSEF               317   1056   867   461   SSSRSSHGDSPPHSQTPCDTNRGLDTKH*/DSQSIEEKDSSQS                               E*NRIERRKEVERILQTNSDYM*HWSN*PENILPKKFFSKHQK                               CTATLSMRNTSIM/KKEGLF*AQFPSLLLSHLPAVGLGIYTGT                               HLTTSTSTF               318   1057   544   784   TFHSSLEKNILQPCR*RRA\ICLPLLL*PSVPLLAPQYFSDLR                               NSIVNSQPPEKQQAMHLCFENLMEGIERNLLTKNRDR               319   1058   1606   228   GTSGVQQEISRLTNENLDLKELVEKLEKNERKLKKQLKIYMKK                               AQDLEAAQALAQSERKRHELNRQVTVQRKEKDFQGMLEYHKED                               EALLIRNLVTDLKPQMLSGTVPCLPAYILYMCIRHA\DYTNDD                               LKVHSLLTSTINGIKKVLKKHNDDFEMTSFWLSNTC\RLLHCL                               KQYSGDEGFMTQNTAKQN\EHCLKNFDLTEYRQV\L\SDLSIQ                               IYQQLIKIAEGVLQPMIVSAMLEN*SIQGLSGVKPTGSQKHSS                               SMADEDNSYRLEAIIRQMNAFHTVMCDQGLDPEIILQVFKQLF                               YMINAVTLNDLLLRKDVCSWSTGMQLRYNISQLEEWLRGRNLH                               QSGAVQTMEPLIQAAQLLQLKKKTQEDAEAICSLCTSLSTQQT                               VKILNLYTPLNEFEERVTVAFIRTIQAQLQERNDPQQLLLDAK                               HMFPVLFPFNPSSLTMDSIHIPACLNLEFLNEV               320   1059   3   250   HEENTILKAAEVQVPPK*VVTPEAKAFI*RCLAYQKEDCIDAQ                               QLACDP\YLLHYIQKLVFVSSPAGAAIASTFGVSNSCSSN               321   1060   1332   500   GTTDEIMTRWARVSTTYNKRPLPATSWEDMKKGSFEGTSQNLP                               KRKQLEANRLSLKNDAPQAKHKKNKKKKEYLNEDVNGFMEYLR                               QNSQMVHNGQIIATDSEEVREEIAVALKKDSRREGRRLKRQAA                               KKNAMVCFHCRKPGHGIADCPAALENQDMGTGICYRCGSTEHE                               ITKCKAKVDPALGEFPFAKCFVCGEMGHLSRSCPDNPKGLYAD                               GGGCKLCGSVEHLKKDCPESQNSERMVTVGRWAKGMSADYEEI                               LDVPKPQKPKTKIPKVVNF               322   1061   384   102   DHVRKSLLKNRAENIVNIFKCNVVSLPNLPAFGQAQWLTPVIP                               ALWEAEVGGS*GQEIETILANAVK/SPFLLKIQKKKISRAWWR                               AP/VSPRYSGG               323   1062   1   777   SDAWADAWARSLSVSPSSYPELHTEVPLSVLILGLLVVFILSV                               CFGAGLFVFVLKRRKGVPSVPRNTNNLDVSSFQLQYGSYNTET                               HDKTDGHVYNYIPPPVVQMCQNPIYMAGREGRPSSLLPKPGKE                               FQLLGNLEEKKEEPATPAYTISATELLEKQATPREPELLYQNI                               AE/PSQGTS/TAQA*STITFVPYLKGQFAPSYESRRQNQDRIN                               KTVLYGTPRKCFVGQSKPNHPLLQAKPQSEPDYLEVLEKQTAI                               SQL               324   1063   1   1496   ALCHIAVGQQMNLHWLHKIGLVVILASTVVAMSAVAQLWEDEW                               EVLLISLQGTAPFLHVGAVAAVTMLSWIVAGQFARAERTSSQV                               TILCTFFTVVFALYLAPLTISSPCIMEKKDLGPKPALIGHRGA                               PMLAPEHTLMSFRKALEQKLYGLQADITISLDGVPFLMHDTTL                               RRTTNVEEEFPELARRPASMLNWTTLQRLNAGQWFLKTDPFWT                               ASSLSPSDHREAQNQSICSLAELLELAKGNATLLLNLRDPPRE                               HPYRSSFINVTLEAVLHSGFPQHQVMWLPSRQRPLVRKVAPGF                               QQTSGSKEAVASLRRGHIQRLNLRYTQVSRQELRDYASWNLSV                               NLYTVNAPWLFSLLWCAGVPSVTSDNSHTLSQVPSPLWIMPPD                               EYCLMWVTADLVSFTLIVGIFVLQKWRLGGIRSYNPEQIMLSA                               AVRRTSRDVSIMKEKLIFSEISDGVEVSDVLSVCSDNSYDTYA                               NSTATPVGPRGGGSHTKTLIERSGR               325   1064   1899   776   NSADYGDGPDSSDADPDSGTEEGVLDFSDPFSTEVKPRILLMG                               LRRSGKSSIQKVVFHKMSPNETLFLESTNKICREDVSNSSFVN                               FQIWDFPGQIDFFDPTFDYEMIFRGTGALIFVIDSQDDYMEAL                               ARLHLTVTRAYKVNTDINFEVFIHKVDGLSDDHKIETQRDIHQ                               RANDDLADAGLEKIHLSFYLTSIYDHSIFEAFSKVVQKLIPQL                               PTLENLLNIFISNSGIEKAFLFDVVSKIYIATDSTPVDMQTYE                               LCCDMIDVVIDISCIYGLKEDGAGTPYDKESTAIIKLNNTTVL                               YLKEVTKFLALVCFVREESFERKGLIDYNFHCFRKAIHEVFEV                               RMKVVKSRKVQNRLQKKKRATPNGTPRVLL               326   1065   1181   346   RTRGRDPGAGFRRTANKRCCRRRFLIGCGWLPLRSDWPLVSKM                               LSKGLKRKREEEEEKEPLAVDSWWLDPGHAAVAQAPPAVASSS                               LFDLSVLKLHHSLQQSEPDLRHLVLVVNTLRRIQASMAPAAAL                               PPVPSPPAAPSVADNLLASSDAALSASMASLLEDLSHIEGLSQ                               APQPLADEGPPGRSIGGAAPSLGALDLLGPATGCLLDDGLEGL                               FEDIDTSMYDNELWAPASEGLKPGPEDGPGKEEAPELDEAELD                               YLMDVLVGTQALERPPGPGR               327   1066   1844   337   LQEVKARRNTLHKEKDHLVNDYEQNMKLLQTKYDADINLLKQE                               HALSASKASSMIEELEQNVCQLKQQLQESELQRKQQLRDQENK                               FQMEKSHLKHIYEKKAHDLQSELDKGKEDTQKKIHKFEEALKW                               KKWRQI*LDPN/LLREKQSKEFLWQLEDIRQRYEQQIVELKLE                               HEQEKTHLLQQHNAEKDSLVRDHEREIENLEKQLRAANMEHEN                               QIQEFKKRDAQVIADMEAQVHKLREELINVNSQRKQQLVELGL                               LREEEKQRATREHEIVVNKLKAESEKMKIELKKTHAAETEMTL                               EKANSKLKQIEKEYTQKLAKSSQIIAELQTTISSLKEENSQQQ                               LAAERRLQDVRQKFEDEKKQLIRDNDQAIKVLQDELENRSNQV                               RCAEKKLQHKELESQEQITYIRQEYETKLKGLMPASLRQELED                               TISSLKSQVNFLQKRASILQEE/RDYISRQKVQPISR*LHERM                               QRMRISRLCCGTSSSRFEDLDIVNCEISGIF               328   1067   1149   238   VINLVYLISSPRPELKPVDKESEVVMKFPDGFEKFSPPILQLD                               EVDFYYDPKHVIFSRLSVSADLESRICVVGENGAGKSTMLKLL                               LGDLAPVRGIRHAHRNLKIGYFSQHHV\EQL\DLNVQCLWELA                               GHASFPG\RPEEEY\RHQLGFGMGISGEL\AMRPLCQPVLGAR                               KKPKWPFAQMDYCPAPTFYIL\DEPTN\HLGHGRAIEALGPCL                               QTISGVGVILVSHE*SALSRLVCREK\LWVC*G\GGVTRVERKD                               FDQYRALLQGTVSAREGFPLGPPRLKDSPRDMGLVSQTPWGHH                               VGYPLPGRG               329   1068   26   674   CSAVEVKMAARTAFGAVCRRLWQGLGNFSVNTSKGNTAKNGGL                               LLSTNMKWVQFSNLHVDVPKDLTKPVVTISDEPDILYKRLSVL                               VKGHDKAVLDSYEYFAVLAAKELGISIKVHEPPRKIERFTLLQ                               SVHIYKKHRVQYEMRTLYRCLELEHLTGSTADVYLEYIQRNLP                               EGVAMEVTKFCFFIFL\TQLEQLPEHIKEPIWETLSEEKEESK                               S               330   1069   2105   1283   DFWDTAGQERFQSMHASYYHKTHACIMVFDVQRKVTHRNLSTW                               YTELREFRPEIPCIVVANKIDGGAIPAPGC*QFTGDLPSYISS                               SIPRAGNLQ*LVLPPTIRYNPWLVACILPTL*RSQLSRPALFP                               RHRSLLTELFLGPVSQSSLPIPLSGMKASSGPPLQTFFPSLDR                               QTNVLPSLY\ADINVTQKSFNFAKKFSLPLYFVSAADGTNVVK                               LFNDAIRLAVSYKQNSQDFMDEIFQELENFSLEQEEEDVPDQE                               QSSSIETPSEEVASPHS               331   1070   1   1109   GATPLGSVGGRTGKMDAATLTYDTLRFAEFEDFPETSEPVWIL                               GRKYSIFTEKDEILSDVASRLWFTYRKNFPAIGGTGPTSDTGW                               GCMLRCGQMIFAQALVCRHLGRDWRWTQRKRQPDSYFSVLNAF                               IDRKDSYYSIHQIAQMGVGEGKSIGQWYGPNTVAQVLKKLAVF                               DTWSSLAVHIAMDNTVVMEEIRRLCRTSVPCAGATAFPADSDR                               HCNGFPAGAEVTNRPSPWRPLVLLIPLRLGLTDINEAYVETLK                               HCFM\MPQSLGVIGGKPNSAH\YFIG*VG\EELIYLDPHTTQP                               AVEPTDGCFIPDESFHCQHPPCRMSIAELDPSIAVVRGGHLST                               QAFGAECCLGMTRKTFGFLRFFFSMLG               332   1071   39   284   ALCVVPFNTFHN\DFLLLDKEGTLDPVMDSFSTHWTTIGPADM                               FFS\FRQHYKNFKSHGTNPSKSVWAHATCQSCAFPNLLGW               333   1072   2   1484   TRLAEFGTRDPCAQAPCEQQCEPGGPQGYSCHCRLGFRPAEDD                               PHRCVDTDECQIAGVCQQMCVNYVGGFECYCSEGHELEADGIS                               CSPAGAMGAQASQDLGDELLDDGEDEEDEDEAWKAFNGGWTEM                               PGILWMEPTQPPDFALAYRPSFPEDREPQIPYPEPTWPPPLSA                               PRVPYHSSVLSVTRPVVVSATHPTLPSAGQPPVIPATHPALSR                               DHQIPVIAANYPDLPSAYQPGILSVSESAQPPAHQPPMISTKY                               PELFPAHQSPMFPDTRVAGTQTTTHLPGIPPNHAPLVTTLGAQ                               LPPQAPDALVLRTQATQLPIIPTAQPSLTTTSRSPVSPAHQIS                               VPAATQPAALPTLLPSQSPTNQTSPISPTHPHSKAPQIPREDG                               PSPKLALWLPSPAPTAAPTALGEAGLAEHSQRDDRWLLVALLV                               PTCVFLVVLLALGIVYCTRCGPHAPNKRITDCYRWVIHAGSKS                               PTEPMPPRGSLTGVQTCRTSV               334   1073   1   1406   LRVRRRPHLPAPPALRARRSDRRSSPAPAAFPPRPPHASPAPG                               PAMAQAVWSRLGRILWLACLLPWAPAGVAAGLYELNLTTDSPA                               TTGAVVTISASLVAKDNGSLALPADAHLYRFHWIHTPLVLTGK                               MEKGLSSTIRVVGHVPGEFPVSVWVTAADCWMCQPVARGFVVL                               PITEFLVGDLVVTQNTSLPWPSSYLTKTVLKVSFLLHDPSNFL                               KTAKFLYSWDFGDGTQMVTEDSVVYYNYSIIGTFTVKLKVVAE                               WEEVEPDATPAVKQKTGDFSASLKLQETLRGIQVLGPTLIQTF                               QKMTVTLNFLGSPPLTVCWRLKPECLPLEEGECHPVSVASTAY                               NLTHTFRDPGDYCFSIPAENIISKTHQYHKIQVWPSRIQPAVF                               AFPCATLITVMLAFIMYMTLPNATQQKDMVENPEPPSGVRCCC                               QMCCGPFLLETPSEYKEIVRENHGLLPPLYKSVKTYTV               335   1074   1   866   VVEFAFQLSSVSVCLTVSFGWQLGTVSSCLSRDWFLKGNLLII                               IVSVLIILPLALMKHLGYLGYTSGLSLTCMLFFLVSVIYKKPQ                               LGCAIGHNETAIESEALVGLPSQGLNSSCEAQMFTVDSQMSYT                               VPIMAFAFVCIWEVLPIYTELCRPSKRRMQAVANVSIGAMFCM                               YGLTATFGYLTFYSSVKAEMLHMYSQKDPLILCVRLAVLLA\V                               TLTVPVVLFPIRRALQQLLFPGKAFSWPRHVAIALILLVLVNV                               LVICVPTIRDIFGVIGSTSAPSLIFILPSCI               336   1075   3   825   GAGSKSSMMQLMHLESFYEK\PPPGLIKEDDTKPEDCIPDVPG                               NEHAREFLAHTPTKGLWMPLEKEVKVKH/CTFHWIAS*FLGDG                               KFIPKATRLKDVWVSN*FTCLFWDLTRFIHDCIFF*NWSLMNK                               NFNIIY*FFISLR*NTLILQKYFPFSLKLGWHCKWYGHRTGYK                               ECPFFIKDNQKLQQFRVAHEDFMYDIIRDNKQHEKNVRIQQLK                               QLLEDSTSGEDRSSSSSSECKEKHKKKKKKEKHKKRKKEKKKK                               KKRKHKSSKSNEGSDSE               337   1076   3   2451   EIAGAAAENMLGSLLCLPGSGSVLLDPCTGSTISETTSEAWSV                               EVLPSDSEAPDLKQEERLQELESCSGLGSTSDDTDVREVSSRP                               STPGLSVVSGISATSEDIPNKIEDLRSECSSDFGGKDSVTSPD                               MDEITHDFLYILQPKQHFQHIEAEADMRIQLSSSAHQLTSPPS                               QSESLLAMFDPLSSHEGASAVVRPKVHYARPSHPPPDPPILEG                               AVGGNEARLPNFGSPMF*LPAEMEAFKQRHS/YTPERLVRSRS                               S\DIVSSVRRPMSDPSWNRRP\GNEERELPPAAAIGATSLVAA                               PHSSSSSPSKDSSRGETEERKDSDDEKSDRNRPWWRKRFVSAM                               PKAPIPFRKKEKQEKDKDDLGPDRFSTLTDDPSPRLSAQAQVA                               EDILDKYRNAIKRTSPSDGAMANYESTEVMGDGESAHDSPRDE                               ALQNISADDLPDSASQAAHPQDSAFSYRDAKKKLRLALCSADS                               VAFPVLT\HSTRNGLPDHTDPEDNEIVCFLKVQIAEAINLQDK                               NLMAQLQETMRCVCRFDNRTCRKLLASIAEDYRKRAPYIAYLT                               RCRQGLQTTQAHLERLLQRVLRDKEVANRYFTTVCVRLLLESK                               EKKEREFIQDFQKLTAADDKTAQVEDFLQFLYGAMAQDVIWQN                               ASEEQLQDAQLAIERSVMNRIFKLAFYPNQDGDILRDQVLHEH                               IQRLSKVVTANHRALQIPEVYLREAPWPSAQSEIRTISAYKTP                               RDKVQCILRMCSTIMNLLSLANEDSVPGADDFVPVLVFVLIKA                               NPPCLLSTVQYISSFYASCLSGEESYWWMQFTAAVEFIKTIDD                               RK               338   1077   536   1305   WPMSLARGHGDTAASTAAPLSEEGEVTSGLQALAVEDTGGPSA                               SAGKAEDEGEGGREETEREGSGGEEAQGEVPSAGGEEPAEEDS                               EDWCVPCSDEEVELPADGQPWMPPPSEIQRLYELLAAHGTLEL                               QAEILPRRPPTPEAQSEEERSDEEPEAKEEEEEKPHMPTEFDF                               DDEPVTPKDSLIDRRRTPGSSARSQKREARLDKVLSDMKRHKK                               LEEQILRTGRDLFSLDSEDPSPASPPLRSSGSSLFPRQRKY               339   1078   2   1771   LGRGTFGQVV*CWKRGTNEIVAIKILKNHPSYARQGQIEVSIL                               ARLSTESADDYNFVRAYECFQHKNHTCLVFEMLEQNLYDFLKQ                               NKFSPLPLKYIRPVLQQVATALMKLKSLGLIHADLKPENIMLV                               DPSRQPYRVKVIDFGSASHVSKAVCSTYLQSRYYRAPEIILGL                               PFCAEIDMWSLGCVIAELFLGWPLYPGASEYDQI/RYISQTQG                               LPAEYLLSAGTKTTRFFNRDTDSPYPLWRLKTPDDHEAETGIK                               SKEARKYIFNCLDDMAQVNMTTDLEGSDMLVEKAVRREFIDLL                               KKMLSIDSVKRFSPVGSLNHPFVTMSLFLDFPHSTHVKSCFQN                               MEICKRRVNMYDTVNQSKTPFITHVAPSTSTNLTMTFNNQLTT                               VHNQPSAASMAAVAQRSMPLQTGTAQICARPDPFQQALIVCPP                               GFQGLQASPSKHAGYSVRMENAVPIVTQAPGAQPLQIQPGLLA                               QQAQPSGTQQILLPPAQQQLTGVATHTSVQHAAVIPETMAGTQ                               QLADWRNTHAHGSHYNPIMQQPALLTGHVTLPAAQPLNVGVAH                               VMRQQPTSTTSSRKSKQHLYCGRARVSKIASR               340   1079   2   2721   EFAICRYPLGMSGGQIPDEDITASSQWSESTAAKYGRLDSEEG                               DGAWCPEIPVEPDDLKEFLQIDLHTLHFITLVGTQGRHAGGHG                               IEFAPMYKINYSRDGTRWISWRNRHGKQVLDGNSNPYDIFLKD                               LEPPIVARFVRFIPVTDHSMNVCMRVELYGCVWLDGLVSYNAP                               AGQQFVLPGGSIIYLNDSVYDGAVGYSMTEGLGQLTDGVSGLD                               DFTQTHEYHVWPGYDYVGWRNESATNGYIEIMFEFDRIRNFTT                               MKVHCNNMFAKGVKIFKEVQCYFRSEASEWEPNAISFPLVLDD                               VNPSARFVTVPLHIRMASAIKCQYHFADTWMMFSEITFQSDAA                               MYNNSEALPTSPMAPTTYDPMLKVDDSNTRILIGCLVAIIFIL                               LAIIVITLWRQFWQKMLEKASRRMLDDEMTVSLSLPSDSSMFN                               NNRSSSPSEQGSNSTYDRIFPLRPDYQEPSRLKRKLPEFAPGE                               EESGCSGVVKPVQPSGPEGVPHYAEADIVNLQGVTGGNTYSVP                               AVTIDLLSGKRCGCGREFPPGKLLTFKEKLGEGQFGEVHLCEV                               EGMEKFKDKDFALDVSANQPVLVAVKMLRADANKNARNDFLKE                               IKIMSRLKDPNIIHLLSVCITDDPLCMITEYMENGDLNQFLSR                               HEPPNSSSSDVRTVSYTNLKFMATQIASGMKYLSSLNFVHRDL                               ATRNCLVGKNYTIKIADFGMSRNLYSGDYYRIQGRAVLPIRWM                               SWESILLGKFTTASDVWAFG\VTLWE\TFTFCQRKGPYS\QLS                               \DETGY*RNTGEFFPRPKGGQTYLPSTSPFVPDSCVIKLMLSC                               WRRDTKNRPSFQEIHLLLLQQGDERCCQCLAMFLRLRSSLQDL                               PLTHAYATPSGHLMKLRDRGLFALPSFPGHPHSLPLTHIYFFF                               FTLKN               341   1080   916   3   CSASPLRPGLLAPDLLYLPGAGQPRRPEAEPGQKPVVPTLYVT                               EAEAHSPALPGLSGPQPKWVEVEETIEVRVKKMGPQGVSPTTE                               VPRSSSGELFTLPGATPGGDPNSNNSNNKLLAQEAWAQGTAMV                               GVREPLVFRVDARGSVDWAASGMGSLEEEGTMEEAGEEEGEDG                               DAFVTEESQDTHSLGDRDPKILTHNGRMLTLADLEDYVPGEGE                               TFHCGGPGPGAPDDPPCEVSVIQREIGEPTVG\SLCCSAWGMH                               WVPEALSASLGLSPMGR\HHRDPRSVALRAPPSSCGRPRLGLW                               AVLPG               342   1081   862   444   QGLAAEFLQVPAVTRAYTAACVLTTAAVQLELLSPFQLYFNPR                               LVFRKFQAPFLPWALMGFSLLLGNSILVDLLGIAVGHIYYFLE                               DVFPNQPGGKRLLQTPGFLGLQSSKAPAGSSLTIWTQQSQGGP                               GTAGELAAPS               343   1082   3658   337   EKNALEPTVYFGMGV*APQVPRFQQRITGYQYYLQLRKDIWEE                               GIPCTLEQPIHLAGLAVQAIFGDFDQYESQDFLQKFALFPVGW                               LQDEKVLEEATQKVALLHQKYRGLTAPDAEMLYMQEVERMDGT                               GEESYPAKDSQGSDISIGACLEGIFVKHKNGRHPVVFRWHDIA                               NMSHNKSFFALELANKEETIQFQTEDMETAKYIWRLCVARHKF                               YRLNQCNLQTQTVTVNPIRRRSSSRMSLPKPQPYVMPPPP\QL                               HYNGHYTEPYASSQDNLFVPNQEG\YYGQFQTSLNRAQIDFNG                               RIR\NASVYSAHSTNSLNNPQPYLQPSPMSSNPSITGSDVMRP                               DYLPSHRHSAVIPPSYRPTPDYETVMKQLNRGLVHAERQSHSL                               RNLNIGSSYAYSRPAALVYSQPEIREHAQLPSPAAAHCPFSLS                               YSFHSPSPYPYPAERRPVVGAVSVPELTNAQLQAQDYPSPNIM                               RTQVYRPPPPYPPPRPANSTPDLSRHLYISSSNPDLITRRVHH                               SVQTFQEDSLPVAHSLQEVSEPLTAARHAQLHKRNSIEVAGLS                               HGLEGLRLKERTLSASAAEV\APRAVSVGSQP\SVFTERTQRE                               GPEEAEGLRYGHKKSLSDATMLIHSSEEEEDEDFEEESGARAP                               PARAREPRPGLAQDPPGCPRVLLAGPLHILEPKAHVPDAEKRM                               MDSSPVRTTAEAQRPWRDGLLMPSMSESDLTTSGRYRARRDSL                               KKRPVSDLLSGKKNIVEGLPPLGGMKKTRVDAKKIGPLKLAAL                               NGLSLSRVPLPDEGKEVATRATNDERCKILEQRLEQGMVFTEY                               ERILKKRLVDGECSTARLPENAERNRFQDVLPYDDVRVELVPT                               KENNTGYINASHIKVSVSGIEWDYIATQGPLQNTCQDFWQMVW                               EQGIAIIAMVTAEEEGGREKSFRYWPRLGSRHNTVTYGRFKIT                               TRFRTDSGCYATTGLKMKHLLTGQERTVWHLQYTDWPEHGCPE                               DLKGFLSYLEEIQSVRRHTNSTSDPQSPNPPLLVHCSAGVGRT                               GVVILSEIMIACLEHNEVLDIPRVLDMLR\QQRMMLVQTLCQY                               TFVYRVLIQVPEKAPRLILSSPQFPYGAQSCEAFTA               344   1083   6   304   RKKQKLAEE*VELSKLADLKDAEAVQKFFLEEI*L\GEEILAK                               GVDHLTNPSAVCGQPQWLLQVLQQTLPLPVIQMLLTKPLPVNQ                               RLVSAG/SLAXDDVE               345   1084   1255   635   SFCLHEFGWLGSSPQSDHPVPALLGLGAFVHHSLLQVHSSPGA                               GPVSFLFLGESCSPVDEPRCVPSCAFGFLSCFPLLNSAALERG                               LFFFVVFFFLESGSCQVARAGVRD/RDRGSLQPPPPGLKQFCL                               SLPSRWDHRHPPPLRVP*FVFVFLVELGFHHVAQAGLKLLTLS                               DPPAPASHSAGITGVSQRDQPVLFLRWASCSELVG               346   1085   116   415   EGFPGRSLSGGLCCRLRRRFPIDGYRPRRRRRWSCCPSGVRPV                               RRMSQKSWIESTLTKRECVYIIPSSKDPHRCLPGCQICQQLVR                               RGFTVLARMVSIS               347   1086   918   760   QNSTCLTAQTHSLLQHQPLQLTTLLDQYIREQREKDSVMSANG                               KPDPDTVPDS               348   1087   1   750   LNPWKNALQDFCLPFLRITSLLQHHLFGEDLPSCQEEEEFSVL                               ASCLGLLPTFYQTEHPFISASCLDWPVPAFDIITHWCFEIKSF                               TERHAEQGKALLIQESKWKLPHLLQLPENYNTIFQYYHRKTCS                               VCTKVPKDPAVCLVCGTFVCLKGLCCKQQSYCECVLHSQNCGA                               GTGIFLLINASVIIIIRGHRFCLWGSVYLDAHGEEDRDLRRGK                               PLYICKERYKVLEQQWISHTFDHINKRWGPHYNGL               349   1088   3   1374   KGQLVNLLPPENFPWCGGSQGPRMLRTCYVLCSQAGPRSRGWQ                               SLSFDGGAFHLKGTGELTRALLVLRLCAWPPLVTHGLLLQAWS                               RRLLGSRLSGAFLRASVYGQFVAGETAEEVKGCVQQLRTLSLR                               PLLAVPTEEEPDSAAKSGEAWYEGNLGAMLRCVDLSRGLLEPP                               SLAEASLMQLKVTALTSTRLCKELASWVRRPGASLELSPERLA                               EAMDSGQNLQVSCLNAEQNQHLRASLSRLHRVAQYARAQHVRL                               LVDAEYTSLNPALSLLVAALAVRWNSPGEGGPWVWNTYQACLK                               DTFERLGRDAEAAHRAGLAFGVKLVRGAYLDICERAVAQL\HG\                               MEDPPTQADYEATS\QSYS\RCLELMLTHVARHGPMCHLMVAS                               HNEESVRQATK\GQAGYVVYKSIPYGSLEEVIPYLIRRAQENR                               SVLQGARREQELLSQKKWRRLLPGCRRIPH               350   1089   1036   306   VVEFGEMSTARAPEGLRWFQLYVHPDLQLNKQLIQRVESLGFK                               ALVITLDTPVCGNRRHDIRNQLRRNLTLTDLQSPKKGNAIPYF                               QMTPISTSLCWNDLSWFQSITRLPIILKGILTKEDAELAVKHN                               VQGIIVSNHGGRQLDEVLASIDALTEVGAAE*GNMKYYLDAGV                               RTGNDVQKALALGAKCIFLGRPILWGLACKGEHGVKEVLNILT                               NEFHTSMA\LTGCRSVAEINRNLVQFSRL               351   1090   1229   957   FFLRWSFTL\LPRLE/CQWLNLGSLQPPPPGFK*SSCLRLLSS                               WGLQVPTSMLG*FFCIFSREGISPCWPGWSQTPKVIHLPRPPR                               VKRKQA               352   1091   1145   365   LLCFVHTALQSFQGELYEPHVVIAIVVFLVKLGICK*RASWRK                               KVTLVVK*S/LKICFTKYGSCYHPGEKSSSWLFN*RMVNDCLA                               TSCSNRSFVIQQIPSSNLFMVVVDSSCLCESVAPITMAPIEIR                               YILLCAGPLTTTETSKGYQW*GNLGEKY*RRKITSFPLLERES                               S*ESCHCQILTSEMQSRKCQSLETCLNYSQHNESLKCERLKAQ                               KIRRRPESCHGFHPEENARECGGAPSLQAQTVLLLLPLLLMLF                               SR               353   1092   1140   790   VPSPTHDPKPAEAPMPA*PAPPGPASPGGAAEPPAAARAGGSP                               TAVRSILTKERRPEGGYKAVWFGEDIGTEADVVVLNAPTLDVD                               GASDSGSGDEGEGAGRGGGPYDAPGGDDSYI               354   1093   3   2293   LISLAGPTDDIQSTGPOVHALNILRALFRDTRIGENIIPYVAD                               GAKAAILGPTSPVWAVRUSSTLLFSALITRIFGVKRAKDEHSK                               TNRMTGREPFSRFPELYPFLLKQLETVANTVDSDMGEPNRHPS                               MFLLLLVLERLYASPMDGTSSALSMGPFVPFIMRCGHSPVYHS                               REMAARALVPFVMIDHIPNTIRTLLSTLPSCTDQCFRQNHIHG                               TLLQVFHLVQAYSDSKHGTNSDFQHELTDITVCTKAKLWLAKR                               QNPCLVTRAVYIDILFLLTCCLNRSAKDNQPVLESLGFWEEVR                               GIISGSELITGFPWAFKVPGLPQYLQSLTRLAIAAVWAAAAKS                               GERETNVPISFSQLLESAFPEVRSLTLEALLEKFLAAASGLGE                               KGVPPLLCNMGEKFLLLAMKENHPECFCKILKILHCMDPGEWL                               PQTEHCVHLTPKEFLIWTMDIASNERSEIQSVALRLASKVISH                               HMQTCVENRELIAAELKQWVQLVILSCEDHLPTESRLAVVEVL                               TSTTPLFLTNPHPILELQDTLAIWKCVLTLLQSEEQAVRDAAT                               ETVTTAMSQENTCQSTEFAFCQVDASIALALALAVLCDLLQQW                               DQLAPGLPILLGWLLGESDDLVACVESMHQVEEDYLFEKAEVN                               FWAETLIFVKYLCKHLFCLLSKSGWRPPSPEMLCHLQRMVSEQ                               C\HLLSQFFRELPPAAEFVKTVEFTRLRIQEERTLACLRKLAF                               LEGKEGEDTLVLSVWDSYAESRQLTLPRTEAAC               355   1094   25   1265   HAFRPIALQRGVSFRGCSNQYAESRRLQGESGSRAFAHLMESL                               LQHLDRFSELLAVSSTTYVSTWDPATVRRALQWARYLRHIHRR                               FGRHGPIRTALERRLHNQWRQBGGFGRGPVPGUlNFQALGHCD                               VLLSLRLLENRALGDAARYHLVQQLPPGPGVRDADEETLQESL                               ARLARRRSAVHMLRFNGYRENPNLQEDSLMKTQAELLLERLQE                               VGKAEAERPARFLSSLWERLPQNNFLKVIAVALLQPPLSRRPQ                               EELEPGIHKSPGEGSQVLVHWLLGNSEVFAAFCRALPAGLLTL                               VTSRHPALSPVYLGLLTDWGQRLHYDLQKGIWVGTESQDVPWE                               ELHNRFQSLCQAPPPLKDKVLTALETCKAQDGDFEEPGLSIWT                               DLLLAIARSGAFRKRQVLGLSAGLSSV               356   1095   3   1027   SHLIQHQRIHT*E*AHECNECGKAFSQTSCLIQHHKMHRKEKS                               YECNEYEGSFSHSSDLILQQEVLTRQKAFDCDVWEKNSSQRAH                               LVQHQSIHTKE/K/PHECNEDGKIF/NQIQA/LIQHLRVHTRE                               K\YVCTACGKAPSnSSAIAQHQIIHTREKPSECDE*RKGISVK                               LLIDSC/RIYTSEKSYKCIECGKFFMKLVFSYLSUIWRIHMGI                               KFHCCNECEKAISQRNYLV*YQIHAMQKDYKCN/EACMCVRRF                               SHNPTLIQHQRIYT*ENLFGCSK/C/GRSFNRSLTSLCHIRIS                               I/RRQEFDVTQMEKLDTTFQA/STQHRNNGEKIVDYLFMKLLI                               HSPNLFHCTKI               357   1096   2638   2867   AVTLTAKICSFTPEPSETMSPPAGTNNSRHAALRAVTLPVKVC                               SFTPEPARSRTHQKEETPNTSEHQKEQTPEAPP               358   1097   4747   4550   MAYSWQTDPNPNESHEKQYEHQEFLFVNQPHSSSQVSLGFDQI                               VDEISGKIPHYESEIDENTFFVPTAPKWDSTGHSLNEAHQISL                               NEFTSKSRELSWHQVSKAPAIGFSPSVLPKPQNTNKECSWGSP                               IGKHHGADDSRFSILAPSFTSLDKINLEKELENENHNYHIGFE                               SSIPPTNSSPSSDFMPKEENKRSGHVNIVEPSLMLLKGSLQPG                               MWESTWQKNIESIGCSIQLVEVPQSSNTSLASFCNKVKKIRER                               YHAADVNFNSGKIWSTTTAFPYQLFSKTKFNIHIFIDNSTOPL                               HFMPCANYLVKDLIAEILHFCTNDQLLPKDHILSVWGSEEFLQ                               NDHCLGSHKMFQKDKSVIQLHLQKSREAPGKLSRKHEEDHSQF                               YLNQLLEFMHIWKVSRQCLLTLIRKYDFHLKYLLKTQENVYNI                               IEEVKKICSVLGCVETKQITDAVNELSLKLQRKGENFYQSSET                               SAKGLIEICVTTELSTSIYQLINVYCNSFYADFQPVVPRCTSY                               LNPGLPSHLSFTVYAAHNIPETWVHRINFPLEIKSLPRESMLT                               VKLFGIACATNNANLLAWTCLPLFPKEKSILGSMLFSMTLQSE                               PPVEMITPGVWDVSQPSPVTLQIDFPATGWEYMKPDSEENRSN                               LEEPLKECIKHIARLSQKQTPLLLSEEKKRYLWFYRFYCNNEN                               CSLPLVLGSAPGWDERTVSENHTILRRWTFSQPLEALGLLTSS                               FPDQEIRXVAVQQLNNLKNDELLEYLPQLVQAVKFEWNLESPL                               VQLLLHRSLQSIQVQHRLYWLLKNARNEAYFKSWYQKLLAALQ                               FCAGKALNDEFSKEQKLIKILGDIGERVKSASDRQRQEVLKKE                               IGRLEEFFQDVNTCELPLNPALCIKGIDHDACSYFTSNALPLK                               ITFINANLMGKNISIIFKAGDDLRQDMLVLQLIQVMDNIWLQE                               GLDMQMIIYRCLSTGKDQDLVQMVPDAVTLAKIHRHSGLIGPL                               KENTIKKWFSQHNHLKADYEKALRNFFYSCAGWCVVTFILGVC                               DRHNDNIMLTKSGHMFHIDFGKFLGHAQTFGGIKRDRAPFIFT                               SEM\EYFITEGG\KNPQHFQDFV\ELCCRAYNIIRKHSQLLL\                               NLL\EMMLYAG\LPELSGI\QDLKYVYNNLRPQDTDLEATSHF                               TKKIKESLECFPVKLNNLIHTLAQMSAISPAKSTSQTFPQESC                               LLSTTRSIERATILGFSKKSSNLYLIQVTHSNNETSLTEKSFE                               QFSKLHSQLQKQFASLTLPEFPHWWHLPFTNSDHRRFRDLNHY                               MEQILNVSHEVTNSDCVKSFFLSEAGQQTVEESSPVYLGEKFP                               DKKPKVQLVISYEDVKLTILVKHMKNIHLPDGSAPSAHVEFYL                               LPYPSEVRRRKTKSVPKCTDPTYNEIVVYDEVTELQGHVLMLI                               VKSKTVFVGAINIRLCSVPLDKEKWYPLGNSII*PLLLFYTSN                               FMQSVLH               359   1098   679   346   FFLRWSLDSVTQAGVQSHDLSSLQPPPPGFKQSSLFGLPSSWE                               *RWVPPCPANFFVFLVETGFRHVGQAGLELLTSNDLPVSACQS                               AGITGVTTVPQRKSMILYEVTICYP               360   1099   2   1601   FVREIRGPAVPRKTSAEDRHRHGPHAHSPELQRTGRDYSLDYL                               PFRLWVGIWVATFCLVLVATEASVLVRYFTRFTEEGFCALISL                               IFIYDAVGKMLNLTHTYPIQKPGSSAYGCLCQYPGPGGNESQW                               IRTRPKDRDDIVSMDLGLINASLLPPPECTRQGGHPRGPGCHT                               VPDIAFFSLLLFLTSFFFANALKCVKTSRFFPSVVRKGLSDPS                               SVLAILLGCGLDAFLGLATPKLMVPREFKPTLPGRGWLVSPFG                               RNPWWWSVAAALPALLLSILIFNDQQITAVILNRMEYRLQKGA                               GFHLDLFRVAVLMLLTSALGLPWYVSATVISLAHMDSLRRESR                               ACAPGERPNFLGIREQRLTGLVVFILTGASIFLAPVLKFIPMP                               VLYGIFLYMGVAALSSIQFTNRVKLLL\MPAKHQPDLLLLRHV                               PLTRVHLFTAISFA\CLGLLW\IIKSTPAAIIFPLMLIRGLVGV                               RKALERVFSPQELLWLDELMPEEERSIPEKGLEPEHSFSGSDS                               EDSELMYQPKAPEINISVN*LE*EFVREIRGPAVPRLTSAEDR                               HRHGPHAHSPELQRTGRDYSLDYLPFRLWVGIWVATPCLVLVA                               TEASVLVRYFTRFTEEGFCALISLIFIYDAVGKMLNLTHTYPI                               QKPGSSAYGCLCQYPGPGGNESQWIRTRPKDRDDIVSMDLGLI                               NASLLPPPECTRQGGHPRGPGCHTVPDIAFFSLLLFLTSFFFA                               MALKCVKTSRFFPSVVRKGLSDFSSVEAILLGCGLDAFLGLAT                               PKKMVPREFKPTLPGRGWLVSPFGANPWWWSVAAALPALLLSI                               LIFMDQQITAVILNRMEYRLQKGAGFHLDLFCVAVLMLLTSAL                               GLPWYVSATVISLAHMDSLRRESRACAPGERPNFLGIREQRLT                               GLVVFILTGASIFLAPVLKFIPMPVKYGIFLYMGVAALSSIQF                               TNRVKLLLDASKTPRRPATLAACASDQGPPLHSHQLCPVWGCF                               GIIKSTPAAIIFPKMLLGLVGVRKALERVFSPQELLWLDELMP                               EEERSIPEKGLEPEHSFSGSDSEDSELMYQPKAPEINISVN               361   1100   1   2636   MGLKARRAAGAAGGGGDGGGGGGGAANPAGGDAAAAGDEERKV                               GLAPGDVEQVTLALGAGADKDGTLLLEGGGRDEGQRRTPQGIG                               LLAKTPLSRPVKRNNAKYRRIQTLIYDALERPRGWALLYH\AL                               VFLIVLG\CLILAVL\TTFKEYETVSGDWLLLLETFAIFIFGA                               EFALRIWAAGCCCRYKGWRGRLKFARKPLCMLDIFVLIASVPV                               VAVGNQGNVLATSLRSLRFLQILRMLRDGPGEGGTWKLLG\SA                               ICAHSKELITAWYIGFLTLILSSFLVYLVEKDVPEVDAQGEEM                               KEEFETYADALWWGLITLATIGYGDKTPKTWEGRLIAATFSLI                               GVSFFALPAGILGSGLALKVQEQHRQKHFEKRRKPAAELIQAA                               WRYYATNPNRIDLVATWRFYESVVSFPFFRKEQLEAASSQKLG                               LLDRVRLSNPRGSNTKGKLFTPLNVDAIEESPSKEPKPVGLNN                               KERFRTAFRMKAYAFWQSSEDAGTGDPMAEDRGYGNDFPIEDM                               IPTLKAAIRAVRILQFRLYKKKFKETLRPYDVKDVIEQYSAGH                               LDMLSRIKYLQTRIDMIFTPGPPSTPKHKKSQKGSAFTFPSQQ                               SPRNEPYV\ARPST\SEI\EDQRH*WGKFVKSLKGQV\QGLGR                               KLDFLVDMHMQHMERLQVQVTEYYPTKGTSSPAEAEKKEDNRY                               SDLKTIICNYSETGPPEPPYSFHQVTIDKVSPYGFFAHDPVNL                               PRGGPSSGKVQATPPSSATTYVERPTVLPILTLLDSRVSCHSQ                               ADLQGPYSDRISPRQRRSITRDSDTPLSLMSVNHEELERSPSG                               FSISQDRDDYVFGPNGGSSWMREKRYLAEGETDTDTDPFTPSG                               SMP\LSSTGDGISDSVWTPSNKPI               362   1101   1   5433   RTRGIIEFDPKYTAFEVEEDVGLIMIPVVRLHGTYGYVTADFISQSSSASPGG                               VDYILHGSTVTFQHGQNLSFINISIIDDNESEFEEPIEILLTGATGGAVLGRH                               LVSRIIIAKSDSPFGVIRFLNQSKISIANPNSTMILSLVLERTGGLLGETQVN                               WETVGPNSQEALLPQNRDIADPVSGLFYFGEGEGGVRTIILTIYPHEEIEVEE                               TFIIKLHLVKGEAKLDSRAKDVTLTIQEFGDPNGVVQFAPETLSKKTYSEPLA                               LEGPLLITFFVRRVKGTFGEIMVYWELSSEFDITEDFLSTSGFFTIADGESEA                               SFDVHLLPDEVPEIEEDYVIQLVSVEGGAELDLEKSITWFSVYANDDPHGVFA                               LYSDRQSILIGQNLIRSIQINITRLAGTFGDVAVGLRISSDHKEQPIVTENAE                               RQLVVKDGATYKVDVVPIKNQVFLSLGSNFTLQLVTVMLVGGRFYGMPTILQE                               AKSAVLPVSEKAANSQVGFESTAFQLMNITAGTSHVMISRRGTYGALSVAWTT                               GYAPGLEIPEFIVVGNMTPTLGSLSFSHGEQRKGVFLWTFPSPGWPEAFVLHL                               SGVQSSAPGGAQLRSGFIVAEIEPMGVFQFSTSSRNIIVSEDTQMIRLHVQRL                               FGFHSDLIKVSYQTTAGSAKPLEDFEPVQNGELFFQKFQTEVDFEITIINDQL                               SEIEEFFYINLTSVEIRGLQKPDVNWSPRLNLDFSVAVITILDNDDLAGMDIS                               FPETTVAVAVDTTLIPVETESTTYLSTSKTTTILQPTNVVAIVTEATGVSAIP                               EKLVTLHGTPAVSEKPDVATVTANVSIHGTFSLGPSIVYIEEEMKNGTFNTAE                               VLTRRTGGFTGNVSITVKTFGERCAQMEPNALPFRGIYGISNLTWAVEEEDFE                               EQTLTLIFLDGERERKVSVQILDDDEPEGQEFFYVFLTNPQGGAQIVEGKDDT                               GFAAFAMVIITGSDLHNGIIGFSEESQSGLELREGAVMRRLHLIVTRQPNRAF                               EDVKVFWRVTLNKTVVVLQKDGVNLMEELQSVSGTTTCTMGQTKCFISIELKP                               EKVPQVEVYFFVELYEATAGAAINNSARFAQIKILESDESQSLVYFSVGSRLA                               VAHKKATLISLQVARDSGTGLMMSVNFSTQELRSAETIGRTIISPAISGKDFV                               ITEGTLVFEPGQRSTVLDVILTPETGSLNSFPKRFQIVLFDPKGGARIDKVYG                               TANITLVSDADSQAIWGLADQLHQPVNDDILNRVLHTISMKVATENTDEQLSA                               MMHLIEKITTEGKIQAFSVASRTLFYEILCSLINPKRKDTRGFSHFAELTENF                               AFSLLTNVTCGSPGEKSKTILDSCPYLSILALHWYPQQINGHKFEGKEGDYIR                               IPERLLDVQDAEIMAGKSTCKLVQFTEYSSQQWFISGNNLPTLKNKVLSLSVK                               GQSSQLLTNDNEVLYRIYAAEPRIIPQTSLCLLWNQAAASWLSDSQFCKVIEE                               TADYVECACLHMSVYAVYARTDNLSSYNEAFFTSGFICISGLCLAVLSHIFCA                               RYSMFAAKLLTHMMAASLGTQILFLASAYASPQLAEESCSAMAAVTHYLYLCQ                               FSWMLIQSVNFWYVLVMNDEHTERRYLLFFLLSWGLPAFVVILLIVILKGIYH                               QSMSQIYGLIHGDLCFIPNVYAALFTAALVPLTCLVVVFVVFIHAYQVKPQWK                               AYADDVFGRTNAAEIPLILYLFALISVTWLWGGLHMAYRHFWMLVLFVIFNSL                               QLL\YPLFYFLLL*PQSSSASPGGVDYILHGSTVTFQHGQNLSFINISIIDDN                               ESEFEEPIEILLTGATGGAVLGRHLVSRIIIAKSDSPFGVIRFLNQSKISIAN                               PNSTMILSLVLERTGGLLGEIQVNWETVGPNSQEALLPQNRDIADPVSGLFYF                               GEGEGGVRTIILTIYPHEEIEVEETFIIKLHLVKGEAKLDSRAKDVTLTIQEF                               GDPNGVVQFAPETLSKKTYSEPLALEGPLLITFFVRRVKGTFGEIMVYWELSS                               EFDITEDFLSTSGFFTIADGESEASFDVHLLPDEVPEIEEDYVIQLVSVEGGA                               ELDLEKSITWFSVYANDDPHGVFALYSDRQSILIGQNLIRSIQINITRLAGTF                               GDVAVGLRISSDHKEQPIVTENAERQLVVKDGATYKVDVVPIKNQVFLSIGSN                               FTLQLVTVMLVGGRFYGMPTILQEAKSAVLPVSEKAANSQVGFESTAFQLMNI                               TAGTSHVMISRRGTYGALSVAWTTGYAPGLEIPEFIVVGNMTPTLGSLSFSHG                               EQRKGVFLWTFPSPGWPEAFVLHLSGVQSSAPGGAQLRSGFIVAEIEPMGVPQ                               FSTSSRNIIVSEDTQMIRLHVQRLEGFHSDLIKVSYQTTAGSAKPLEDFEPVQ                               NGELFFQKFQTEVDFEITIINDQLSEIEEFFYINLTSVEIRGLQKFDVNWSPR                               LNLDFSVAVITILDNDDLAGMDISFPETTVAVAVDTTLIPVETESTTYLSTSK                               TTTILQPTNVVAIVTEATGVSAIPEKLVTLHGTPAVSEKPDVATVTANVSIHG                               TFSLGPSIVYIEEEMKNGTFNTAEVLIRRTGGFTGNVSITVKTFGERCAQMEP                               NALPFRGIYGISNLTWAVEEEDFEEQTLTLIFLDGERERKVSVQILDDDEPEG                               QEFFYVFLTNPQGGAQIVEGKDDTGFAAFAMVIITGSDLHNGIIGFSEESQSG                               LELREGAVMRRLHLIVTRQPNRAFEDVKVFWRVTLNKTVVVLQKDGVNLMEEL                               QSVSGTTTCTMGQTKCFISIELKPEKVPQVEVYFFVELYEATAGAAINNSARF                               AQIKILESDESQSLVYFSVGSRLAVAHKKATLISLQVARDSGTGLMMSVNFST                               QELRSAETIGRTIISPAISGKDFVITEGTLVFEPGQRSTVLDVILTPETGSLN                               SFPKRFQIVLFDPKGGARIDKVYGTANITLVSDADSQAIWGLADQLHQPVNDD                               ILNRVLHTISMKVATENTDEQLSAMMHLIEKITTEGKIQAFSVASRTLFYEIL                               CSLINPKRKDTRGFSHFAELTENFAFSLLTNVTCGSPGEKSKTILDSCPYLST                               LALHWYPQQINGHKFEGKEGDYIRIPERLLDVQDAEIMAGKSTCKLVQFTEYS                               SQQWFISGNNLPTLKNKVLSLSVKGQSSQLLTNDNEVLYRIYAAEPRIIPQTS                               LCLLWNQAAASWLSDSQFCKVIEETADYVECACLHMSVYAVYARTDNLSSYNE                               AFFTSGFICISGLCLAVLSHIFCARYSMFAAKLTHMMAASLGTQILFLAASAY                               ASPQLAEESCSAMAAVTHYLYLCQFSWMLIQSVNFWYVLVMNDEHTERRYLLP                               FLLSWGLPAFVVILLIVILKGIYHQSMSQIYGLIHGDLCFIPNVYAALFTAAL                               VPLTCLVVVFVVFIHAYQVKPQWKAYDDVFRGRTNAAEIPLILYLFALISVTW                               LWGGLHMAYRHFWMLVLFVIFNSLQLLVPSVLLFTSMRSTFFSFHTGTLTSRE                               KKSTFVLTCLLSPDSKGLGVLCVLNTEWAFQVH               363   1102   2   2855   AAGATMERDGCAGGGSRGGEGGRAPREGPAGNGRDRGRSHAAE                               APGDPQAAASLLAPMDVGEEPLEKAARARTAKDPNTYKVLSLV                               LSVCVLTTILGCIFGLKPSCAKEVKSCKGRCFERTFG\NCRCD                               AACVELG\NCCLGLPGGTCI\EP\EHIW\TCNKFRCG\EKRLT                               RSLCACSDDCKD\RGDCLPSNLQFLCVQGE\KSWGRKNPCESH                               LMEP\QCP\AGFETPSLPLLIF/SLDGFRAEYLHTWGGLLPVI                               SKLKKCGTYTKNMRPVYPTKTFPNHYSIVTGLYPESHGIINNK                               MYDPKMNASFSLKSKEKFNPEWYKGEPIWVTAKYQGLKSGTFF                               WPGSDVEINGIFPDIYKMYNGSVPFEERILAVLQWLQLPKDER                               PHFYTLYLEEPDSSGHSYGPVSSEVIKALQRVDGMVGMLMDGL                               KELNLHRCLNLILISDHGMEQGSCKKYIYLNKYLGDVKNIKVI                               YGPAARLRPSDVPDKYYSFNYEGIARNLSCREPNQHFKPYLKH                               FLPKRLHFAKSDRIEPLTFYLDPQWQLALNPSERKYCGSGFHG                               SDNVFSNMQALFVGYGPGFKHGIEADTFENIEVYNLMCDLLNL                               TPAPNNGTHGSLNHLLKNPVYTPKHPKEVHPLVQCPFTRNPRD                               NLGCSCNPSILPIEDFQTQFNLTVAEEKIIKHETLPYGRPRVL                               QKENTICLLSQHQFMSGYSQDILMPLWTSYTVDRNDSFSTEDF                               SNCLYQDFRIPLSPVHKCSFYKNNTKVSYGFLSPPQLNKNSSG                               IYSEALLTTNIVPMYQSFQVIWRYFHDTLLRKYAEERNGVNVV                               SGPVFDFDYDG\RCDSL\ENLRQKRRVHPVTQENFWIPNSTSF                               Y/VVLTSC\KDTSQTPLHC\ENL\DTLGFPFCLHRDWINSETC                               \VHG\KHDSSW\VEEFVKCLHRA\RITGC*GTSLGLSFYQQRK                               EPVSDILKLKTHLPTFSQED               364   1103   657   1   TVPPPPGGPSPAPLHPKRSPTSTGEAELKEERLPGRKASCSTA                               GSGSRGLPPL\SPMVSSAHNPNKAEIPERRKDSTSTPNNLPPS                               MMTRRNTYVCTERPGAERPSLLPNGKENSSGTPRVPPASPSSH                               SLAPPSGERSRLARGSTIRSTFHGGQVRDRRAGGWGWFFNKHA                               LQRAPRNAGAPSLMPGHRTVLINYGGGQDLKNWETCLAAPPNK                               HRR               365   1104   1   1313   HTLHHSSPTSEAEEFVSRLSTQNYFRSLPRGTSNMTYGTFNFL                               GGRLMIPNTGISLLIPPDAIPRGKIYEIYLTLHKPEDVRLPLA                               GCQTLLSPIVSCGPPG\VLLTRPVILG\MDHCG\EPSPDSW\S                               LRLKKQSCEGSWEDVLHLGEEAPSHLYYCQLEASACYVFTEQL                               SRYALVGEALSVAAAKRLKLLLFAPVACTSLEYNILVYCLHDT                               HDALNVVVQLEKQLQGQLIQEPLVLHFKDSYHNLRLSIHDVPS                               SLWKSKLLVSYQEIPFYEIWNGTQRYLHCTFTLERVSPSTSDL                               ACKLWVWQVEGDGQSFSINFNITKDTRFAELLALESEAGVPAL                               VGPSAFKIPFLIRQKIISSLDPPCRRGADWRTLAQKLHLDSHL                               SFFASKPSPTAMILNLWEARHFPNGNLSQLAAAVAGTGPAGRW                               LLSQCSEAEC               366   1105   1   343   GSAAGQVQQQQQRRHQQGKVTVKYDRKELRKRLVLEEWIVEQL                               GQLYGCEEEEMPEVEIDIDDLFDAYSDEQRASKLQEALVDCYK                               PTEEFIKELLSRIRGMRKLSP\PQKKSV               367   1106   2   1398   IMLDGRVRWLTPVISALWEAEMEDVIARMQDEKNGIPIRTVKS                               FLSKIPSVFSGSDIVQWLIKNLTIEDPVEALHLGTLMAAHGYF                               FPISDHVLTLKDDGTFYRFQTPYFWPSNCWEPENTDYAVYLCK                               RTMQNKARLELADYEAESLARLQRAFARKWEFIFMQAEAQAKV                               DKKRDKIERKILDSQERAFWDVHRPVPGCVNTTEVDIKKSSRM                               RNPHKTRKSVYGLQNDIRSHSPTHTPTPETKPPTEDELQQQIK                               YWQIQLDRHRLKMSKVADSLLSYTEQYLEYDPFLLPPDPSNPW                               LSDDTTFWELEASKEPSQQRVKRWGFGMDEALKDPVGREQFLK                               FLESEFSSENLRFWLAVEDLKKRPIKEVPSRVQEIWQEFLAPG                               APSAINLDSKSYDKTTQNVKEPGRYTFEDAQEHIYKLMKSDSY                               PRFIRSSAYQELLQAKK\KGKSLTSKRLTSIAQSY                368   1107   1   461   GTRDYPRIVNHLDHTYVTAPQAFMMFQYFVKVVPTVYMKVDGE                               VLTTNQIYVTRHEKAAYVLMGDQGLPGVFILYELSPMMVNLTE                               IHTFFSLFLTIVGA\TIGGMFFEHFVINYLTHKWGLGFYFKNE                               NSLQGGHRTLYGVNFFMYWSLRGGS                369   1108   2   1522   SVWWNSQRQFVVRAWGCAGPCGRAVFLAFGLGLGLIEEKQAES                               RRAVSACQEIQAIFTQKSKKPGPDPLDTRRLQGFRLEEYIGQS                               IGKGCSAAVYEATMPTLPQNLEVTKSTGLLPGRGPGTSAPGEG                               QERAPGAPAPPLAIKMMWNISAGSSSEAILNTMSQELVPASRV                               ALAGEYGAVTYRKSKRGPKQLAPHPNIIRVLRAFTSSVPLLPG                               ALVDYPDVLPSRLHPEGLGHGRTLFLVMKNYPCTLRQYLCVNT                               PSPRLAAMMLLQLLEGVDHLVQQGIAHRDLKSDNILVELDPDG                               CPWKVIADFGCCLADESIGLQLPFSSWYVDRGGNGCLMAPEVS                               TARPGPRAVIDYSKADAWAVGAIAYEIFGLVNPFYGQGKAHLE                               SRSYQEAQLPALPESVPPDVRQLVRALLQREASKRPSARVAAN                               VLHLSLWGEHILALKNLKLDKMVGWLLQQSAATLLANRLTEKC                               CVETKMKMLFLANLECETLCQAALKLCSWRR               370   1109   105   1252   RPLLRLAELPDHCYRMNSSPAGTPSPQPSRANGNINLGPSANP                               NAQPTDFDFLKVIGKGNYGKVLLAKRKSDGAFYAVKVLQKKSI                               LKKKEQSHIMAERSVLLKNVRHPFLVGLRYSFQTPEKLYFVLD                               YVNGGELFFHLQRERRFLEPRARFYAAEVASAIGYLHSLNIIY                               RDLKPENILLDCQGHVVLTDFGLCKEGVEPEDTTSTFCGTPEY                               LAPEVL\RKEPYDRAVDNWCLGAVLYEMLHGLPPFYSQDVSQM                               YENILHQPLQIPGGRTVAACDLLQSLLHKDQRQRLGSKADFLE                               IKNHVFFSPINWDDLYHKRLTPPFNPNVTGPADLKHFDPEFTQ                               EAVSKSIGCTPDTVASSSGASSAFLGFSYAPEDDDILDC               371   1110   3   1608   RPQTLKGHQEKIRQRQSILPPPQGPAPIPFQHRGGDSPEAKNR                               VGPQVPLSEPGFRRRESQEEPRAVLAQKIEKETQILNCALDDI                               EWFARLQKAAEAFKQLNQRRKGKKKGKKARPAEGVKTKRARPP                               \SEGEFIDCFQKIKLAINLLAKLQKHIQNPSAAELVHFLFGPL                               DLIVNTCSGPDIARSVSCPLLSRDAVDFLRGHLVPKEMSLWES                               LGESWMRPRSEWPREPQVPLRVPKFHSGWEPPVDVLQEAPWEV                               EGLASAPIEEVSPVSRQSIRNSQKHSPTSEPTPPGDALPPVSS                               PHTHRGYQPTPAMAKYVKILYDFTARNANELSVLKDEVLEVLE                               DGRQWWKLRSRSGQAGYVPCNILGEAPPEDAGAPFEQAGQKYW                               GPASPTHKKPPSFPGNKDELMQHMDEVNDELIRKISNIRAQPQ                               PHFRVERSQPVSQPLTYESGPDEVRAWLEAKAFSPRIVENLGI                               LTGPQLFSLNKEELKKVCGEEGVRVYSQLTMQKAFLEKQQSGS                               ELEELMNKFHSMNQRRGEDS               372   1111   3   1046   AWHEGLVSSPAIGAYLSASYGDSLVVLVATVVALLDICFILVA                               VPESLPEKMRPVSWGAQISWKQADPFASLKKVGKDSTVLL\IC                               ITVCLSYLPEAG\QYSSFF\LYLR\QVIGFG\SVKIAAPIAMV                               GILSIVAQTAFLSILMRSLGNKNTVLLGLGFQMLQLAWYGFGS                               QAWMMWAAGTVAAMSSITFPAISAKVSPNAESDQQGVAQGIIT                               GIRGLCNGLGPALYGFIFYMFHVELTELGPKIMSNNVPLQGAV                               IPGPPFLFGACIVLMSFLAALFIPEYSKASGVQKHSNSSSGSL                               TNTPERGSDEDIEPLKQDSSIWELSSFEEPGNQCTEL*TRQKV                               GFCIRHL               373   1112   1   1950   MAAGIATWLPFARAAAVGWLPLAQQPLPPAPGVKASRGDEVLV                               VNVSGRRFETWKNTLDRYPDTILGSSEKEFFYDADSGEYFFDR                               DPDMFRINLNFYRTGRIMCPRQECIQAFDEELAPYGLVPELVG                               DCCLEEYRDRKKENAERLAEDEEABQAGDGPALPAGSSLRQRL                               WRAFENPHTSTAALVFYYVTGFFIAVSVIASVVETIPCRGSAR                               RSSREQPCGERFPQAFFCNDTACVLIFTGEYLKRLFAAPSRCR                               FLRSVMSLIDVVAILPYYIGLLVPKNDDVSGAFVTLRVFRVFR                               IFKFSRHSQGLRILGYTLKSCASELGFLLFSLTMAIIIFATVM                               FYAEKGTNKTNFTSIPAAPWYTIVTMTTLGYGDMVPSTIAGKI                               FGSICSLSGVLVIALPVPVIVSNFSRIYHQNQRADKRRAQQKV                               RLARIRLAKSGTTNAFLQYKQNGGLEDSGSGEEQAVCVRNRSA                               FEQQHHHLLHCLEKTTCHEFTDELTFSEALGAVSPGGRTSRST                               SVSSQPVGPGSLLSSCCPRRAKRRAIRLANSTASVSRG\SMQE                               LDMLAGL\RRSHAP\QSRSSL\NAKPHDSLDLNCDSG\DFVAA                               IISIPTPPRNTPDESQPSSPGGGGRAGSTLRNSSLGTPCLFPE                               TVKISSL               374   1113   4   664   GWGKPFKDWTTGGQDTGGEPALLVGAGEGRAPRLNCPSGQIRS                               PGPGDLSIYDNWIRYFNRSSPVYGLVP/RSKTSARIYPTYHTA                               FDTFDYVDKFLDPGEEGDKGHPETRTGEAED*ALALSPCRR\F                               SSHQAVARTAGSVILRLSDSFFLPLKVSDYSETKRSFLQAAQQ                               DLGALKEQHSISLGPLVTAVEKFEAEAAALGQRISTLQKGSPD                               PLQVRML               375   1114   1   1147   GIRGGGSLASGGPGPGHASLSQRLRLYLADSWNQCDLVALTCF                               LLGVGCRLTPGLYHLGRTVLCIDFMVFTVRLLHIFTVNKQLGP                               KIVIVSKMMKDVFFFLFFLGVWLVAYGVATEGLLRPRDSDFPS                               ILRRVFYRPYLQIFGQIPQEDMDVALMEHSNCSSEPGFWAHPP                               GAQAGTCVSQYANWLVVLLLVIFLLVANILLVNLLIAMFSYTF                               GKVQGNSDLYWAQRYRLIREFHSRPALAPPFIVISRLRIRLLR                               QLCRRPRSPQPSSPALEHFRVYLSKEAERKLLTWESVHKENFL                               LARARDKRESDSERLKRTSQKVDLALKQLGHIREYEQRLKVLE                               REVQQCSRVLGWVAEALSRSALLPPGGPPPPDLPGSR                376   1115   3   329   LIKLCKSKAKSCENDLEMGMLNSKFKKTRYQAGMRNSENLTAN                               NTLSKPTRY/QGELKEIKQDISSLRYELLEEKSQATGELADLI                               QQLSEKFGKNLNKDHLRVNKGKDI               377   1116   1   2043   LPLLHAGFNRRFMENSSIIACYNELIQIEHGEVRSQFKLRACN                               SVFTALDHCHEAIEITSDDHVIQYVNPAFERMMGYHKGELLGK                               ELADLPKSDKNRADLLDTINTCIKKGKEWQGVYYARRKSGDSI                               QQHVKITPVIGQGGKIRHFVSLKKLCCTTDNNKQIHKIHRDSG                               DNSQTEPHSFRYKNRRKESIDVKSISSRGSDAPSLQNRRYPSM                               ARIHSMTIEAPITKVINIINAAQENSPVTVAEALDRVLEILRT                               TELYSPQLGTKDEDPHTSDLVGGLMTDGLRRLSGNEYVFTKNV                               HQSHSHLAMPITINDVPPCISQLLDNEESWDFNIFELEAITHK                               RPLVYLGLKVFSRFGVCEFLNCSETTLRAWFQVIEANYHSSNA                               YHNSTHAADVLHATAFFLGKERVKGSLDQLDEVAALIAATVHD                               VDHPGRTNSFL\CNAGSELAVLYNDT\AV\LESHHTALAFQ\L                               TVKDTK\CNIFKNID/RGNHYRTLRQAIIDMVLATEMTKHFEH                               VNKFVNSINKPMAAEIEGSDCECNPAGKNFPENQILIKRMMIK                               CADVANPCRPLDLCIEWAGRISEEYFAQTDEEKRQGLPVVMPV                               FDRNTCSIPKSQISFIDYFITDMFDAWDAFAHLPALMQHLADN                               YKHWKTLDDLKCKSLRLPSDRLKPSHRGGLLTDKGHCESQ               378   1117   1   3585   AFLSKVEEDDYPSEELLEDENAINAXRSKEKNPGNQGRQFDVN                               LQVPDRAVLGTIHPDPEIEESKQETSMILDSEKTSETAAKGVN                               TGGREPNTMVEKERPLADKKAQRPFERSDFSDSIKIQTPELGE                               VFQNKDSDYLKNDNPEEHLKTSGLAGEPEGELSKEDHENTEKY                               MGTESQGSAAAEPEDDSFHWTPHTSVEPGHSDKREDLLIISSF                               FKEQQSLQRFQKYFNVHELEALLQEMSSKIKSAQQESLPYNME                               KVLDKVFRASESQILSIAEKMLDTRVAENRDLGMNENNIFEEA                               AVLDDIQDLIYFVRYKHSTAEETATLVMAPPLEEGLGGAMEEM                               QPLHEDNFSREKTAELNVQVPEEPTHLDQRVIGDTHASEVSQK                               PNTEKDLDPGPVTTEDTPMDAIDANKQPETAAEEPASVTPLEN                               AILLIYSFMFYLTKSLVATLPDDVQPGPDFYGLPWKPVFITAF                               LGIASFAIFLWRTVLVVKDRVYQVTEQQISEKKKTIMKENTEL                               VQKLSNYEQKIKESKKHVQETRKQNMILSDEAIKYKDKIKTLE                               KNQEILDDTAKNLRVMLESEREQNVKNQDLISENKKSIEKLKD                               VISMNASEFSEVQIMJNEAXLSEEKVKSECHRVQEENARLKKK                               KEQLQQEIEDWSKHAELSEQIKSFEKSQKDLEVAIRTHKDDNI                               NALTNCITQLNLLECESESEGQNKGGNDSDELANGEVGGDRNE                               KMKNQIKQMMDVSRTQTAISVVEEDLKLLQLKL\RASVSTKC\                               NLEDQVKKLEDDRNSLQAAKAGLEDECKTLRQKVEILNELYQQ                               KEMALQKKLSQEEYERQEREHRLSAADEKAVSAAEEVKTYKRR                               IEEMEDELQKTERSFKNQIATHEKKAHENWLKARAAERAIAEE                               KREAANLRHKLLDLTQKMAMLQEEPVIVKPMPGKPNTQNPPRP                               GPLSQNGSFGPSPVSGGECSPPLTVEPPVRPLSATLNRRDMPR                               SEFGSLDGPLPHPRWSAEASGKPSPSDPGSGTATMMNSSSRGS                               SPTRVLDEGKVNMAPKGPPPFPGVPLMSTPMGGPVPPPIRYGP                               PPQLCGPFGPRPLPPPFGPGMRPPLGLREFAPGVPPGRRDLPL                               HPRGFLPGHAPFRPLGSLGPREYFIPGTRLPPPTHGPQEYPPP                               PAVRDLLPSGSRDEPPPASQSTSQDCSQAIRKQSP               379   1118   3   2946   MAADSEPESEVFEITDFTTASEWERFISKVEEVLNDWKLIGNS                               LGKPLEKGIFTSGTWEEKSDEISFADFKFSVTHHYLVQESTDK                               EGKDELLEDVVPQSMQDLLGMNNDFPPRAHCLVRWYGLREFVV                               IAPAAHSDAVLSESKCNLLLSSVSIALGNTGCQVPLFVQIHHK                               WRRMYVGECQRPGVRTDFENVHLRKVPNQYTHLSGLLDIFKSK                               IGCPLTPLPPVSIAIRPTYVLQDWQQYFWPQQPPDIDALVGGE                               VGGLEFGKLPFGACEDPISELHLATTW\PHLTEGIIVDNDVYS                               DLDPIQAPHWSVRVRKAENPQCLLGDFVTEFFKICRRKESTDE                               ILGRSAFEEEGKETADITHALSKLTEPASVPIHKLSVSNMVHT                               AKKKIRKHRRVRESPLNNDVLNTILLFLFPDAVSEKPLDGTTS                               TDNNNPPSESEDYNLYNQFKSAPSDSLTYKLALCLCMINFYHG                               GLKGVAHLWQEFVLEMRFRWENNFLIPGLASGPPDLRCCLLHQ                               KLQMLNCCIERKKARDEGKKTSASDVTNIYPGDAGKAGDQLVP                               DNLKETDKEKGEVGKSWDSWSDSEEEFFECLSDTEEIKGNGQE                               SGKKGGPKEMANLRPEGRLYQHGKLTLLHNGEPLYIPVTQEPA                               PMTEDLLEEQSEVLAKLGTSAEGAHLRARMQSACLLSDMESFK                               AANPGCSLEDFVRWYSPRDYIEEEVIDEKGNVVLKGELSARMK                               IPSNMWVEAWETAKPIPARRQRRLFDDTREAEKVLHYLAIQKP                               RDLARHLLPCVIHAAVLKVKEEESLENISSVCKIIKQIISHSS                               KVLHFPNPEDKKLEEIIHQITNVEALIARARSLKAKFGTEKCE                               QEEEKEDLERFVSCKLEQPEVLVTGAGRGHAGRIIHKKFVNAQ                               RAAAMTPPEEELKRMGSPEERRQNSVSDFPPPAGREFILRTTV                               PRPAPYSKALPQRMYSVLTKEDFRLAGAFSSDTSFF               380   1119   2333   670   SPTRTGDRSVSLIVFLTEGKPTVGETHTLKILNNTREAARGQV                               CIFTIGIGNDVDFRLIEKLSLENCGLTRRVHEEEDAGSQLIGF                               YDEIRTPLLSDIRIDYPPSSVVQATKTLFPNYFNGSEIIIAGK                               LVDRKKDHLHVEVTASNSKKFIILKTDVPVRPQKAGKDVTGSP                               RPGGDGEGDTNHIERLWSYLTTKELLSSWLQSDDEPEKEPLRQ                               PAQALAVSYRFLTPFTSMKLRGPVPRMDGLEEAHGMSAAMGPE                               PVVQSVRGAGTQPGPLLKKPYQPRIKISKTSVDGDPHFVVDFP                               LSRLTVCFNIDGQPGDILRIVSDHRDSGVTVNGELIGAPAPPN                               GHKKQRTYLRTITILINKPERSYLEITPSRVILDGGDRLVLPC                               NQSVVVGSWGLEVSVSANANVTVTIQGSIARVILIHLYKKPAP                               FQRHHLGFYIRNSEGLSSNCHGLLGQFLNQDARLTEDPAGPSQ                               NLTHPLLLQVGEGPEAVLTVKGHQVPVVWKQRKIYNGEEQIDC                               WFAPDNAAXIRIDGEYKDYLASHPFDTGMTLGQGMSREL               381   1120   102   426   VPLESLSCSHADNWKQELTKFISPDQLPVEFGGTMTDPDGNPK                               CLTKINYGGEVPKSYYLCKQVRLQYEHTRSVGRGSSLQVENEI                               LFPGCVLRCPEVLQHLQPGSF               382   1121   3   3726   PAAPEHTDPSEPRGSVSCCSLLRGLSSGWSSPLLPAPVCNPNK                               AIFTVDAKTTEILVANDKACGLLGYSSQDLIGQKLTQFFLRSD                               SDVVEALSEEHMEADGHAAVVFGTVVDIISRSGEKIPVSVWMK                               RIRQERRLCCVVVLEPVERVSTWVAFQSDGTVTSCDSLFAHLH                               GYVSGEDVAGQHITDLIPSVQLPPSGQHIPKNLKIQRSVGRAR                               DGTTFPLSLKKKSQPSSEEATTGEAAPVSGYRASVWVFCTISG                               LITLLPDGTIHGINHSFALTLFGYGKTELLGKNITFLIPGFYS                               YMDLAYNSSLQLPDLASCLDVGNESGCGERTLDPWQGQDPAEG                               GQDPRINVVLAGGHVVPRDEIRKLMESQDIFTGTQTELIAGGQ                               LLSCLSPQPAPGVDNVPEGSLPVHGEQALPKDQQITALGREEP                               VAIESPGQDLLGESRSEPVDVKPFASCEDSEAPVPAEDGGSDA                               GMCGLCQKAQLERMGVSGPSGSDLWAGAAVAKPQAKGQLAGGS                               LLMHCPCYGSEWGLWWRSQDLAPSPSGMAGLSFGTPTLDEPWL                               GVENDREELQTCLIKEQISQLSLAGALDVPHAELVPTECQAVT                               APVSSCDLGGRDLCGGCTGSSSACYALATDLPGGLEAVEAQEV                               DVNSFSWNLKELFFSDQTDQTSSNCSCATSELRETPSSLAVGS                               DPDVGSLQEQGSCVLDDRELLLLTGTCVDLGQGRRFRESCVGH                               DPTEPLEVCLVSSEHYAASDRESPGHVPSTLDAGPEDTCPSAE                               EPRLNVQVTSTPVIVMRGAAGLQREIQEGAYSGSCYHRDGLRL                               SIQFEVRRVELQGPTPLFCCWLVKDLLHSQRDSAARTRKFLAS                               LPGSTHSTAAELTGPSLVEVLRARPWFEEPPKAVELEGLAACE                               GEYSQKYSTMSPLGSGAFGFVWTAVDKEKNKEVVVKFIKKEKV                               LEDCWIEDPKKGKVTLEIAILSRVEHANIIKVLDIFENQGFFQ                               LVMEKHGSGLDLFAFIDRHPRKDEPLASYIFRQVRAG\QSRKV                               SAVGYLRLKDIIHRDIKDENIVIAEDFTIKKIDFGSAAYLERG                               KKFYTFCGTIEYCAPEVLMGNPYRGPELEMWSLGVTLYTLVFE                               ENPFCELEETVEAAIHPPYLVSKEKMSLVSGLLQPVPERRTTL                               EKLVTDPWVTQPVNLADYTWEEVFRVNKPESGVLSAASLEMGN                               RSLSDVAQAQELCGGPVPGEAPNGQGCLHPGDPRLLTS               383   1122   177   1365   PGTSAATCRFLSPPVISLSFTGLCISDLVVAVNGVWILVETFM                               LKGGNFFSKHVPWSYLVFLTIYGVELFLKVAGLGPVEYLSSGW                               NLFDFSVTVFAFLGLLALAKNMEPFYFIVVLRPLQLLRKFKLK                               ERYRNVLDTMFELLPRMASLGLTLLIFYYSPAIVGMEFFCGIV                               FPNCCNTSTVADAYRWRNHTVGNRTVVEEGYYYLNNFDNILNS                               FVTLFELTVVNNWYIIMEGVTSQTSHWSRLYFMTFYIVTMVRM                               TIIVAFILHAFVFRNNYSRKNQDSEVDGGITLEKEISKEELVA                               VLELYREARGASSDVTRLLETLSQMERYQQHSMVFLGRRSRTK                               SDLSLKMYQEEIQEWYEEHAREQEQQRQLSSSAAPAAQQPPGS                               RQRSQTVT               384   1123   1   986   LAGVGTQAPPRRPGGEMAAGQNGHEEWVGSAYLFVESSLDKVV                               LSDAYAHPQQKVAVYRALQAALAESGGSPDVLQMLKIHRSDPQ                               LIVQLRFCGRQPCGRFLRAYREGALRAALQRSLAAALAQHSVP                               LQL\DLRAGAERLEALLADEERCLSCILAQQPDRLRDEELAEL                               EDAKRNLKCGSGARGGDGEVASAPLQPPVPSLSEVKPPPPPPP                               AQTFLFQGQPVVNRPLSLKDQQTFARSVGLKWRKVGRSLQRGC                               RAKRDPALDSLAYEYEREGLYEQAFQLLRRFVQAEGRRATLQR                               LVEALEENELTSLAEDLLGLTDPNGGLA               385   1124   2409   399   SSKPKLKKRFSLRSVGRSVRGSVRGILQWRGTVDPPSSAGPLE                               TSSGPPVLGGNSNSNSSGGAGTVGRGLVSDGTSPGERWTHRFE                               RLRLSRGGGALKDGAGMVQREELLSFMGAEEAAPDPAGVGRGG                               GVAGPPSGGGGQPQWQKCRLLLRSEGEGGGGSRLEFFVPPKAS                               RPRLSIPCSSITDVRTTTALEMPDRENTFVVKVEGPSEYIMET                               VDAQHVKAWVSDIQECLSPGPCPATSPRPMTLPLAPGTSFLTR                               ENTDSLELSCKNHSESLPSQDLLLGPSESNDRLSQGAYGGLSD                               RPSASISPSSASIAASHFDSMELLPPELPPRIPIEEGPPAGTV                               HPLSAPYPPLNTPETATGSFLFQG\EPEGGEGDQPLSGYPWFH                               GMLSRLKAAQLVLTGGTGSHGVFLVRQSETRPGEYVLTFNFQG                               KAKHLRLSLNEEGQCRVQHLWFQSIFDMLEHFRVHPIPLESGG                               SSDVVLVSYVPSSQRQQGEQSRSAGEEVPVHPRSEAGSRLGAM                               RGCAREMDATPNASCTLMPFGASDC\EPTTSHDPPQPPEPPSW                               TDPPQPGEE\EASR\APGSGGQQAAAAAKERQEKEKAGG\GGV                               PEE\LVPVV*LVPVGELGEGHRPQAQEAQGRLGPGGDAGVPP\                               MVQLQQSPLGG\DGEEGGHPR\AI\NNQYSFV               386   1125   2204   1042   FRAPVGTAARSPQVVIRRLPPGLTKEQLEEQLRPLPAHDYFEF                               FAADLSLYPHLYSRAYINFRNPDDILLFRDRFDGYIFKDSKDP                               EYKKFLETYCVEEEKTSANPETLLGEMEAKTRELIARRTTPLL                               EYIKNRLKLEKQRIREEKRERRRRELEKKRLREEEKRRRREEE                               RCKKKETDKQKKIAEKEVRIKLLKKPEKGEEPTTEKPKERGEE                               IDTGGGKQESCAPGAVVKARPMEGSLEEPQETSISGSDKEHRD                               VERSQEQESEAQRYHVDDGRRHRAHHEPERLSRRSEDEQRWGK                               GPGQDRGKKGSQDSGAPGEAMERLGRAQRCDDSPAPRKERLAN                               KDRPALQLYDPGARFRARECGGNRRICKAEGSGTGPEKREEAE               387   1126   176   800   GVWGVCVSGLLQVGSQRAQAWRAWSPMETPLTGTFLWPHIPQG                               LFFDDSYGFYPGQVLIGPAKIFSSVQWLSGVKPVLSTKSKFRV                               VVEEVQVVELKVTWITKSFCPGGTDSVSPP/PSVITQENLGRV                               KRLGCFDHAQR/HAWGALSVCLPSQGRASQDCLGMSRKKIRPG                               GGLYGQEGEAPVEEAGCADHVMLPRHPVFPGPFHGRPR               388   1127   1   2017   FRDSSPCSAFEFHCLSGECIHSSWRCDGGPDCKDKSDEENCAV                               ATCRPDEFQCSDGNCIHGSRQCDREYDCKDMSDEVGCVNVTLC                               EGPNKFKCHSGECITLDKVCNMARnCRDWSDEPIKECGTNECL                               DNNGGCSHVCNDLKIGYECLCPDGFQLVAQRRCEDIDECQDPD                               TCSQLCVNLEGGYKCQCEEGFQLDPHTKACKAVGSIAYLFFTN                               RHEVRKMTLDRSEYTSLIPNLRNVVALDTEVASNRIYWSDLSQ                               RMICSTQLDRAHGVSSYDTVISRDIQAPDGLAVDWIHSNIYWT                               DSVLGTVSVADTKGVKRKTLFRENGSKPRAIVVDPVHGFMYWT                               DWGTPAKIKKGGLNGVDIYSLVTENIQWPNGITLDLISGRLYW                               VDSKKHSISSIDVNGGNRKTILEDEKRLAHPFSLAVFEDKVFW                               TDIINEAIFSANRKTGSDVNLLAENLLSPEDMVLFHNLTQPRG                               VNWCERTTLSNGGCQYLCLPAPQINPHSPKFTCACPDGMLLAR                               DNRSCLTEG\EAAVATQETSTVRLKVSSTAVRTQHTTTRPVPD                               TSRLPGATPGLTRREIVTMSHQALGDVAG\PGN\EKKPSSVRA                               LSIVLPIV\LLVFLCLGVFLLWKNWRLKNINSINFDNPVYQKT                               TEDEVHKHNQDGYSYPSRQMVSLEDDVA               389   1128   2299   1148   RIPGLGPPGSPPPPPHVRGMPGCPCPGCGMAGPRLLFLTALAL                               ELLGRAGGSQPALRSRGTATACRLDNKESESWGALLSGERLDT                               WICSLLGSLMVGLSGVFPLLVIPLEMGTMKRSEAGAWRLKQLL                               SFALGRLLGNVFLHLLPEAWAYTCSASPGGEGQSLQQQQQLGL                               WVIAGILTFLALEKMFLDSKEEGTSQAPNKDPTAAAAAINGGH                               CLAQPAAEPGLGAVVRSIKVSGYLNLLANTIDNFTHGLAVAAS                               FLVSKKIGLLTTMAILLHEIPHEVGDFAILLRAGFDRWSAAKL                               QLSTALGGLLGAGFAICTQSPKGVEETAAWVLPFTSGGFLYIA                               LVNVLPDLKEEEDPWRSLQQLLLLCAGIVVMVLFSLFVD               390   1129   1   523   GKVSAGQAGADRTLRPAPEPRFSQEPTGNSAYPQLRPFLDPQG                               RDLKPSALVPPTRSHTGRRPWLHTQPLPGPQGRAWGPTC/TPA                               CVDRVLESEEGRREYLAFPTSKSSGQKGRKELLKGNGRRIDYM                               LHAEEGLCPDWKAEVEEFSFITQLSGLTDHLPVANRLMVSSGE                               EEA               391   1130   1459   765   PCGGLLSASEAATLFGYLVVPAGGGGTFLGGFFVNKLRL*RGS                               AVIKFCLFCTVVSLLGILVFSLHCPSVPMAGVTASYGGSLLPE                               GHLNLTAPCNAACSCQPEHYSPVCGSDGLMYFSLCHAGCPAAT                               ETNVDGQKVSGAAAYRPCPPLDPGKGPPCLPLVIGAIVGLPRC                               TETVAVSLRIFPLVLAM\HCREMHFNLSEKAPPSGFHIRCNFL                               YIPQQHSCTNGNSTMCP               392   1131   1668   962   LLRKVGAPGGARGVIRLLDWFERPDGFLLVLERPEPA\QD\LF                               DFITERGALDEPLARRF\FAQVLAAVRHCHSCGVVHRDIKDEN                               LLVDLRSGELKLIDFGSGALLKDTVYTDFDGTRVYSPPEWIRY                               HRYHGRSATVWSLGVLLYDMVCGDIPFEQDEEILRGRILFRRR                               VSPECQQLIRWCLSLRPSERPSLDQIAAHPWMLGADGGAPESC                               DLRLCTLDPDDVASTTSSSESL               393   1132   3   817   GKNSQKASPVDDEQLSVCLSGFLDEVMKKYGSLVPLSEKEVLG                               RLKDVFNEDFSNRKPFINREITNYRARHQKCNFRIFYNKHMLD                               MDDLATLDGQNWLNDQVINMYGELIMDAVPDKVHFFNSFFHRQ                               LVTKGYNGVKRWTKKVDLFKKSLLLIPIHLEVHWSLITVTLSN                               RIISFYDSQGIHFKFCVENIRKYLLTEAREKNR\LNLQGWQTA                               VTKCIPQQKNDSDCGVFVLQYCKCLAL\KQPFQFSQEDMPRVR                               KRIYKELCECRLMD               394   1133   1252   628   PPGG*QGSAAKHR/FP/KGYRHPALEARLGRRRTVQEARALLR                               CRRAGISAPVVFFVDYASNCLYMEEIEGSVTVRDYIQSTMETE                               K\TPQGLSNLAKTIGQVLARMHDEDLIHGDLTTSNMLLKPPLE                               QLNIVLIDFGLSFISALPEDKGVDLYVLEKAFLSTHPNTETVF                               EAFLKSYSTSSKKARPVLKKLDEVRLRGKKRSMVG               395   1134   2   1595   RACVFRPEDMMQGEAHPSASLIDRTIKMRKETEARKVVLAWGL                               LNVSMAGMIYTEMTGKLISSYYNVTYWPLWYIELALASLFSLN                               ALFDFWRYFKYTVAPTSLVVSPGQQTLLGLKTAVVQTTPPHDL                               AATQIPPAPPSPSIQGQSVLSYSPSRSPSTSPKFTTSCMTGYS                               PQLQGLSSGGSGSYSPGVTYSPVSGYNKLASFSPSPPSPYPTT                               VGPVESSGLRSRYRSSPTVYNSPTDKEDYMTDLRTLDTFLRSE                               EEKQHRVKLGSPDSTSPSSSPTFWNYSRSMGDYAQTLKKFQYQ                               LACRSQAPCANKDEADLSSKQAAEEVWARVAMNRQLLDHMDSW                               TAKFRNWINETILVPLVQEIESVSTQMRRMGCPELQIGEASIT                               SLKQAALVKAPLIPTLNTIVQYLDLTPNQEYLFERIKELSQGG                               CMSSFRWNFRGGDFKGRKWDTDLPTDSAIIMHVFCTYLSRLPP                               HPKYPDGKTFTSQHFVQTPNKPDVTNENVFCIYQSAINPPHYE                               LIYQRHVYIPAKGQK               396   1135   16   1542   SSAVEFINRNNSVVQVLLAAGADPNLGDDFSSVYKTAKEQGIH                               SLEVLITREDDFNNRLNNRASFKGCTALHYAVLADDYRTVKEL                               LDGGANPLQRNEMGHTPLDYAREGEVMKLLRTSEAKYQEKQRK                               REAEERRRFPLEQRLKEHIIGQESAIATVGAAIRRKENGWYDE                               EHPLVFLFLGSSGIGKTELAKQTAKYMHKDAKKGFIRLDMSEF                               QERHEVAKFIGSPPGYVGHEEGGQLTKKLKQCPNAVVLFDEVD                               KAHPDVLTIMLQLFDEGRLTDGKGKTIDCKDAIFIMTSNVASD                               EIAQHALQLRQEALEMSRNRIAENLGDVQISDKITISKNFKEN                               VIRPILKAHFRRDEFLGRINEIVYFLPFCHSELIQLVNKELNF                               WAKRAKQRHNITLLWDREVADVLVDGYNVHYGARSIKHEVERR                               VGNQLAAAYEQDLLP\GGCTLRITVEDSDKQLLKSPELPSPQA                               EKRLPKLRLEIIDKDSKTRRLDLAPLHPEKVCNTI               397   1136   1848   1602   SSCDRERHGSLGMMSGSFILCLALVTRWSPQASSVPLAVYESK                               TRKSYRSQRDRDGKDRSQGMGLSLLVETRKLLLSANQG               398   1137   1497   717   HTPMA/FFL/SFLSTSET/VYTFVILPKL4LINLLSVRTISFN                               CCALQMFFFLGFAITNCLLLGVMGYDRYAAICHPLHYPTLMSW                               QVCGKLAAACAIGGFLASLTVVNLVFSLPFCSTNKVNHYFCDI                               SAVILLACTNTDVNGFVIFICGVLVLVVPFLFICVSYFCILRT                               ILKIPSAEGRRKAFSTCASHLSVVIVHYGCASFIYLRPTANYV                               SNKDRLVTVTYTIVTPLLNPMVYSLRNKDVQLAIRKVLGKKGS                               LKLYN               399   1138   2   1185   RPPAATRYPREKLKSMTSRDNYKAGSREAA\AAAAAAVAAAAA                               AAAAAEPYPVSGAKRKYLEDSDPERSDYEEQQLQEEEEARKRR                               SGIRQMRLFSQDECAKIEARIDEVVSRAEKGLYNEHTVDRAPL                               RNKYFFGEGYTYGAQLQKRGPGQERLYPPGDVDEIPERRMQLV                               IQKLVEHRVIPEGFVNSAVINDYQPGGCIVSHVDPIHIFERPI                               VSVSFFSDSALCFGCKFQFKPIRVSEPVLSLPVRRGSVTVLSG                               YAADEITHCIRPQDIKERRAVIILRKTRLDAPRLETKSLSSSV                               LPPSYASDRLSGNNRDPALKPKRSHRKADPDAAHRPRILEMDK                               EENRRSVLLPTHRRRGSFSSENYWRKSYESSEDCSEAAGSPAR                               KVKMRRH               400   1139   60   1699   VTWHFYFCSDHKNGHYIIPQMADRSRQKCMSQSLDLSELAKAA                               KKKLQALSNRLFEELAMDVYDEVDRRENDAVWLATQNHSTLVT                               ERSAVPFLPVNPEYSATRNQGRQKLARFNAREFATLIIDILSE                               AKRRQQGKSLSSPTDNLELSLRSQSDLDDQHDYDSVASDEDTD                               QEPLRSTGATRSNRARSMDSSDLSDGAVT\LQEYLELKKALAT                               SEAKVQQLMKVNSSLSDEL\RRLQREHFAPI\IHKLQAENLQL                               RQPPGPVPTPPLPSERAEHTPMAPGGSTHRRDRQAFSMYEPGS                               ALKPFGGPPGDELTTRLQPFHSTELEDDAIYSVHVPAGLYRIR                               KGVSASAVPFTPSSPLLSCSQEGSRHTSKLSRHGSGADSDYEN                               TQSGDPLLGLEGKRFLELGKEEDFHPELESLDGDLDPGLPSTE                               DVILKTEQVTKNIQELLRAAQEFKHDSFVPCSEKIHLAVTEMA                               SLFPKRPALEPVRSSLRLLNASAYRLQSECRKTVPPEPGAPVD                               FQLLTQQVIQCAYDIAKARAKQLVTITTPRRQ               401   1140   1   1863   RYLSYGSGPKRFPLVDVLQYALEFASSKPVCTSPVDDIDASSP                               PSGSIPSQTLPSTTEQQGAISSELPSTSPRSVAAISSRSVIHK                               PFTQSRIPPDLPMHPAPRHITEEELSVLESCLHRWRTEIENDT                               RDLQESISRIHRTIELMYSDKSMIQVPYRLHAVLVHEGQANAG                               HYWAYIFDHRESRRRMKYNDIAVTKSSWEELVRDSFGGYRASA                               YCLMYINDKAQFLIQEEFN/K/ETGQPLVGIETLPPDLRDFVE                               EDNQRFEKELEEWDAQLAQKALQEKLLASQKLRESETSVTTAQ                               AAGDPKYLEQPSRSDFSKHLKEETIQIITKASHEHEDKSPETV                               LQSAIKLEYARLVKLAQEDTPPETDYRLHHVVVYFIQNQAPKK                               IIEKTLLEQFGDRNLSFDERCHNIMKVAQAKLEMIKPEEVNLE                               EYEEWHQDYRKFRETTMYLIIGLENFQRESYIDSLLFLICAYQ                               NNKELKSFCGLYRGHDELISHYRRECLLKLNEQAAELFESGED                               REVNNGLIIMNEFIVPFLPLLLVDEMEEKDILAVEDMRNRWCS                               YLGQEMEPHLQEKLTDFLPKLLDCSMEIKSFHEPPKLPSYSTH                               ELCERFARIMLSLSRTPADGR               402   1241   1   465   AQVYVRNDSFDEDLARPSGLLAQERKLCRDLVHSRRBRQEFRS                               IFQHIQSAQSQRSPSELFAQHM\VPIVHHVKEHHFGSSGMTLH                               ERFT\KYLKRG\TEQEAAKNKKSPEIHRRIDISPSTFRKHGLA                               HDEMKSPREPGYKDGKNSRELQRVNFY               403   1142   2   369   TYTFCFSLMI\ILLTIIQGLILEAFGELRDQLDQVKEDMETKC                               FICGIGNDYFDTVPHGFETHTLQEHNLANYLFFLMYLINKDET                               EHTGQESYVWKMYQERCWEFFPAGDCFRKQYEDQLN               404   1143   3115   557   FRRKGGGGPKDFGAGLKYNSRHEKVNGLEEGVEFLPVNRVKKV                               EKHGPGRWVVLAAVLIGLLLVLLGIGFLVWHLQYRDVRVQKVF                               NGYMRITNENFVDAYENSNSTEFVSLASKVKDALKLLYSGVPP                               LGPYHKESAVTAFSEGSVIAYYWSEFSIPQHLVEEAERVMAEE                               RVVMLPPRARSLKSFVVTSVVAFPTDSKTVQRTQDNSCSFGLH                               ARGVELMRFTTPGFPDSPYPAHARCQWALRGDADSVLSLTFRS                               FDLASCDERGRHLV\TVYNT\LSPMEPHA\LVQLCGTYPPSYN                               LTFHS\S\QNVLLITLITNTERRHPG\FEATFFQLPRMSSCGG                               RLRKAQGTFNSPYYPGHYPPNIDCTWNIEVPNNQHVKVRFKFF                               YLLEPGVPAGTCPKDYVEINGEKYCGERSQFVVTSNSNKITVR                               FHSDQSYTDTGFLAEYLSYDSSDPCPGQFTCRTGRCIRKELRC                               DGWADCTDHSDELNCSCDAGHQFTCKNKFCKPLFWVCDSLNDC                               GDNSDEQGCSCP\AQTFRCSNGKCLSKSQQCNGKDDCGDGSDE                               ASCPKVNVVTCTKHTYRCLNGLCLSKGNPECDGKEDCSDGSDE                               KDCKCGLRSFTRQARVVGGTDADEGEWPWQVSLHALGQGHICG                               ASLISPNWLVSAAHCYIDDRGFRYSDPTQWTAFLGLHDQSQRS                               APGVQERRLKRIISHPFFNDFTFDYDIALLELEKPAEYSSMVR                               PICLPDASHVFPAGKAIWVTGWGHTQYGGTGALILQKGEIRVI                               NQTTCENLLPQQITPRMMCVGFLSGGVDSCQGDSGGPLSSVEA                               DGRIFQAGVVSWGDGCAQRKPGRTRLPLFRDWLR               405   1144   1   424   RHEEDLGNLWENTRFTDCSFFVRGQEFKAHKSVLAARSPVFNA                               MFEHEMEESKKNRVEINDLDPEVFKEMMRFIYTGRAPNLDKMA                               DNLLAAADKYALERLKVMCEKALCSNLSVENVADTLVLADLHS                               \AEQLKAQAIDFINFRCSVLRQLGCKDGKNWNSNQATDIMETSG                               GKSMIQSHPHLVAEAFRALASAQFGPQFGIPRKRKQS*NLGNL                               WENTRFTDCSFFVRGQEFKAHKSVLAARSPVFNAMFEHEMEES                               KKNRVEINDLDPEVFKEMMRFIYTGRAPNLDKMADNLLAAADK                               YALERLKVMCEKALCSNLSVENVADTLVLADLHSGRTVESTSH                               RLY               406   1145   1   1021   QRGGIPGKFQEDSGSVDWALGPFWGIFQADFGCMRFYLSAQTS                               DPVLRM*WGPSPISHPTSLCPGRGGRGQTTGSLCLGQQCCPLS                               CPNIPSRHKRWRL*AALVAGSRGSCTLRS*R*RTPLPVTRNLP                               R/CHLHLHPTGDLRVHVHQHCLLHGHVPPGAALLQCGGCDLRG                               EAAGLLFLGHACLRGSVNLRRDQWLPV\PYSRLCFSGAREGHL                               PSLLAMIHVRHCTPIPALLVC\PIKVNLLIPVAYLVFWAFLLV                               FSFISEHMVCGVGVIIILTGVPIFFLGVFWRSKPKCVHRLTES                               MTHWGQELCFVVYPQDAPEEEENGPCPPSLLPATDRSKPQ               407   1146   2   1280   AAALVAEYLALLEDHRHLPVGCVSFQNISSNVREESAISDDIL                               SPDEEGFCSGKHFTELGLVGLLEQAAGYFTMGGLYEAVNEVYK                               NLIPILEAHRDYKKLAAVHGKLQEAFTKIMHQSSGWERVFGTY                               FRVGFYGAHFGDLDEQEFVYKEPSITKLAEISHRLEEFYTERF                               GDDVVEIIKDSNPVDKSKLDSQKAYIQITYVEPYFDTYELKDR                               VTYFDRNYGLRTFLFCTPFTPDGRAHGELPEQHKRKTLLSTDH                               AFPYIKTRIRVCHREETVLTP\VEVAIEDMQKKTRELAFATEQ                               DPPDAKMLQMVLQGSVGPTVNQGPLEVAQVFLAEIPEDPKLFR                               HHNKLRLCFKDF\*KKCEDALRKNKALIGPDQKEYHRELERNY                               CRLREALQPLLTQRLPQLMAPTPPGLRNSLNRASFRKADL               408   1147   55   651   GEGQQWQSTPLSPLQPTVADFLNLAWWTSAAAW*VLSGRWVEK                               VLPGREGSEEK*GMASSSADHLHSAPRALQ\SLFQQLLYGLIY                               HSWFQAGR*GFGGASSSPGPQSELRRLHGEGGVYD*GRPETLP                               FSVGGAEALWALADPAEAEGSPETRESSCVMKQTQYYFGSVNA                               SYNAIIDCGNCSRCWQWGGTRGQGRNL               409   1148   1855   904   VAGIPACFDN/FTEALAETACRQMGYSSKPTFRAVEIGPDQDL                               DVVEITENSQELRMRNSSGPCLSGSLVSLHCLACGESLKTPRV                               VGGEEASVDSWPWQVSIQYDKQHVCGGSILDPHWVLTAAHCFR                               KHTDVFNWKVRAGSDKLGSFPSLAVAKIIIIEFNPMYPKDNDI                               ALMKLQFPLTFSGTVRPICLPFFDEELTPATPLWIIGWGFTKQ                               NGGKMSDILLQASVQVIDSTRCNADDAYQGEVTEKMMCAGIPE                               GGVDTCQGDSGGPLMYQSDQWHVVGIVSWGYGCGGPSTPGVYT                               KVSAYLNWIYNVWKAEL               410   1149   3   964   TISTVRWNSRIGMVLGVAIQKRAV\PGLY\AFEEAYARADKEA                               PRPCHKGSWCSSNQLCRECQAFMAHTMPKLKAFSMSSAYNAYR                               AVYAVAHGLHQLLGCASGACSRGRVYPQWLLEWIHKVHFLLHK                               DTVAFNDNRDPLSSYNIIAWDWNGPKWTFTVLGSSTWSPVQLN                               INETKIQWHGKDNQVPKSVCSSDCLEGHQRVVTGFHHCCFECV                               PCGAGTFLNKS/SYLGKDLPENYNEAKCVTFSLLFNFVSWIAF                               FTTASVYDGKYLPAMTIMAGLSSLSSGFGGYFLPKCYVILCRP                               DLNSTEHFQASKQDYTRRCGST               411   1150   2   1378   VARGAFHPKMGPSFPSPKPGSERLSFVSAKQSTGQDTEAELQD                               ATLALHGLTVEDEGNYTCEFATFPKGSVRGMTWLRVIAKPKNQ                               AEAQKVTFSQDPTTVALCISKEGRPPARISWTSSLDWEAKETQ                               VSGTLAGTVTVTSRFTLVPSGRADGVRVTCKVEHESFEEPALI                               PVTLSVRYPPEVSISGYDDNWYLGRTDATLSCDVRSNPEPTGY                               DWSTISGTFPTSAVAQGSQLVIHAVDSLFNTTFVCTVTNAVGM                               GRAEQVIFVRETPNTAGAGATGGIIGGIIAAIIATADA\TGIL                               ICRQQRKEQTLQGAEEDEDLEGPPSYKPPTPKAKLEAQEMPSQ                               LFTLGASEHSPLKTPYFDAGASCTEQEMPRY                                TLEERSGP                               LHPGATSLGSPIPVPPGPPAVEDVSLDLEDEEGEEEEEYLDKI                               NPIYDAIISYSSPSDSYQGKGFVMSRAMYV               412   1151   1   1828   GTRLREDKNHNMYVAGCTEVEVKSTEEAFEVFWRGQKKRRIAN                               THLNRESSRSHSVFNIKLVQAPLDADGDNVLQEKEQITISQLS                               LVDLAGSERTNRTRAEGNRLREAGNINQSLMTLRTCMDVLREN                               QMYGTNKMVPYRDSKLTHLFKNYFDGEGKVRMIVCVNPKAEDY                               EENLQVMRFAEVTQEVEVARPVDKAICGLTPGRRYRNQPRGP\                               IGNEPLVTDVVLQSFPPLPSCEILDINDEQTLPRLIEALEKRH                               NLRQMMIDEFNKQSNAFKALLQEFDNAVLSKENHMQGKLNEKE                               KMISGQKLEIERLEKKNKTKEYKIEILEKTTTIYEEDKRNLQQ                               ELETQNQKLQRQFSDKRRLEAPLQGMVTETTMKWEKECERRVA                               AKQLEMQNKLWVKDEKLKQLKAIVTEPKTEKPERPSRERDREK                               VTQRSVSPSPVPLLFQPDQNAPPIRLRHRRSRSAGDRWVDHKP                               ASNMQTETVMQPHVPHAITVSVANEKALAKCEKYMLTHQELAS                               DGEIETKLIKGDIYKTRGGGQSVQFTDIETLKQESPNGSRKRR                               SSTVAPAQPDGAESEWTDVETRCSVAVEMRAGSQLGPGYQHHA                               QPKRKKP               413   1152   1   336   PFSSSSVSSKGSDPFGTLDPFGSGSFNSAEGFADFSQMS/KGK                               STPVSQLGSADFPEAPDPFQPLGADSGDPFQSKKGFGDPFSGK                               DPFVPSSAAKPSKASASGFADFTSVS               414   1153   1   1334   MSLMVVSMACVGLFLVQRAGPHMGGQDKPFLSAWPSAVVPRGG                               HVTLRCHYRHRFNNFMLYKEDRIHIPIFHGRIFQESFNMSPVT                               TAHAGNYTCRGSHPHSPTGWSAPSNPVVIMVTGNHRKPSLLAH                               PGPLVKSGERVILQCWSDIMFEHFFLHKEGISKDPSRLVGQIH                               DGVSKANFSIGPMMQDLAGTYRCYGSVTHSPYQLSAPSDPLDI                               VITGLYEKPSLSAQPGPTVLAGESVTLSCSSRSSYDMYHLSRE                               GEAHERRFSAGPKVNGTFQADFPLGPATHGGTYRCFGSFRDSP                               YEWSNSSDPLLVSVTGNPSNSWPSPTEPSSETGNPRHLHVLIG                               TSVVIILFILLLFFLLHRWCSN\KKNAAVMDQESAGNRTANSE                               DSDEQDPQEVTYTQLNHCVFTQRKITRPSQRPKTPPTDIIVYT                               ELPNAESRSKVVSCP                415   1154   1   1570   MSLRVHTLPTLLGAVVRPGCRELLCLIMITVTVGPGASGVCPT                               ACICATDIVSCTNKNLSKVPGNLFRLIKRLDLSYNRIGLLDSE                               WIPVSFAKLNTLILRHNNITSISTGSFSTTPNLKCLDLSSNKL                               KT\VKNAVFQELKVLEVLLLYNNHISYLDPSAFGGLSQLQKLY                               LSGNFLTQFPMDLYVGRFKLAELMFLDVSYNRIPSMPMHHINL                               VPGKQLRGIYLHGNPFVCD\CSLVSLLVFWYRRHFSSVMDFKN                               DYTCRLWSDSPHSRQVLLLQDSFMNCSDSIINGSFRALGFIHE                               AQVGERLMVHCDSKTGNANTDFIWVGPDNRLLEPDKEMENFYV                               FHNGSLVIESPRFEDAGVYSCIAMNKQRLLNETVDVTINVSNF                               TVSRSHAHEAFNTAFTTLAACVASIVLVLLYLYLTPCPCKCKT                               KRQKNMLHQSNAHSSILSPGPASDASADERKAGAGKRVVFLEP                               LKDTAAGQNGKVRLFPSEAVIAEGILKSTRGKSDSDSVNSVFS                               DTPFVAST               416   1155   2   1928   ASDFIRSLDHCGYLSLEGVFSHKFDFELQDVSSVNEDVLLTTG                               LLCKYTAQRFKPKYKFFHKSFQEYTAGRRLSSLLTSHEPEEVT                               KGNGYLQKMVSISDITSTYSSLLRYTCGSSVEATRAVMKHLAA                               VYQHGCLLGLSIAKRPLWRQESLQSVKNTTEQEILKAININSF                               VECGIHLYQESTSKSALSQEFEAFFQGKSLYINSGNIPDYLFD                               FFEHLPNCASALDFIKLGFYGGAMASWEKAAEDTGGIHMEEAP                               ETYIPSRAVSLFFNWKQEFRTLEVTLRDFSKLNKQDIRYLGKI                               FSSATSLRLQIKRCAGVAGSLSLVLSTCKNIYSLMVEASPLTI                               EDERHITSVTNLKTLSIHDLQNQRLPGGLTDSLGNLKNLTKLI                               MDNIKMNEEDAIKLAEGLKNLKKMCLFHLTHLSDIGEGMDYIV                               KSLSSEPCDLEEIQLVSCCLSANAVKILAQNLHNLVKLSILDL                               SENYLEKDGNEALHELIDRMNVLEQLTALMLPWGCDVQGSLSS                               LLKHLEEVPQLVKLGLKNWRLTDTEIRILGAFFGKNPLKNFQQ                               LNLAGNRVSSDGWLAFMGVFENLKQLVFFDFSTKEFLPDPALV                               RKLSQVLSKLTFLQEALVGWQFDDDDLSVITGRRA               417   1156   342   718   ASDRKVAMTCDCFWFRTMLDQHASCMEVGTERERQAG\GLVMP                               DPSGFPTGEKVLQDDEFTCDLFRFLQLLCEGHNSGL*VPGTSD                               DTKA*IMFSSQ**QEPVSSNYASF*RQQIILEHGSAKGSG               418   1157   1   135   EITHIVGETAAFLCPRLRLRRGGKDGSPKPGFLASVIPVDRRP                               GE*DITHIVGETAAFLCPRLRLRRGGKDGSPKPGFLASVIPVD                               RRPGE               419   1158   173   943   SKFIFYVDSQSMIFFFQTPTRHKVLIMEFCPCGSLYTVLEEPS                               NAYGLPESEFLIVLRDVVGGMNHLRENGIVHRDIKPGNIMRVI                               GEDGQSVYKLTDFGAARELEDDEQFVSLYGTEEYLHPDMYERA                               VLRKDHQ\KKYGAT\VDLW\SIGVTFYQGKPTGS\LAI*HPFE                               GASVRDKASDGIKIITGKGLLGAIS\GVQKSKKNG\PI\DWEW                               EDMPVSCSPSSGVLRVPNLPPVLA\NILESRSRKKCWGF*PSF                               LQEN               420   1159   987   500   GSTISCERSLRSLWTAHWALPEMDSRIPYDDYPVVFLPAYENP                               PAWIPPHERVHHPDYNNELTQFLPRTITLKKPPGAQLGFNIRG                               GKASQLGIFISKVIPDSDAHRAGLQEGDQVLAVNDVDFQDIEH                               SKAVEILKTAREISMRVRFFPYNYHRQKERTVH               421   1160   3   890   HEQVSALHRRIKAIVEVAAMCGVNIICFQEAWTMPFAFCTREK                               LPWTEFAESAEDGPTTRFCQKLAKNHDMVVVSPILERDSEHGD                               VLWNTAVVISNSGAVLGKTRKNHIPRVGDFNESTYYMEGNLGH                               PVFQTQFGRIAVNICYGRHHPLNWLMYSINGAEIIFNPSATIG                               ALSESLWPIEARNAAIANHCFTCAINRVGTEHFPNEFTSGDGK                               KAHQDFGYFYGSSYVAAPDSSRTPGLSRSRDGLLVAKLDLNLC                               QQVNDVWNFKMTGRYEMYARELAEAVKSNYSPTL               422   1161   5214   352   MAKSGGCGAGAGVGGGNGALTWVNNAAKKEESETANKNDSSKK                               LSVERVYQKKTQLEHILLRPDTYIGSVEPLTQFMWVYDEDVGM                               NCREVTFVPGLYKIFDEILVNAADNKQRDKNMTCIKVSIDPES                               NIISINNNGKGIPVVEHKVEKVYVPALIFGQLLTSSNYDDDEK                               KVTGGRNGYGAKLCNIFSTKFTVETACKEYKHSFKQTWMNNMM                               KTSEAKIKHFDGEDYTCITFQPDLSKFKMEKLDKDIVALMTRR                               AYDLAGSCRGVKVMFNGKKLPVNGFRSYVDLYVKDKLDETGVA                               LKVIHELANERWDVCLTLSEKGFQQISFVNSIATTKGGRHVDY                               VVDQVVGKLIEVVKKKNKAGVSVKPFQVKNHIWVFINCLIENP                               TFDSQTKENMTLQPKSFGSKCQLSEKFFKAASNCGIVESILNW                               VKFKAQTQLNKKCSSVKYSKIKGIPKLDDANDAGGKHSLECTL                               ILTEGDSAKSLAVSGLGVIGRDRYGVFPLRGKILNVREASHKQ                               IMENAEINNIIKIVGLQYKKSYDDAQSLKTLRYGKIMIMTDQD                               QDGSHIKGLLINFIHHNWPSLLKHGFLEEFITPIVKASKNKQE                               LSFYSIPEFDEWKKHIENQKAWKIKYYKGLGTSTAKEAKEYFA                               DMERHRILFRYAGPEDDAAITLAFSKKKIDDRKEWLTNFMEDR                               RQRRLHGLPEQFLYGTATKHLTYNDFINKELILFSNSDNERSI                               PSLVDGFKPGQRKVLFTCFKRNDKREVKVAQLAGSVAEMSAYH                               HGEQALMMTIVNLAQNFVGSNNINLLQPIGQFGTRLHGGKDAA                               SPRYIFTMLSTLARLLFPAVDDNLLKFLYDDNQRVEPEWYIPI                               IPMVLINGAEGIGTGWACKLPNYDAREIVNNVRRMLDGLDPHP                               MLPNYKNFKGTIQELGQNQYAVSGEIFVVDRNTVEITELPVRT                               WTQVYKEQVLEPMLNGTDKTPALISDYKEYHTDTTVKFVVKMT                               EEKLAQAEAAGLHKVFKLQTTLTCNSMVLFDHMGCLKKYETVQ                               DILKEFFDLRLSYYGLRIGWLVGMLGAEFTKLNNQARFILEKI                               QGKITI*NRSKKDLIQMLVQRGYESDPVKAWKEAQEKAAEEDE                               TQNQHDDSSSDSGTPSGPDFNYILNMSLWSLTKEKVEELIKQR                               DAKGREVNDLKRKSPSDLWKEDLAAFVEELDKVESQEREDVLA                               GMSGKAIKGKVGKPKVKKKQLEETMPSPYGRRIIPEITAMKAD                               ASKKLLKXKKGDIDTAAVKVEFDEEFSGAPVEGAGBEALTPSV                               PINKGPKPKREKKEPGTRVRKTPTSSGKPSAKKVKRNTPWSDD                               ESKSESDLEETEPVVIPRDSLLRRAAAERPKYTFDFSEEEDDD                               ADDDDDDDNNDLEELKVKASPITNDGEDEFVPSDGLDKDERFS                               PGKSKATPEKSLHDKKSQDFGNLFSFPSYSQKSEDDSAKFDSN                               EEDSASVFSPSFGLKQTDKVPSKTVAAKKGKPSSDTVPKPKRA                               PKQKKVVEAVNSDSDSEFGIPKKTTTPKGKGRGAKKRKASGSE                               NEGDYNPGRKTSKTTSKKPKKTSFDQDSDVDIFPSDFPTEPPS                               LPRTGRREVKYFABSDEEEDDVDFAMFN                423   1162   1   219   KGCLAASFNCIFLYTGELYPTMIR*VEA*WENDSLFIGKDILL                               CTGQTPELNQVHPSPKAPPNTHHCRHSSH               424   1163   1454   446   ENSFECKDCGKAFSRGYQLSHHQKIHTGEKPYECKECKKAFRW                               GNQLTQHQKIHTGEKPYECKDCGKAFRWGSSLVIHKRIHTGEK                               PYECKDCGKAFRRGDELTQHQRFHTGEKDYECKDCGKTFSRVY                               KLIQHKRIHSGEKPYECKDCGKAFICGSSLIQHKRIHTGEKPY                               ECQECGKAFTRVNYLTQHQKIHTGEKPHECKECGKAFRWGSSL                               VKHERIHTGEKPYKCTECGKAFNCGYHLTQHERIHTGETPYKC                               KECGKAFIYGSSLVKHERIHTGVKPYGCTECRKSFSHGHQLTQ                               HQKTHSGAKSYECKECGKACNHLNHLREHQRIHNS               425   1164   826   407   HQYLDDLYPLHVMTILLKSHFFTMLKRPVGSSSFASLPFYHQS                               ILLRKNQMKRKKTQQDLTHINWTLQAVSIQTCIWLQKKPSSYF                               HQLPNQVL*PENSGPESCLYDLAAVVVHHGSG               426   1165   464   29   XLDPDTLPAVATLLMDVMFYSNGVKDPMATGDDCGHIRFFSFS                               LIEGYISLVMDVQTQQRFPSNLLFTSASGELWKMVRIGGQPLG                               FGPVWESGPTGPTSPLILPVTPSSSHRQAASQVTTTKQGQWLC                               LKRPSARSPDHTACLG*               427   1166   649   901   EAPLTSVCFSLERRFGSSSNTTSFGTLASQNAPTFGSLSQQTS                               GFGTQSSGFSGFGSGTGGFSFGSNNS*VSPRSLTLIKSIK               428   1167   3   340   EEPQGSPIWVWLAGSLTSVSCFLPFQRMRIKPHQGQYIGEMSF                               LQEHKGECRPQKD*ARQENPCGPCSERRKHLLGQDPKTCKCSC                               FNITDSRCKARPLELNERTCRCDKPRR               429   1168   355   1312   TLWAGPGLCPQSESSSSVPAPWEPHVERALRTDRNQGQRPLLS                               ASWAPAPARPLFLTSPVLLPKSRAIPAARDPS*AGIFCLLEMA                               GGQASVVIIGSAGVKGCRWGSSGKSHSLSPSRKGNLHLLSQEP                               QTTVVHNATDGIKGSTESCNTTTEDEDLKVRXQEIIKITEQLI                               EAINNGDFEAYTKICDPGLTSFEPEALGNLVEGMDFHKFYFEN                               REWVRAADILLPAPLPLCLCLLLTFSSQLPTFPLFDLRAAKKL                               CMLVPLCPDGCRQAPLKAKLLSSKCHSFCSCFVAVPVTTIKLT                               YFLPGAVAYACNPNTLGG               430   1169   439   728   ERAGAGGAAACRAGTRSGATSRTPWPLHRQLSMMLMLAQSNPQ                               LFALMGTRAGIARELERVEQQSRLEQLSAAELQSRNQGHWADW                               LQAYRARLGQ               431   1170   3   440   NGTLFIMVMHIKDLVSDYKE*WL*RKPLPW*EALLLRDCFFF*                               VTENGADPNPYVKTYKLPDNHKTSKRKTKISRKTRNPTFNEML                               VYSGYSKETLRQRELQLSVLSAESLRENFFLGGVTLPLKDFNL                               SKETVKWYQLTAATYL               432   1171   433   1824   LHRIMQLAVVVSQVLENGSSVLVCLEEGWDITAQVTSLVQLLS                               DPFYRTLEGFQMINEKEWLSFGHKFSQRSRLTIMCQGSGFAPV                               FLQFLDCVHQVHNQYPTEFEFNLYYLKFLRFHYVSNRFKTFLL                               DSDYERLEHGTLFDDKGEKHAKKGVCIWECIDRIHKRSPIFFN                               YLYSPLEIEALKPNVNVSSLKKWDYYIEETLSTGPSYDWMMLT                               PKHFPSEDSDLAGEAGPRSQRRTVWPCYDDVSCTQPDALTSLF                               SEIEKIEHKINQAPEKWQQLWERVTVDLKEEPRTDRSQRHLSR                               SPGIVSTNLPSYQKRSLLHLPDSSMGEEQNSSISPSNGVERRA                               ATLYSQYTSKNDENRSFEGTLYKRGALLKGWKPRWFVLDVTKH                               QLRYYDSGEDTSCKGHIDLAEVEMVIPAGPSMGAPKHTSDKAF                               FDLKTSKRVYNFCAQDGQSAQQWMDKIQSCISDA               433   1172   1714   946   EVEGPRRVSPAPETLGMEESVVRPSVFVVDGQTDIPFTRLGRS                               HRRQSCSVARVGLGLLLLLMGAGLAVQGWFLLQLHWRLGEMVT                               RLPDGPAGSWEQLIQERRSHEVNPAAHLTGANSSLTGSGGPLL                               WETQLGLAFLRGLSYHDGALVVTKAGYYYIYSKVQLGGVGCPL                               GLASTITHGLYKRTPRYPEELELLVSQQSPCGRATSSSRVWWD                               SSFLGGVVHLEAGEEVVVRVKDERLVRLRDGTRSYFGAFMV               434   1173   16   367   QSAELGPRRREGSRRPSCTKASKPWRRRPGGPTSGLG*GPLSP                               GPYQCRPSLPAQLYPQSLMAAATLRTPTQVSAASSRPHTPSPT                               HVLKPSVRGACSSPRCPGSGTLRRSWVGPFF               435   1174   27   1139   LWWPPLSRRAAHRQWPGPTAPRGLGHKVKGRGASPAAMWSCSW                               FNGTGLVEELPACQDLQLGLSLLSLLGLVVGVPVGLCYNALLV                               LANLHSKASMTMPDVYFVNMAVAGLVLSALAPVRLLGPPSSRW                               ALWSVGGEVHVAKQIPFNVSSLVAIYSTALLSLDHYIERALPR                               TYMASVYNTRHVCGFVWGGALLTSFSSLLFYICSHVSTRALEC                               AXMQNAEAADATLVFIGYVVPALATLYALVLLSRVRREDTPLD                               RDTGRLEPSAHRLLVATVCTQFGLWTPHYLILLGHTVIISRGK                               PVDAHYLGLLHFVKDFSKLLAFSSSFVTPLLYRYMRQSFPSKK                               QRLMKKLPCGDRHCSPDHMGVQQVLA               436   1175   322   756   SESELFTLMPSLPTTNCVHSLQMIPPLSPAPNQELVLGLCYMS                               YLAFLYMTFDFCCLYFSTVYAPSFKYICVHTDTHICVCVCIYL                               SSVVSKSSAEADGVLQPRRHPASLLIVFATSISESSLLIFSFQ                               KTEAKLIVFAVSLAAK               437   1176   2   153   FFFLRQSLTLSPRLECSGATSASPSAGITGMSHHSQPIVNFLR                               ACIPISK               438   1177   1   692   RQHAEERGRRNPKTGLTLERVGPESSPYLLRRHQRQGQEGEHY                               HSCVQLAPTRGLEES/GHGPL/SLAGGPRVGGV/AAAATEAPR                               MEWKVKVRSDGTRYVAKRPVRDRLLKARALKIREERSGMTTDD                               DAVSEMKMGRYWSKEERKQHLIRAREQRKRREFMMQSRLECLR                               EQQNGDSKPELNIIALSHRKTMKKRNKKILDNWITIQEMLAHG                               ARSADGKRVYNPLLSVTTV               439   1178   2   616   SDRGCSAAAGRNMTAVGVQAQRPLGQRQPRRSFFESFIPTLII                               TCVALAVVLSSVSICDGHWLLAEDRLFGLWHFCTTTNQSVPIC                               FRDLGQAHVPGLAVGMGLVRSVGALAVVAAZFGLEFLMVSQLC                               EDKHSQCKWVMGSILLLVSFVLSSGGLLGFVILLRNQVTLIGF                               TLMFWCEFTASFLLFLNAISGLHINSITHPWE               440   1179   2   540   WILPNLYLGSARDSANLESLAKLGIRYILNVTPNLPNFFEKNG                               DFHYKQIPISDHWSQNLSRFFPEAIEFIDEALSQNCGVLVHCL                               AGVSRSVTVTVAYLMQKLHLSLNDAYDLVKRKKSNISPNFNFM                               GQLLDFERSLRLEERHSQEQGSGGQASAASNPPSFFTTPTSDG                               AFELAPT               441   1180   940   463   RKSLHENKLKRLQEKVEVLEAKKEELETENQVLNRQNVPFEDY                               TRLQKRLKDIQRRHNEFRSLILVPNMPPTASINPVSFQSSAMG                               SKHGTTISSSYAGGTTSKGTLSTSQKTRRTGNNTKKTTRGTWI                               FRPIVIMFLENRQIKRGEVGDSVKIDILTCGI               442   1181   1   986   GRPGAGASELFPSVTTDLSVSKQNACLTCVDFVTVHVCMGFWG                               IGPGALSTSCIPYPLSHGPGSVKAEMLHMYSQKDPLILCVRLA                               VLLAVTLTVPVVLFPIRRALQQLLFPGKAFSWPRHVAIALILL                               VLVNVLVICVPTIRDIFGVIGSTSAFSLIFILPSIFYLRIVPS                               EVEPFLSWPKIQALCFGVLGVIFMAVSLGFMFADWATGQSRMS                               GH*SGPAGPGPCAHAHGGVRAAP*GPSCPTCGGGWFP*TWLSE                               AGDSRGCRLAHFPPPQGCQAWIMALIPTPTPWEEEEEEEEEEE                               EEEEEEEEEARSWWSLCPAQSSLPPPG               443   1182   460   27   INELRYHLEESPDKNVLLCLEERDWDPGLAIIDNLMQSINQSK                               KTVFVLTKKYAKSRNFKTAFYLALQRLMDENNDVIIFILLEPV                               LQHSQYLRLRQRIKKSSILQWPDNPKAEGLFWQTLRNVVLTEN                               DSRYNNMYVDSIKQY               444   1183   1682   230   DDPIKTSWTPPRYVLSMSEERHERVRKKYHILVEGDGIPPPIK                               SFKEMKFPAAILRGLKKKGIHHPTPIQIQGIPTILSGRDMIGI                               AFTGSGKTLVFTLPVIMFCLEQEKRRLPFSKREGPYGLIKPSR                               ELARQTHGILEYYCRLLQEDSSPLLRCALCIGGMSVKEQMETI                               RHGVHMMVATPGRLMDLLQKKMVSLDICRYLALDEADRMIDMG                               FEGDIRTIFSYFKGQRQTLLFSATMPKKIQNFAKSALVKPVTI                               NVGRAGAASLDVIQEVEYVKEEAKMVYLLECLQKTPPPVLIFA                               EKKADVDAIHEYLLLKGVEAVAIHGGKDQEERTKAIEAFREGK                               KDVLVATDVASKGLDFPAIQHVINYDMPEEIENYVHRIGRTGR                               SGNTGIATTFINKACDESVLMDLKALLLEAKQKVPPVLQVLHC                               GDESMLDIGGERGCAFCGGLGHRITDCPKLEAMQTKQVSNIGR                               KDYLAHSSMDF               445   1184   1   375   IETTQPSEDTNANSQDNSMQPETSSQQQLLSPTLSDRGGSRQD                               AADAGKPQRKFGQWRLPSAPKPISHSVSSVNLRFGGRTTMKSV                               VCKIVRPMTDAASCGSEVKKWWTRQLTVESDESGDDLLDI               446   1185   2   223   NDRFSACYFTLKLKEAAVRQREALKKLTKNIATDSYISVNLRD                               VYARSIMEMLRKKGRERASTRSSGGDDFWF               447   1186   2   1031   FTVFILGITIRPLVEFLDVKRSNKKQQAVSEEIYCRLFDHVKT                               GIEDVCGHWGHNFWRDKFKKFDDKYLRKLLRLENQPKSSIVSL                               YKKLEIKHAIEMAETGMISTVPTFASIMDCPREEKLKVTSSET                               DEIRELLSRNLYQIRQRTLSYNRHSLTADTSERQAKEILIRRR                               HSLRESIRKDSSLNREHRASTSTSRYLSLPKNTKLPEKLQKRR                               TISIADGNSSDSDADAGTTVLNLQPRARRFLPEQFSKKSPQSY                               KMEWKNEVDVDSGRDMPSTPPTPHSREKGTQTSGLLQQPLLSK                               DQSGSEREDSLTEGIPPKPPPRLVWRASEPGSRKARFGSEKP               448   1187   3   444   HEEASGLSVWMGKQMEPLHAVPPAAITLILSLLVAVFTECTSN                               VATTTLFLPIFASMSRSIGLNPLYIMLPCTLSASFAFMLPVAT                               PPNAIVFTYGHLKVADMVKTGVIMNIIGVFCVFLAVNTWGRAI                               FDLDHFPDWARVTHIET               449   1188   3   125   HELENNWLQHEKAPTEEGKKELLALSNANPSLLERHCAYL               450   1189   1   188   GNIIYMYMQPGARSSQDQGKFLTLFYNIVTPLLNPLIYTLRNR                               EVKGALGRLLLGKRELGKE               451   1190   10   1879   PLEQRSNCRVDPRVRTHTMASDTSSLVQSHTYKKREPADVPYQ                               TGQLHPAIRVADLLQHITQMKCAEGYGFKEEYESFFEGQSAPW                               DSAKKDENRMKNRYGNIIAYDHSRVPLQTIEGDTNSDYINGNY                               IDGYHRPNHYIATQGPMQETIYDFWRMVRHENTASIIMVTNLV                               EVGRVKCCKYWPDDTEIYKDIKVTLIETELLAEYVIRTFAVEK                               RGVHEIREIRQFHFTGWPDHGVPYHATGLLGFVRQVKSKSPPS                               AGPLVVHCSAGAGRTGCFIVIDIMLDMAEREGVVDIYNCVREL                               RSRRVNMVQTEEQYVFIHDAILEACLCGDTSVPASQVRSLYYD                               MNKLDPQTNSSQIKEEFRTLNMVTPTLRVEDCSIALLPRRHEK                               NRCMDILPPDRCLPFLITIDGESSNYINAALMDSYKQPSAFIV                               TQHPLPNTVKDFWRLVLDYHCTSVVMLNDVDPAQLCPQYWPEN                               GVHRHGPIQVEFVSADLEEDIISRIFRIYNAARPQDGYRMVQQ                               FQFLGWPMYRDTPVSKRSFLKLIRQVDKWQEEYNGGEGRTVVH                               CLNGGGRSGTFCAISIVCEMLRHQRTVDVFHAVKTLRNNKPNM                               VDLLDQYKFCYEVALEYLNSG               452   1191   603   342   PLTYNKKYTYPWWGDALGWLLALSSMVCIPAWSLYRLGTLKGP                               FRERIRQLMCPAEDLPQRNPAGPSAPATPRTSLLRLTELESHC               453   1192   120   449   TLSESGALFSLGPPPLSLKSSSAPRPYSTLRDCLEHFAELFDL                               GFPNPLAERIIFETHQIHFANCSLGQPTFSDPPEDVLLAMIIA                               PKLIPFLITKVVWRSKDSEAQA               454   1193   1838   1066   CEEREQEKDDVDVAKLPTIVEKVILPKLTVIAENMWDPFSTTQ                               TSRMVGITLKLINGYPSVVNAENKNTQVYLKALLLRMRRTLDD                               DVFMPLYPKNVLENKNSGPYLFFQRQFWSSVKLLGNFLQWYGI                               FSNKTLQELSIDGLLNRYILMAFQNSEYGDDSIKKAQNVINCF                               PKQWFMNLKGERTISQLENFCRYLVHLADTIYPNSIGCSDVEK                               RNARENIKQIVKLLASVRALDHAMSVASDHNVKEFKSLIEGH               455   1194   112   1361   TPFCFLCSLVFRSRVWAEPCLIDAAKEEYNGVIEEFLATGEKL                               FGPYVWGRYDLLFMPPSFPFGGMENPCLTFVTPCLLAGDRSLA                               DVIIHEISHSWFGNLVTNANWGEFWLNEGFTMYAQRRISTIKF                               GAAYTCLEAATGRALLRQHMDITGEENPLNKKRVKIEPGVDPD                               DTYNETPYEKGFCFVSYLAHLVGDQDQFDSFLKAYVHEFKFRS                               ILADDFLDFYLEYFPELKKKRVDIIPGFEFDRWLNTPGWPPYL                               PDLSPGDSLMKPAEELAQLWAAEELDMKAIEAVAISPWKRYQL                               VYFLDKILQKSPLPPGNVKKLGDTYPSISNARNAELRLRWGQI                               VLKNDHQEDFWKVKEFLHNQGKQKYTLPLYHAMMGGSEVAQTL                               AKETFASTASQLHSNVVNYVQQIVAPKGS               456   1195   1   889   CASGSSGWRPVLWAGAFTMASAELDYTIEIPDQPCWSQKNSPS                               PGGKEAETRQPVVILLGWGGCKDKNLAKYSAIYHKRGCIVIRY                               TAPWHMVFFSESLGIPSLRVLAQKLLELLFDYEIEKEPLLFHV                               FSNGGVMLYRYVIELLQTRRFCRLRVVGTIFDSAPGDSNLVGA                               LRALAAILERRAAMLRLLLLVAFALVVVLFHVLLAPITALFHT                               HFYDRLQDAGSRWPELYLYSRADEVVLARDIERMVEARLARRV                               LARSVDFVSSAHVSHLRDYPTYYTSLCVDFMR\NRVRC               457   1196   2   295   PRVRDRLPSTGVRDRKGDKPWKESGGSVEAPRMGFTHPPGHLS                               GCQSSLASGETGTGSADPPGGPRPGLTRRAPVKDTPGRAPAAD                               AAPAGPSSCLG               458   1197   1299   682   QGRTSCIGLYTYQRRICKYRDQYNWFFLARPTTFAIIENLKYF                               LLKKDPSQPFYLGHTIKSGDLEYVGMEGGIVLSVESMKRLNSL                               LNIPEKCPEQGGMIWKISEDKQLAVCLKYAGVFAENAEDADGK                               DVFNTKSVGLSIKEAMTYHPNQVVEGCCSDMAVTFNGLTPNQM                               HVMMYGVYRLRAFG\HIFNDALVFLPPNGSDND               459   1198   779   61   HEGKPTRGRGRGGSLSTRGRGSEVPDSAHLAPTPLFSESGCCG                               LRSRFLTDCKMEEGGNLGGLIKMVHKLVLSGAWGMQMWVTFVS                               GFLLFRSLPRHTFGLVQSKLFPFYFHISMGCAFINLCILASQH                               AWAQLTFWEASQLYKLFLSLTLATVNARWLEPRTTAAMWALQT                               VEKERGLGGEVPGSRQGPDPYRQLREKDPKYSAKRQNFFRYHG                               LSSLCNLGCVLSNGKCLA\AKPWK               460   1199   517   815   KQLDKQLRADPSGSLPPKPPSPPPPLEAGGRPPEVP/PRGPSA                               VPSFPSVSGDWGGPVEAG/EGGQQGRGRARARPCSLPPLLPPS                               PVCRKSGSRAPLGCDG               461   1200   1   583   RNQLSSQKSVPWVPILKSLPLWAIVVAHFSYNWTFYTLLTLLP                               TYMKEILRFNVQENGFLSSLPYLGSWLCMILSGQAADNLRAKW                               NFSTLCVRRIFSLIGMIGPAVFLVAAGFIGCDYSLAVAFLTIS                               TTLGGFCSSGFSINHLDIAPSYAGILLGITNTFATIPGMVGPV                               IAKSLTPDMGISLHRPGWSAVA               462   1201   25   383   GPSGTTHASAHSGHPGSPRGSLSRHPSSQLAGPGVEGGEGTQK                               PRDYIILAILSCFCPMWPVNIVAFAYAVMSRNSLQQGDVDGAQ                               RLGRVAKLLSIVALVGGVLIIIASCVINLGVYK               463   1202   573   372   SLFLSFPPLSFKMTLNDANRNKARLSITGSTGENGRVMTPEFP                               KAVHAVPYVSPGMGMNVSVTDLS               464   1203   2018   491   DDVPPPAPDLYDVPPGLRRPGPGTLYDVPRERVLPPEVADGGV                               VDSGVYAVPPPAEREAPAEGKRLSASSTGSTRSSQSASSLEVA                               GPGREPLELEVAVEALARLQQGVSATVAHLLDLAGSAGATGSW                               RSPSEPQEPLVQDLQAAVAAVQSAVHELLEFARSAVGNAAHTS                               DRALHAKLSRQLQKMEDVHQTLVAHGQALDAGRGGSGATLEDL                               DRLVACSRAVPEDAKQLASFLHGNASLLFRRTKATAPGPEGGG                               TLHPNPTDKTSSIQSRPLPSPPKFTSQDSPDGQYENSEGGWME                               DYDYVHLQGKEEFEKTQKELLEKGSITRQGKSQLELQQLKQFE                               RLEQEVSRPIDHDLANWTPAQPLAPGRTGGLGPSDRQLLLFYL                               EQCEANLTTLTNAVDAFFTAVATNQPPKIFVAHSKFVILSAHK                               LVFIGDTLSRQAKAADVRSQVTHYSNLLCDLLRGIVATTKAAA                               LQYPSPSAAQDMVERVKELGHSTQQFRRRGQRR               465   1204   299   189   EMEEPQKSYVNTMDLERDEPLKSTGPQISVSEFSCHCCYDILV                               NPTTLNCGHSFCRHCLALWWASSKKTECPECREKWEGFPKVSI                               LLRDAIEKLFPDAIRLRFEDIQQNNDIVQSLAAFQKYGNDQIP                               LAPNTGRANQQMGGGFFSGVLTAKTGVAVVLLVRRWSSRESEH                               DLLVHKAVAKWTAEEVVLWLEQLGPWASLYRERFLSERVNGRL                               LLTLTEEEFSKTPYTIENSSHRRAILMELERVKALGVKPPQNL                               WEYKAVNPGRSLFLLYALKSSPRLSLLYLYLFDYTDTFLPFIH                               TICPLQEDSSGEDIVTKLLDLKEPTWKQWREFLVKYSFLPYQL                               IAEFAWDWLEVHYWTSRFLIINAMLLSVLELFSFWRIWSRSEL                               K*VGFRFLRLGVAALGSVEVAGLRGVVKGERPLLYGHGAGARF                               PHSVLLLPVAKPLPLPLLPRGLC               466   1205   2   242   EKARMIYEDYISILSPKEVSLDSRVREVINRNLLDPNPHMYED                               AQLQIYTLMHRDSFPRFLNSQIYKSFVESTAGSSSES               467   1206   2   619   LYYSQDEESKIMISDFGLSKMEGKGDVMSTACGTPGYVAPEVL                               AQKPYSKAVDCWSIGVIAYTLLCGYPPFYDENDSKLFEQILKA                               EYEFDSPYWDDISDSAKDFIRNLMEKDPNKRYTCEQAARHPWI                               AGDTALNKNIHESVSAQIRKNFAKSKWRQAFNATAVVRHMRKL                               HLGSSLDSSNASVSSSLSLASQKDCASGTFHAL               468   1207   1   352   RTRGGAVSFEDFIKGLSILLRGTVQEKLNWAFNLYDINKDGYI                               TKEEMLDIMKAIYDMMGKCTYPVLKEDAPRQHVETFFQKMDKN                               KDGVTIDEFIESCQKDENIMRSMQLFENVI               469   1208   3   1015   PRSPEHHTPAWHEGRSLGPIMASMADRNMKLFSGRVVPAQGEE                               TFENWLTQVNGVLPDWNMSEEEKLKRLMKTLRGPAREVMRVLQ                               ATNPNLSVADFLRAMKLVFGESESSVTAHGKFFNTLQAQGEKA                               SLYVIRLEVQLQNAIQAGIIAEKDANRTRLQQLLLGGELSRDL                               RLRLKDFLRMYANEQERLPNFLELIKMVREEEDWDDAFIKRKR                               PKRSESMVERAVSPVAFQGSPPIVIGSADCNVIEIDDTLDDSD                               EDVILVESQDPPLPSWGAPPLRDRARPQDEVLVIDSPHNSRAQ                               FPSTSGGSGYNGPGELARKRRTLCSYCGEE               470   1209   1543   1351   SVACTVPLRSMSDPDQDFDKEPDSDSTKHSTPSNSSNPSGPPS                               PNSPHRSQLPLEGLEQPACDT               471   1210   3   952   YSAVEFAERGSGGSSGDELREDDEPVKKRGRKGRGRGPPSSSD                               SEPEAELEREAKKSAKKPQSSSTEPARKPGQKEKRVRPEEKQQ                               AKPVKVERTRKRSEGFStRRKVEKKKEPSVEEKLQKLHSEIKF                               ALKVDSPDVKRCLNALEELGTLQVTSQILQKNTDVVATLKKIR                               RYKANKDVMEKAAEVYTRLKSRVLGPKIEAVQKVNKAGMEKEK                               AEEKLAGEELAGEEAPQEKAEDKPSTDLSAPVNGEATSQKGES                               AEDKEHEEGRDSEEGPRCGSSEDLHDSVREGPDLDRPGSDRQE                               RERARGDSEALDEES               472   1211   5204   2902   LAELSSLSVLRLSHNSISHIAEGAFKGLRSLRVLDLDHNEISG                               TIEDTSGAFSGLDSLSKLTLFGNKIKSVAKRAFSGLEGLEHLN                               LGGNAIRSVQFDAFVKMKNLKELHISSDSFLCDCQLKWLPPWL                               IGRNLQAFVTATCAHPESLKGQSIFSVPPESFVCDDFLKPQII                               TQPETTMAMVGKDIRFTCSAASSSSSPMTFAWKKDNEVLTNAD                               MENFVHVHAQDGEVMEYTTILHLRQVTFGHEGRYQCVITNHFG                               STYSHKARLTVNVLPSFTKTPHDITIRTTTMARLECAATGHPN                               PQIAWQKDGGTDFPAARERRMHVMPDDDVFFITDVKIDDAGVY                               SCTAQNSAGSISANATLTVLETPSLVVPLEDRVVSVGETVALQ                               CKATGNPPPRITWFKGDRPLSLTERHHLTPDNQLLVVQNVVAE                               DAGRYTCEMSNTLGTERAHSQLSVLPAAGCRKDGTTVGIFTIA                               VVSSIVLTSLVWVCIIYQTRKKSEEYSVTNTDETVVPPDVPSY                               LSSQGTLSDRQETVVRTEGGPQANGHIESNGVCPRDASHFPEP                               DTHSVACRQPKLCAGSAYHKKPWKAMEKAEGTPGPHKMEHGGR                               VVCSDCNTEVDCYSRGQAFHPQPVSRDSAQPSAPNGPEPGGSD                               QEHSPHHQCSRTAAGSCPECQGSLYPSNHDRMLTAVKKKPMAS                               LDGKGDSSWTLARLYHPDSTELQPASSLTSGSPERAEAQYLLV                               SNGHLPKACDASPESTPLTGQLPGKQRVPLLLAPR               473   1212   2   2466   AAAGAARRVSVRCGRSGPGPGRGAAGLSPADIALASEQGASCS                               VRAPERKLRNKLLWQAKMSSIQDWGEEVEEGAVYHVTLKRVQI                               QQAANKGARWLGVEGDQLPPGHTVSQYETCKIRTIKAGTLEKL                               VENLLTAFGDNDFTYISIFLSTYRGFASTKEVLELLLDRYGNL                               TSPNCEEDGSQSSSESKMRTLNAIASILPAWLDQCAEDFREPP                               HFPCLQKLLDYLTRMMPGSDPERRAQNLLEQFQKQEVETDNGL                               PNTISFSLEEEEELEGGESAEFTCFSEDLVAEQLTYMDAQLFK                               KVVPHHCLGCIWSRRDKKENKHLAPTIRATISQFNTLTKCVVS                               TILGGKELKTQQRAKIIEKWINIAHECRLIKNFSSLRAIVSAL                               QSNSIYRLKKTWAAVPRDRMLMFEELSDIFSDHNNHTTSRELL                               MKEGTSKFANLDSSVKENQKRTQRRLQLQKDMGVMQGTVPYLG                               TFLTDLTMLDTALQDYIEGGLINFEKRRREFEVIAQIKKLQSA                               CNSYCMTPDQKFIQWFQRQQLLTEEESYALSCEIEAAADASTT                               SPKPWKSMVKRLNLLFLGADMITSPTPTKEQPKSTASGSSGES                               MDSVSVSSCESNHSEAEEGYITPMDTPDEPQKKLSESSSYCSS                               IHSMDTNFLQGMSSLINPLSSPPSCNNNPKIHKRSVSVTSITS                               TVLPPVYNQQNEDTCIIRISVEDNNGNMYKSIMLTSQDKTPAV                               IQRANLKHNLDSDPAEEYELVQVISEDKELVIPDSANVFYAMN                               SQVNFDFILRKKNSMEEQVKLRSRTSLTLPRTAKRGCWSNRHS                               KITL               474   1213   1   867   AREKMDSCIEAFGTTKQKRALNTRRMNRVGNESLNRAVAKAAE                               TIIDTKGVTALVSDAIHNDLQDDSLYLPPCYDDAAKPEDVYKF                               EDLLSPAEYEALQSPSEAFRNVTSEEILKMIEENSHCTFVIEA                               LKSLPSDVESRDRQARCIWFLDTLIKFRAHRVVKRKSALGPGV                               PHIINTKLLKHFTCLTYNNGRLRNLISDSMKAKITAYVIILAL                               HIHDFQIDLTVLQRDLKLSEKRNMEIAKAMRLKISKRRVSVAA                               GSEEDHKLGTLSLPLPPAQTSDRLAKRRKIT               475   1214   2   2621   LSLFGSRALGRSGARAMAKAKKVGARRKASGAPAGARGGPAKA                               NSNPFEVKVNRQKFQILGRKTRHDVGLPGYSRARALRKRTQTL                               LKEYKERDKSNVFRDKRFGEYNSNMSPEEKMMKRFALEQQRHH                               EKKSIYNLNEDEELTHYGQSLADIEKHNDIVDSDSDAEDRGTL                               SGELTAAHFGGGGGLLHKKTQQEGEEREKPKSRKELIEELIAK                               SKQEKRERQAQREDALELTEKLDQDWKEIQTLLSHKTPKSENR                               DKKEKPKPDAYDMMVRELGFEMKAQPSNRMKTEAELAKEEQEH                               LRKLEAERLRRMLGKDEDENVKKPKHMSADDLNDGFVLDKDDR                               RLLSYKDGKMNVEEDVQEEQSKEASDPESNEEEGDSSGGEDTE                               ESDSPDSHLDLESNVESEEENEKPAKEQRQTPGKGLISGKERA                               GKATRDELPYTFAAPESYEELRSLLLGRSMEEQLLVVERIQKC                               NHPSLAEGNKAKIREKLFGFLLEYVGDLATDDPPDLTVIDKLW                               HLYHLCQMFPESASDAIKFVLRDANHEMEEMIETKGRAALPGL                               DVLIYLKITGLLFPTSDFWHPVVTPALVCLSQLLTKCPILSLQ                               DVVKGLFVCCLFLEYVALSQRFIPELINFLLGILYIATPNKAS                               QGSTLVHPFRALG1RSELLVVSAREDVATWQQRSLSLRWASRL                               RAPTSTEANHIRLSCLAVGLAKKKRCVLMYGSLPSFHAIMGPL                               RALLTDHLADCSHPQELQELCQSTLTEMESQKQLCRPLTCEKS                               KPVPLKLFTPRLVKVLEFGRKQGSSKEEQERKRLIHKHKREFK                               GAVREIRKDNQFLARMQLSEIMERDAERKRKVKQLFNSLATQE                               GEWKALKRKKFKK               476   1215   3   961   LTKQEDCCGSIGTAWGQSKCHKCPQLQYTGVQKPGPVRGEVGA                               DCPQGYKRLNSTHCQDINECAMPGVCRHGDCLNMPGSYRCVCP                               PGHSLGPSRTQCIADKPEEKSLCFRLVSPEHQCQHPLTTRLTR                               QLCCCSVGKAWGARCQRCPTDGTAAFKEICPAGKGYHILTSHQ                               TLTIQGESDFSLFLRPDGPPKPQQLPESPSQAPPPEDTEEERG                               VTTDSPVSEERSVQQSHPTATTTPARPYPELISRPSPPTMRWF                               LPDLPPSRSAVEIAPTQVTETDECRLNQNICGHGECVPGPPDY                               SCECNPGYRSRPQHRYCV               477   1216   3652   1207   MAGGHCGSFPAAAAGSGEIVQLNVGGTRFSTSRQTLMWIPDSF                               FSSLLSGRISTLRDETGAIFIDRDPAAFAPILNFLRTKELDLR                               GVSINVLRHEAEFYGITPLVRRLLICEELERSSCGSVLFHGYL                               PPPGIPSRKINNTVRSADSRNGLNSTEGEARGNGTQPVLSGTG                               EETVRLGFPVDPRKVLIVAGHHIWIVAAYAHFAVWYRIKESSG                               WQQVFTSPYLDWTIERVALNAKVVGGPHGDKDKMVAVASESSI                               ILWSVQDGGSGSEIGVFSLGVPVDALFFIGNQLVATSHTGKSG                               VWNAVTQHWQVQDVVPITSYDTAGSFLLLGRNNGSIYYIDMQK                               FPLRMKDNDLLVTELYHDPSNDAITALSVYLTPKTSVSGNWIE                               IAYGTSSGAVRVIVQHPETVGSGPQLFQTFTVHRSPVTKIMLS                               EKHLVSVCADNNHVRTWTVTRFRGMISTQPGSTPLASFKILSL                               EETESHGSYSSGNDIGPFGERDDQQVFIQKVVPITNKKFVRLS                               STGKRICEIQAVDCTTISSFTGRECEGSSRMGSRPRRYLFTGH                               TNGSIQMWDLTTAMDMVNKSEDKDVGGPTEEELLKLLDQCDLS                               TSRCATPNISPATSVVQHSHLRESNSSLQLQHHDTTHEAATYG                               SMRPYRESPLLARARRTESFHSYRDFQTINLNRNVERAVPENG                               NLGPIQAEVKGATGEcNISERKSPGVEIKSLRELDSGLEVHKI                               AEGFSESKKRSSEDENENKIEFRKKGGFEGGGFLGRKKVPYLA                               SSPSTSDGGTDSPGTASPSPTKTTPSPRHKKSDSSGQEYSL               478   1217   1   1379   RRPTRPILTDELFKRTIQLPHLKTLILNGNKLETLSLVSCFAN                               NTPLEHLDLSQNLLQHKNDENCSWPETVVNNNLSYNKLSDSVF                               RCLPKSIQILDLNNNQIQTVPKETIHLMALRELNIAFNFLTDL                               PGCSHFSRLSVLNIEMMFILSPSLDFVQSCQEVKTLNAGRNPF                               RCTCELKNFIQLETYSEVMMVGWSDSYTCEYPLNLRGTRLKDV                               HKHELSCNTALLIVTIVVIMLVLGLAVAFCCLHFDLPWYLRML                               GQCTQTWHRVRKTTQEQLKRNVRFHAFISYSEHDSLNVKNELI                               PNLEKEDGSILKKYESYFDPGKSISENIVSFIEKSYKSIFRTL                               SPNFVQNEWCHYEFYFAHHNLFHENSDHIILILLEPIPFYCIP                               TRYHKLKALLEKKAYLREWPKDRRKCGLFWANLRAINVNVLAT                               REMYELQTFTELNEESRGSTISLMRTDCL               479   1218   1   1099   PTRPPTRPPTRPLLTPSWTSTGRMWSHLNRLLFWSIFSSVTCR                               KAVLDCEAMKTNEFPSPCLDSKTKVVMKGQNVSMFCSHKNKSL                               QITYSLFRRKTHLGTQDGKGEPAIFNLSITEAHESGPYKCKAQ                               VTSCSKYSRDFSFTIVDPVTSPVLNIMVIQTETDRHITLHCLS                               VNGSLPINYTFFENHVAISPAISKYDREPAEFNLTKKNPGEEE                               EYRCEAKNRLPNYATYSHPVTMPSTGGDSCPFCLKLLLPGLLL                               LLVVIILILAFNVLPKYKTRKAMRNNVPRDRGDTANEVGIYAR                               ILEKQAKEESVPEVGSRPCVSTAQDEAKRSQELQYATPVFQEV                               APREQEACDSYKSGYVYSELNF               480   1219   1   293   FFFFEERRTGSHSVGHPRMEYSGVSMAHCSKNLLGSSNSPSSA                               SQDARTTGACQHAQLIGFFFF\VETASPQVTHAG/LKHLVSRN                               PSAVTSQSARIKT               481   1220   1   727   NREGARKIQNKWLRPSPRSHRTPESVSPERYSYGTSSSSKRTE                               GSCRRRRQSSSSANSQQGQWETGSPPTKRRRRSRGRPSGGAKR                               RRRGAPAAPQQQSEPARPSSEGKVTCDIRLRVRAEYCEHGPAL                               EQGVASRRPQALARQLDVFGQATAVLRSRDLGSVVCDIKFSEL                               SYLDAFWGDYLSGALLQALRGVFLTEAKREAVGREAVLLLVSV                               DEADYEAGRRRLLLMEEEGGRRPTEAS               482   1221   1   1321   APNTAELRICRVNIGWGSVRGGDEIFLLCDKVQKDDIEVRFVL                               NDWEAKGIFSQADVHRQVAIVFKTPPYCKAITEPVTVKMQLRR                               PSDQEVSESMDFRYLPDEKDTYGNKAXKQKTTLLFQKLCQDHV                               ETGFRRVDQDGLELLTSGDPPTLASQSAGITVNFPERPRPGLL                               GSIGEGRYFKKEPNLFSHDAVVREMPTGVSSQAESYYPSPGPI                               SSGLSHHASMAPLPSSSWSSVAHPTPRSGNTNPLSSFSTRTLP                               SNSQGIPPFLRIPVGNDLNASNACIYNNADDIVGMEASSMPSA                               DLYGISDPNMLSNCSVNMMTTSSDSMGETDNPRLLSMNLENPS                               CNSVLDPRNLRQLHQMSSSSMSAGANSNTTVFVSQSDAFEGSD                               FSCANNSMINESGPSNSTNPNSHGFVQDSQYSGIGSMQNEQLS                               DSFPYEFFQV               483   1222   1   1311   RRLSLLDLQLGPLGRDPPQECSTFSPTDSGEEPGQLSPGVQFQ                               RRQNQRRFSMEDVSKRLSLPMDIRLPQEFLQKLQMESPDLPKP                               LSRMSRRASLSDIGFGKLETYVKLDKLGEGTYATVFKGRSKLT                               ENLVALKEIRLEHEEGAPCTAIREVSLLKNLKHANIVTLHDLI                               HTDRSLTLVFEYLDSDLKQYLDHCGNLMSMHNVKIFMFQLLRG                               LAYCHHRKILHRDLKPQNLLINERGELKLADFGRARAKSVPTK                               TYSNEVVTLWYRPPDVLLGSTEYSTPIDMWGVGCIHYEMATGR                               PLFPGSTVKEELHKINRLLRTPTEETWPGVTAFSEFRTYSFPC                               YLPQPLINHAPRLDTDGIHLLSSLLLYESKSRLSAEAAKSHSY                               FRSLGERVHQLEDTASIFSLKEIQLQKDPGYRGLAFQQPGRGK                               NRRQSIF               484   1223   807   356   CTPHGSSSSWKIPLWPRHMSPLHSCLPVGTSTSSGPLAVPRDC                               FHLCCLWGQLLLISCPLACGQGCRVAGGQQHVPGQALGTLSPL                               VSLLTWAGPSLDWPHPGSLVTPRCPILPAVPVLVKGLGGWPPT                               RPSRAAPVSGPWDQLPYFPGL               485   1224   1199   370   LISPVWGNIQRSRSVPLFPSGLVLGGIWARGPLLAKLASFNII                               SVLNAECYLKQILHPTSHFTVSETPPLSGNDTDSLSCDSGSSA                               TSTPCVSRLVTGHHLWASKNGRHVLGLIEDYEALLKQISQGQR                               LLAERDIQTQEAPSSTSQELGTKGPHPAPLSKFVSSVSTAKLT                               LEEAYRRLKLLWRVSLPEDGQCPLHCEQIGEMKAEVTKLHKKL                               FEQEKKLQNTMKLLQLSKRQEKVIFDQLVVTHKILRKARGNLE                               LRPGGAHPGTCSPSRPGS               486   1225   2469   1660   LGLFCILPIDTLCAVLERDTLSIRESRLFGAVVRWAEAECQRQ                               QLPVTFGNKQKVLGKALSLIRFPLMTIEERAAGPAQSGILSDR                               EVVNLFLHFTVNPKPRVEYIDRPRCCLRGKECCINRFQQVESR                               WGYSGTSDIRLFTVNPRISIVGFGLYGSIHGPTDYQVNIQIIE                               YEKKQTLGQNDTGFSCDGTANTFRVMFKEPIEILPNVCYTACA                               TLKGPDSHYGTKGLKKVVHETPAASKTVFFFFSSPGNNNGTSI                               EDGQIPEIIFYT               487   1226   1193   372   SVWWNSEVKDWMQKKRRGLRNSRATAGDIAHYYRDYVVKKGLG                               HNFVSGAVVTAVEWGTPDPSSCGAQDSSPLFQVSGFLTRNQAQ                               QPFSLWARNVVLATGTFDSPARLGIPGEALPFIHHELSALEAA                               TRVGAVTPASDPVLIIGAGLSAADAVLYARHYNIPVIHAFRRA                               VDDPGLVFNQLPKMLYPEYHKVHQMMREQSILSPSPYEGYRSL                               PRHQLLCFKEDCQAVFQDLEGVEKVFGVSLVLVLIGSHPDLSF                               LPGAG\LTLQWILTSR               488   1227   756   1016   KLRPFIFSNQSLWLHSYEGAELEKTFIKGSWATFWVKVASCWA                               CVKLYLGLLLAPLCWPPTQKPQPLILRRRRHRIISPDNKYPPV               489   1228   1   747   QLIHLSHGYQIHWTDYYNVGTGRPEFGTRAAHKSLAGAELKTL                               KDFVTVLAXLFPGRPPVKKLLEMIQEWLASLPLDRIPYNAVLD                               LVNNKMRISGIFLTNHIKWVGCQGSRSELRGYPCSLWKLFHTL                               TVEASTHPDALVGTGFEDDPQAVLQTMRRYVHTFFGCKECGEH                               FEEMAKESMDSVKTPDQAILWLWKKHNMVNGRLAGEKPLGMGG                               SARAEGGPGPGTARTARKPWGLSLSFAASCHPLC               490   1229   4797   2398   HGGATFINAFVTTPMCCPSRSSMKTGKYVHNHNVYTNNENCSS                               PSWQANHEPRTFAVYLNNTGYRTAFFGKYLNEYNGSYIPPGWR                               EWLGLIKNSRFYNYTVCRNGIKEKHGFDYAKDYFTDLITNESI                               NYFKMSKRMYPHRPVMMVISHAEPHGPEDSAPQFSKLYPNASQ                               HITPSYNYAPNNDKHWIMQYTGPMLPIHMEFTNILQRKRLQTL                               MSVDDSVERLYNMLVETGELENTYIIYTRDHGYHIGQFGLVKG                               KSMPYDFDIRVPFFIRGPSVEPGSIVPQIVLNIDLAPTILDIA                               GLDTPPDVDGKSVLKLLDPEKPGNRFRTNKKAKIWRDTFLVER                               GKFLRKKEESSKNIQQSNHLPKYERVKELCQQARYQTACEQPG                               QKWQCIEDTSGKLRIHKCKGPSDLLTVRQSTRNLYARGFHDKD                               KECSCRESGYRASRSQRKSQRQFLRNQGTPKYKPRFVHTRQTR                               SLSVEFEGEIYDINLEEEEELQVLQPRNIAKRHDEGHKGPRDL                               QASSGGNRGRMLADSSNAVGPPTTVRVTHKCFILPNDSIHCER                               ELYQSARAWKDHKAYIDEEIEALQDKIKNLREVRGHLKRRKPE                               ECSCSKQSYYNKEKGVKKQEKLKSHLHPFKEAAQEVDSKKQLF                               KENNRRRKKERKEKRRQRKGEECSLPGLTCFTHDNNHWQTAPF                               WNLGSFCACTSSNNNTYWCLRTVNETHNFLFCEFATGFLEYFD                               MNTDPYQLTNTVHTVERGILNQLHVQLMELRSCQGYKQCNPRP                               KNLDVGNKDGGSYDLHRGQLWDGWEG               491   1230   2480   385   HLLIAQELADRVGEGRACWSLGNAYVSMGRPAQALTFAKKHLQ                               ISQEIGDRHGELTARMNVAQLQLVLGRLTSPAASEKPDLAGYE                               AQGARPKRTQRLSAETWDLLRLPLEREQNGDSHHSGDWRGPSR                               DSLPLPVRSRKYQEGPDAERRPREGSHSPLDSADVRVHVPRTS                               IPRAPSSDEECFFDLLTKFQSSRMDDQRCPLDDGQAGAAEATA                               APTLEDRIAQPSMTASPQTEEFFDLIASSQSRRKDDQPASVGS                               LPGLRITHSNAGHLRGHGEPQEPGDDFFNNLIKYQSSPIDDQR                               CPPPDVLPRGPTMPDEDFFSLIQRVQAKRNDEQRVDLAGGPGA                               GGRRPARAPAAVPAWCELRPCAHPQAHPAPTPGRRSHSHSHVL                               PRPLPRTGTGHAAPRPPRPRATGSGQAARGGRACFHPGLAPMA                               LSFLPSAPAAGRTGPSACRPRPGAVRLPHPLPQALPVLPCPAK                               CETLLSPSPSPKVSLSRLLGPPRTGPCSVPPELVLGWPCDRRA                               PPLQLRPGAGLPPSLSPHSPARGQQPQKAPQTTHGRPGCSGSP                               EVPPAESQGPAGASTGAGPISKAEGMAGHELPHSKTPSQEKGQ                               GLVLGMLTGSKSSAQSGWEVAPGSVTLTQVGGWSVEAGEASLS                               STLQTPHMRTPLLPPAGGDDITAKSMGRGLTGHQVRDPRTGRT                               CWSLRWAPGA               492   1231   3   398   NSAADLAIFALWGLKPVVYKLASSFLGLGLHPISGHFVAEHYM                               FLKGHETYSYYGPLNWITFRVGYHVEHHDFPSIPGYNLPLVRK                               IAPEYYDHLPQHHSWVKVLWDFVFEDSLGPYARVKRVYRLAKD                               GL               493   1232   1   214   QESGFSCKGPGQNVAVTRAHPDSQGRRRRPERGARGGQVFYNS                               EYGELSEPSEEDHCSPSARVTFFTDNSY               494   1233   3   443   VIVHARPIRTRASKYYIPEAVYGLPAYPAYAGGGGFVLSGATL                               HRLAGACAQVELFPIDDVFLGMCLQRLRLTPEPHPAFRTFGIP                               QPSAAPHLSTFDPCFYRELVVVHGLSAADIWLMWRLLHGPHGP                               ACAHPQPVAAGPFQWDS               495   1234   1   897   MASAACSMDPIDSFELLDLLFDRQDGILRHVELGEGWGHVKDQ                               VLPNPDSDDFLSSILGSGDSLPSSPLWSPEGSDSGISEDLPSD                               PQDTPPRSGPATSPAGCHPAQPGKGPCLSYHPGNSCSTTTPGP                               VIQQQHHLGASYLLRPGAGHCQELVLTEDEKKKLAKEGITLPT                               QLPLTKYEERVLKKIRRKIRNKQSAQESRKKKKEYIDGLETRS                               CCCPLPSSSSPPSALLAPTKPRALGTLRLYECSPELCTTMLPP                               AWLLMLCQAPRPQDPDPRLTQPEKSLQEAPGQTGASRTPRT               496   1235   4235   940   ARGRRSRPVWAASWGGRGRPAARRRPRGLAATMGFELDRFDGD                               VDPDLKCALCHKVLEDPLTTPCGHVFCAGCVLPWVVQEGSCPA                               RCRGRKSAKELNHVLPLKRLILKLDIKCAYATRGCGRVVKKQQ                               LPEHLERCDFAPARCRHAGCGQVLLRRDVEAHMRDACDARPVG                               RCQEGCGLPLTHGEQRAGGHCCARALRAHNGALQARLGAIHKA                               LKKEALRAGKREKSLVAQLAAAQLELQMTALRYQKKFTEYSAR                               LDSLSRCVAAPPGGKGEETKSLTLVLHRDSGSLGFNIIGGRPS                               VDNHDGSSSEGIFVSKIVDSGPAAKEGGLQIHDRIIEVNGRDL                               SRATHDQAVEAFKTAKEPIVVQVLRRTPRTKMFTPPSESQLVD                               TGTQTDITFEHIMALTKMSSPSPPVKDPYLLPEEHPSAHEYYD                               PNDYTGDIHQEMDREELELEEVDLYRNNSQDKLGLTVCYRTDD                               EDDIGIYISEIDPNSIAAKDGRIREGDRIIQINGIEVQNREEA                               VALLTSEENKNFSLLIARAELQLDEGWMDDDRNDFLDDLHMDM                               LEEQHHQAMQFTASVLQQKKHDEDGGTTDTATILSNQHEKDSG                               VGRTDESTPNDESSEQENNGDDATASSNPLAGQRKLTCSQDTL                               GSGDLPFSNKSFISPECTGAAYLGIPVDECERFRELLELKCQV                               KSATPYGLYYPSGPLDAGKSDPESVDKELELLNEELRSIELEC                               LSIVRAHKMQQLKEQYRESWMLHNSGFRNYNTSIDVRRBELSD                               ITELPEKSDKDSSSAYNTGESCRSTPLTLEISPDNSLRRAAEG                               ISCPSSEGAVGTTEAYGPASKNLLSITEDPEVGTPTYSPSLKE                               LDPNQPLESKERPASDGSRSPTPSQKLGSAYLPSYHHSPYKHA                               HIPAHAQHYQSYMQLIQQKSAVEYAQSQMSLVSMCKDLSSPTP                               SEPRMEWKVKIRSDGTRYITKRPVRDRLLRERALKIREERSGM                               TTDDDAVSEMKMGRYWSKEERKQHLVKAKEQRRRREFMMQSRL                               DCLKEQQAANDRKEMNILELSHKKMMKKRNKKIFDNWMTIQEL                               LTHGTKSPDGTRVYNSFLSVTTV               497   1236   2   157   FFFLVEMGFCHVGQGGLTLIGSSNLPASASKSAGITGVSHCAR                               PDFKSCVE               498   1237   1   211   LAGRKVLLFVSGRVVGWGPITWLLMSEVKPLRARGVASGLCVL                               ASWLTAFVLTKSFLPGGVSVQPQAPGP               499   1238   2   345   FWAPGPPGVGAAVGDASTRSLRESCPSPSPGRLRRTTAPWSSQ                               ARAAAPAPSSSCRGPDGASSPRDLPWRPWKILRRTPLSGDVEL                               SQVHPDQRILRRFILSRTCGNTIPGMAE               500   1239   1   523   MRRFLSKVYSFPMRKLILFLVFPVVRQTPTQHFKNQFPAKHWE                               HELGLAFTKNRMNYTNKFLLIPESGDYFIYSQVTFRGMTSECS                               EIRQAGRPNKPDSITVV1TKVTDSYPEPTQLLMGTKSVCEVGS                               NWFQPIYLGAMFSLQEGDKLMVNVSDISLVDYTKEDKTFFGAF                               LL               501   1240   2   1277   FVWDEVAQRSGCEERWLVIDRKVYNISEFTRRHPGGSRVISHY                               AGQDATDPFVAFHINKGLVKKYMNSLLIGELSPEQPSFEPTKN                               KELTDEFRELRATVERMGLMKANHVFFLLYLLHILKLDGAAWL                               TLWVFGTSFLPFLLCAVLLSAVQAQAGWLQHDFGHLSVFSTSK                               WNHLLHHFVIGHLKGAPASWWNHMHFQHHAKPNCFRKDPDINM                               HPFFFALGKILSVELGKQKKKYMPYNHQHKYFFLIGPPALLPL                               YFQWYIFYFVIQRKKKVDLAWMITFYVRFFLTYVPLLGLKAFL                               GLFFIVRFLESNWFVWVTQMNHIPMHIDHDRNMDWVSTQLQAT                               CNVHKSAFNDWFSGHLNFQIEHHLFPTMPRHNYHKVAPLVQSL                               CAKHGIEYQSKPLLSAFADIIHSLKESGQLWLDAYLHQ               502   1241   999   540   QCGGIPYNTTQFLMNDRDPEEPNLDVPHGISHPGSSGESEAGD                               SDGRGRAHGEFQRKDFSETYERFHTESLQGRSKQELVRDYLEL                               EKRLSQAEEETRRLQQLQACTGQQSCRQVEELAAEVQRLRTEN                               QRLRQENQMWNREGCRCDEEPGT               503   1242   1448   875   SPERSSLSVGREKAMEVPPPAPRSFLCRALCLFPRVFAAEAVT                               ADSEVLEERQKRLPYVPEPYYPESGWDRLRELFGKD\VTGSLF                               RINVGLRGLVAGGIIGALLGTPVGGLLMAFQKYSGETVQERLQ                               KDRKALHELKLEEWKGRLQVTEHLPEKIESSLQEDEPENDAKK                               IEALLNLPRNPSVIDKQDKD               504   1243   149   1293   RSLGLAVTEMVPWVRTMGQKLKQRLRLDVGREICRQYPLFCFL                               LLCLSAASLLLNRYIHILMIFWSFVAGVVTFYCSLGPDSLLPN                               IFFTIKYKPKQLGLQELFPQGHSCAVCGKVKCKRHRPSLLLEN                               YQPWLDLKISSKVDASLSEVLELVLENFVYPWYRDVTDDESFV                               DELRITLRFFASVLIRRIHKVDIPSIITKKLLKAAMKHIEVIV                               KARQKVKNTEFLQQAALEEYGPELHVALRSRRDELHYLRKLTE                               LLFPYILPPKATDCRSLTLLIREILSGSVFLPSLDFLADPDTV                               NHLLIIFIDDSPPEKATEPASPLVPFLQKFAEPRNKKPSVLKL                               ELKQLEQQDLLFRFMNFLKQEGAVHVLHVLFDCGGI               505   1244   2   1116   QSLAEVLQQLGASSELQAVLSYIFPTYGVTPNHSAFSMHALLV                               LHYMKGGFYPRGVTSEIAFHTIPVIQRAGGAVLTKATVQSVLL                               DSAGKACGVSVKKGHELVNIYCPIVVSNAGLFNTYEHLLPGNA                               RCLPGVKQQLGTVRPGLGMTSVFICLRGTKEDLELPSTNYYVY                               YDTDMDQAMERYVSMPREEAAEHIPLLFFAFPSAKDPTWEDRF                               PGRSTMIMLIPTAYEWFEEWQAELKGK\RGSDYETFKNSFVEA                               SMSVVLKLFPQLEGKVESVTAGSPLTNQFYL\AAPRGACYGAD                               HDLGRLHPCVMASLRAQSPIPNLYLTGQDIFTCGLVGALQGAL                               LCSSTILINLYSDLKNLDSRLAQKKKN               506   1245   1759   873   RPQETRVLQVSCGRAHSLVLTDREGVFSMGNNSYGQCGRKVVE                               NEIYSESHRVHRMQDFDGQVVQVACGQDHSLFLTDKGEVYSCG                               WGADGQTGLGHYNITSSPTKLGGDLAGVNVIQVATYGDCCLAV                               SANGGLFGWGNSEYLQLASVTDSTQVNVPRCLHFSGVGKVRQA                               ACGGTGCAVLNGEGHVFVWGYGILGKGPNLVESAVPEMIPPTL                               FGLTEFNPEIQVSRIRCGLSHFAALTNKGELFVWGKNIRGCLG                               IGRLEDQYFPWRVTMPGEPVDVACGVDHMVTLAKSFI               507   1246   520   2   LPFREWLMIVVSLSAAAVAAAFMAKCRLVLSSRYFCSHFVMSA                               SRARIRSSFSRTSSRRAGALYSGMLAGWPFPCFCWVLSASSSL                               SSQVRSLRSICSRFSHADCSWVRACCSFSTFSTYACFSRNSSS                               SLMTLAWALLKAWSRISMCLRWSSLAVRTAANSISNFSFSFKN               508   1247   1   1083   MQAVRATASQSLSCARAPREPTQHALRAHWFPPAAAVQPSPHS                               GVAAAAGTWSSAFRGEHPLVSSGLLLGVREQSFRLLRSKAGTH                               MYLEHTSHCPHHDDDTAMDTPLPRPRPLLAVERTGQRPLWAPS                               LELPKPDMQPLPAGAFLEEVAEGTPAQTESEPKVLDPEEDLLC                               IAKTFSYLRESGWYWGSITASEARQHLQKMPEGTFLVRDSTHP                               SYLFTLSVKTTRGPTNVRIEYADSSFRLDSNCLSRPRILAFPD                               VVSLVQHYVASCTADTRSDSPDPAPTPAKPMPKEDAPSDPAKP                               APPPATAVHLKLVQPFVRRSSARSLQHLCRLVINRLVADVDCL                               PLPRRMADYLRQYPFQL               509   1248   2   841   FVDIFQRWKECRGKSPAQAELSYLNKAXWLEMYGVDMHVVRGR                               DGCEYSLGLTPTGILIFEGANKIGLFFWPKITKMDFKKSKLTL                               VVVEDDDQGREQEHTFVFRLDSARTCKHLWKCAVEHHAFFRLR                               TPGNSKSNRSDFIRLGSRFRFSGRTEYQATHGSRLRRTSTFER                               KPSKRYPSRRHSTFKASNPVIAAQLCSKTNPEVHNYQPQYHPN                               IHPSQPRWHPHSPNVRPSFQDDRSHWKASASGDDSHFDYVHDQ                               NQKNKGGMQSMMYRDKLMTAK               510   1249   2   763   GGIRLIQKLTWRSRQQDRENCAMKGKHKDECHNFIKVFVPRND                               EMVFVCGTNAFNPMCRYYRVSIFYVICFF*STFLPSLICC*5*                               NLSAFQ*FVLSLVQ*KNKDRILQMEF*YK*NSIAFKRAR*IDM                               TLAIYFSFV\LSTL*YDGEEISGLARCPFDARQTNGALFADGK                               LYSATVADFLASDAVIYRSMGDGSALRTIKYDSKWIKE/PHFL                               YAIK/Y/GNYVYFSFREIVAT**LG/KAVDS/RVARYEKQLVG                               PTV               511   1250   1555   629   ARALARERESESARADDVTLGVSAILAVDRGGNLGSA\DGWAY                               IDVEVRRPWAFVGPGCSRSSGNGSTAYGLVGSPRWLSPFHTGG                               AVSLPRRPRGPGPVLGVARPCLRCVLRPE\HYEPGSHYSGFAG                               RDASRAFVTGDCSEAGLVDDVSDLSAAEMLTLHNWLSFYEKNY                               VCVGRVTGRFYGEDGLPTPALTQVEAAITRGLEANKLQLQEKQ                               TFPPCNAEWSSARGSRLWCSQKSGGVSRDWIGVPRKLYKPGAK                               EPRCVCVRTTGPPSGQMPDNPPRRNRGDLDHPNLAEYTGCPPL                               AITCSFPL               512   1251   1100   798   YFIICRDGVLLFCPGWSQTPGAQAILLHWATQNAGMTDMSHSA                               QPIYLFIYLIRTRSHYVAQAGQLLDSNDSPNVASQNVGITGMS                               HHAWLKIVLYFCII               513   1252   3   1395   PAARPPSLVRLSPSPPKPRARARAPQSVEPAAPLVARGSSPPA                               RPAPAVRPRRAPYRSGAGGPLGGRGRPPIRPLVVRAVRSRSWP                               ASPRGPQPPR\IRARSAPPMEGARVFGALGPIGPSSPGLTLGG                               LAVSEHRLSNKLLAWSGVLEWQEKPRPYSDSTAKLKRTLPCQA                               YVNQGENLETDQWPQKLIMQLIPQQLLTTLGPLFRNSQLAQFH                               FTNRDCDSLKGLCRIMGNGFAGCMLFPRISPCEVRVLMLLYSS                               KKKIFMGLIPYDQSGFVSAIRQVITTRKQAVGPGGVMSGPVQI                               VNNKFLAWSGVMEWQEPRPEPNSRSKRWLPSHVYVNQGEILRT                               EQWPRKLYMQLIPQQLLTTLVPLFLNSRLVQFHFTKDLETLKS                               LCRIMDNGFAGCVHFSYKASCEIRVLMLLYSSEKKIFIGLIPH                               DQGNFVNGLRVIANQQQVLQRNLEQEQQQRGMGG               514   1253   320   964   GRPALGREAPPQAGLSSTPPPCSETCTMGPHSILRTVHCRPTK                               TPPEPSAEPHPLSLLTSSNTSLAGTSLGRDLTPGGGKPPSGQT                               PRNPESPRHRLGSPRGRRWLASPTPTGSGRSGPASRGQRRLSC                               AAQDPTSEGASVGAMEAGLGPPTAAPRGVVSEAAESLGGTLSW                               GAWGRPPAGPSGLAGRRSRREAKRPDRKEASVMMAAVSAIQP               515   1254   704   107   PGVPTHGWPRSRVLTRVRGSRGSGKMAAAVVLAAGLRAARRAV                               AATGVRGGQVRGAAGVTDGNEVAKAQQATPGGAAPTIFSRILD                               KSLPADILYEDQQCLVFRDVAPQAPVHFLVIPKKPIPRISQAE                               EEDQQ/LTYVPPLSL*LLGHLLLVAKQTAKAEGLGDGYRLVIN                               DGKLGAQSVYHLHIHVLGGRQLQWPPG               516   1255   2299   924   VPNYLPSVSSAIGGEVPQRYVWRFCIGLHSAPRFLVAFAYWNH                               YLSCTSPCSCYRPLCRLNFGLNVVENLALLVLTYVSSSEDF/T                               WVPG*GRSGEVFPEGTGLPLPHSDLPTSWCGHSLQCGSQSSFP                               PAIHENAFIVFIASSLGHMLLTCILWRLTKKHTVSQE\DGLSL                               AGAPRQPRRKSRTSVLRIRVMVRWELSSNGNPGRGVLGLGLGL                               GNKKRVVGQNLGL*HCVWVVWETGE*KRWRLQMGIE*GVASRR                               Q*VRNSVRGLVCHNSSAPPMYMGFFSPTVFGGGVGG*LHVTFI                               LHPPEVEAAGIPLLLGPSLPQRQGREHIVVILAAPACAPFHDR                               *WEPREIRPSP*ELGLRGEPTLSYPASCRVIRQPIP*DRKSYS                               WKQRLFIINFISFFSALAVYFRHNMYCEAGVYTIFAILEYTVV                               LTNMAFHMTAWWDFGNKELLITSQPEEKRF               517   1256   3   254   IDLLEIRNGPRSHESFQEMDLNDDWKLSKDEVKAYLKKEFEKH                               GAVVNESHHDALVEDIFDKEDEDKDGFISAREFTYKHDEL               518   1257   2   611   PRVRGRVGKEGAAAKPRSLLRRFQLLSWSVCGGNKDPWVQELM                               SCLDLKECGHAYSGIVAHQKHLLPTSPPISQASEGASSDIHTP                               AQMLLSTLQSTQRPTLPVGSLSSDKELTRPNETTIHTAGHSLA                               AGPEAGENQKQPEKNAGPTARTSATVPVLCLLAIIFILTAALS                               YVLCKRRRGQSPQSSPDLPVHYIPVAPDSNT               519   1258   1002   418   LIISNFLKAKQKPGSTPNLQQKKSQARLAPDIVSASQYRKFDE                               FQTGILIYELLHQPNPFEVRAQLRERDYRQEDLPPLPALSLYS                               PGLQQLAHLLLEADPIKRIRIGEAKRVLQCLLWGPRRELVQQP                               GTSEEALCGTLHNWIDMKRALMMMKFAEKAVDRRRGVELEDWL                               CCQYLASAEPGALLQSLKLLQLL               520   1259   2   2019   KRGLIVVMAHEMIGTQIVTERGVALLESGTEKVLLIDSRPFVE                               YNTSHILEAININCSKLMKRRLQQDKVLITRLIQHSAKHKVDI                               DCSQKVVVYDQSSQDVASLSSDCFLTVLLGKLEKSFNSVHLLA                               GGFAEFSRCFPGLCEGKSTLVPTCISQPCLPVANIGPTRILPN                               LYLGCQRDVLNKELMQQNGIGYVLNASNTCPKPDFIPESHFLR                               VPVNDSFCEKILPWLDKSVDFIEKAKASNGCVLVHCLAGISRS                               ATIAIAYIMKPMDMSLDEAYRFVKEKRPTISPNFNFLGQLLDY                               EKKIKNQTGASGPKSKLKLLHLEKPNEPVPAVSEGGQKSETPL                               SPPCADSATSEAAGQRPVHPASVPSVPSVQPSLLEDSPLVQAL                               SGLHLSADRLEDSNKLKRSFSLDIKSVSYSASMAASLHGFSSS                               EDALEYYKPSTTLDGTNKLCQFSPVQEL/CGADSRNQS**GGS                               Q/PSPRSCRPPGLQTARASDCIRSEPAAVAPPRGPFYLHCIEV                               GAWRTITTPASFSAFPP\PAAPHEVCWPGP*GLANPDILAPQT                               STPSLTSSWYFATESSHFYSASAIYGGSASYSAYSCSQLPTCG                               DQVYSVRRRQKPSDRADSRRSWHEESPFEKQFKRRSCQMEFGE                               SIMSENRSREELGKVGSQSSFSGSMEIIEVS               521   1260   20   803   ASSSKRVSRQKMLQLWKLVLLCGVLTGTSESLKDNLGNDLSNV                               VDKLEPVLHEGLETVDNTLKGILEKLKVDLGVLQKSSAWQLAK                               QKAQEAEKLLNNVISKLLPTNTDIFGLKISNSLILDVKAEPID                               DGKGLNLSFPVTANVTEAGPIIDQIIN\LRASLNLLTAVTIET                               DPQTHHPVAGLGECARDPTSISLCLLDKHSQIINKFVNSVINT                               LKSTVSSLLQKEKPLLIFIHSLDVNVIQQVVDNPQHKTQLQ                               TLI               522   1261   1246   411   CSLRRPRSAAEPDADHVPLLGLLRLQLFAARQPGAMRPQGPAA                               SPQRKRGLLLLLLLQLPAPSSASEIPKGKQKAQLRQREVVDLY                               NGMCLQGPAGVPGRDGSPGANGIPGTPGIPGRDGFKGEKGECL                               RESFEESWTPNYKQCSWSSLNYGIDLGKIAECTFTKMRSNSAL                               RVLFSGSLRLKCPNACCQRWYFTFNGAECSGPLPIEAIIYLDQ                               GSPEMNSTINIHRTSSVEGLCEGIGAGLVDVAIWVGTCSDYPK                               GDASTGWNSVSRIIIEELPK               523   1262   2009   921   MHSAMLGTRVNLSVSDFWRVMMRVCWLVRQDSRHQRIRKPHLE                               AVVIGRGPETKITDKKCSRQQVQLKAECNKGYVKVKQVGVNPT                               SIDSVVIGKDQEVKLQPGQVLHMVNELYPYIVEFEEEAKNPGL                               ETHRKRKRSGNSDSIERDAAQEAEAGTGLEPGSNSGQCSVPLK                               KGKDAPIKKESLGHWSQGLKISMQDPKMQVYKDEQVVVIKDKY                               PKARYHWLVLPWTSISSLKAVAR\EHKELLKIRHTVGEKVIVD                               FAGSSKLRFRLGYHRIPSMSHVHLHVISQDFDSPCLKNKKHWN                               SFNTEYFLESQAVIEMVQEAGRVTVRDGMPELLKLPLRCRECQ                               QLLPSIPQLKEHLRKHWTQ               524   1263   2067   198   DMSDTSESGAGLTRFQAEASEKDSSSMMQTLLTVTQNVEVPET                               PKASKALEVSEDVKVSKASGVSKATEVSKLPEAREAPATQASS                               TTQLTDTQVLAAENKSLAANTKKQNANPQAVTMPATETKKVSH                               VANTKVNTKAQETEAAPSQAPANEPEPESAAAQSQENQDTRPK                               VKAKKARKVKHLDGEEDGSSDQSQASGTTGGRRVSKALMASMA                               RPASRGPIAFWARRASRTRLACFGPGEPLLSPWRSP\KARRQR                               GFAVRVAKFQ\SSQEPEAPPPW\DVALLQGRAN\DLVKYLLAK                               DQTKIPIKRS\DMLKDIIKEYTDVYPEII\ERAGYSLE\KVFG                               IQLKEIDKNDHLYILLSTLEPTDAGILGTTKDSPKLGLLMVLL                               SIIFVRNGNRS\SEAVIWEVLR/RSLGLRLGIHHS\LLGDVK\                               KLITNEV\VKQKYL\DYARVPHSNSP\EYEFFWG\LRSYYEDQ                               QR*KSFKFACK\VQK\KDPK\EWAAQSPPGKAR/ERMEAN\LK                               AAS*GSPWKPRLRAEIKARMGIGLGSENAAGPCNWDEADIGPW                               AKARIQAGAEAKAKAQESGSASTGASTSTNNSASASASTSGGF                               SAGASLTATLTFGLFAGLGGAGASTSGSSGACGFSYK               525   1264   1   1397   ARPPVCTGSTMSLTVVSMACVGFFLLQGAWPLMGGQDKPFLSA                               RPSTVVPRGGHVALQCHYRRGFNNFMLYKEDRSHVPIFHGRIF                               QESFIMGPVTPAHRGTYRCRGSRPHSLTGWSAPSNPLVIMVTG                               NHRKPSLLAHPGPLLKSGETVILQCWSDIMFEHFFLHKEGISK                               DPSRLVGQIHDGVSKANFSIGPMMLALAGTYRCYGSVTHTPYQ                               LSAPSDPLDIVVTGPYEKPSLSAQPGPKVQAGESVTLSCSSRS                               SYDMYHLSREGGAHERRLPAVRKVNRTFQADFPLGPATHGGTY                               RCFGSFRHSPYEWSDPSDPLLVSVTGNPSSSWPSPTEPSSKSG                               NLRHLHILIGTSVVKIPFTILLFFLLHRWCSNKK\NAAVMDQE                               PAGNR\VMSEDSDEQDHQEVSYP*LEHCVFTQRXITRPSQRPK                               TPPTDTSMYIELPNAEPRSKVVFCPRAPQSGLEGIF               526   1265   6657   988   LHNLRERYFSGLIYTYSGLFCVVVNPYKHLPIYSEKIVDMYKG                               KKRHEMPPHIYAIADTAYRSMLQDREDQSILCTGESGAGKTEN                               TKKVIQYLAVVASSHKGKKDTSITGELEKQLLQRNPILEAFGN                               AKTVKNDNSSRFGKFIRINFDVTGYIVGANIETYLLEKSPAIR                               QARDERTFHIFYYMIAGAKEKMRSDLLLEGFNNYTFLSNGFVP                               IPAAQDDEMFQETVEALAIMGFSEEEQLSILKVVSSVLQLGNI                               VFKKERNTDQASMPDNTAAQKVCHLMGINVTDFTRSILTPRIK                               VGRDVVQKAQTKEQADFAVEALAKATYERLFRWILTRVNKALD                               KTHRQGASFLGILDIAGFEIFEVNSFEQLCINYTNEKLQQLFN                               HTMFIL\EQEEYQREGIEWNFIDFGLDLQPCIELIERPNNPPG                               VLALLDEECWFPKATDKSFVEKLCTEQGSHPKFQKPKQLKDKT                               EFSIIHYAGKVDYNASAWLTKNNDPLNDNVTSLLNASSDKFVA                               DLWKDVDRIVGLDQMAKMTESSLPSASKTKKGMFRTVGQLYKE                               QLGKLMTTLRNTTPNFVRCIIPNHEKRSGKLDAFLVLEQLRCN                               GVLEGIRICRQGFPNRIVFQEFRQRYEILAANAIPKGFMDGKQ                               ACILMIKALELDPNLYRIGQSKIFFRTGVLAHLEEERDLKITD                               VIMAFQAMCRGYLARKAFAKRQQQLTAMKVIQRNCAAYIKLRN                               WQWCRLFTKV*PLLQVTRQE*EMQAKEDELQKTKERQQKAENE                               LKELEQKHSQLTEEKNLLQEQLQAETELYAEAEEMRVRLAAKK                               QELEEILHEMEARLEEEEDRGQQLQAERKKMAQQMLDLEEQLE                               EEEAARQKLQLEKVTAEAKIKKLEDEILVMDDQNNKLSKERKL                               LEERISDLTNNLAEEEEKAKNLTKLKNKHESMISELEVRLKKE                               EKSRQELEKLKRKLEGDASDFHEQIADLQAQIAELKMQLAKKE                               EELQAALARLDDEIAQKNNALKKIRELEGHISDLQEDLDSERA                               ARNKAEKQKRDLGEELEALKTELEDTLDSTATQQELRAKREQE                               VRVLKR\ALNEETRSHEAQVQEMRQKHAQAVQSLTEQLEQ\*K                               RAKANLDKNKQTLEKENTD\LAGELRVLGQA\KQEVEHRMKKL                               QAQVQELQSKCSDGERARAELNDKVHK\LQNEVESVTG\MLNE                               AEGKAIKLAKDVASLSSQL\QDTQELLQEESRQKLNVST\SLR                               \QLEEERNSLQDQLDEEMEAKQNLERHISTLNIQLSDSKKKLQ                               DFASTVEALEEGKKRFQKEIENLTQQYEEKAAAYDKLEKTKNR                               LQQELDDLVVDLDNQRQLVSNLEKKQRKFDQLLAEEKNISSKY                               ADERDRVEAEAREKETKALSL\ARALEEALEAKEELERTNKML                               KA\EMGRPGSASKD\DVGQELSHDL\EKSK\RALGDPRLEEMK                               T\QLEELGRTELASPRRDA\KLRLEVNMQAPSRASFER\DLQA                               RTEQNE\ESRR\HLQRQLHEYETELEDERKQRALAAAAKIKLG                               WDPVRTLDL*ADSAIKGRGGKAIKQLRKKQAQMKDFQRELEDA                               \RASRDEIF\ATA\KENEKKAKSLEA\DLMQLQE\DLAREREG                               RKQ\ADLE\KEELAEEL\ASSLSGRNALQDEKRRLEARIQQLE                               EELEEEQGNMEAMSDRVRKATQQAEQLSNELATERSTAQKNES                               ARQQLERQNKELRSKLHEMEGAVKSKFKSTIAALEAKIAQLEE                               QVEQEAREKQAATKSLKQKDKKLKEILLQVEDERKMAEQYKEQ                               AEKGNARVKQLKRQLEEAEEESQRINANRRKLQRELDEATESN                               EAMGREVNALKSKLRRGNETSFVPSRRSGGRRVIENADGSEEE                               TDTRDADFNGTKASE               527   1266   1   775   KLHFAKSLNSELSCSTREAMQDEDGYITLNIKTRKPALVSVGP                               ASSSWWRVMALILLILCVGMVVGLVAKGIWSVMQRNYLQDENE                               NRTGTLQQLAKRFCQYVVKQSELKGTFKGRKCSPCDTNWRYYG                               DSCYGFFRHNLTWEESKQYCTDMNATLLKIDNRNIVEYIKAR\                               THLIRWVGLSRQKSNEVWKWEDGSVISENMFEFLEDGKGNMNC                               AYFHNGKMHPTFCENKHYL\MCE\RKAGHDPRWTQLPLMPKRW                               TG               528   1267   1053   424   NQGLRDVGLCRTCLVNKIFASSILGKSHHHSLVSINQGHNAPW                               KAAGS\LPLKAAYC\QGFSPCDCLKYG\SWDEKDLMVPQPDTH                               KGSVLRWISKRGKPLAVEMEEGHCL\CLPLGTECLGVKP\IVH                               LFNSEMGEK\RPVAG\ARRVGSSAALLFFTPLRCLGGEKHKSG                               LRARPGIVPSLELNYDIDSFAHMFF/SVDLLLIITLLSYYIPF                               C               529   1268   1435   1560   MWWRLAPTQAIWRAAGCCMRFSRRRSTCCCLASCIFLKYKIVR                               GDQPAAKRRQRRRPAAPSAPPQAARKHPPPKKRRFDGVQDPAR                               YSWAINGKVFDVTQRPANFLRGPRGPETLSDWESQFTFKYHHV                               GKLLKEGEEPTVYSDEEEPKDESARKND*               530   1269   705   166   GPRMAKFLSQDQINEYKECFSLYDKQQRGKIKATDLMVAMRCL                               GASPTPGEVQRHLQTHGIDGNGELDFSTFLTIMHMQIKQEDPK                               KEILLAMLMVDKEKLGYVMASDLRSKLTSLGEKLTHKEV\DDL                               FRE\ADIEPNGKVKYDEFIHKI/TLLPGRDLLKEENGRASPGP                               ENLEQLIFL               531   1270   25   1396   ADPHTTVIRFFPAASATKRVLPPVLRVSSPRTWNPNVPESPRI                               PAPRLPKRMSGAPTAGAALMKCAATAVLLSAQGGPVQSKSPRF                               ASWDEMNVLAHGLLQLGQGLPEHAERTRSQLSALERRISACGS                               ACQGTEGSTDLPLAPESRVDPEVLHSLQTQLKAQNSRIQQLFH                               KVAQQQRHLEKQHLRIQHLQSQFGLLDHKHLDHEVAKPARRKR                               LPEMAQPVDPAHNVSRKHRLPRDCQELFQVGERQSGLFEIQPQ                               GSPPFLVNCKMTSDGGWTVIQRRHDGSVDFNRPWEAYKAGFGD                               PHGEFWLGLEKVHSITGDRNSRLAVQLRDWDGNAELLQFSVHL                               GGEDTAYSLQLTAPVAGQLGATTVPPSGLSVPFSTWDQDHDLR                               RDKNCAKSLSGGWWFGTCSHSNLNGQYFRSIPQQRQKLKKGIF                               WKTWRGRYYPLQATTMLIQPMAAEAAS               532   1271   1276   90   ALDFGDSCQWPRPQDTMKQLPVLEPGDKPRKATWYTLTVPGDS                               PCARVGHSCSYLPPVGNAKRGKVFIVGGANPNRSFSDVHTMDL                               GKHQWDLDTCKGLLPRYEHASFIPSCTPDRIWVFGGANQSGNR                               NCLQVLNPETRTWTTPEVTSPPPSPRTFHTSSAAIGNQLYVFG                               GGERGAQPVQDTKLHVFDANTLTWSQPETLGNPPSPRHGHVMV                               AAGTKLFIHGGLAGDRFYDDLHCIDISDMKWQKLNPTGAA\PA                               GCAS/HTPAVAMGK\HVYI\FGGMTPAGAPGTQCTQYHTEEQH                               WDPCLKF\DTPSYPPGTIGTHSHVVSFPW\PVTCASEKEDS\N                               SLTLNHEAEKEDSADKVMSHSGDSHEESQTATLLCLVFGGMNT                               EGEIYDDCIVTVVD               533   1272   1169   639   GFSIGKATDRNDAFRKAKNFAVHHLHYIERYEDHTIFHDISLR                               FKRTHIKMKKQPKGYGLRCHRAIITICRLIGIKDMYAKVSGSI                               NMLSLTQGLFRGLSRQETHQQLADKKGLHVVEIREECGPLPIV                               VASPRGPLRKDPEPEDEVPDVKLDWEDVKTAQGMKRSVWSNLK                               RAAT               534   1273   25   1396   ADPHTTVIRFFPAASATKRVLPPVLRVSSPRTWNPNVPESPRI                               PAPRLPKRMSGAPTAGAALMLCAATAVLLSAQGGPVQSKSPRF                               ASWDEMNVLAHGLLQLGQGLREHAERTRSQLSALERRLSACGS                               ACQGTEGSTDLPLAPESRVDPEVLHSLQTQLKAQNSRIQQLFH                               KVAQQQRHLEKQHLRIQHLQSQFGLLDHKHKDHEVAKPARRKR                               LPEMAQPVDPAHNVSRKHRLPRDCQELFQVGERQSGLFEIQPQ                               GSPPFLVNCKMTSDGGWTVIQRRHDGSVDFNRPWEAYKAGFGD                               PHGEFWLGLEKVHSITGDRNSRKAVQLRDWDGNAELLQFSVHL                               GGEDTAYSLQLTAPVAGQLGATTVPPSGLSVPFSTWDQDHDLR                               RDKNCAKSLSGGWWFGTCSHSNLNGQYFRSIPQQRQKLKKGIF                               WKTWRGRYYPLQATTMLIQPMAAEAAS               535   1274   23   1102   TLRSRPAGEAGYLGWDPEQAGEGSALSRPGAMAAKMTPGTGAP                               PAPGDFSGEGSQGLPDPSPEPKQLPELIPMKRDGGRLSEADIR                               GFVAAVVNGSAQGAQIGAWGGLGVPDPDWEVSPRDFGSLGVRR                               CPTTSTGPRVPHRCGLPPSRVPPHTRG\MLMAIRLRGMDLEET                               SVLTQALAQSGQQLEWPEAWRQQLVDKHSTGGVGDKVSLVLAP                               ALAACGCKVINHLLSRREPIPHMQQPVHPQAAPNLKPGPKPPR                               PYQGFSPPCSPAQFSPPRSPAQRLGPLWKQTRPLGAGKRSTDG                               IQTPFPLGPQTAPPREELRTSLPLPQALFPQGQVPTSSPTDTS                               QPRKLPFHSLTSWAPL               536   1275   3   439   RALRELRERVTHGLAEAGRDREDVSTELYRALEAVRLQNSEGS                               CEPCPTSWLPFGGSCYYFSVPKTTWAEAQGHCADASAHLA\IV                               GGLGEQDFLSRDTSALEYWIGRRAVQHLRKVQGYSWVDGVPLS                               FR*/WEG/HPGETWGPQVRL               537   1276   1   564   RWPRSWPPRAGAARGAAEAAMVGALCGCWFRLGGARPLIPLGP                               TVVQTSMSRSQVALLGLSLLLMLLLYVGLPGPPEQTSCLWGDP                               NVTVLAGLTPGNSPIFYREVLPLNQAHRVEV\CCFMERPLTLT                               RGSSWAHCSYCHRGATGPWPLTFQVLGTRHLQRRQAQRQGGQR                               CWSGRCGTWRYRMPCW               538   1277   102   1549   QENQLEKKMKFLIFAFFGGVHLLSLCSGKAICKNGISKRTFEE                               IKEEIASCGDVAKAIINLAVYGKAQNRSYERLALLVDTVGPRL                               SGSKNLEKAIQIMYQNLQQDGLEKVHLEPVRIPRWERGEESAV                               MLEPRIHKIAILGLGSSIGTPPEGITAEVLVVTSFDELQRRAS                               EARGKIVVYNQPYINYSRTVQYRTQGAVEAAKVGALASLIRSV                               ASFSIYSPHTGIQEYQDGVPKIPTACITVEDAENMSRMASHGI                               KIVIQLKMGAKTYPDTDSFNTVAEITGSKYPEQVVLVSGHLDS                               WDVGQGAMDDGGGAFISWEALSLIKDLGLRPKRTLRLVLWTAE                               EQGGVGAFQYYQLHKVNISNYSLVMESDAGTFLPTGLQFTGSE                               KARAIMEEVMSLLQPLNITQVLSHGEGTDINFWIQAGVPGASL                               LDDLYKYFFFHHSHGDTMTVHGIQTQMNV\AAAV\WAVVSYV\                               VADMEEMLPRS               539   1278   2438   1148   TKPRKRRHQPASQRQRPWSSDSTGDLLARGKGRKEENKGSDRV                               SLAPPSLRRPMMCQSEARQGPELRAAKWLHFPQLALRRRLGQL                               SCMSRPALKLRSWPLTVLYYLLPFGALRPLSRVGWRPVSRVAL                               YKSVPTRLLSRAWGRLNQVELPHWLRRPVYSLYIWTFGVNMKE                               AAVEDLHHYRNLSEFFRRKLKPQARPVCGLHSVISPSDGRILN                               FGQVKNCEVEQVKGVTYSLESFLGPRMCTEDLPFPPRRSCDSF                               KNQLVTREGNELYHCVIYLAPGDYHCFHSPTDWTVSHRRHFPG                               SLMSVNPGMARWIKELFCHNERVVLTGDWKHGFFSLTAVGAT\                               NWGSIRIYFDRDLHTNSPRHSKGSYRDFSFVTHTNREGVPMRK                               GEHLGEFNLGSTIVLIFEAPKDFNFQLKRGQKI\RFGEALGSL               540   1279   3   1911   LPERAFGPRTPRAPRPRRPRLLLSPPPRPPPPLDRRPRAPGPW                               LCPSRAGTAQDPARIRERRGRVAGGAAGPAMELRARGWWLLCA                               AAALVACARGDPASKSRSCGEVRQIYGAKGFSSS\DVPQAEIS                               GEHLRICPQGYTCCTSEMEENLANRSHAELETALRDSSRVLQA                               MLATQLRSFDDHFQHLLNDSERTLQATFPGAFGELYTQNARAF                               RDLYSELRLYYRGANLHLEETLAEFWARLLERLFKQLHPQLLL                               PDDYLDCLGKQAEALRPF\GEAP\RELRLRAT\RA\FVAAR\S                               FVQGLGVAS\DVVRKVAQVPLG\PEC\SRAVIEAGSYC/ALHC                               VGVPGARPCPDYCRNVLKGCLANQADLDAEWRNLLDSMVLITD                               KFWGTSGVESVIGSVHTWLAEAINALQDNRDTLTAKVIQGCGN                               PKVNPQGPGPEEKRRRGKLAPRERPPSGTLEKLVSEAKAQLRD                               VQDFWISLPGTLCSEKMALSTASDDRCWNGMARGRYLPERRGD                               GLRNQINNPEVEVDITKPDMTIRQQIMQLKIMTNPRKRSARGN                               DVDFQDASDDGSGSGSGDGCLDDLCGRKVSRKSSSSRTPLTHA                               LPGLSEQEGQKTSAASCPQPPTFLLPLLLFLLRPRWR               541   1280   590   189   ATELTRAGMEASALTKSA\VTSVAKVVR\VASGSAVVLPLARI                               ATSCD*RVGGP/VQAVPMVL\SAMGLQLRAGIASSSIAAKMMS                               AAAIA\NGGGVSPGQPLWLLLQSLGATGL\SGLTKFILGSIGS                               AIA\AVIARFY               542   1281   41   1415   TNGRNLLHHWILGVCGMHPHHQETLKKNRVVLAKQLLLSELLE                               HLLEKDIITLEMRELIQAKVGSFSQNVELLNLLPKRGPQAFDA                               FCEALRETKQGHLEDMLLTTLSGLQHVLPPLSCDYDLSLPFPV                               CESCPLYKKLRLSRDTVEHSLDNKDGPVCLQVKPCTPEFYQTH                               FQLAYRLQSRPRGLALVLSNVHFTGEKELEFRSGGDVDHSTLV                               TLFKLLGYDVHVLCDQTAQEMQEKLQNFAQLPAHRVTDSCIVA                               LLSHGVEGAIYGVDGKLLQLQEVFQLFDNRNCPSLQNKPKMFF                               IQACRGGAIGSLGHLLLFTAATASLAL\ETDRGVDQQDGKNHA                               GSPGCEESDAGKEKLPKMRLPTRSDMICGYACLKGTAAMRNTK                               RGSWYIEALAQVFSERACDMHVADMLVKVNALIKDREGYAPGT                               EFHRCKEMSEYCSTLCRHLYLFPGHPPT               543   1282   862   275   VRGKEVMAALCRTRAVAAESHFLRVFLFFRPFRGVGTESGSES                               GSSNAKEPKTRAGGFASALERHSELLQKVEPLQKGSPKNVESF                               ASMLRLSPLTQMGPAXDKKVIGRIFHIVENDL\YIDFGGKFHC                               VCRRPEVDGEKY\QKGTRVR\LRLLDLELTSRFLGATTD\TTV                               LEANAVLLGIQESKDSRSKEEHLEKYI               544   1283   2   4503   IPGASPAPRRAAPLRLGLRLASGWARAPGGVSPVPGPGMGGDA                               PTMARAQAKVLELTFQLCAPETETPEVGCTFEEGSDPAVPCEY                               SQAQYDDFQWEQVRIHPGTRAPADLPHGSYLMVNTSQHAPGQR                               AHVIFQSLSENDTECVQFSYFLYSRNGHSPGTLGVYVRVNGGP                               LGSAVWNMTGSHGRQWHQAELAVSTFWPNEYQVLFEALISPDR                               RGYMGLDDILLLSYPCAXAPHFSRLGDVEVNAGQNASFQCMAA                               GRAAEAERFLLQRQSGALVPAAGVRHISHRRFLATFPLAAVSR                               AEQDLYRCVSQAPRGRGTSLNFAEFMV/KEPPTPIAPPQLLRA                               GPTYLIIQLNTNSIIGDGPIVRKEIEYRMARGPWAEVHAVSLQ                               TYKLWHLDPDTEYEISVLLTRPGDGGTGRPGPPLISRTKCAEP                               MRAPKGLAFAEIQARQLTLQWEPLGYNVTRCHTYTVSLCYHYT                               LGSSHNQTI\RECVKTEQGVSRYTMKNLLPYPRVHVRLVLTNP                               EGRKEGKEVTFQTDEDVPSGIAAESLTFTPLEDMIFLKWEEPQ                               EPNGLITQYEISYQSIESSDPAVNVPGPRRTISKLRNETYHVF                               SNLHPGTTYLFSVRAPTGKGFGQAALTEITTNISAPSFDYADM                               PSPLGESENTITVLLRPAQGRGAPISVYQVIVEEEQGSRRLRR                               EPGGQDCFPVPLTFEAALARGLVDYFGAELAASSLPEAMPFTV                               GDNKTYRGFWNPPLEPPLKAYLIYFQAASHKKGETRLNCLIAR                               KAACKESKRPLEVSQRSEEMGLILGICAGGLAVLILLKGAIIV                               IIRKGRDHYAYSYYPKPVNMTKATVNYRQEKTHMMSAVDRSFT                               DQSTLQEDERLGLSFMDTHGYSTRGDQRSGGVTEASSLLGGSP                               RRPCGRKGSPYHTGQLHPAVRVADLLQHINQMKTAEGYGFKQE                               YESFFEGWDATKKKDKVKGSRQEPMPAYDRHRVKLHPMLGDPN                               ADYINANYIDIRINREGYHRSNHFIATQGPKPEMVYDFWRMVW                               QEHCSSIVMITKLVEVGRVKCSRYWPEDSDTYGDIKIMLVKTE                               TLAEYVVRTFALERRGYSARHEVRQFHFTAWPEHGVPYHATGL                               LAFIRRVKASTPPDAGPIVIHCSAGTGRTGCYIVLDVMLDMAE                               CEGVVDIYNCVKTLCSRRVNMIQTEEQYIFIHDAILEACLCGE                               TTIPVSEFKATYKEMIRIDPQSNSSQLREEFQTLNSVTPPLDV                               EECSIALLPRNPKKNRSMDVLPPDRCLPFLISTDGDSNNYINA                               ALTDSYTRSAAFIVTLHPLQSTTPDFWGLVYDYGCTSIVMLNQ                               LNQSNSAWPCLQYWPEPGRQQYGLMEVEFMSGTADEDLVARVF                               RVQNISRLQEGHLLVRHFQFLRWSAYRDTPDSKKAFLHLLAEG                               DKWQAESGDGRTIVHCLNGGGRSGTFCA\CATVLEMIRCHNLV                               DVFFAAKTLRNYKPNNVETMDQYHFCYDVALEYLEGLESR               545   1284   2443   1152   TKPRKRRHQPASQRQRPWSSDSTGDLLARGKGRKEENKGSDRV                               SLAPPSLRRPMMCQSEARQGPELRAAKWLHFPQLAIRRRLGQL                               SCMSRPALKLRSWPLTVLYYLLPFGALRPLSRVGWRPVSRVAL                               YKSVPTRLLSRAWGRIMQVELPHWLRRPVYSLYIWTFGVNMKE                               AAVEDLHHYRNLSEFFRRKLKPQARPVCGLHSVISPSDGRILN                               FGQVKNCEVEQVKGVTYSLESFLGPRMCTEDLPFPPAASCDSF                               KRQLVTREGNELYHCVIYLAPGDYHCFHSPTDWTVSHRRHFPG                               SLMSVNPGMARWIKELFCHNERVVLTGDWKHGFFSLTAVGAT\                               NWGSIRIYFDRDLHTNSPRHSKGSYNDFSFVTHTNREGVPMAL                               RGEHLG/QSFNLGSTIVLIFEAPKDFNFQLKTGQKIRFGEALG                               SL               546   1285   185   3057   AELGLFGSLRFSSLLHFPPRPRSPASACGPGEGRMERGLPLLC                               AVLALVLAPAGAFRNDKCGDTIKIESPGYLTSPGYPHSYHPSE                               KCEWLIQAPDPYQRIMINFNPHFDLEDRNCKYDYVEVFDGENE                               NGHFRGKFCGKIAPPPVVSSGPFLFIKFVSDYETHGAGFSIRY                               EIFKRGPECSQNYTTPSGVIKSPGFPEKYPNSLECTYI\VFAP                               KMSEIIL\DFESFDLEPDSNPPGGMFCRYDRLEIWDGFPDVGP                               HIGRYCGQKTPGRIRSSSGILSMVFYTDSAIAKEGFSANYSVL                               QSSVSEDFKCMEALGMESGEIHSDQITASSQYSTNWSAERSRL                               NYPENGWTPGEDSYREWIQVDLGLLRFVTAVGTQGAISKETKK                               KYYVKTYKIDVSSNGEDWITIKEGNKPVLFQGNTNPTDVVVAV                               FPKPLITRFVRIKPATWETGISMRFEVYGCKITDYPCSGMLGM                               VSGLISDSQITSSNQGDRNWMPENIRLVTSRSGWALPPAPHSY                               INEWLQIDLGEEKIVRGIIIQGGKHRENKVFMRXFKIGYSNNG                               SDWKMIMDDSKRKAKSFEGNNNYDTPELRTFPALSTRFIRIYP                               ERATHGGLGLRMELLGCEVEAPTAGPTTPNGNLVDECDDDQAN                               CHSGTGDDFQLTGGTTVLATEKPTVIDSTIQSEFPTYGFNCEF                               GWGSHKTFCHWEHDNHVQLKWSVLTSKTGPIQDHTGDGNFIYS                               QADENQKGKVARLVSPVVYSQNSAHCMTFWYHMSGSHVGTLRV                               KLRYQKPEEYDQLVWMAIGHQGDHWKEGRVLLHKSLKLYQVIF                               EGEIGKGNLGGIAVDDISINNHISQEDCAKPANLDKKNPEIKI                               DETGSTPGYEGEGEGDKNISRKPGNVLKTLEPILITIIAMSAL                               GVLLGAVCGVVLYCACWHNGMSERNLSALENYNFELVDGVKLK                               KDKLNTQSTYSEA               547   1286   3   521   HEGSAKTWASHYQERLNSEQSCLNEWTAMADLESLRPPSAEPG                               GSVCGGEGLGGGEGRIMQWGAWWRGERAP*LRGSAPRSSEQEQ                               MEQAIRAELWKVLDVSDLESVTSKEIRQAKELRLGLPLQ/PVP                               *LHRQPDAAAGGTAGPSLPHLPPPLPGLRVERSKPGGAAEEQV                               GL               548   1287   1742   1200   MAALDLRAELDSLVLQLLGDLEELEGKRTVLNARVEEGWLSLA                               KARYAMGAKSVGPLQYASHMEPQVCLHASEAQEGLQKFKVVRA                               GVHAPEEVGPREAGLRRRKGPTKTPEPESSEAPQDPLNWFGIL                               VPHSLRQAQASFRDGLQLAADIASLQNRIDWGRSQLRGLQEKL                               KQLEPGAA*               549   1288   1   649   HSDVGAATAVLPLLTAVLGVTVVTRRDTEGPGRAALVHLTGSP                               RQKVGTSGREGLPGLGASCAESELERETQEPRSRGRCIFGAAR                               WRQVPLASPQRPFLLSPGPRLHRMGLPVSWAPPALWVLGCCAL                               LLSLWALCTACRRPEDAVAPRKRARRQRAPLQGSATAAEAVSA                               KLSRGPGWGPQGTDQPSSPPVPTEADPPLLPQQVGHQTAPAAP                               G               550   1289   433   632   LTGPGQRLAGTTEGPRRCRGSSQAPTPTWKLVDTRLCAAAPWL                               ASRAPGHYSQMLLVN*PCRKDWLVSKWMRTPVCGQSPAMTDRP                               RSEAGRDHRRAKALPGLIPGSNPNLEACGHQALCSSSVASVQG                               PWPLLPNASSPPTPGQPQP               551   1290   102   612   KHRLCSLEQLMTLISAAREYEIEFIYAISPGLDITFSNPKEVS                               TLKRKLDQVSQFGCRSFALLFDDIDHNMCAADKEVFSSFAHAQ                               VSITNEIYQYLGEPETFLFCPT/EYCI*WLYI*LVFLEYITYK                               GPWAPFSLHFPPPLVCKSRNLFLEDIFQDPKLEKF*ELINDN               552   1291   269   565   TSAKTQGLERIPDQLGYLVLSEGAVLASSGDLENDEQAASAIS                               ELVSTACGFRLHRGMNVPFKRLSVVFGEHTLLVTVSGQRVFVV                               KRQNRGREPIDV               553   1292   660   233   AKRAERTSRLQGLQHPSPPYPPATLGVTPGQDRTLQLQHQCPA                               GRKSRKKKSKATQLSPEDRVEDALPPSKAPSRTRRAKRDLPKR                               TATQRPEGTSLQQDPEAPTVPKKGRRKGRQAASGHCRPRKVKA                               DIPSLEPEGTSAS               554   1293   590   323   RKSSWLGAVAHACRPSSLGGPGRQITRSGVRDQPGQYGETPSL                               LKIQTLAGRGGACL*SHILRRKRQKNRKNLGGRGCSELRSRHC                               APA               555   1294   1   242   AWNSARGAVSPLWVPGCFLTLSVTWIGAAPLILSRIVGGWECE                               KHSQPWQVLVASRGRAVCGGVLVHPQWVLTAAHCIRK               556   1295   1074   230   AEMADDLGDEWWENQPTGAGSSPEASDGEGEGDTEVMQQETVP                               VPVPSEKTKQPKECFLIQPKERKENTTKTRKRRKKKITDVLAK                               SEPKPGLPEDLQKLMKDYYSSRRLVIELEELNLPDSCFLKAND                               LTHSLSSYLKEICPKWVKLRKNHSEKKSVLMLIICSSAVRALE                               LIRSMTAFRGDGKVIKLFAKHIKVQAQVXLLEKRVVHLGVGTP                               GRIKELVKQGGLNLSPLKFLVFDWNWRDQKLRRMMDIPEIRKE                               VFELLEMGVLSLCKSESLKLGLF               557   1296   929   289   RPGTAIWVVECEHGRPIAESEGQEGRGHSPPGPCSVAGFLRGR                               LGRNLEIMGSTWGSPGWVRLALCLTGLVLSLYAKHVKAARARD                               RDYRALCDVGTAISCSRVFSSRWGRGFGLVEHVLGQDSILNQS                               NSIFGCIFYTLQLLLGCLRTRWASVLMLLSSLVSLAGSVYLAW                               ILFFVLYDFCIVCITTYAINVSLMWLSFRKVQEPQGKAKRH               558   1297   2   1063   ESPAPPAFRPAMAAVALMPPPLLLLLLLASPPAASAPSARDPF                               APQLGDTQNCQLRCRDRDLGPQPSQAGLEGASESPYDRAVLIS                               ACERGCRLFSICRFVARSSKPNATQTECEAACVEAYVKEAEQQ                               ACSHGCWSQPAEPEPEQKRKVLEAPSGALSLLDLFSTLCNDLV                               NSAQGFVSSTWTYYLQTDNGKVVVFQTQPIVESLGFQGGRLQR                               VEVTWRGSHPEALEVHVDPVGPLDKVRKAKIRVKTSSKAKVES                               EEPQDNDFLSCMSRRSGLPRWILACCLFLSVLVMLWLSCSTLV                               TAPGQHLKFQPLTLEQHKGFMMEPDWPLYPPPSHACEDSLPPY                               KLKLDLTKK               559   1298   2   485   FPELGTSLSAMRFLAATFLLLALSTAAQAEPVQFKDCGSVDGV                               IKEVNVSPCPTQPCQLSKGQSYSVNVTFTSNIQSKSSKAVVHG                               ILMGVPVPFPIPEPDGCKSGINCPIQKDKTYSYLNKLPVKSEY                               PSIKLVVEWQLQDDKNQSLFCWEIPVQIVSEL               560   1299   1304   919   APETFRCVWRLQGLTFIAFTELQAKVIDTQQKVKLADIQIEQL                               NRTKKHAHLTDTEIMTLVDETNMYEGVGRMFILQSKEAIHSQL                               LEKQKIAEEKIKELEQKKSYLERSVKEAEDNIREMLMARRAQ               561   1300   3   799   HSLLLGTRVRDASSKIQGEYTLTLRKGGNRKLSRVFHRDGHYG                               FSEPLTFCSVVDLINHYRHESLAQYNAKKDTRLLYPVSKYQQV                               RAGLGAREGSTWLAPGLSFLGRPDQAMHLPSFRHVSP\DQIVK                               EDSVEAVGAQLKVYHQQYQDKSREYDQLYEEYTRTSQELQMKR                               TAIEAFNETIKIFEEQGQTQEKCSKEYLERFRREGN/QTKEMQ                               RILLNSERLKSRIA\EIHESPHRSWEQQLLVPRASDNKRD/ID                               KPH*TSLKPDL               562   1301   1772   301   AAAAAGRGRSSGRRRRRRPGALFASLGVLLGPRPPPGIPRTRA                               CSMGGVGEPGPREGPAQPGAPLPTFCWEQIRAHDQPGDKWLVI                               ERRVYDISRWAQRHPGGSRLIGHHGAEDATDAFRAFHQDLNFV                               RKFLQPLLIGELAPEEPSQDGPLNAQLVEDFRALHQAAEDMKL                               FDASPTFFAFLLGHILAMEVLAWLLIYLLGPGWVPSALAAFIL                               AISQAQSWCLQHDLGHASIFKKSWWNHVAQKFVMGQKKGFSAH                               WWNFRHFQHRAKPNIFHKDPDVTVAPVFLLGESSVEYGKKKRR                               YLPYHQQHLYFFLIGPPLLTLVNFEVENLAYMLVCMQWADLLW                               AASFYARFFLSYLPFYGVPGVLLFFVAVRVLESHWFVWITQNN                               HIPKEIGHEKHRDNVSSQLAATCNVEPSLFTNWFSGHLNFQIE                               HHLFPRMPRHNYSRVAPLVKSLCALIGLSYEVKPFLTALVDIV                               RSLKKSGDIWLDAYLHQ               563   1302   424   93   KSRATRLRESAEMTGFLLPPASRGTRRSCSRSRKRQTRRRRNP                               SSFVASCPTLLPFACVPGASPTTLAFPPVVLTGPSTDGIPFAL               564   1303   1   414   IQYRSDLELHSITMKKSGVLFLLGIILLVLIGVQGTPVVRKGR                               CSCISTNQGTIHLQSLKDLKQFAPSPSCEKIEIIATLKNGVQT                               CLNPDSADVKELIKKWEKQVSQKKKQKNGKKHQKKKVLKVRKS                               QRSRQKKTT               565   1304   7   3007   IPGSTISCRGCCGKWPVQEADPPRAALRGRFPALLTRKCPSPR                               ABKEKRSLRRCGCRPLLVELAGPAGQAVEVLPHFESLGKQEKI                               PNKMSAFRNHCPHLDSVGEITKEDLIQKSIGTCQDCKVQGPNL                               WACLENRCSYVGCGESQVDHSTIHSQETKHYLTVNLTTLRVWC                               YACSKEVFLDRKLGTQPSLPHVRQPHQIQENSVQDFKIPSNTT                               LKTPLVAVFDDLDIEADEEDELRARGLTGLKNIGNTCYMNAAL                               QALSNCPPLTQFFLDCGGLARTDKKPAICKSYLKLMTELWYKS                               RPGSVVPTTLFQGIKTVNPTFRGYSQQDAQEFLRCLMDLLHEE                               LKEQVMEVEEDPQTITTEETMEEDKSQSDVDFQSCESCSNSDR                               AENENGSRCFSEDNNETTMLIQDDELNSEMSKDWQKEKMCNKI                               NKVNSEGEFDKDRDSISETVDLNNQETVKVQIHSRASEYITDV                               HSNDLSTPQILPSNEGVNPRLSASPPKSGNLWPGLAPPHKKAQ                               SASPKRKKQHKKYRSVISDIFDGTIISSVQCLTCDRVSVTLET                               FQDLSLPIPGKEDLAKLHSSSEPTSIVKAGSCGEAYAPQGWIA                               FFMEYVKRFVVSCVPSWFWGPVVTLQDCLAAFFARDELKGDNM                               YSCEKCKKLPNGVKFCKVQNFPEILCIHLKRFRHELMFSTKIS                               THVSFPLEGLDLQPFLAKDSPAQIVTYDLLSVKHIIGTASSGH                               YIAYCRNNLNNLWYEFDDQSVTEVSESTVQNAEAYVLFYRKSS                               EEAQKERRRISNLLNIMEPSLLQFYISRQWKNKFKTFAEPGPI                               SNNDFLCIHGGVPPRKAGYIEDLVLMLPQNIWDNLYSRYGGGP                               AVNHLYICHTCQIEAEKIEKRRKTELEIFIRLNRAFQKEDSPA                               TFYCISMQWFREWESFVKQKDGDPPGPIDNTKIAVTKCGNVML                               RQGADSGQISEETWNFLQSIYGGGPEVILRPPVVHVDPDILQA                               EEKIEVETRSL               566   1305   28   450   SPSAAGGLAWVSLALGSGSRGRDHSGSGVGTAMAGALVRKAAD                               YVRSKDFRDYLMSTHFWGPVANWGLPIAAINDMKKSPEIISGR                               MTFALCCYSLTFMRFAYKVQPRNWLLFACHATNEVAQLIQGGR                               LIKHEMTKTASA               567   1306   133   1292   LGSRQAAGTMRGQRSLLLGPARLCLRLLLLLGYRLRCPPLLRG                               LVQRWRYGKVCKRSLLYNSFGGSDTAVDAAFEPVYWLVDNVIR                               WFGVVFVVKVIVLTGSIVAIAYLCVLPLILRTYSVPRLCWHFF                               YSHWNLILIVFHYYQAITTPPGYPPQGRNDIATVSICKKCIYP                               KPARTHHCSICNRCVLKMDHHCPWLNNCVGHYNHRYFFSFCFF                               MTLGCVYCSYGSWDLFREAYAAIEKMKQLDKNKLQAVANQTYH                               QTPPPTFSFRERMTHKSLVYLWFLCSSVALALGALTVRHAVLI                               SRGETSIERHINKKERRRLQAKGRVFRNPYNYGCLDNWKVFLG                               VDTGRHWLTRVLLPSSHLPHGNGMSWEPPPWVTAHSASVMAV               568   1307   66   962   ATRREAAEAGMAAVLQRVERLSNRVVRVLGRNPGPMTLQGTNT                               YLVGTGPRRILIDTGEPAIPEYISCLKQALTEFNTAIQEIVVT                               HWHRDHSGGIGDICKSINNDTTYCIKKLPRNPQREEIIGNGEQ                               QYVYLKDGDVIKTEGATLRVLYTPGHTDDHMALLLEEENAIFS                               GDCIKGEGTTVFEDLYDYMNSLKELLKIKADIIYPGHGPVIHN                               AEAKIQQYISHRNIREQQILTLFRENFEKSFTVMELVKIIYKN                               TPENLHEMAILLLLKLEKEGKIFSNTDPDKWKAHL               569   1308   96   1017   ELHPAGOVAGGARRSRRESMELERIVSAALLAFVQTHLPEADL                               SGLDEVIFSYVLGVLEDLGPSGPSEENFDMEAFTEMMEAYVPG                               FAHIPRGTIGDMMQKLSGQLSDARNKENLQRQSSGVQGQVPIS                               PEPLQRPEMLKEETRSSAAAAADTQDEATGAEEELLPGVDVLL                               EVFPTCSVEQAQWVLAKARGDLEEAVQMLVEGKEEGPAAWEGP                               NQDLPRRLRGPQKDELKSFILQKYMMVDSREDQKIHRPMAPKE                               APKKLIRYIDNQVVSTKGERFKDVRNPEAEEMKATYINLKPAR                               KYRFH               570   1309   3   526   FITGKGIVAILRCLQFNETLTELRFHNQRBMLGHHAEMEIARL                               LKANNTLLKMGYHFELPGPRMVVTNLLTRNQDKQRQKRQEEQK                               QQQLKEQKKLIANLENGLGLPPGMWELLGGPKPDSRMQEFFQP                               PPPRPPNPQNVPFSQRSEMMKKPSQAPKYRTDPDSFRVVKLKR                               IQ               571   1310   3   1858   GGRAGTQCCWRAGARLRGISPSPALPEAPGLCRVRAGLGAGAL                               GRSPAGRRRRGPRVSSSPAPHPRRVLCRCLLFLFFSCHDRRGD                               SQPYQALKYSSKSHPSSGDHRHEKMRDAGDPSPPNKMLRRSDS                               PENKYSDSTGHSKAKNVHTHRVRERDGGTSYSPQENSHNHSAK                               HSSNFTFFLIPSN*PQGKTFRIAPYDS\ADDW/SLEHISSSGE                               KYYYNCRTEVSQWGKTPKSGLERGQRQKEANKMAVNSFPKDRN                               YRREVMQATATSGFASGKSTSGDKPVSHSCTRPSTSSASGLNP                               TSAPPTSASA\VPVSP\VPQ\SPIPPLLQDPNLLRQLL\PALE                               ATLQLNNSNVDI\SIINEVLTGDVTQASKQTIIHKCLTAGPSV                               FKITSLISQAAQLSTQAQASNQSPMSLTSDASSPR\SYVSPPL                               KAHKKLNTVPIQTFGFSTPPVSSQPKVSTPVVKQGPVSQSATQ                               QPVTADKQQGHEPVSPRSLQRSSSQRSPSPGPNHTSNSSNASN                               ATVVPQNSSARSTCSLTPAIAAHFSENLIKHVQGWPADHAEKQ                               ASRLREEAHNMGTIHMSEICTELKNLRSLVRVCEIQATLREQR                               ILFLRQQIKELEKLKNQNSFMV               572   1311   2   1165   VAPECRGAYPFRARMPGTALKAVLLAVLLVGLQTATGRLLSGQ                               PVCRGGTQRPCYKVIYFHDTSRRLNFEEAKEACRPDGGQLVSI                               ESEDEQKLIEKFIENLLPSDGDFWIGLRRREEKQSNSTACQDL                               YAWTDGSISQFRNWYVDEPSCGSEVCVVMYHQPSAPAGIGGPY                               MFQWNDDRCNMKNNFICKYSDEKPAVPSREAEGEETELTTPVL                               PEETQEEDAKKTFKESREAAKNLAYILIPSIPLLLLLVVTTVV                               CWVWICRKRKREQPDPSTKKQHTIWPSPHQGNSPDLEVYNVIR                               KQSEADLAETRPDLKNISFRVCSGEATPDDMSCDYDNMAVNPS                               ESGFVTLVSVESGFVTNDIYEFSPDQMGRSKESGWVENEIYGY               573   1312   3   1416   TEWGLSGSCPGCSPLEPGSRGRGAAAWRILRCRRLPEPSPFLT                               QPNLAQSQPPAPVPVTDPSVTMHPAVFLSLPDLRCSLLLLVTW                               VFTPVTTEITSLDTENIDEILNNANVALVNFYANWCRFSQMLH                               PIFEEASDVIKEEFPNENQVVFARVDCDQHSDIAQRYRISKYP                               TLKLFRNGMMMKREYRGQRSVKALADYIRQQKSDPIQEIRDLA                               EITTLDRSKPNIIGYFEQKDSDNYRVFERVANILHDDCAFLSA                               FGDVSKPERYSGDNIIYKPPGHSAPDMVYLGAMTNFDVTYNWI                               QDKCVPLVREITFENGEELTEEGLPFLILFHMKEDTESLEIFQ                               NEVARQLISEKGTINFLHADCDKFRHPLLHIQKTPADCPVIAI                               DSFRHMYVFGDFKDVLIPGKLKQFVFDLHSGKLHREFHRGPDP                               TDTAPGEQAQDVASSPPESSFQKLAPSEYRYTLLRDRDEL               574   1313   928   142   LTPSVGPVFPGRPTRPLASPFPVPLHRCSAGSQPPGPVPEGLI                               RIYSMRFCPYSHRTRLVLKAKDIRHEVVNINLRNKPEWYYTKH                               PFGHIPVLETSQCQLIYESVIACEYLDDAYPGRKLFPYDPYER                               ARQKMLLELFCKVPHLTKECLVALRCGRECTNLKAALRQEFSN                               LEEILEYQNTTFFGGTCISMIDYLLWPWFERLDVYGILDCVSH                               TPALRLWISAMKWDPTVCALLMDKSIFQGFLNLYFQNNPNAFD                               FGLC               575   1314   884   363   NTATNMTQPNAGTRKYSVPAISVHTSSSSFAYDREFLRTLPGF                               LIVAEIVLGLLVWTLIAGTEYFRVPAFGWVMFVAVFYWVLTVF                               FLIIYITMTYTRIPQVPWTTVGLCFNGSAFVLYLSAAYVDASS                               VSPERDSHNFNSWAASSFFAFLVTICYAGNTYFSFIAWRSRTI                               Q               576   1315   165   944   GLRDPFRRKRRLKPQVKMSNYVNDMWPGSPQEKDSPSTSRSGG                               SSRLSSRSRSRSFSRSSRSHSRVSSRFSSRSRRSKSRSRSRRR                               HQRKYRRYSRSYSRSRSRSRSRRYRERRYGFTRRYYRSPSRYR                               SRSRSRSRSRGRSYCGRAYAIARGQRYYGFGRTVYPEELSRWR                               DRSRTRSRSRTPFRLSEKDRMELLEIAKTNAAKALGTTNIDLP                               ASLRTVPSAKETSRGIGVSSNGAKPEVSILGLSEQNFQKANCQ                               I               577   1316   265   2300   AEGSTMDLTKMGMIQLQNPNHPTGLLCKANQMRLAGTLCDVVT                               MVDSQEFHAHRTVLACTSKMFEILFHRNSQHYTLDFLSPKTFQ                               QILEYAYTATLQAKAEDLDDLLYAAEILEIEYLEEQCLKMLET                               IQASDDNDTEATMADGGAEEKKDRKARYLKNIFISKHSSEESG                               YASVAGQSLPGPMVDQSPSVSTSFGLSAMSPTKAAVDSLMTIG                               QSLLQGTLQPPAGPEEPTLAGGGRHPGVAEVKTEMMQVDEVPS                               QDSPGAAESSISGGMGDKVEERGKEGPGTPTRSSVITSARELH                               YGREESAEQVPPPAEAGQAPTGRPEHPAPPPEKHLGIYSVLPN                               HKADAVLSMPSSVTSGLHVQPALAVSMDFSTYGGLLPQGFIQR                               ELFSKLGELAVGMKSESRTIGEQCSVCGVELPDNEAVEQHRKL                               HSGMKTYGCELCGKRFLDSLRLRMHLLAHSAGAKAFVCDQCGA                               QFSKEDALETHRQTHTGTDMAVFCLLCGKRFQAQSALQQHMEV                               HAGVRSYICSECNRTFPSHTALKRHLRSHTGDHPYECEFCGSC                               FRDESTLKSHKRIHTGEKPYECNGCGKKFSLKHQLETHYRVHT                               GEKPFECKLCHQRSRDYSAMIKHLRTHNGASPYQCTICTEYCP                               SLSSMQKHMKGHKPEEIPPDWRIEKTYLYLCYV               578   1317   686   908   IWEAPTLIFTLAGGRALGHPPMQKGSQGCALPHPLPGASLPAQ                               PGPADHRGWECRIGGEASVFTRFCLPHSPT               579   1318   150   1204   ASGSPAPSSSSAMAAACGPGAAGYCLLLGLHLFLLTAGPALGW                               NDPDRMLLRDVKALTLHYDRYTTSRRLDPIPQLKCVGGTAGCD                               SYTPKVIQCQNKGWDGYDVQWECKTDLDIAYKFGKTVVSCEGY                               ESSEDQYVLRGSCGLEYNLDYTELGLQKLKESGKQHGFASFSD                               YYYKWSSADSCNMSGLITIVVLLGIAFVVYKLFLSDGQYSPPP                               YSEYPPFSHRYQRFTNSAGPPPPGFKSEFTGPQNTGHGATSGF                               GSAFTGQQGYENSGPGFWTGLGTGGILGYLFGSNRAATPFSDS                               WYYPSYPPSYPGTWNRAYSPLHGGSGSYSVCSNSDTKTRTASG                               YGGTRR               580   2319   1208   276   GRCGAMAAGLARLLLLLGLSAGGPAPAGAAKMKVVEEPNAFGV                               NNPFLPQASRLQAKRDPSPVSGPVHLFRLSGKCFSLVESTYKY                               EFCPFHNVTQHEQTFRWNAYSGILGIWHEWEIANNTFTGMWMR                               DGDACRSRSRQSKVELACGKSNRLAHVSEPSTCVYALTFETPL                               VCHPHALLVYPTLPEALQRQWDQVEQDLADELITPQGHEKLLR                               TLFEDAGYLKTPEENEPTQLEGGPDSLGFETLENCRKAHKELS                               KEIKRLKGLLTQHGIPYTRPTETSNLEHLGHETPRAKSPEQLR                               GDPGLRGS               581   1320   1074   132   NSFWSVLFLVQEETEVARCNAQRLRQSPRSKRPDPSFRSQPID                               SSISFAGSDIQPLFSFASVDGTQVGEAEEWAGPWAEATLLPGP                               GNRWPPRAGLSGNWLEEDGDWPSLPEVVGFVSERELFRDALGA                               GCRILLICEMQLTHQLDLFPECRVTLLLFKDVKNAGDLRRKAM                               EGTIDGSLINPTVIVDPFQILVAANKAVHLYKLGKMKTRTLST                               EIIFNLSPNNNISEALKKFGISANDTSILIVYIEEGEKQINQE                               YLISQVEGHQVSLKNLPEIMNITEVKKIYKLSSQEESIGTLLD                               AIICRMSTKDVL               582   1321   5021   7694   QRSWAGPGAGPEAGTRPPARGRRRQPGNVDPRRRAPQLRSQMQ                               VAMARATTATGNRLWPGKLIMLGSLCHRGSPCGLSTHIEIGHR                               ALEFLQLHNGRVNYRELLLEHQDAYQAGIVFPDCFYPSICKGG                               ALEFLQLHNGRVNYRELLLEHQDAYQAGIVFPDCFYPSICKGG                               KFHDVSESTHWTPFLNASVHYIRENYPLPWEKDTEKLVAFLFG                               ITSHMAADVSWHSLGLEQGFLRTMGAIDFHGSYSEAHSAGDFG                               GDVLSQFEFNFNYLARRWYVPVKDLLGIYEKLYGRKVITENVI                               VDCSHIQFLEMYGEMLAVSKLYPTYSTKSPFLVEQFQEYFLGG                               LDDMAFWSTNIYHLTIFMLENGTSDCNLPENPLFIACGGQQNH                               TQGSKMQKNDFHRNLTTSLTESVDRNINYTERGVFFSVNSWTP                               DSMSFIYKALERNIRTMFIGGSQLSQKHVSSPLASYFLSFPYA                               RLGWAMTSADLNQDGHGDLVVGAPGYSRPGHIHIGRVYLIYGN                               DLGLPPVDLDLDKEAHRILEGFQPSGRFGSALAVLDFNVDGVP                               DLAVGAPSVGSEQLTYKGAVYVYFGSKQGGMSSSPNITISCQD                               IYCNLGWTLLAADVNGDSEPDLVIGSPFAPGGGKQKGIVAAFY                               SGPSLSDKEKLNVEAANWTVRGEEDFSWPGYSLHGVTVDNRTL                               LLVGSPTWKNASRLGHLLHIRDEKKSLGRVYGYFPPNGQSWFT                               ISGDKAMGKLGTSLSSGHVLMNGTLKQVLLVGAPTYDDVSKVA                               FLTVTLHQGGATRMYALTSDAQPLLLSTFSGDRRFSRFGGVLH                               LSDLDDDGLDEIIMAAPLRIADVTSGLIGGEDGRVYVINGKET                               TLGDMTGKCKSWITPCPEEKAQYVLISPEASSRFGSSLITVRS                               KAKNQVVIAAGRSSLGARLSGALHVYSLGSD               583   1322   1   357   SKRNSARGLKMAASAARGAPAKRRSINQPVAFVRRIPWTAASS                               QLKEHFAQFGHVRRCILPFDKETGFHRGLGWVQFSSEEGLENA                               LQQENHIIDGVKVQVHTRRPKLPQTSDDEKKDF               584   1323   1205   433   GSSNIHSASTHGFCHWFSSPSTLKRQKQAIRFQKIRRQMEAPG                               APPRTLTWEAMEQIRYLHEEFPESWSVPRLAEGFDVSTDVIRR                               VLKSKFLPTLEQKLKQDQKVLKKAGLAHSLQHLRGSGNTSKLL                               PAGHSVSGSLLMPGHEASSKDPNBSTALKVIESDTHRTNTPRR                               RKGRNKEIQDLEESFVPVAAPLGHPRELQKYSSDSESPRGTGS                               GALPSGQKLEELKAEEPDNFSSKVVQRGREFFDSNGMFLYRI               585   1324   134   954   ETRVKTSLEKLRTQLEPTGTVGNTIMTSQPVPNETIIVLPSNV                               INFSQAEKPEPTNQGQDSLKKHLHAEIKVIGTIQILCGMMVLS                               LGIILASASFSPNFTQVTSTLLNSAYPFIGPFFFIISGSLSIA                               TEKRLTKLLVHSSLVGSILSAKSALVGFIILSVKQATLNPASL                               QCELDKNNIPTRSYVSYFYHDSLYTTDCYTAKASLAGTLSLML                               ICTLLEFCLAVLTAVLRWKQAYSDFPGSVLFLPHSYIGNSGMS                               SKMTHDCGYEELLTS               586   1325   106   1537   EMVGAMWKVIVSLVLLMPGPCDGLFRSLYRSVSMPPKGDSGQP                               LFLTPYIEAGKIQKGRELSLVGPFPGLNMKSYAGFLTVNKTYN                               SNLFFWFFPAQIQPEDAPVVLWLQGGPGGSSMFGLFVEHGPYV                               VTSNMTLRDRDFPWTTTLSMLYIDNPVGTGFSFTDDTHGYAVN                               EDDVARDLYSALIQFFQIFPEYKNNDFYVTGESYAGKYVPAIA                               ELIHSLNPVREVKINLNGIAIGDGYSDPESIIGGYAEFLYQIG                               LLDEKQKKYFQKQCHECIEHIRKQNWFEAFEILDKLLDGDLTS                               DPSYFQNVTGCSNYYNFLRCTEPEDQLYYVKFLSLPEVRQAIH                               VGNQTFNDGTIVEKYLREDTVQSVKPWLTEIMNNYKVLIYNGQ                               LDIIVAAALTERSLMGMDWKGSQEYKKAEKKVWKIFKSDSEVA                               GYIRQAGDFHQVIIRGGGHILPYDQPLRAFDMINRFIYGKGWD                               PYVG               587   1326   883   541   RDERAKVPFRSTEG\GRRRRRRMEAVVFVFSLLDCCALIFLSV                               YFIITLSDLECDYINARSCCSKLNKWVIPELIGHTEVTVLLLM                               SLHWFIFLLNLPVATWNIYRYIMVPSGNMGVFDPTEIHNRGQL                               KSHMKEAMIKLGFHLLCFFMYLYSMILALIND               588   1327   1126   732   QSPGHGAPCQLSSSHSRSNRLLSPMARATLSAAPSNPRLLRVA                               LLLLLLVAASRRAAGAPLATELRCQCLQTLQGIHLKNIQSVKV                               KSPGPHCAQTEVIATLKNGQKACLNPASPMVKKIIEKMLKNGK                               SN               589   1328   197   330   HPLSLVFLALNTGKEKSHPGGGGERPGLAGQGEPDHPAGARDG                               R               590   1329   1   1575   CTPVARSMATTATCTRFTDDYQLFEELGKGAFSVVRRCVKKTS                               TQEYAAKIINTKKLSARDHQKLEREARICRLLKHPNIVRLHDS                               ISEEGFHYLVFDLVTGGELFEDIVAREYYSEADASHCIHQILE                               SVNHIHQHDIVHRDLKPENLLLASKCKGAAVKLADFGLAIEVQ                               GEQQAWFGFAGTPGYLSPEVLRKDPYGKPVDIWACGVILYILL                               VGYPPFWDEDQHKLYQQIKAGAYDFPSPEWDTVTPEAKNLINQ                               MLTINPAKRITADQALKHPWVCQRSTVASMMHRQETVECLRKF                               NARRKLKGAILTTMLVSRNFSAAKSLLNKKSDGGVKPQSNNKN                               SLVSPAQEPAPLQTAMEPQTTVVHNATDGIKGSTESCNTTTED                               EDLKVPRKQEIIKITEQLIEAINNGDFEAYTKKDPGLTSFEPE                               ALGNLVEGMDFHKFYFENLLSKNSKPIHTTILNPHVHVIGEDA                               ACIAYIRLTQYIDGQGRPRTSQSEETRVWHRRDGKWLNVHYHC                               SGAPAAPLQ               591   1330   17   636   NRRTVKMLLELSEEHKEHLAFLPQVDSAVVAEFGRIAVEFLRR                               GANPKIYEGAARKLNVSSDTVQHGVEGLTYLLTESSKLMISEL                               DFQDSVFVLGFSEELNKLLLQLYLDNRKEIRTILSEL\APSLP                               SYHNLEWRLDVQLASRSLRQQIKPAVTIKLHLNQNGDHNTKVL                               QTDPATLLELVQQLEQALEEMKTNHCRVRIK               592   1331   1   237   GTSIYLAHRVA\RAWELAQFIHHTSKKADVVLACGDSIVHPED                               LICCPLTGRSCLCDVHLLSSLLARLGRGYAVSLTNL               593   1332   2506   1684   RGCGSCGYKPSAGPAWRPRPPPAVSPLRHPEPAKVLSFSSCPL                               PALGRTGPSRAARAQSLTMASLFKKKTVDDVIKEQNRELRGTQ                               RAIIRDRAALEKQEKQLELEIKKMAKIGNKEACKVLAKQLVHL                               RKQKTRTFAVSSKVTSMSTQTKVMNSQMKMAGAMSTTAKTMQA                               VNKKMDPQKTLQTMQNFQKENMKMEMTEEMINDTLDDIFDGSD                               DEEESQDIVNQVLDEIGIEISGKMAKAPSAARSLPSASTSKAT                               ISDEEIERQLKALGVD               594   1333   905   432   STDGNGAERLFAELRKMNARGLGSELKDSIPVTELSASGPFES                               HDLLRKGFSCVKNELLPSHPLELSEKNFQLNQDKMNFSTLRNI                               QGLFAPLKLQMEFKAVQQVQRLPFLSSSNLSLDVLRGNDETIG                               FEDILNDPSQSEVMGEPHLMVEYKLGLL               595   1334   111   117   RNMKLHYVAVLTLAILMFLTWLPESLSCNKALCASDVSKCLIQ                               ELCQCRPGEGNCSCCKECMLCLGALWDECCDCVGMCNPRNYSD                               TPPTSKSTVEELHEPIPSLFRALTEGDTQLNWNIVSFPVAEEL                               SHHENLVSFLETVNQPHHQNVSVPSNNVHAPYSSDK/E*LPTV                               DFFHSAPSCGLSM*SIIFFEET               596   1335   817   278   VGGVPTWLEGCGSGNPSPRSGGGPGARLTLPALQMTVHNLYLF                               DRNGVCLHYSEWHRKKQAGIPKEEEYKLMYGMLFSIRSFVSKM                               SPLDMKDGFLAFQTSRYKLHYYETPTGIKVVMNTDLGVGPIRD                               VLHHIYSALYVELVVKNPLCPLGQTVQSELFRSRKDSYVRSLP                               FFSARAG               597   1336   171   881   PGLSQEPSGSMETVVIVAIGVLATIFLASFAALVLVCRQRYCR                               PRDLLQRYDSKPIVDLIGAMETQSEPSELELDDVVITNPHIEA                               ILENEDWIEDASGLMSHCIAILKICHTLTEKLVAMTMGSGAKM                               KTSASVSDIIVVAKRISPRVDDVVKSNYPPLDPKLLDARTTAL                               LLSVSHLVLVTRNACHLTGGLDWIDQSLSAAEEHLEVLREAAL                               ASEPDKGLPGPEGFLQEQSAI               598   1337   1078   594   VGMELPAVNLKVILLGHWLLTTWGCIVFSGSYAWANFTILALG                               VWAVAQRDSIDAISMFLGGLLATIFLDIVHISIFYPRVSLTDT                               GRFGVGMAILSLLLKPLSCCFVYHMYRERGGELLVHTGFLGSS                               QDRSAYQTIDSAEAPADPFAVPEGRSQDRGY               599   1338   717   116   PASRPLLGPDTGSVANIFKGLVILPEMSLVIRNLQRVIPIRRA                               PLRSKIEIVRRILGVQKFDLGIICVDNKNIQHINRIYRDRNVP                               TDVLSFPFHEHLKAGEFPQPDFPDDYNLGDIFLGVEYIFHQCK                               ENEDYNDVLTVTATHGLCHLLGFTHGTEAEWQQMFQKEKAVLD                               ELRRRTGTRLQPLTPGPLPEGAEGRRF               600   1339   1   804   LRNALDVLHREVPRVLVNLVDFIMPTIMRQVFLGNPDKCPVQQ                               A/MLEPLGSKTETLDLRAEMPITCPTQNEPFLRTPRNSNYTYP                               IKPAIENWGSDFLCTEWKASNSVPTSVHQLRPADIKVVAALGD                               SLTTAVGARPNNSSDLPTSWRGLSWSIGGDGNLETHTTLPNIL                               KKFNPYLLGFSTSTWEGTAGLNVAAEGARARDMPAQAWDLVER                               MKNSPDINLEKDWKLVTLFIGGNDLCHYCENPEAHLATEYVQH                               IQQALDILSE               601   1340   1   860   VVEFLWSRRPSGSSDPRPRRPASKCQMMEERANLMHMMKLSIK                               VLLQSALSLGRSLDADHAPLQQFFVVMEHCLKHGLKVKKSFIG                               QNKSFFGPLELVEKLCPEASDIATSVRNLPELKTAVGRGRAWL                               YLALMQKKLADYLKVLIDNKHLLSEFYEPEALMMEEEGMVIVG                               LLVGLNVLDANL\CLKGEDLDSQVGVIDFSLYSKDVQDLDGGK                               EHERITDVLDQKNYVEELNRHLSCTVGDLQTKIDGLEKTNSKL                               QERVSAATDRKSLQEEQQQLREQNELL               602   1341   60   762   KPEGARRVQFVMGLFGKTQEKPPKELVNEWSLKIRKEMRVVDR                               QIRDIQREEEKVKRSVKDAAKKGQKDVCIVLAKEMIRSRKAVS                               KLYASKAHMNSVLMGMKNQLAVLRVAGSLQKSTEVMKAMQSLV                               KIPEIQATMRELSKEMMKAGIIEEMLEDTFESMDDQEEMEEEA                               EMEIDRILFEITAGALGKAPSKVTDALPEPEPPGAMAASEDEE                               EEEEALEAMQSRLATLRS               603   1342   3   456   RWNSIMELALLCGLVVMAGVIPIQGGILNLNKMVKQVTGKMPI                               LSYWPYGCHCGLGGRGQPKDATDWCCQTHDCCYDHLKTQGCGI                               YKDYYRYNFSQGNIHCSDKGSWCEQQLCACDKEVAFCLKRNLD                               TYQKRLRFYWRPHCRGQTPGC               604   1343   249   632   KTVAEEASVGNPEGAFMKMLQARKQHMSTELTIESEAPSDSSG                               INLSGFGSEQLDTNDESDVSSALSYILPYLSLRNLGAESILLP                               FTEQLFSNVQDGDRLLSILRRKSPSQSSLLGRKRIF               605   1344   2   382   LPLTLLLAAPFAHLLLPPGHDQSPCWHPGPALSPGTLGPLSWA                               MANSGLQLLGYFLALGGWVGIIASTALPQWKQSSYAGDASIQL                               RSKVFRESEWGGDSLGLPRDCGWSCLIMSARSEKGRS               606   1345   2   987   DPRVRPPLLQPPPPLLPRLVILKMAPLDLDKYVEIARLCKYLP                               ENDLKRLCDYVCDLLLEESNVQPVSTPVTVCGDIHGQFYDLCE                               LFRTGGQVPDTNYIFMGDFVDRGYYSLETFTYLLALKAKWPDR                               ITLLRGNHESRQITQVYGFYDECQTKYGNANAWRYCTKVFDML                               TVAALIDEQILCVHGGLSPDIKTLDQIRTIERNQEIPHKGAFC                               DLVWSDPEDVDTWAISPRGAGWLFGAKVTNEFVHINNLKLICR                               AHQLVHEGYKFMFDEKLVTVWSAPNYCYRCGNIASIMVFKDVN                               TREPKKFRAVPDSERVIPPRTTTPYFL               607   1346   10   768   SFAGAAARPSTPPASGRGAAPGRPGPSPMDLRAGDSWGMLACL                               CTVLWHKPAVPALNRTGDPGPGPSIQKTYDLTRYLEHQLRSLA                               GTYLNYLGPPFNEPDFNPPRLGAETLPRATVDLEVWRSLNDKL                               RLTQNYEAYSHLLCYLRGLNRQAATAELRRSLAHFCTSLQGLL                               GSIAGVMAALGYPLPQPLPGTEPTWTPGPAHSDFLQKMDDFWL                               LKELQTWLWRSAWFNRLKQPPARGRGF               608   1347   114   700   IKISLKKRSMSGISGCPFFLWGLLALLGLALVISLIFNISHYV                               EKQRQDKMYSYSSDHTRVDEYYIEDTPIYGNLDDMISEPMDEN                               CYEQMKARPEKSVNKMQEATPSAQATNETQMCYASLDHSVKGK                               RRKPRKQNTHFSDKDGDEQLHAIDASVSKTTLVDSFSPESQAV                               EENIHDDPLLFGLLAREPIN               609   1348   2   807   VEFHPQRARAGARAPSMGVLLTQRTLLSLVLALLFPSMASMAA                               IGSCSKEYRVLLGQLQKQTDLMQDTSRLLDPYIRIQGLDVPKL                               REHCRERPGAFPSEETLRGLGRRCFLQTLNATLGCVLHRLADL                               EQRLPKAQDLERSGLNIEDLEKLQMARPNILGLRNNIYCMAQL                               LDNSDTAEPTKARRGASQPPTPTPASDAFQRXLEGCRFLHGYH                               RFMHSVGRVFSKWGESPNRSRRHSPHQALRKGVRRTRPSRKGK                               RLMTRGQLPR               610   1349   2   418   DFPGRRFRLVWLLVLRLPWRVPGQLDPTTGRRFSEHKLCADDE                               CSMLMYRGEALEDFTGPDCRFVNFKKGDPVYVYYKLARGWPEV                               WAGSVGRTFGYFPKDLIQVVHEYTKEELQVPTNETDFVCFDGG                               RDDFHNYNV               611   1350   823   115   SPLGKEGQEEVRVKIKDLNEHIVCCLCAGYFVDATTITECLHT                               FCKSCIVKYLQTSKYCPMcNIKIHETQPLLNLKLDRVMQDIVY                               KLVPGLQDSEEKRIREFYQSRGLDRVTQPTGEEPALSNLGLPF                               SSFDHSKAHYYRYDEQLNLCLERLSSGKDKNKSVLQNKYVRCS                               VRAEVRKLRRVLCHRLMLNPQHVQLLFDNEVLPDHMTMKQIWL                               SRWFGKPSPLLLQYSVKEKRR               612   1351   9   545   LWWYSAHAAVDAMMDVFGVGFPSKVPWKKMSAEELENQYCPSR                               WVVRLGAEEALRTYSQIGIEATTRARATRKSLLHVPYGDGEGE                               KVDIYFPDESSEATTRARATRKSLLHVPYGDGEGEKVDIYFPD                               ESSEALPFFLFFHGGYWQSGRHPGPHGRPGDPQRCVCPEAVSK                               QQAPSW               613   1352   49   902   GVRMASRGRRPEHGGPPELFYDETEARKYVRNSRMIDIQTRMA                               GRALELLYLPENKPCYLLDIGCGTGLSGSYLSDEGHYWVGLDI                               SPAMLDEAVDREIEGDLLLGDMGQGIPFKPGTFDGCISISAVQ                               WLCNANKKSENPAKRLYCFFASLFSVLVRGSRAVLQLYPENSE                               QLELITTQATKAGFSGGMVVDYPNSAKAKKFYLCLFSGPSTFI                               PEGLSENQDEVEPRESVFTNERFPLRMSRRGMVRKSRAWVLEK                               KEPHRRQGREVRPDTQYTGRKRKPRF               614   1353   1960   871   TLICRMAGCGEIDHSINMLPTNRKANESCSNTAPSLTVPECAI                               CLQTCVHPVSLPCKHVFCYLCVKGASWLGKRCAKCRQEIPEDF                               LDKPTLLSPEELKAASRGNGEYAWYYEGRNGWWQYDERTSREL                               EDAFSKGKKNTEMLIAGFLYVADLENMVQYRRNEHGRRRKIKR                               DIIDIPKKGVAGLRLDCDANTVNLARESSADGADSVSAQSGAS                               VQPLVSSVRPLTSVDGQLTSPATPSPDASTSLEDSFAHLQLSG                               DNTAERSHRGEGEEDHESPSSGRVPAPDTSIEETESDASSDSE                               DVSAVVAQHSLTQQRLLVSNANQTVPDRSDRSGTDRSVAGGGT                               VSVSVRSRRPDGQCTVTEV               615   1354   5653   4549   GATPLGSVGGRTGKMDAATLTYDTLRFAEFEDFPETSEPVWIL                               GRKYSIFTEKDEILSDVASRLWFTYRKNFPAIGGTGPTSDTGW                               GCMLRCGQMIFAQALVCRHLGRDWRWTQRKRQPDSYFSVLNAF                               IDRKDSYYSIHQIAQMGVGEGKSIGQWYGPNTVAQVLKKLAVF                               DTWSSLAVHIAMDNTVVMEEIRRLCRTSVPCAGATAFPADSDR                               HCNGFPAGAEVTNRPSPWRPLVLLIPLRLGLTDINEAYVETLK                               HCFMMPQSLGVIGGKPNSAHYFIGYVGEELIYLDPHTTQPAVE                               PTDGCFIPDESFHCQHPPCRMSIAELDPSIAVVRGGHLSTQAF                               GAECCLGMTRKTFGFLRFFFSMLG               616   1355   416   65   PTTSNRAITLTAWPKIPFLGICEAKNPRSENMRLATILEVACH                               HLGSGPPPSWELWEQGPPGNSSRYIEFLNKHTYIKGTLRVYTK                               KFCMLVIKSFESKSCVCVYDFDSKSSVNVTV               617   1356   2   382   PRVRFRLLHVTSIRSAWILCGIIWILIMASSIMLLDSGSEQNG                               SVTSCLELNLYKIAKLQTVNYIALVVGCLLPFFTLSICYLLII                               RVLLKVEVPESGLRVSHRKALTTIIITLIIFFLCFLPYHT               618   1357   3   672   GRHWLGSAQLTDGGSARKPKMAVPAALILRESPSMKKAVSLIN                               AIDTGRFPRLLTRILQKLHLKAESSFSEEEEEKLQAAFSLEKQ                               DLHLVLETISFILEQAVYHNVKPAALQQQLENIHLRQDKAEAF                               VNTWSSMGQETVEKFRQRILAPCKLETVGWQLNLQMAHSAQAK                               LKSPQAVLQLGVNNEDSKSLEKVLVEFSHKELFDFYNKLETIQ                               AQLDSLT               619   1358   557   208   EASSAKTKRKEEKGPKAKMKLMVLVFTIGLTLLLGVQAMPANR                               LSCYRKILKDHNCHNLPEGVADLTQIDVNVQDHFWDGKGCEMI                               CYCNFSELLCCPKDVFFGPKISFVIPCNNQ               620   1359   335   1735   KMAEAVFHAPKRKRRVYETYESPLPIPFGQDHGPLKEFKIFRA                               EMINNNVIVRNAEDIEQLYGKGYFGKGILSRSRPSFTISDPKL                               VAKWKDMKTNMPIITSKRYQHSVEWAAELMRRQGQDESTVRRI                               LKDYTKPLEHPPVKRNEEAQVHDKLNSGMVSNMEGTAGGERPS                               VVNGDSGKSGGVGDPREPLGCLQEGSGCHPTTESFEKSVREDA                               SPLPHVCCCKQDALILQRGLHHEDGSQHIGLLHPGDRGPDHEY                               VLVEEAECAMSEREAAPNEELVQRNRLICRRNPYRIFEYLQLS                               LEEAFFLVYALGCLSIYYEKEPLTIVKLWKAFTVVQPTFRTTY                               MAYHYFRSKGWVPKVGLKYGTDLLLYRKGPPFYHASYSVIIEL                               VDDHFEGSLRRPLSWKSLAALSRVSVNVSKELMLCYLIKPSTM                               TDKEMESPECMKRIKVQEVILSRWVSSRERSDQDDL               621   1360   5693   4435   RDIWTMNLQRYWGEIPISSSQTNRSSFDLLPREFRLVEVHDPP                               LHQPSANKPKPPTMLDIPSEPCSLTIHTIQLIQHNRRLRNLIA                               TAQAQNQQQTEGVKTEESEPLPSCPGSPPLPDDLLPLDCKNPN                               APFQIRHSDPESDFYRGKGEPVTELSWHSCRQLLYQAVATILA                               HAGFDCANESVLETLTDVAHEYCLKFTKLLRFAVDREAPLGQT                               PFPDVMEQVFHEVGIGSVLSLQKFWQHRIIWYHSYMLQISKQL                               SEEYERIVNPEKATEDAKPVKIKEEPVSDITFPVSEELEADLA                               SGDQSLPMGVLGAQSERFPSNLEVEASPQASSAEVNASPLWNL                               AHVKMEPQESEEGNVSGHGVLGSDVFEEPMSGMSEAGIPQSPD                               DSDSSYGSHSTDSLMGSSPVFNQRCKKRMRKI               622   1361   15   678   REQILFIEIRDTAXGGETEQPPSLSPLHGGRMPEMGEGIQSLA                               RETQSHRGRRQGWDATWVTRCRESLNRGGAGAGKPAGALAHHV                               FLALIEPNLAEREASEEEVKACSDETVVADLLVKVVYVLGAIL                               KIFLREGNVLNQHSGMDIEKYSEHYQHDHSPGAEDDAAGGQLR                               PTAQERRHKEGSRGSPRCKRARKAVGESPGCPRPRVRPRVRPR                               VRPRV               623   1362   1080   835   GTRGCCREGTAYAKAYQFMASHLSLGKPVSTGSIPRFNKARLR                               KQAKCKPNHYSFIGLSMLSPENFSIGCKYSVWFSETKGF               624   1363   872   441   GAQGVRVGIGEVGRVQAPRVSLLHSQGVPRGGTGEAVKEEGRG                               SSLHPPLPPQGLGEYAACQSHAFMKGVFTFVTGTGMAFGLQMF                               IQRKFPYPLQWSLLVAVVAGSVVSYGVTRVESEKCNNLWLFLE                               TGQLPKDRSTDQRS               625   1364   1   585   GTSELLCIQRWNWGPAFPPRPGLALAPTLQLLVEMGSAKAVPV                               TPARPPPHNKHLARVADPRSPSAGILRTPIQVESSPQPGLPAG                               EQLEGLKHAQDSDPRSPLGKN*GHGWQVGQGSDLGSPQPLPPS                               ASHL/YSSRASRCSQPPCLSLPWFGVRSSPANTYHVPVTSLCP                               SPALHYTAKQAGIISTSQARAPR               626   1365   36   381   PLLLPRFIDIPCLLCYLTQVTPDDMYAKAFLIKPNTAITGTDR                               RKL\RADETTDFP\TLGTDQIYELLPGKDELNIVKSNAHKRDA                               *TAYVSGENHILSEP*KNLYPAVNTLSSYP               627   1366   763   1003   SRQPPPLLTMVFLLEFLFLVFFPGCVNQLLLSYPWQGQGTSLW                               SSLSFHWLLPQEDSSRLSIFPLRAGSPPQPAQAPQRI               628   1367   296   1199   KSREQSSLFAADAERSWGGKSCCLLRWRFVGKASHFPRLLPLP                               GEERPETKERAWKMEQTWTRDYFAEDDGEMVPRTSHTA/ASVS                               LTAPLSDTKDRGPPVQSQIWRSGEKVPFVQTYSLRAFEKPPQV                               QTQALRDFEKHLNDLKKENFSLKLLIYFLEEPMQQKYEASRED                               IYKRNTELKVEVESLKRELQDKKQHLDKTWADVENLNSQNEAE                               LRRQFEERQQEMEHVYELLENKMQLLQEESRLAKNEAARMAAL                               VEAEKECNLELSEKLKGVTKNWEDVPGDQVKPDQYTEAKAQRD                               K               629   1368   191   1116   TRRRGTTWRSPRPRRASTSRPSTRPRGVASWPWETAGTATTGP                               GPSARTRRRAARRRRSRPRRRAHGGLSQPRGWQSLLSFTILFL                               AWLAGFSSRLFAVIRFESIIHEFDPWFNYRSTHHLASHGFYEF                               LNWFDERAWYPLGRIVGGTVYPGLMITAGLIHWILNTLNITVH                               IRDVCVFLAPTFSGLTSISTFLLTRELWNQGAGLLAACFIAIV                               PGYISRSVAGSFDNEGIAIFALQFTYYLWVKSVKTGSVFWTMC                               CCLSYFYMVSAWGGYVFIINLIPLHAFVLVLM/Q/RYSKRVYI                               *YSTRIVG               630   1369   852   214   RRLIVVLSDAFLSRAWCSHSF/RVGPARGWVGPSVAPTPLTVP                               PRREGLCRLLELTRRPIFITFEGQRRDPAHPALRLLRQHRHLV                               TLLLWRPGSVTPSSDFWKEVQLAKPRKVRYRPVEGDPQTQLQD                               DKDPMLILRGRVPEGRALDSEVDPDPEGDLGVRGPVFGEPSAP                               PHTSGVSLGESRSSEVDVSDLGSRNYSARTDFYCLVSKDDM               631   1370   246   1091   LSHEGWRRGREGERINSSVASLAPLCILPDLPSNMHLARLVGS                               CSLLLLLGALSGWAASDDPIEKVIEGINRGLSNAEREVGKAID                               GINSGITHAGREVEKVFNGLSNMGSHTGKELDKGVQGLNHGMD                               KVAHEINHGIGQAGKEAEKLGHGVNNAAGQAGKEADKAVQGFH                               TGVHQAGKEAEKLGQGVNHAADQAGKEVEKLGQGAHHAAGQAG                               KELQNAHNGVNQASKEANQLLNGNHQSGSSSHQGGATTTPLAS                               GASVNTPFINLPALWRSVANIMP               632   1371   3150   2792   SASGGLGMTVEGPEGSEREILPPEKPPRPPRPLHLSDRSFRRK                               KDSVESHPTWVDDTRIDADAIVEKIVQSQDFTDGSNTEDSNKR                               LFVSRDGSATLSGIQLATRVSSGVYEPWIESH               633   1372   667   993   ERSGWPQPEGTVTAQGPLFWERLSGAVTVSSGYKADMWPSFPQ                               \VRVGSFLFGILFFSFGSSSLPPGLPPPASLLCCAVQWGARAL                               FLPCLKERALGMEMRNNTLSFRQ               634   1373   636   2   SSSNLRLSFLINENILGKCFRSGPSCAGPRISPLAAQYECPRP                               SLLIMASVPKTNKIEPRSYSIIPSCGI\RRLGPALNTLIF\QS                               KRFGPRG\HSAKSIEGAPRGKGRGRAVARLAADRPPAPKIQLR                               AF*LQQL*YTLLELELPRLLAPDLPSNGSSLKDLKWTHSNYRA                               SKESCIVIF\VTTSPGREWVKALAAFLGCGS\LSQAPSPES               635   1374   61   519   LRIINTYFCFKFLIVNYIHGTTKARKPHVLGESLISAMSRQEP                               KMFVLLYVTSFAICASGQPRGNQLKGENYSPRYICSIPGLPGP                               PGPPGPNGSPGPHGRIGLPGRDGRDGRKGEKGEKGTAGLRGKT                               GPLGLAGEKGDQGETGKKGPIGPE               636   1375   129   579   FASAMLGSRVDRPKLSVAPSVVLEEDQVKVSPAVDLEAGCRLR                               DFTEKIMNVKGKVILSMLVVSTVIIVFWEFINSTEGSFLWIYH                               SKNPEVDDSSAQKGWWFLSWFNNGIHNYQOGEEDIDKEKGREE                               TKGRKMTQQSFGYGTGLIQT               637   1376   127   1376   GSHRFSLASPLDPEVGPYCDTPTMRTLFNLLWLALACSPVHTT                               LSKSDAKKAASKTLLEKSQFSDKPVQDRGLVVTDKKAESVVLE                               HRSYCSAKARDRHFAGDVLGYVTPWNSHGYDVTKVFGSKFTQI                               SPVQLQLKRRGREMFEVTGLHDVDQGWMRAVRKHAKGLHIVPR                               LLFEDWTYDDFRNVLDSEDEIEELSKTVVQVAKNQHFDGFVVE                               VWNQLLSQKRVGLIHMLTHLAEAKHQARLLALLVIPPAITPGT                               DQLGMFTHKEFEQLAPVLDGFSLMTYDYSTAHQPGPNAPLSWV                               RACVQVLDPKSKWRSKILLGLNFYGMDYATSKDAREPVVGARY                               IQTLKDHRPRMVWDSQVSEHFFEYKKSRSGRHVVFYPTLKSLQ                               VRLELARELGVGVSIWELGQGLDYFYDLL               638   1377   998   48   GREGTGWGPAMSEVTRSLLQRWGASFRRGADFDSWGQLVEAID                               EYQILARHLQKEAQAQHNNSEFTEEQKKTIGKIATCLELRSAA                               LQSTQSQEEFKLEDLKKLEPILKNILTYNKEFPFDVQPVPLRR                               ILAPGEEENLEFEEDEEEGGAGAGSPDSFPARVPGTLKPRKPS                               EPGMTLLTIRIEKIGLKDAGQCINPYITVSVKDLNGIDLTPVQ                               DTPVASRKEDTYVHFNVDIELQKHVEKLTKGAAIFFEFKHYKP                               KKRFTSTKCFAFMENDEIKLGPIVIELYKKPTDFKRKQLQLLT                               KKPLYLHLHQTLHKE               639   1378   1298   1569   GSITSEPSLDSLQPLPPGFKRFSCLSLPSSWDYPRPPPGLAYF                               CIFSRDEVSPCWPGCSPSPDLMIRLPRPPSVGITGVSHRAWPT                               IDNF               640   1379   196   1197   KMPVPWFLLSLALGRSPVVLSLERLVGPQDATHCSPGLSCRLW                               DSDILCLPGDIVPAPGPVKAPTHLQTELVLRCQKETDCDLCLR                               VAVHLAVHGHWEEPEDEEKFGGAADSGVEEPRNASLQAQVVLS                               FQAYPTARCVLLEVQVPAALVQFGQSVGSVVYDCFEAALGSEV                               RIWSYTQPRYEKELNHTQQLPDCRGLEVWNSIPSCWALPWLNV                               SADGDNVHLVLNVSEEQHFGLSLYWNQVQGPPKPRWHKNLVRP                               PPSQVHSHCRP\CLCK\DAVPYQRGSLKRTHPKQGKIGGGTSA                               FLVSLTLASSSSSLSSPTSFLYLFHRLDRRSLP               641   1380   756   1110   LRLWNRNQMMHNIIVKELIVTFFLGITVVQMLISVTGLKGVEA                               QNGSESEVFVGKYETLVFYWPSLLCLAFLLGRFLHMFVKALRV                               HLGWELQVEEKSVLEVHQGEHVKQLLRIPRP               642   1381   631   1278   KVNRKLRKKGKISHDKRKKSRSKAIGSDTSDIVHIWCPEGMKT                               SDIKELNIVLPEFEKTHLEHQQRIESKVCKAAIATFYVNVKEQ                               FIKMLKESQMLTNLKRKNAKMISDIEKKRQRMIEVQDELLRLE                               PQLKQLQTKYDELKERKSSLRNAAYFLSNLKQLYQDYSDVQAQ                               EPNVKETYDSSSLPALLFKARTLHGAESHLRNINHQLEKLLDQ                               G               643   1382   1167   755   VWVAMEEPPVREEE*EEGEEDEERDEVGPEGAKGKSPFQLTAE                               DVYDISYLLGRELMALGSDPRVTQLQFKVVRVLEMLEALVNEG                               SLALEELKMERDHLRKEVEGLRRQSPPASGEWPDSTKRRPRRK                               KRKRCCGY               644   1383   1   271   PRNDHRLTQSRRDSSSKTRAFLVPRFLPAHAGVTSEERTAMKR                               EGGAADLCSDSLPESQQQDGNHAPNFSSHGSCRPRQRRRHDKA                               LHAR               645   1384   1   499   THASEKSRATMSSWSRQRPKSPGGIQPHVSRTLFLLLLLAASA                               WGVTLSPKDCQVFRSDHGSSISCQPPAEIPGYLPADTVHLAVE                               FFNLTHLPANLLQGASKLQELHLSSNGLESLSPEFLRPVPQLR                               VLDLTRNALTGLPPGLFQASATLDTLVLKENQLEVLE               646   1385   178   675   ERPRIMDLAGLLKSQFLCHLVFCYVFIASGLIINTIQLFTLLL                               WPINKQLFRKINCRLSYCISSQLVMLLEWWSGTECTIFTDPPA                               YLKYGKENAIVVLNHKF\EI\DFLCGWSLSERFGLLGVSQKCI                               PPCLTHFFGSAPPLVFLLLVIQNLQKNQQSFYLMKWS               647   1386   630   1499   MIVFGWAVFLASRSLGQGLLLThEEHIAHFLGTGGAATTMGNS                               CICRDDSGTDDSVDTQQQQAENSATPTADTRSQPRDPVRPPRR                               GRGPHEPRRKKQNVDGLVLDTLAVIRTLVDNDQEPPYSMITLH                               EMAETDEGWLDVVQSLIRVIPLEDPLGPAVITLLLDECPLPTK                               DALQKLTEILNLNGEVACQDSSHPAKHRNTSAVLGCLAEKLAG                               PASIGLLSPGILEYLLQCLLQSHPTVMLFAKIALEKFAQTSEN                               KLTISESSISDRL\VTLESW\ANDPDYLKRQVG               648   1387   1   962   RFGTRGLAKSKGVVLMALCALTRALRSLNLAPPTVAAPAPSLF                               PAAQMMNNGLLQQPSALMLLPCRPVLTSVALNANFVSWKSRTK                               YTITPVKMRKSGGRDHTGRIRVHGIGGGHKQRYRMIDFLRFRP                               EETKSGPFEEKVIQVRYDPCRSRDIALVAGGSRKRWIIATENM                               QAGDTILNSNHIGRMAVAAREGDAHPLGALPVGTLINNVESEP                               GRGAQYIRAAGTCGVLLRKVNGTAIIQLPSKRQMQVLETCVAT                               VGRVSNVDHNKRVIGKAGRNRWLGKRPNSGRWHRKGGWAGRKI                               RPLPPMKSYVKLPSASAQS               649   1388   291   714   PVQGARCWLDARRRVRVFSGVCCGCGIHGYWAEPCGGCGAMEG                               LRSSVELDPELTPGKLDEEMVGLPPHDASPQVTFHSLDGKTVV                               CPHFMGLLLGLLLLLTLSVRNQLCVRGERQLAETLHSQVKEKS                               QLIGKKTDCRD               650   1389   874   2220   GARGRPLAETWPFLTAPVLPGQLQITEPTMAEKGDCIASVYGY                               DLGGRFVDFQPLGFGVNGLVLSAVDSRACRKVAVKKIALSDAR                               SMKHALREIKIIRRLDHDNIVKVYEVLGPKGTDLQGELFKFSV                               AYIVQEYMETDLARLLEQGTLAEEHAKLFMYQLKRGLKYIHSA                               NVLHRDLKPANIFISTEDLVLKIGDFGLARIVDQHYS\EKGYL                               SEGLVTKWYRSPRLLLSPNNYTKAIDMWAAGCILAEMLTGRML                               FAGAHELEQMQLILETIPVIREEDKDELLRVMPSFVSSTWEVK                               RPLRKLLPEVNSEAIDFLEKILTFNPMDRLTAEMGLQHPYMSP                               YSCPEDEPTSQHPFRIEDEIDDTVLMAANQSQLSNWDTCSSRY                               PVSLSSDLEWRPDRCQDASEVQRDPRAGSAPLAENVQVDPRKD                               SHSSSASCQAGRNGVSRYQ               651   1390   1   2451   MRTLGTCLATLAGLLLTAAGETFSGGCLFDEPYSTCGYSQSEG                               DDFNWEQVTLTKPTSDPWMPSGSFMILVNASGRPEGQRAHLLL                               PQLKENDTHCIDFHYFVSSKSNSPPGLLNVYVKVNNGPLGNPI                               WNISGDPTRTNNPAELAISTFWPNFYQVIFEVITSGHQGYLAI                               DEVKVLGHPCTRTPHFLRIQNVEVNAGQFATFQCSAIGRTVAG                               DRLWLQGIDVRDAPLKEIKVTSSRRFIASFNVVNTTKRDAGKY                               RCMI\RTEGGVGISNYAEL\VVKEPPVPIAPPQLASVGATYLW                               IQLNANSINGDGPIVAREVEYCTASGSWNDRQPVDSTSYKIGH                               LDPDTEYEISVLLTRPGEGGTGSPGPAKRTRTKCADPMRGPRK                               LEVVEVKSRQITIRWEPFGYNVTRCHSYNLTVHYCYQVGGQEQ                               VREEVSWDTENSHPQHTITNLSPYTNVSVKLIKMNPEGRKESQ                               ELIVQTDEDLPGAVPTESIQGSTFEEKIFLQWREPTQTYGVIT                               LYEITYKAVSSFDPEIDLSNQSGRVSKLGNETHFLFFGLYPGT                               TYSFTIRASTAKGFGPPATNQFTTKISAPSMPAYELETPLNQT                               DNTVTVMLKPAHSRGAPVSVYQIVVEEERPRRTKKTTEILKCY                               PVPIHFQNASLLNSQYYFAAEFPADSLQAAQPFTIGDNKTYNG                               YWNTPLLPYKSYRIYFQAASRANGETKIDCVQVATKGAATPKP                               VPEPEKQTDHTVKIAGVIAGILLFVIIFLGVVLVMKKRLYKHG                               ASICSASGEASGSFQSWRKAKHKQACPMARAGARERAGGCLKL               652   1391   30   459   GIRQLLQLSRASMAARKSWTALRLCATVVVLDMVVCKGFVQDL                               DESFKENPNDDIWLVHFYAPWCGHCKKLEPIWNEAGLEMKSIG                               SPVKAGKMDATSYSSIASEFGVRGYPTIKLALIRPLPSQQMFE                               HMHKRHRVFFVYV               653   1392   168   1016   GLVIVISHFSPSPGLLPATQSPAMSDPITLNVGGKLYTTSLAT                               LTSFPDSMLGAMFSGKMPTKRDSQGNCFIDRDGKVFRYILNFL                               RTSHLDLPEDFQEMGLLRREADFYQVQPLIEALQEKEVELSKA                               EKNAMLNITLNQRVQTVHFTVREAPQIYSLSSSSMEVFNANIF                               STSCLFLKLLGSKLFYCSNGNLSSITSHLQDPNHLTLDWVANV                               EGLPEEEYTKQNLKRLWVVPANKQINSFQVFVEEVLKIAKSDG                               FCIDSSHPHALDFMNNKILLLY               654   1393   3   927   SCADNLVAASGGCWFVLGERPAGSLLSASYGTFAMPGMVKFGR                               RWAIASDDLVFPGFFELVVRVLWWIGILTLYLMHRGKLDCAGG                               ALLSSYLIVLMILLAVVICTVSAIMCVSMRGTICNPGPRKSMS                               KLLYIRLALFFPEMVWASLGAAWVADGVQCDRTVVNGIIATVV                               VSWIIIAATVVSIIIVFDPLGGKMAPYSSAGPSHLDSHDSSQL                               LNGLKTAATSVWETRIKLLCCCIGKDDHTRVAFSSTAELFSTY                               FSDTDLVPSDIARGLALLHQQQDNIRNNQ\DLPRWSAMPQGAP                               PKLLWMQN               655   1394   1   716   FRAATAAAKGNGGGGGRAGAGDASGTRKKKGPGPLATAYLVIY                               NVVMTAGWLVIAVGLVRAYLAKGSYHSLYYSIEKPLKFFQTGA                               LLEILHCAIGIVPSSVVLTSFQVMSRVFLIWAVTHSVKEVQSE                               DSVL\FVIAWTITEIIRYSFYTFSLLNHLPYLIKRARYTLFIV                               LYPMGVSGELLTIYAALPFVRQAGLYSISLPNSTKKIFLISQV                               WWHMLAVSADAKAAEMPAVLKPGP               656   1395   72   766   MLTGVGCLVSSESLSCVQCNSWEKSCVNSIASECPSHANTSCI                               SSSASSSLETPVRLYQNMFCSAENCSEETHITAFTVHVSAEEH                               FHFVSQCCEGKECSNTSDMRDPPLKNVSSNRECPACYESNGTS                               CRGKPWKCYEEEQCVFLVAELKNDIESKSLVLKGCSNRSNATC                               QFLSGENKTLGGVIFRKFECLNVNSLTPTSAPTTSHNVGSKAS                               LYLLALASLLLRGLLP               657   1396   97   746   VPARRRAMEIGTEISRKIRSAIKGKLQELGAYVDEELPDYIMV                               MVANKKSQDQMTEDLSLFLGNNTIRFTVWLHGVLDKKRSVTTE                               PSSLKSSDTNIFDSNVPSNKSNFSRGDERRHEAAVPPL\AIPS                               ARPEKRDSRVSTSSQESKTTNVRQTYDDGAATRLMSTV/KPLR                               EPAPSEDVIDIKPEPDDLIDEDLNFVQEKPLSQKKPTVTLTYG                               SSR               658   1397   155   560   ASRVLAAVMGLPWGQPHLGLQMLLLALNWLRPSLSLELVPYTP                               QITAWDLEGKVTATTFSLEQPRCVFDGLASASDTVWLVVAFSN                               ASRGFQNPETLADIPASPQLLTDGHYMTLPLSPDQLPCGDPMA                               GSGSAP               659   1398   416   539   NSLNNFFFETESCCVAQAGVQWRDLGSLQAPPPGFRFSCL               660   1399   281   736   KSLPLQKHPKPSCQEDQGLGRGSLSGHSPLTLLTFLTSCALGD                               QQLLPPRTSGSLCQESMSEQSCQMSELRLLLLGKCRSGKSATG                               NAILGKHVFKSKFSDQTVIKMCQRESWVLRERKVVVIDTPDLF                               SSIACAEDKQRNIQHLLELSAP               661   1400   2   974   FVETTVSVQSAESSDALSWSRLPRALASVGPEEARSGAPVGGG                               PWQLSDRVEGGSPTLGLLGGSPSAQPGTGNVEAGIPSGRMLEP                               LPCWDAAKDLKEPQCPPGDRVGVQPGNSRVWQGTMEKAGLAWT                               RGTGVQSEGTWESQRQDSDALPSPELLPQDQDKPFLRKACSPS                               NIPAVIITDMGTQEDGAKEETQGSPRGNLPLRKLSSSSASSTG                               FSSSYEDSEEDISSDPERTLDPNSAFLHTLDQQKPRVVESRSV                               TQAGVQWHDIGSLQPLPP/WIQAIL/HASAFRIAGTTGACHHA                               RIIFGFLVERGFHRVGQDGLYLLIL               662   1401   232   3   KICSSYFLRIICILQKEAQEASNLYTSCDFFSPAFYFVIYRLY                               NFKIHWPGAVAHTYSPSTLGGRGRWVT*GREFM               663   1402   250   556   LILSLPLLYGHLKSYTFPSEHYLHLLQTFATFNKYLNVCVLIF                               IHHKPVVPAIQGTNVGGSLEPRRLRLQQAMIVPLHFGLGNRVR                               PCLKKQQQQQQQQQKK               664   1403   1   373   RMETKPVITCLKTLLIIYSFVFWITGVILLAAGVWGKLTLGSY                               ISLIAENSTYAPYVLIVTGTTIVAYPLV*FFFSYSSGFSYILA                               VRLIAGIALVYNYIPRSSSRAKVRLVVLLRFLLSRHPS               665   1404   3   413   NAEHPGMDRHDLCQKAKLAEHAERDDDMAACMKTVTDQGAELS                               NEERNLLSDAHTNAV*ARRSSWMGA*RIEQKTEGADTQQQMAP                               DCREIFATELRDICDDVLSLLEKKLIPNASHA*SLVYYLHMIG                               DYYRYWK               666   1405   2   334   GGGPLGKMPRAQLADPWQMMAVESPSDCADNGQQIMREPMGED                               EISPQTE*VSIKEVAVTHCVKEGHDKADPSQIELLRVLRQGSL                               GKVYLGKKVSGSDAKQLYAMKVLT               667   1406   2   332   DAAGIRHEAHFGKLECLVQLVRAGA\SLFVSTTRYAQTPA\HI                               AAFGGHPQCLVWLIQAGANINKPDCEGETPIHKAARSGSLECI                               SALVANGAHVDNPKKGLVLEWLFE               668   1407   242   1157   LLKLMFIAELGDYDLAEHSPELVSEFRFVPIQTEEMELAIFEK                               WKEYRGQTPAQAETNYLNKAKWLEMYGVDMHVVKARDGNDYSL                               GLTPTGVLVFEGDTKIGLFFWPKITRLDFKKNKLTLVVVEDDD                               QGKEQEHTFVFRLDHPKACKHLWKCAVEHHAFFRLRGPVQKSS                               HRSGFIRLGSRFRYSGKTEYQTTKTNKARRSTSFERRPSKRYS                               RRTLQMKACATKPEELSVHNNVSTQSNGSQQAWGMRSALPVSP                               SISSAPVPVEIENLPQSPGTDQHDRKWLSAASDCCQRGGNQWN                               TRAL               669   1408   278   1   ATAPGLFNFF*FLFQCREEHKKKNPEVPVNFAEFSKKCSGRWK                               TMSSKEKFKFGEMAKADEVCYDREMKDYGPAKGGKKKDPNAPK                               RPPSGF               670   1409   139   646   AEGLGSWAVWAGLGWAGRHMEAGGATGALGVGSKLPSAFCFPG                               SSVAMDMFQKVEKIGEGTYGVVYKAKNRETGQLVALKKIRLDL                               *VTGRPLSYPPWAITTWALPDPFPLSWSPRLTPLGAAQQPLPV                               LSPVHCLLTSLCRGPDCGVWWMTCQGAQVSIAGALVILWG               671   1410   3   442   LCVSVLCSFSYLQNGWTASDPVHGYWFR\AGDHVSRNIPVATN                               NPVRAVQEETRDRFHLLGDPQNKDCTLSIRDTRESDAGTYVFC                               VERGNMKWNYKYDQLSVNVTASQDLLSRYRLEVPESVTVQEGL                               CVSVP/WQCPLPPLQLDCL               672   141   184   836   QLQLCQNCTKRGECHCVPFDTYIKTKKEKKRLSVLPPTRLMEA                               RFSPINQILPWCRQDLAISISKAINTQEAPVKEKHARRIILGT                               HHEKGAFTFWSYAIGLPLPSSSILSWKFCHVLHKVLRDGHPNV                               LHDCQRYRSNIREIGDLWGHLHDRYGQLVNVYTKLLLTKISFH                               LKHPQFPAGLEVTDEVLEKAAGTDVNNM*VTLHGYMASSPRLP                               HSFLPRLTPRRPHGAVGLNESVALLVDAHAPRDRG               673   1412   307   664   AAPHRMPRAPHFMPLLLLLLLLSLPHTQAAFPQDPLPLRISDL                               QGTSPLSWLPSLEDDAVAA*LGLDFQRFLTLNRTLLVAARDHV                               FSFDLQAEEEGEGLVPNKYLTWRSQDVENCAVR*KLTLNRTLL                               VAARDHFSFDLQAEEEGEGLVPNKYLTWRSQDVENCAVR               674   1413   24   420   HLVPKTRGRGTPSGDQSPVLTLTP*GDPPTILGPQTNQPKEHL                               TNFKSGKRSFHSLLQPLLLLLHPSISPFLNFGSFPFLVETEET                               CFIHKLKTPAKVTPDSLPLVFNHCGDACLIIHPHFRDVEFHHT                               GN               675   1414   1   1101   CCSTKNISGDKACNLMIFDTRKTARQPNCYLFFCPNEEACPLK                               PAKGLMSYRIITDFPSLTRNLPSQELPQEDSLLHGQFSQAVTP                               LAHHHTDYSKPTDISWRDTLSQKFGSSDHLEKLFKMDEASAQL                               LAYKEKGHSQSSQFSSDQEIAHLLPENVSALPATVAVASPHTT                               SATPKPATLL\PTNASVTPSGTSQPQLA\TTAPPVTTVTSQPP                               TTLISTVFTRAAATLQAMATTAVLTTTFQAPTDSKGSLETIPF                               TEISNLTKNTGNVYNPTALSMSNVESSTMNKTASWEGREASPG                               SSSQGSVPENRYGLPFEKWLLIGSLLFGVLFLVIGLVLLGRIL                               SESLRRKRYSRLDYLINGLLVDI               676   1415   178   621   IFAGSGVMRLKISLLKEPKEQELVSCVGWTTAEELYSCSDDHH                               IVKRNLLTSETTQIVKLPDDIYPIDFHWFPKSLGVKKQTHAES                               FVLTSSDGKFHLISKLGRVEKSVEAHCGAVLAGRWNYEGTALV                               TVGEDGQI*IWSKTGMLIS               677   1416   1258   944   RRATTKRHFILLFLFFLRRC\LFLSPRMECNGAILAHCNLHLP                               GSSSSSASAS*VAGITDVRHHAQLILFVFLVETGFHRVGQAGL                               KLLTSGDLLTSASQSAGIIMGISHCAQPKKAF*TKTF               678   1417   876   1291   EAGSNDDLAT*KTCGRARPSSRSRQFGSRVWNHRQGVRSSPGE                               GAGSRSPCRRRHRRKHRRNVQSP*RRRSRSCSRRSGRCSVALL                               GACPVAGHSRGKVVCRRAHAITQRRRCCGFDPMVHPKEHRG*R                               ERSRKWSRS               679   1418   262   539   ATAPGLFNFF*FLFQCREEHKKKNPEVPVNFAEFSKKCSGRWK                               TMSSKEKFKFGEMAKADEVCYDREMKDYGPAKGGKKKDPNAPK                               RPPSGF               680   1419   104   236   LTVNYVLVFSRDSGLRAIENLMQKKGKFDYILLETTGLADPGK                               K               681   1420   3   277   HEAALCRTRAVAAERHFLRVFLFFRPFRGVGTESGSESGSSKA                               KEPRTPSSSYGTAQYRRWPIAQEYKHCTAHNDTGTLCSELREP                               WRRPQ               682   1421   3   576   EGSSQANTLRSRKENRRNLLACLESHVLR*QFTESELCSLMGD                               NPFQPKSNSKMAELFMECEEEELEPWQKKVKEVEDDDDDEPIF                               VGEISSSKPAISNILNRVNPSSYSRGLKNGALSRGITAAFKPT                               SQHYTNPTSNPVPASPINFHPESRSSDSSVIGQPFSKPVSVSK                               TLPAQGSIGCCLSISTV               683   1422   6   627   CFSLEDILNFFLQGFSAGLFAFYHDKDGNPLTSRFADGLPPFN                               YSLGLYQWSDKVVRKVERLWDVRDNKIVRHTVYLLVTPRVVEE                               ARKHFDCPVLEGMELENQGGVGTELNHWEKRLLENEAMTGSHT                               QNRVLSRITLAKMEDTGRQMLSPYCDTLRSNPLQLTCRQDQRA                               VAV\CNLQKFPKPLPQEYQYFDELSGIPAEDLPYYG               684   1423   1   1272   AARRRRQLVSRRRTAE\YPRDRRSSPSARPPDVPGQQPKAAKS                               PSPVQGKKSPRLLCIEKVTTDKDPKEEKEEEDDSAKPQEVSIA                               ASRPSRGWRSSRTSVSRHRDTENTRSSRSKTGSLQLICKSEPN                               TDQLDYDVGEEHQSPGGISSEEEEEEEEEMLISEEEIPFKDDP                               RDETYKPHLERETPKPRRKSGKVKEEKEKKEIKVEVEVEVKEE                               ENEIREDEEPPRKRGRRRKDDKSPRLPKRRKKPPIQYVRCEME                               GCGTVLAHPRYLQHHIKYQHLLKKKYVCPHPSCGRLFRKQKQL                               LRHAKHHTDQRDYICEYCARAFKSSHNLAVHRMIHTGEKPLQC                               EICGFTCRQKASLNWHMKKHDADSFYQFSCNICGKKFEKKDSV                               VAHKAKSHPEVLIAEALAANAGALITSTDILGTNPES               685   1424   56   526   MTANRLAESLLALSQQEELADLPKDYLLSESEDEGDNDGERKH                               QKLLEAISSLDGKNRRKLAERSEASLKVSEFNVSSEGSGEKLV                               LADLLEPVKTSSSLATVKKQLSRVKSKKTVELPLNKEEIERIH                               REVAFNKTAQVLSKWDPVVLLRQAEQL*               686   1425   132   344   RIDFMFHSSAMVNSHRKPMFNIHRGFYCLTAILPQICICSQFS                               VPSSYHFTEDPGAFPVATNGERFPWQELRLPSVVIPLHYDLFV                               HPNLTSLDFVASEKIEVLVSNATQLIILHSKDLEITNATLQSE                               EDSRYMKPGKELKVLSYPAHEQIALLVPEKLTPHLKYYVAMDF                               QAKLGDGFEGFYKSTYRTLGGETRILAVTDFEPTQARMAFPCF                               DEPLFKPINFSIKLRESRHIALSNMPKVKTIELEGGLLEDHFE                               TTVKMSTYLVAYI/DL*FPLMGNDFLGRS               687   1426   3   678   RSKIPRSDPRVRTPAPAEAEQGKSQCPSGSTAQSWSAMDILVP                               LLQLLVLLLTLPLHLMALLGCWQPLCKSYFPYLMAVLTPKSNR                               KMESKKRELFSQIKGLTGASGKVAKLELGCGTGANFQFYPPGC                               RVTCLDPNPHFEKFLTKSMAENRHLQYERFVVAPGEDMRQLAD                               GSMDVVVCTLVLCSVQSPRKVLQEVRRVLRPGGVLFFWEHVAE                               PYGSWAFMW               688   1427   240   641   RKQNSSLMDPKLGRMAASLLAVLLLLLLERGMFSSPSPPPALL                               EKVFQYIDLHQDEFVQTLKEWVAIESDSVQPVPRFRQELFRMM                               AVAADTLQRLGARVASVDMGPQQLPDGQSLPIPPVILAELGSD                               PTKG               689   1428   1   116   FFFFEMESCSVTQAGVPWHDLSSLQPPPPRFKRFSCLS               690   1429   75   511   DPKAQLPEPLRVLWTAHLVAMAPGSRTSLLLAFALLCLPWLQE                               AGAVQTVPLSRLFDHAMLQAHRAHQLAIDTYQEFEETYIPKDQ                               KYSFLHDSQTSFCFSDSIPTPSNMEETQQKSNLELLRISLLLI                               ESWLEPVRILMSIVPN               691   1430   2   1364   FVKLIKKHQAAMEKEAKVMSNEEKKFQQHIQAQQKKELNSFLE                               SQKREYKLRKEQLKEELNENQSTPKKEKQEWLSKQKENIQHFQ                               AEEEANLLRRQRQYLELECRRFKRRMLLGRHNLEQDLVREELN                               KRQTQKDLEHAMLLRQHESMQELEFRHLNTIQKMRCELIRLQH                               QTELTNQLEYNKRRERELRRKHVMEVRQQPKSLKSKELQIKKQ                               FQDTCKIQTRQYKALRNHLLETTPKSEHKAVLKRLKEEQTRKL                               AILAEQYDHSINEMLSTQALRLDEAQEAECQVLKMQLQQELEL                               LNAYQSKIKMQAEAQHDRELRELEQRVSLRRALLEQKIEEEML                               ALQNERTERIRSLLERQAREIEAFDSESMRLGFSNMVLSNLSP                               EAFSHSYPGASGWSHNPTGGPGPHWGHPMGGPPQAWGHPMQGG                               PQPWGHPS\GPMQ\GVPR/GSSMGVR               692   1431   50   504   LAHGSFGVSDFPAPAAAPAHTLTSFSGSLSPQFRKPLGRAPAM                               PLVRYRKVVILGYRCVGKTSLAHQFVEGEFSEGYDPTVENTYS                               KIVTLGKDEFHKHLVDTAGQDEYSILPYSFIIGVHGYVLVYSV                               TSLHSFQVIESLYQKLHEGHGK               693   1432   130   1671   SSPSRELCFYGFWIASSWWSRWVGSLGPGILPSPPARGRTFAS                               VSRLPPPWSAGITLTPFLICQSGSVCPGLGAGFGVRSFHHPVA                               RSAVLLLPLAPAAAQDSTQASTPGSPLSPTEYERFFALLTPTW                               KAETTCRLRATHGCRNPTLVQLDQYENHGLVPDGAVCSNLPYA                               SWFESFCQFTHYRCSNHVYYAKRVLCSQPVSILSPNTLKETEA                               SAEVSPTTMTSPISPHFTVTERQTFQPWPERLSNNVEELLQSS                               LSLGGQEQAPEHKQEQGVEHRQEPTQEHKQEEGQKQEEQEEEQ                               EEEGKQEEGQGTKEGREAVSQLQTDSEPKFHSESLSSNPSSFA                               PRVREVESTPMIMENIQELIRSAQEIDEMNEIYDENSYWRNQN                               PGSLLQLPHTEAKLVLCYSIVENTCIITPTAKAWKYMEEEILG                               FGKSVCDSLGRRHMSTCALCDFCSLKLEQCHSEASLQRQQCDT                               SHKTPFVSPLLASQSLSIGNQVGSPESGRFYGLDLYGGLHM               694   1433   517   578   VSWVPSKDGDVEGARRPFTRLNTSLGPGLQEGRRRTWLVPIPG                               AVLPGRTQEQPRASPLY*PGAPPCQPQGLVAGPWAQ*AGLRSD                               GFGPWPW\RLVGTAGPREKKVQKSKCWHFRCGRHPARRSGWAG                               RHASLLATGRPCSSAPSQQPLGTAGDSRQELLRPPLV*VNGAQ                               SSAAGDWGSSPRTAQALARPHRLGHHPAAVAPAARLRTQSGHS                               PRGPLCRSPGSPRRMGTWRGPAGHSHD               695   1434   249   632   KTVAEEASVGNPEGAFMKMLQARKQHMSTELTIESEAPSDSSG                               INLSGFGSEQLDTNDESDVSSALSYILPYLSLRNLGAESILLP                               FTEQLFSNVQDGDRLLSILKNNRKSPSQSSLLGNKFKNKIF               696   1435   333   881   GECFIMAAVVQQNDLVFEFASNVMEDERQLGDPAIFPAVIVEH                               VPGADILNSYAGLACVEEPNDMITESSLDVAEEEIIDDDDDDI                               TLTVEASCHDGDETIETIEAAEALLNMDSPGPMLDEKRINNNI                               FSSPEDDMVVAPVTHVSVTLDGIPEVMETQQVQEKYADSPGAS                               SPEQPKRKKK               697   1436   3   466   HEASGVSRALLQSAPGTPATVGISVGELWPFARCCSHSYVRSL                               RGLSVSTHLLCFTIYIMNPSMKQKQEEIKENIKTSSVPRRTLK                               MIQPSASGSLVGRENELSAGLSKRKHRNDHLTSTTSSPGVIVP                               ESSENKNLGRVTQESFDLMIKGMK               698   1437   50   241   PLPARGKSTLPATFCSPSAPELASMSVVPPNRSQTGWPRGVTQ                               FGNKYIQQTKPLTLERTINL               699   1438   1   422   AEGEDVPPLPTSSGDGWEKDLEEALEAGGCDLETLRNIIQGRP                               LPADLRAKVWKIALNVAGKGDSLASWDGILDLPEQNTIHKDCL                               QFIDQLSVPEEKAAELLLDIESVITFYCKSRNIKYSTSLSWIH                               LLKPLVHLQL               700   1439   161   413   ALPKFLTHGVKSNERVVVWLFPPSFRAATMVHMNVLPDALKSI                               NNAERRGKPQVLLLCSKIIIWFLTVMVKYGYIGKFEPTRP               701   1440   211   977   AMAQYGHPSPLGMAAREELYSKVTPRRNRQQRPGTIKHGSALD                               VLLSMGFPRARAQKALASTGGRSVQAACDWLFSHVGDPFLDDP                               LPREYVLYLRPTGPLAQKLSDFWQQSKQICKGKNKAHNIPHIT                               LCQFFMCEDSKVDALGEALQTTVSRWKCKFSAPLPLELYTSSN                               FIGLFVKEDSAEVLKKFAADFAAEAASKTEVHVEPHKKQLHVT                               LAYHFQASHLPTLEKLAQNIDVKLGCDWVATIFSRDLFA               702   1441   3   408   QTRPASPRTARESVLGVSQNMSFNLQSSKKLFIFLGKSLFSLL                               EAMIFALLPKPRKNVAGEIVLITGAGSGLGRLLALQFARLGSV                               LVLWDINKEGNEETCKMAREAGATRVHAYTCDCSQKEGVYRVA                               DQVKK               703   1442   708   244   MVARKGQKSPRFRRVTCFLRLGRSTLLELEPAGRPCSGRTRHR                               ALHPRLVACVTVSSRRHRKEAGRGRAESFIAVGMAAPSMKERQ                               VCWGARDEYWKCLDENLEDASQCKKLRSSFESSCPQQWIKYFD                               KRRDYLKFKEKFEAGQFEPSETTAKS               704   1443   3   475   PAPAARSRELLKELRNGQDMDTVVFEDVVVDFTLEEWALLNPA                               QRKLYRDVMLETFKHLASVDNEAQLKASGSISQQDTSGEKLSL                               KQKIEKFTRKNIWASLLGKNWEEHSVKDKHNTKERHLSRNPRV                               ERPCKSSKGNKRGRTFRKTRNCNRHLRR               705   1444   276   437   CVCGFFVCFETKSCFVAQAGVQWHNLSSLQALPPGFKQFSCLS                               LLSSWHYRRV               706   1445   2   322   GTRLRRRREAVWFEVVNMDFSRLHMYSPPQCVPENTGYTYALS                               SSYSSDALDFETEHKLDPVFDSPRMSRRSLRLATTACTLGDGE                               AVGADSGTSSAVSLKNRAAR               707   1446   123   410   DTMQAVVPLNKMTAISPEPQTLASTEQNEVPRVVTSGEQEAIL                               RGNAADAESFRQRFRWFCYSEVAGPRKALSQLWELCNQWLRPD                               IHTKE\QILE               708   1447   2   384   PICLFSRPTLRPSRSKVSLIEGRGANMAARWRFWCVSVTMVVA                               LLIVCDVPSASAQRKKEMVLSEKVSQLMEWTNKRPVIRMNGDK                               FRRLVKAPPRNYSVIVMFTALQLHRQCWCRELQLRFKIK               709   1448   104   535   QMRVKDPTKALPEKAKRSKRPTVPHDEDSSDDIAVGLTCQHVS                               HAISVNHVKRAIAENLWSVCSECLKERRFYDGQLVLTSDIWLC                               LKCGFQGCGKNSESQHSLKHFKSSRTEPHCIIINLSTWIIWWY                               EWDEKIFTPLNKKG               710   1449   116   479   AKERGEERQGEGGGWLSGSRWPLVRSAFVPAPSSLILSMCLSP                               GIPEAAPDSPLTASAPTP*VMLLGDTGVGKTCFLIQFKDGAFL                               SGTFIATVGIDFRVRWLQALASSREPGLWLRHGGV               711   1450   2   232   FYPRSSADLPFQTTRCEFQTSVMELAHSLLLNEEALAQITEAK                               RPVFIFEWLRFLDKLVARNCSFFPRT               712   1451   105   393   MNMKQKSVYQQTKALLCKNFLKKWRMKRESLLEWGLSILLGLC                               IALFSSSMRNVQFPGMAPQNLGRVDKFNSSSLMVVYTPISNLT                               QQIMNTAL               713   1452   2   525   SPQGNGCPDVTGDSVIRVPLTLLVHNLAGLTGLLHHCLSGPLP                               APSPPPAMSSSRKDHLGASSSEPLPVIIVGNGPSGICLSYLLE                               GYTPYTKPDAIHPHPLLQRKLTEAPGVSILDQDLDYLSEGLEG                               RSQSPVALLFDALLRPDTDFGGNMKSVLTWKHRKEHAIPHVVL                               GR               714   1453   2   1557   NRRTRAQRCQRGRSCGAREEEEPGTARKPPPAASAMDASLEKI                               ADPTLAEMGKNLKEAVKMLEDSQRRTEEENGKKLISGDIPGPL                               QGSGQDMVSILQLVQNLMHGDEDEEPQSPRIQNIGEQGHMALL                               GHSLGAYISTLDKEKLRKLTTRILSDTTLWLCRIFRYENGCAY                               FHEEEREGLAKICRLAIHSRYEDFVVDGFNVLYNKKPVIYLSA                               AARPGLGQYLCNQLGLPFPCLCRVPCNTVFGSQHQMDVAFLEK                               LIKDDIERGRLPLLLVANAGTAAVGHTDKIGRLKELCEQYGIW                               LHVEGVNLATLALGYVSSSVLAAAKCDSMTMTPGPWLGLPAVP                               AVTLYKHDDPALTLVAGLTSNKPTDKLRALPLWLSLQYLGLDG                               FVERIKHACQLSQRLQESLKKVNYIKILVEDELSSPVVVFRFF                               QELPGSDPVFKAVPVPNMTPSGVGRERHSCDALNRWLGEQLKQ                               LVPASGLTVMDLEAEGTCLRFSPLMTAAGKPGLVDIPCFCSGA                               AG               715   1454   319   873   LCIMDTKEEKKERKQSYFARLKKKKQAKQNAETASAVATRTHT                               GKEDNNTVVLEPDKCNIAVEEEYMTDEKKKRKSNQLKEIRRTE                               LKRYYSIDDNQNKTHDKKEKKMVVQKPHGTMEYTAGNQDTLNS                               IALKFNITPNKLVELNKLFTHTIVPGQVLFVPDANSPSSTLRL                               SSSSPGATVSPSS               716   1455   60   681   SAGGDSCRAVPMLRFPTCFPSFRVVGEKQLPQEIIFLVWSPKR                               DLIALANTAGEVLLHRLASFHRVWSFPPNENTGKEVTCLAWRP                               DGKLLAFALADTKKIVLCDVEKPESLHSFSVEAPVSCMHWMEV                               TVESSVLTSFYNAEDESNLLLPKLPTLPKNYSNTSKIFSEENS                               DEIIKLLGDVRLNILVLGGSSGFIELYAYGMFKI               717   1456   357   658   PRDPVTDRARAMPRRGLVAGPDLEYFQRHYFTPAEVAQHNRPE                               DLWVSYLGRVYDLTSLAQEYKGNLLLKPIVEVAGQDISHWFDP                               KTRDVSYAGTWDCG               718   1457   2   481   RIPGRRFRAAFVLGSANVASSVRLRCSFPLSLGGPSGPAAASV                               ALGPAGPGRSLGRTPDTGDWENDSVSFEDVAVAFTQEEWALLD                               PSQKNLYRDVMQEIFRNLASVGNKSEDQNIQDDFKNPGRNLSS                               HVVERLFEIKEGSQYGETFSQDSNLNLNKI               719   1458   6   469   SLSLSVSPFLRLSLGRVGGMAEEMESSLEASFSSSGAVSGASG                               FLPPARSRIFKIIVIGDSNVGKTCLTYRFCAGRFPDRTEATIG                               VDFRERAVEIDGERIKIQLWDTAGQERFRKSMVQHYYRNVHAV                               VFVYDMTNMASFHSLPSWIEECKQH               720   1459   82   490   RRPSPGSIVIMAAESDVLHFQFEQQGDVVLQKMNLLRQQNLFC                               DVSIYINDTEFQGHKVILAACSTFMRDQFLLTQSKHVRITILQ                               SAEVGRKLLLSCYTGALEVKRKELLKYLTAASYLQMVHIAEKR                               TEAFVKF               721   1460   48   708   AEGLQSAAGIRIDTKAGPPEMLKPLWKAAVAPTWPCSMPPRRP                               WDRQAGTLQVLGALAVLWLGSVALICLLWQVPRPPTWGQVQPK                               DVPRSWEHGSSPAWEPLEAEARQQPDSCQLVLVESIPQDLPSA                               AGSPSAQPLGQAWLQLLDTAQESVHVASYYWSLTGPDIGVNDS                               SSQLGEALQQLLGRNISLAVATSSPTLARTSTDLQRR                               RGAH               722   1461   436   677   RKKKMPLPFGLKLKPTRRYTVSSKSCLVARIQLLNNEFVEFTL                               SVESTGQESLEAVAQRLELREVTYFSLWYYNKQNQRR               723   1462   45   569   LQPLSSWESASEVTRSPVSPEDVKQATSNFENLQKQLARKMKL                               PIFIADAFTARAFRGNPAAVCLLENELDEDMHQKIAREMNLSE                               TAFIRKLHPTDNFAQSSCFGLRWFTPASEVPLCGHATLASAAV                               LFHKIKNMNSTLTFVTLSGELRARPRAEDGIVLDLPLYPRPQD                               FHE*               724   1463   79   530   AADTMQSDDVIWDTLGNKQFCSFKIRTKTQSFCRNEYSLTGLC                               NRSSCPLANSQYATIKEEKGQCYLYMKVIERAAFPRRLWERVR                               LSKNYEKALEQIDENLIYWPRFIRHKCKQRFTKITQYLIRIRK                               LTLKRQRKLVPLSKKVERREK               725   1464   2   261   FVERGLGDPALPTLMFEEPEWAEAAPVAAGLGPVISRPPPAAS                               SQNKVSDSREQWELFQAAKRTLVDPSAVCIAGRDTCGTVKGES               726   1465   1   860   VVEFLWSRRPSGSSDPRPRRPASKCQMMEERANLMHMMKLSIK                               VLLQSALSLGRSLDADHAPLQQFFVVMEHCLKHGLKVKKSFIG                               QNKSFFGPLELVEKKCPEASDIATSVRNLPELKTAVGRGRAWL                               YLALMQKKLRDYLKVLIDNKHLLSEFYEPEALMMEEEGMVIVG                               LLVGLNVLDANL\CLKGEDLDSQVGVIDFSLYLKDVQDLDGGK                               EHERITDVLDQKNYVEELNRHLSCTVGDLQTKIDGLEKTNSKL                               QERVSAATDRKSLQEEQQQKREQNELIR               727   1466   69   452   GCYAPSPHLGGSLTPRFFPNGVFHRRLPRPRPPQPPSVSSAPT                               LRPLCAHFSLGKLRKRVRKSAEVAPPRTEKGWGSAEPRHSRAP                               LGLQGLRMAASAQVSVTFEDVAVTFTQEEWGQLDAAQRTLY               728   1467   1   439   FRGSLSSPSSLRGRRLVTGQTSPRGTWCLYPGFCRSVACAMPC                               CSHRSCREDPGTSESREMDPVVFEDVAVNFTQEEWTLLDISQK                               NLFREVMLETFRNLTSIGKKWSDQNIEYERQNPPRSFRSLIEE                               KVNEIKEDSHCGETFTQ               729   1468   103   236   LNFANSAAFAVTMPQNEYIELHRXRYGFRLDYHEKKRKKQSRE                               A               730   1469   213   809   SGDLSPAELMMLTIGDVIKQLIEAHEQGKDIDLNKVKTKTAAK                               YGLSAQPRLVDIIAAVPPQYRKVLMPKLKAKPIRTASGIAVVA                               VMCKPHRCPHISFTGNICVYCPGGPDSDFEYSTQSYTGYEPTS                               MRAIRARYDPFLQTRHRIEQLKQLGHSVDKVEFIEMGGTFMAL                               PEEYRDYFLNLHDALSGHTSNNIYE               731   1470   264   799   WESDVGEGLRPPPPPPPPGRRRTQEPRARDAATVIFACPAALL                               ETLIAYGSSSPSFCKHRAARPLIFLLHRLTAEATARCPICALE                               ARNPGRWGICASWPGMKTPFGKAAAGQRSRTGAGHGSVSVTMI                               KRKAAHKKRRSRPTSQPRGNIVGCIIQHGWKDGDEPLTQWKGT                               VLDQLL               732   1471   2   763   EDLGVAKEAFQWAPAGDCGSGAGRAGGEGVDAGRRVPERQHRG                               RGGGGEPGPRQRGGRRQ\RSSSRRSGGDGGDEVEGSGVGAGEG                               ETVQHFPLARPKSLMQKLQCSFQTSWLKDFPWLRYSKDTGLMS                               CGWCQKTPADGGSVDLPPVGHDELSRGTRNYKKTLLLRHHVST                               EHKLHEANAQESEIPSEEGYCDFNSRPWENSYCYQLLRQLNEQ                               RKKGILCDVSIVVSGKIFKAHKNILVAGSRFFKTLYCFS               733   1472   82   523   SLRAAAAMADVTARSLQYEYKRNSNLVLQADRSLIDRTRRDEP                               TGEVLSLVGKLEGTRMGDKAQRTKPQMQEERRAKRRKRDEDRH                               DINKMKGYTLLSEGIDEMVGIIYKPKTKETRETYEVLLSFIQA                               ALGDQPRDILCGAADEVL               734   1473   536   110   CNSAESRNDVLFVAIFAVPLILGQEYEDEERLGEDEYYQVVYY                               YTVTPSYDDFSADFTIDYSIFESEDRLNRLDKDITEAIETTIS                               LETARADHPKPVIVKPVTTEPQSP\DL\NDAVSS\LRSPIPL\                               LLS\CAFVQVGMYFM               735   1474   2   557   FVRGPGEEQAPAFRKPAPGAMGAQVRLPPGEPCREGYVLSLVC                               PNSSQAWCEITNVSQLLASPVLYTDLNYSINNLSISANVENKY                               SLYVGLVLAVSSSIFIGSSFILKKKGLLQLASKGFTRAGQGGH                               SYLKEWLWWVGLLSILSNNAREKVDL*NITF*PQTSCIFFTIT                               IEKSTFLSYFPTS               736   1475   127   401   ARGSCPTRPRPANGRMAETKDAAQMLVTFKDVAVTFTREEWRQ                               LDLAQRTLYREVMLETCGLLVSLGHRVPKPELVHLLKHGQELW                               IVKRG               737   1476   311   790   YTMLRGTMTAWRGMRPEVTLACLLLATAGCFADLNEVPQVTVQ                               PASTVQKPGGTVILGCVVEPPRNNVTWRLNGKELNGSDDALGV                               LITHGTLVITALNNHTVGRYQCVARMPAGAVASVPATVTLASE                               SAPLPPCHGAVPPHLSHPEAPTIHAASCYS               738   1477   2   421   WGRRRQLVSEAARAQGDPVCSTMSEEEAAQIPRSSVWEQDQQN                               VVQRVVALPLVRATCTAVCDVYSAAKDRHPLLGSACRLAENCV                               CGLTTRALDHAQPLLEHLQPQLATMNSLACRGLDKLEEKLPFL                               QQPSETVVTS               739   1478   256   1250   AKAFTMAESPGCCSVWARCLHCLYSCHWRKCPPERMQTSKCDC                               IWFGLLFLTFLLSLSWLYIGLVLLNDLHNFNEFLFRRWGHWMD                               WSLAFLLVISLLGTYASLLLVLALLLRLCRQPLHLHSLHKVLL                               LLIMLLVAAGLVGLDIQWQQERHSLRVSL/QDCR*L*TPAVRP                               *EESGEGHWRRAHLTSSCPQATAPFLHIGAAAGIALLAWPVAD                               TFYRIHRREPKILLLLKFFGVVLVIYLAPLCISSPCIMEPRDL                               PPKPGLVGHRGAPMLAPENTLMSLRKTAECGATVFETDVMVSS                               DGVPFLMHDEHLSRTTNVASVFPTRITAHSS                    
     [0383] 
    
     
       
         0 
         
           
               
            
               
                   
               
               
                   
               
               
                 SEQUENCE LISTING 
               
            
           
           
               
            
               
                 The patent application contains a lengthy “Sequence Listing” section. A copy of the “Sequence Listing” is available in electronic form from the USPTO 
               
               
                 web site (http://seqdata.uspto.gov/sequence.html?DocID=20040053248). An electronic copy of the “Sequence Listing” will also be available from the 
               
               
                 USPTO upon request and payment of the fee set forth in 37 CFR 1.19(b)(3).